<SEC-DOCUMENT>0001279569-14-001702.txt : 20141024
<SEC-HEADER>0001279569-14-001702.hdr.sgml : 20141024
<ACCEPTANCE-DATETIME>20141024170507
ACCESSION NUMBER:		0001279569-14-001702
CONFORMED SUBMISSION TYPE:	SUPPL
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20141024
DATE AS OF CHANGE:		20141024
EFFECTIVENESS DATE:		20141024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SUPPL
		SEC ACT:		
		SEC FILE NUMBER:	333-197633
		FILM NUMBER:		141172980

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>SUPPL
<SEQUENCE>1
<FILENAME>v391934_suppl.htm
<DESCRIPTION>SUPPL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed pursuant to General Instruction
II.L of Form F-10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>File No. 333-197633</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To Base Shelf Prospectus dated August 1, 2014)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to US$20,000,000 of common shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are hereby qualifying for distribution
common shares of Oncolytics Biotech Inc. having an aggregate offering price of up to US$<B>20,000,000</B> (this &ldquo;<B>Offering</B>&rdquo;).
We have entered into an equity distribution agreement dated October 24, 2014 (the &ldquo;<B>Equity Distribution Agreement</B>&rdquo;)
with Canaccord Genuity Inc., as exclusive agent (the &ldquo;<B>Agent</B>&rdquo;), relating to the sale of common shares offered
by this prospectus supplement and the accompanying short form base prospectus dated August 1, 2014. In accordance with the Equity
Distribution Agreement, and except as noted below, we may distribute common shares having an aggregate offering price of US$<B>20,000,000
</B>through the Agent, as our agent or as principal for the distribution of the common shares. See &ldquo;Plan of Distribution&rdquo;
beginning on page S-15 of this prospectus supplement for more information regarding these arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agent will be entitled to compensation
at a fixed commission rate of 3.0% of the gross sales price per share sold for services rendered in connection with this Offering.
See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate the total expenses of this
Offering, excluding the Agent&rsquo;s fee, will be approximately US$150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No underwriter or dealer involved in this
Offering, no affiliate of such an underwriter or dealer, and no person acting jointly or in concert with such an underwriter or
dealer has over-allotted, or will over-allot, common shares in connection with this Offering or effect any other transactions that
are intended to stabilize or maintain the market price of the common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common shares are listed on the Nasdaq
Capital Market (&ldquo;<B>NASDAQ</B>&rdquo;) under the symbol &ldquo;ONCY&rdquo; and on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;)
under the symbol &ldquo;ONC&rdquo;. On October 23, 2014, the last reported sale price of our common shares was US$0.4938 per common
share on NASDAQ and C$<B></B>0.55 per common share on the TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of common shares, if any, under this
prospectus supplement and the accompanying prospectus may be made in transactions that are deemed to be &ldquo;at-the-market distributions&rdquo;
as defined in National Instrument 44-102 &ndash; Shelf Distributions (&ldquo;<B>NI 44-102</B>&rdquo;), including sales made directly
on the NASDAQ or other existing trading markets for the common shares in the United States. The common shares will be distributed
at market prices prevailing at the time of the sale of such common shares. As a result, prices may vary as between purchasers and
during the period of distribution. No common shares will be sold on the TSX or on other trading markets in Canada as at-the-market
distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the sale of our common
shares on our behalf, the Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the <I>United States Securities
Act of 1933, as amended </I>(the &ldquo;<B>U.S. Securities Act</B>&rdquo;) and the compensation of the Agent will be deemed to
be underwriting commissions or discounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common shares is speculative
and bears certain risks. See &ldquo;Risk Factors&rdquo; beginning on page S-12 of this prospectus supplement and on page 10 of
the accompanying prospectus and the risk factors discussed or referred to in our Annual Information Form and Annual MD&amp;A which
are incorporated by reference into this prospectus supplement and the accompanying prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This offering is made by a Canadian
issuer that is permitted under a multi-jurisdictional disclosure system adopted by the United States and Canada to prepare this
prospectus supplement and the accompanying prospectus in accordance with Canadian disclosure requirements. Prospective investors
should be aware that such requirements are different from those applicable to issuers in the United States. Financial statements
incorporated herein by reference have been prepared in accordance with International Financial Reporting Standards (&ldquo;IFRS&rdquo;)
as issued by the International Accounting Standards Board (&ldquo;IASB&rdquo;), and may not be comparable to financial statements
of United States companies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective investors should be aware
that the acquisition, holding or disposition of the common shares may have tax consequences both in the United States and in Canada.
Such consequences for investors who are resident in, or citizens of, the United States may not be described fully herein. Prospective
investors should read the tax discussion contained in this prospectus supplement under the heading &ldquo;Certain US Federal Income
Tax Considerations&rdquo; and should consult their own tax advisor with respect to their own particular circumstances.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The enforcement by investors of civil
liabilities under the US federal securities laws may be affected adversely by the fact that we are governed by the laws of Canada,
that some or all of our officers and directors are residents of Canada, and that a substantial portion of our assets and the assets
of said persons are located outside the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE UNITED STATES SECURITIES
AND EXCHANGE COMMISSION (THE &ldquo;SEC&rdquo;) NOR ANY STATE SECURITIES REGULATOR HAS APPROVED OR DISAPPROVED OF THE SECURITIES
OFFERED HEREBY OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT OR THE ACCOMPANYING PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Canaccord
Genuity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement
is October 24, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->S-2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal"><U>Prospectus
Supplement</U></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 95%"><A HREF="#a_p1"><FONT STYLE="font-size: 10pt">IMPORTANT NOTICE ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 10pt">S-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p2"><FONT STYLE="font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_p3"><FONT STYLE="font-size: 10pt">PRESENTATION OF FINANCIAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p4"><FONT STYLE="font-size: 10pt">CURRENCY AND EXCHANGE RATE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_p5"><FONT STYLE="font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p6"><FONT STYLE="font-size: 10pt">SUMMARY OF THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_p7"><FONT STYLE="font-size: 10pt">RECENT DEVELOPMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p8"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_p9"><FONT STYLE="font-size: 10pt">DOCUMENTS INCORPORATED BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p10"><FONT STYLE="font-size: 10pt">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_p11"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p12"><FONT STYLE="font-size: 10pt">CONSOLIDATED CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_p13"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p14"><FONT STYLE="font-size: 10pt">TRADING PRICE AND VOLUME</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_p15"><FONT STYLE="font-size: 10pt">PRIOR SALES</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p16"><FONT STYLE="font-size: 10pt">CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_p17"><FONT STYLE="font-size: 10pt">LEGAL MATTERS AND INTEREST OF EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_p18"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right">S-<FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><U>Base Prospectus</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 95%; padding-right: 0.5in"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS AND OTHER MATTERS</FONT></A></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SPECIAL NOTICE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ENFORCEABILITY OF CIVIL LIABILITIES</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DOCUMENTS INCORPORATED BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE CORPORATION</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OUR BUSINESS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONSOLIDATED CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF SHARE CAPITAL</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PRIOR SALES</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TRADING PRICE AND VOLUME</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF SUBSCRIPTION RECEIPTS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_015"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_016"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_017"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTAIN INCOME TAX CONSIDERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_018"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_019"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AUDITOR</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_020"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">REGISTRAR AND TRANSFER AGENT</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_021"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in"><A HREF="#a_022"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</FONT></A></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->S-3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p1"></A>IMPORTANT NOTICE ABOUT INFORMATION
IN THIS PROSPECTUS SUPPLEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is in two parts. The first
part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information
contained in the accompanying prospectus and the documents incorporated by reference herein and therein. The second part is the
accompanying prospectus, which provides more general information. If the description of the common shares varies between this prospectus
supplement and the accompanying prospectus, investors should rely on the information in this prospectus supplement. Before you
invest, you should carefully read this prospectus supplement, the accompanying prospectus, all information incorporated by reference
herein and therein, as well as the additional information described under &ldquo;Where You Can Find Additional Information&rdquo;
on page S-<B>[26]</B> of this prospectus supplement. These documents contain information you should consider when making your investment
decision. This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent
that any statement that we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus
or any documents incorporated by reference therein filed prior to the date of this prospectus supplement, the statements made in
this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated
by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information
contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not, and the Agent
has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. We are offering to sell, and seeking offers to buy, our common shares only in jurisdictions
where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the common shares in certain
jurisdictions may be restricted by law. You should assume that the information contained in this prospectus supplement and the
accompanying prospectus, as well as information we have previously filed with the SEC and with the securities regulatory authority
in each of the provinces and territories of Canada, except Qu&eacute;bec, that is incorporated by reference herein and in the accompanying
prospectus, is accurate only as of its respective date. Our business, financial condition, results of operations and prospects
may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement does not constitute,
and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this
prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statistical information and other
data relating to the pharmaceutical and biotechnology industry included in this prospectus supplement and the prospectus are derived
from recognized industry reports published by industry analysts, industry associations and/or independent consulting and data compilation
organizations. Market data and industry forecasts used throughout this prospectus supplement and the prospectus were obtained from
various publicly available sources. Although the Corporation believes that these independent sources are generally reliable, the
accuracy and completeness of the information from such sources is not guaranteed and has not been independently verified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement is deemed to
be incorporated by reference into the prospectus solely for the purposes of this offering. Other documents are also incorporated
or deemed to be incorporated by reference into this prospectus supplement and into the prospectus. See &ldquo;Documents Incorporated
by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this prospectus supplement, &ldquo;<B>Oncolytics</B>,&rdquo;
the &ldquo;<B>Corporation</B>,&rdquo; &ldquo;<B>we</B>,&rdquo; &ldquo;<B>us</B>,&rdquo; and &ldquo;our&rdquo; refer to Oncolytics
Biotech Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p2"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
prospectus contain certain information that may constitute &ldquo;forward-looking information&rdquo; and &ldquo;forward-looking
statements&rdquo; (&ldquo;<B>forward-looking information</B>&rdquo;) within the meaning of applicable Canadian securities laws
and the <I>United States Private Securities Litigation Reform Act of 1995</I>, respectively. Forward-looking information typically
contains statements with words such as &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;expect&rdquo;, &ldquo;plan&rdquo;,
&ldquo;estimate&rdquo;, &ldquo;intend&rdquo;, &ldquo;may&rdquo; or similar words suggesting future outcomes. Forward-looking information
in this prospectus supplement includes, but is not limited to, statements with respect to: clinical trial study timing, product
development timing, our ability to attract and retain business partners, future levels of government funding, competition from
other biotechnology companies, our ability to obtain the capital required for research, product development, operations and marketing
and the intended uses for the proceeds of this offering. This forward-looking information is subject to various risks and uncertainties,
including those discussed below, that could cause actual results and experience to differ materially from the anticipated results
or other expectations expressed. Our statements of &ldquo;belief&rdquo;, &ldquo;estimates&rdquo;, &ldquo;expectations&rdquo; and
other similar statements are based primarily upon our results derived to date from our research and development program with animals
and early stage human results and upon which we believe we have a reasonable scientific basis to expect the particular results
to occur. It is not possible to predict, based upon studies in animals or early stage human results, whether a new therapeutic
will be proved to be safe and effective in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that the particular
results expected by us will occur. Forward-looking information is provided for the purpose of assisting you in understanding our
current views of future outcomes, and may not be appropriate for other purposes. Readers are cautioned not to place undue reliance
on this forward-looking information, which is provided as of the date of this prospectus unless otherwise stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the assumptions, risks and factors
which could cause future outcomes to differ materially from those set forth in the forward-looking information contained herein
include, but are not limited to: (i) the assumption that we will be able to obtain sufficient and suitable financing to support
operations, clinical trials and commercialization of products, (ii) the risk that we may not be able to capitalize on partnering
and acquisition opportunities, (iii) the assumption that we will obtain favourable clinical trial results in the expected timeframe,
(iv) the assumption that we will be able to adequately protect proprietary information and technology from competitors, (v) the
risks relating to the uncertainties of the regulatory approval process, (vi) the impact of competitive products and pricing and
the assumption that we will be able to compete in the targeted markets, and (vii) the risk that we may be unable to retain key
personnel or maintain third party relationships, including relationships with key collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By its nature, forward-looking information
involves numerous assumptions, inherent risks and uncertainties, both general and specific, that contribute to the possibility
that the predictions, forecasts, projections or other forward-looking statements will not occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &ldquo;Risk Factors&rdquo; beginning
on page S-12 in this prospectus supplement and on page 10 of the accompanying prospectus and the risk factors discussed or referred
to in our Annual Information Form and Annual MD&amp;A which are incorporated by reference into this prospectus supplement and
the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as required by law, we undertake
no obligation to publicly update any forward-looking information, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p3"></A>PRESENTATION OF FINANCIAL INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all financial
information included and incorporated by reference in this prospectus supplement is prepared in accordance with IFRS. Since January
1, 2011, we have prepared our financial statements in accordance with IFRS. Prior to the adoption of IFRS, we followed Canadian
Generally Accepted Accounting Principles (&ldquo;<B>Canadian GAAP</B>&rdquo;). While IFRS has many similarities to Canadian GAAP,
some of our accounting policies have changed as a result of our transition to IFRS. Our financial statements incorporated by reference
in this prospectus supplement and the prospectus and in the documents incorporated by reference herein and therein may not be comparable
to financial statements prepared in accordance with United States generally accepted accounting principles.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p4"></A>CURRENCY AND EXCHANGE RATE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>In this prospectus supplement,
unless otherwise specified or the context otherwise requires, all dollar amounts are expressed in United States dollars.</B>
All references to &ldquo;US$&rdquo; and &ldquo;$&rdquo; are to the lawful currency of the United States and all references to
&ldquo;C$&rdquo; are to the lawful currency of Canada. In this prospectus supplement, where applicable, and unless otherwise
indicated, amounts are converted from United States dollars to Canadian dollars and vice versa by applying the noon rate of
exchange of the Bank of Canada on October 23, 2014. The following table sets forth: (i) the rates of exchange for Canadian
dollars, expressed in U.S. dollars, in effect at the end of the periods indicated; (ii) the average rates of exchange in
effect during such periods; (iii) the high rates of exchange in effect during such periods; and (iv) the low rates of
exchange in effect during such periods, such rates, in each case, based on the noon rates of exchange for conversion of one
Canadian dollar to U.S. dollars as reported by the Bank of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">Nine&nbsp;Months<BR> ended</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR> 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%">Low</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.9430</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.9710</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.9839</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.8888</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>High</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0583</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0418</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0697</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9422</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Average<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9996</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0299</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>End</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9833</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.0051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.9402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.8913</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">The average of the inverse of the noon buying rate on the last day of each month during the applicable
period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 23, 2014, the inverse of the noon exchange rate
quoted by the Bank of Canada for Canadian dollars was C$1.00 = $0.8899.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 2pt 5.4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p5"></A>PROSPECTUS SUPPLEMENT SUMMARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights certain information
about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement
or the prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding
whether to invest in the common shares. For a more complete understanding of the Corporation and this offering, we encourage you
to read and consider carefully the more detailed information in this prospectus supplement and the prospectus, including the information
incorporated by reference in this prospectus supplement and the prospectus, and the information included in any free writing prospectus
that the Corporation has authorized for use in connection with this offering, including the information under the heading &ldquo;Risk
Factors&rdquo; in this prospectus supplement on page S-12. All capitalized terms used in this summary refer to those definitions
contained elsewhere in this prospectus supplement and/or the prospectus, as applicable.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oncolytics Biotech Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Our Business</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We focus on the discovery and development
of oncolytic viruses for the treatment of cancers that have not been successfully treated with conventional therapeutics. Recent
scientific advances in oncology, virology, and molecular biology have created opportunities for new approaches to the treatment
of cancer. The product candidate we are presently developing may represent a novel treatment for Ras-mediated cancers. We may develop
this product candidate to be used as an alternative to existing cytotoxic or cytostatic therapies or as an adjuvant therapy to
conventional chemotherapy, radiation therapy, or surgical resections. It could also potentially be used to treat certain cellular
proliferative disorders for which no current therapy exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our technologies are based primarily on
discoveries made in the Department of Microbiology and Infectious Diseases at the University of Calgary in the 1990s. Oncolytics
was formed in 1998 to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells
with an activated Ras pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lead product candidate, REOLYSIN&reg;,
may represent a novel treatment for certain tumour types and some cellular proliferative disorders. This lead product is a virus
that is able to replicate specifically in, and hence kill, certain tumour cells both in tissue culture as well as in a number of
animal models without damaging normal cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">REOLYSIN is developed from the reovirus.
This virus has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. Activating mutations
of Ras occur in approximately thirty per cent of all human tumours directly, but considering its central role in signal transduction,
activation of the Ras pathway has been shown to play a role in approximately two-thirds of all tumours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functionality of REOLYSIN is based
upon the finding that tumours bearing an activated Ras pathway are deficient in their ability to activate the anti-viral response
mediated by the host cellular protein, Protein Kinase R (&ldquo;PKR&rdquo;). Since PKR is responsible for preventing reovirus replication,
tumour cells lacking the activity of PKR are susceptible to reovirus infections. As normal cells do not possess Ras activations,
these cells are able to thwart reovirus infections by the activity of PKR. In a tumour cell with an activated Ras pathway, reovirus
is able to freely replicate and hence kill the host tumour cell. The result of this replication is progeny viruses that are then
free to infect surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there
are no longer any tumour cells carrying an activated Ras pathway available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 2pt 5.4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following schematic illustrates the
molecular basis of how the reovirus kills cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tpg8.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been issued over 380 patents
including  55 U.S. and 19 Canadian patents&nbsp; as well as issuances in other jurisdictions. We have an extensive patent
portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent
that expires in 2028. Our patent portfolio also includes methods for treating proliferative disorders using modified
adenovirus, herpes simplex virus, parapoxvirus and vaccinia virus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Corporate Information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated
pursuant to the provisions of the Business Corporations Act (Alberta) on April 2, 1998 as 779738 Alberta Ltd. On April 8, 1998,
we amended our articles and changed our name to Oncolytics Biotech Inc. On July 29, 1999, we further amended our articles by removing
the private company restrictions and subdividing our 2,222,222 common shares issued and outstanding into 6,750,000 common shares.
On February 9, 2007, we further amended our articles to permit our shareholder meetings to be held at any place in Alberta or at
any other location as determined by our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta T2N 1X7. Our registered office is located at 3700,
400 &ndash; 3<SUP>rd</SUP> Avenue S.W., Calgary, Alberta, T2P 4H2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two direct wholly-owned subsidiaries:
Oncolytics Biotech (Barbados) Inc., which is incorporated pursuant to the laws of Barbados and Valens Pharma Ltd., which is incorporated
pursuant to the laws of the Province of Alberta; and two indirect wholly-owned subsidiaries: Oncolytics Biotech (U.S.), Inc., which
is incorporated pursuant to the laws of Delaware, and Oncolytics Biotech (U.K.) Ltd., which is incorporated pursuant to the laws
of England and Wales, both of which are wholly-owned direct subsidiaries of Oncolytics Biotech (Barbados) Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 2pt 5.4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p6"></A>SUMMARY OF THE OFFERING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 98%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%"><FONT STYLE="font-size: 10pt"><B>Issuer:</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-size: 10pt">Oncolytics Biotech Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Common shares having an aggregate offering price of up to US$20,000,000.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Manner of Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;At-the-market&rdquo; offering that may be made from time
    to time through our sales agent, the Agent.&nbsp;&nbsp;See &ldquo;Plan of Distribution&rdquo; on page S-15.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Common shares outstanding before this Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">89,566,597 common shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Common shares to be outstanding immediately after this Offering<SUP>(1)(2)</SUP>:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Up to 130,068,825 common shares, assuming an offering price
of $0.4938 per common share, which was the last reported sale price of our common shares on the NASDAQ on October 23, 2014.&nbsp;&nbsp;The
actual number of common shares issued will vary depending on the sales price of this Offering.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Use of Proceeds:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We intend to use the net proceeds from this Offering, if any, for general corporate purposes. See &ldquo;Use of Proceeds&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>NASDAQ Symbol:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ONCY</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>TSX Symbol:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ONC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Risk Factors:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You should carefully read and consider the information set forth
    in &ldquo;Risk Factors&rdquo; beginning on page S-12 of this prospectus supplement and page 10 of the prospectus before investing
    in our common shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notes:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">On a non-diluted basis.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Unless otherwise stated, all information contained in this prospectus supplement reflects an assumed
public offering price of $0.4938 per share, which was the last reported sale price of our common shares on the NASDAQ on October
23, 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p7"></A>RECENT DEVELOPMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Randomized Phase 2 Pancreatic Cancer Study</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2014, we announced overall
and KRAS-mutated patient data from our two-arm randomized phase 2 study of carboplatin, paclitaxel plus REOLYSIN&reg; (test arm)
versus carboplatin and paclitaxel alone (control arm) in the first line treatment of patients with recurrent or metastatic pancreatic
cancer (NCI-8601). The trial was sponsored by the U.S. National Cancer Institute (NCI) through a clinical trials agreement between
the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis and Oncolytics. We provided clinical supplies
of REOLYSIN&reg; for the study and paid for the immune and genetic testing of the patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The overall objectives of the study were
to determine the progression free survival of the overall patient population and the patient population according to KRAS mutation
status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Overall patient population</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The study enrolled 73 patients; 37 were
in the control arm, 36 were in the test arm. The median progression free survival for the control arm was 5.16 months (95% confidence
interval (CI) = 2.267 to 6.176) versus 5.26 months for the test arm (95% CI = 3.187 to 6.307) (see Figure 1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><IMG SRC="tpg10.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Figure 1</B> - Kaplan-Meier plot of
the Progression Free Survival (PFS) of the control arm versus the test arm of the overall patient population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>KRAS mutated patient population</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the study design, patients were
screened for KRAS status at codon 12. Of the 60 patients where KRAS status could be determined (mutant vs wild type), 44 (73%)
had mutations in the KRAS gene (n = 23 in the control arm, n = 21 in the test arm). Median progression free survival in the test
arm was 5.72 months (95% CI = 3.187 to 6.767) versus 4.11 months in the control arm (95% CI = 1.938 to 6.176) (see Figure 2). This
translates into a 1.61 month (39%) improvement in median progression free survival in the test arm versus the control arm. Three
patients on the test arm and one on the control arm had not progressed as of the time of analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><IMG SRC="tpg11.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Figure 2</B> - Kaplan-Meier plot of
the Progression Free Survival (PFS) of the control arm versus the test arm of the KRAS mutated patient population</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Crossover patient population</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients on the control arm who progressed
on carboplatin and paclitaxel had the option of adding REOLYSIN&reg; to their regimen. At the time of the analysis, 16 patients
crossed over to the test arm regime. The best responses after crossover were one partial response (PR), six stable disease (SD),
seven progressive disease (PD), and two not evaluable, giving a disease control rate (complete response (CR) + PR + SD) of 50%
in the carboplatin and paclitaxel failed group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The study was an open-label, multi-institution,
two-arm phase 2 randomized study of patients with metastatic pancreatic cancer. Patients were randomized to receive either carboplatin,
paclitaxel plus REOLYSIN&reg; (test arm) or carboplatin and paclitaxel alone (control arm). Patients in both arms received treatment
every three weeks (21-day cycles) and standard intravenous doses of paclitaxel and carboplatin on day one only. In the test arm,
patients also received intravenous REOLYSIN&reg; at a dose of 3x10<SUP>10</SUP> TCID<SUB>50</SUB> on days one through five. Tumor
response assessment was done by computed tomography (CT) scan and conducted every eight weeks. Patients who progressed on carboplatin
and paclitaxel (control arm) had REOLYSIN&reg; added. If patients experienced significant toxicity related to carboplatin and/or
paclitaxel, they could continue with single agent REOLYSIN&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary endpoint of the trial is to
assess improvement in progression-free survival with REOLYSIN&reg;, carboplatin and paclitaxel relative to carboplatin and paclitaxel
alone in patients with metastatic pancreatic cancer. The primary endpoint is progression free survival in both arms. Secondary
endpoints include safety, overall response rate, overall survival, immune factors and to prospectively establish and validate the
relationship between Ras mutations in tumor samples and response to REOLYSIN&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p8"></A>RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective purchasers of common shares
should consider carefully the risk factors set out herein and contained in and incorporated by reference in the accompanying base
shelf prospectus. Discussions of certain risks affecting the Corporation in connection with its business are set forth under &ldquo;Risk
Factors&rdquo; in the accompanying prospectus and in our Annual Information Form, our Annual MD&amp;A and our other disclosure
documents filed with the various securities regulatory authorities which are incorporated by reference in this prospectus supplement
and the accompanying prospectus.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Volatility of Market Price of common shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of the common shares may
be volatile. The volatility may affect the ability of holders of common shares to sell the common shares at an advantageous price.
Market price fluctuations in the common shares may be due to the Corporation's operating results failing to meet the expectations
of securities analysts or investors in any quarter, downward revision in securities analysts' estimates, governmental regulatory
action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements
by the Corporation or its competitors, along with a variety of additional factors, including, without limitation, those set forth
under &ldquo;Forward-Looking Statements&rdquo; in this prospectus supplement. In addition, the market price for securities in the
stock markets, including NASDAQ and the TSX, recently experienced significant price and trading fluctuations. These fluctuations
have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in
operating performance. These broad market fluctuations may adversely affect the market price of the common shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation will have broad discretion over the use
of the net proceeds from this offering and the Corporation May Not Use These Proceeds in a Manner Desired by the Corporation's
Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management will have broad discretion with
respect to the use of the net proceeds, if any, from this offering and investors will be relying on the judgment of management
regarding the application of these proceeds. Management could spend most of the net proceeds from this offering in ways that the
Corporation's shareholders may not desire or that do not yield a favorable return. You will not have the opportunity, as part of
your investment in the common shares, to influence the manner in which the net proceeds of this offering are used. At the date
of this prospectus supplement, the Corporation intends to use the net proceeds from this offering as described under the heading
&ldquo;Use of Proceeds&rdquo;. However, the Corporation's needs may change as the business and the industry the Corporation addresses
evolve. As a result, the proceeds to be received in this offering may be used in a manner significantly different from the Corporation's
current expectations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation Does Not Currently Intend to Pay any Cash
Dividends on its common shares in the Foreseeable Future; Therefore, the Corporation's Shareholders May Not be Able to Receive
a Return on their common shares Until They Sell Them</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has never paid or declared
any cash dividends on its common shares. The Corporation does not anticipate paying any cash dividends on its common shares in
the foreseeable future because, among other reasons, the Corporation currently intends to retain any future earnings to finance
its business. The future payment of dividends will be dependent on factors such as cash on hand and achieving profitability, the
financial requirements to fund growth, the Corporation's general financial condition and other factors the board of directors of
the Corporation may consider appropriate in the circumstances. Until the Corporation pays dividends, which it may never do, its
shareholders will not be able to receive a return on their common shares unless they sell them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We Expect to be Treated as a &ldquo;Passive Foreign Investment
Company&rdquo; for the Current Taxable Year and for the Foreseeable Future</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, a foreign corporation will be
a passive foreign investment company (&ldquo;<B>PFIC</B>&rdquo;) if, for any tax year, (a) 75% or more of its gross income for
such tax year is passive income or (b) 50% or more of the value of its assets either produce passive income or are held for the
production of passive income, based on the quarterly average of the fair market value of such assets. Based on current business
plans and financial projections, we expect that we will be a PFIC for the current taxable year and for the foreseeable future.
If we are treated as PFIC for any taxable year, a U.S. investor may be subject to materially adverse tax treatment with respect
to their common shares. For a more detailed discussion of the tax consequences of PFIC classification for a U.S. investor, see
&ldquo;Certain U.S. Federal Income Tax Considerations.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p9"></A>DOCUMENTS INCORPORATED BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement is deemed to
be incorporated by reference into the prospectus solely for the purposes of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are incorporating by reference in this
prospectus supplement certain information contained in documents filed by us with certain securities regulatory authorities in
Canada and the SEC. This means that we are disclosing important information to you by referring you to those documents. The information
incorporated by reference is deemed to be part of this prospectus supplement, except for any information superseded by information
contained directly in this prospectus supplement or in any other subsequently filed document which also is or is deemed to be incorporated
by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may obtain copies of the documents
incorporated by reference in this prospectus supplement on request without charge from our Corporate Secretary at 210, 1167 Kensington
Crescent N.W., Calgary, Alberta T2N 1X7 Telephone: (403) 670-7377, as well as through the sources described below under &ldquo;Where
You Can Find Additional Information&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents are specifically
incorporated by reference in and form an integral part of the prospectus and this prospectus supplement:</P>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify">our annual information form, which is comprised of our Annual Report on Form 20-F dated March 19,
2014, for the year ended December 31, 2013 (the &ldquo;<B>Annual Information Form</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify">our management information circular dated May 9, 2014, relating to the annual general meeting of
shareholders held on June 18, 2014;</TD></TR></TABLE>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify">our audited consolidated financial statements, together with the notes thereto, as at December
31, 2013 and 2012, which comprise the consolidated statements of financial position as at December 31, 2013 and 2012, and the consolidated
statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December 31, 2013 and 2012, together
with the auditor&rsquo;s report thereon;</TD></TR></TABLE>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify">our management's discussion and analysis of financial condition and results of operations dated
March 12, 2014, for the year ended December 31, 2013 (the &ldquo;<B>Annual MD&amp;A</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(e)</FONT></TD><TD STYLE="text-align: justify">our management&rsquo;s discussion and analysis of financial condition and results of operations
dated August 6, 2014, for the six month period ended June 30, 2014; and</TD></TR></TABLE>

<P STYLE="color: #010000; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(f)</FONT></TD><TD STYLE="text-align: justify">our unaudited interim condensed consolidated financial statements, together with the notes thereto,
for the six month period ended June 30, 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any documents of the type referred to above,
any material change reports (excluding confidential material change reports), and any business acquisition reports filed by us
with the securities regulatory authorities in Canada after the date of this prospectus supplement and prior to the termination
of this offering will be deemed to be incorporated by reference in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When new documents of the type referred
to in the paragraphs above are filed by us with the securities regulatory authorities in Canada during the currency of this prospectus
supplement, such documents will be deemed to be incorporated by reference in this prospectus supplement and the previous documents
of the type referred to in the paragraphs above and all material change reports, unaudited interim consolidated financial statements
(and management's discussion and analysis relating thereto) and certain prospectus supplements filed by us with the securities
regulatory authorities in Canada before the commencement of our financial year in which the new documents are filed will no longer
be deemed to be incorporated by reference in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent that any document
or information incorporated by reference into this prospectus supplement is included in any report on Form 6-K, Form 40-F, Form
20-F, Form 10-K, Form 10-Q or Form 8-K (or any respective successor form) that is filed with or furnished to the SEC after the
date of this prospectus supplement until the date that all common shares offered hereunder are sold, such document or information
shall be deemed to be incorporated by reference as an exhibit to the registration statement of which this prospectus supplement
forms a part. In addition, we may incorporate by reference into this prospectus supplement other information from documents that
we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act, if and to the extent expressly provided
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any statement contained in this prospectus
supplement or in a document incorporated or deemed to be incorporated by reference in this prospectus supplement shall be deemed
to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained herein or in any
other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such
statement. The modifying or superseding statement need not state that it has modified or superseded a prior statement or include
any other information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement
shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation,
an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary
to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p10"></A>DOCUMENTS FILED AS PART OF THE REGISTRATION
STATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the documents specified
in this prospectus supplement and in the prospectus under &ldquo;Documents Incorporated by Reference&rdquo;, the Equity Distribution
Agreement described in this prospectus supplement and the consents of legal counsel will be filed with the SEC and will form part
of the registration statement of which this prospectus supplement forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p11"></A>USE OF PROCEEDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of proceeds from this offering
will depend upon the number of common shares sold and the market price at which they are sold. There can be no assurance that we
will be able to sell any common shares under or fully utilize the Equity Distribution Agreement with the Agent as a source of financing.
We intend to use the net proceeds, if any, from this Offering for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts and timing of our actual expenditures
will depend on numerous factors, such as the amount of cash used in our operations. We therefore cannot estimate with certainty
the amount of net proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds
for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the uses described above,
we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p12"></A>CONSOLIDATED CAPITALIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since June 30, 2014, the Corporation has
issued an aggregate of 2,029,200 common shares for aggregate net proceeds of US$2,592,980 as described under the heading &ldquo;Prior
Sales&rdquo; in the prospectus. Except as otherwise described in this prospectus supplement and in the accompanying prospectus,
there have been no material changes in our consolidated share and loan capital, on a consolidated basis, since the date of our
most recently filed unaudited financial statements for the six month period ended June 30, 2014.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p13"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of the common shares will be made
in transactions that are deemed to be &ldquo;at-the-market distributions&rdquo; as defined in NI 44-102, including sales made directly
on the NASDAQ or other existing trading markets in the United States. Subject to the terms and conditions of the Equity Distribution
Agreement and upon delivery of a placement notice from us, the Agent will solicit offers to purchase our common shares directly
on the NASDAQ or other existing trading markets in the United States. We will instruct the Agent as to the number of common shares
to be sold by them from time to time. No common shares will be sold on the TSX or on other trading markets in Canada as at-the-market
distributions. We may instruct the Agent not to sell common shares if the sales cannot be effected at or above the price designated
by us from time to time. We or the Agent may suspend the offering of the common shares upon notice and subject to other conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will pay the Agent commissions, in cash,
for its services in acting as agent in the sale of our common shares. The Agent will be entitled to compensation at a fixed commission
rate of 3.0% of the gross sales price per share sold. Because there is no minimum offering amount required as a condition to close
this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.
We have also agreed to reimburse the Agent for certain specified expenses, including the fees and disbursements of its legal counsel,
in an amount not to exceed US$60,000. We estimate that the total expenses for the offering, excluding compensation and reimbursements
payable to the Agent under the terms of the Equity Distribution Agreement, will be approximately US$90,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Settlement for sales of our common shares
will occur on the third business day following the date on which any sales are made, or on such other date as is industry practice
for regular-way trading, in return for payment of the net proceeds to us. Sales of our common shares as contemplated in this prospectus
will be settled through the facilities of The Depository Trust Company or by such other means as we and the Agent may agree upon.
There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agent will use its commercially reasonable
efforts, consistent with its sales and trading practices, to solicit offers to purchase the common shares under the terms and subject
to the conditions set forth in the Equity Distribution Agreement. In connection with the sale of the common shares on our behalf,
the Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the United States Securities Act, and the compensation
of the Agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution
to the Agent against certain civil liabilities, including liabilities under the United States Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering of common shares pursuant
to the Equity Distribution Agreement will terminate upon the earlier of (i) the sale of all common shares subject to the Equity
Distribution Agreement, or (ii) termination of the Equity Distribution Agreement as permitted therein. We and the Agent may each
terminate the Equity Distribution Agreement at any time upon ten days&rsquo; prior notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agent and its affiliates may in the
future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which
services they may in the future receive customary fees. To the extent required by Regulation M, the Agent will not engage in any
market making activities involving our common shares while the offering is ongoing under this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No underwriter or dealer involved in the
offering, no affiliate of such an underwriter or dealer, and no person or company acting jointly or in concert with such an underwriter
or dealer has over-allotted, or will over-allot, the common shares in connection with the offering or effect any other transaction
that are intended to stabilize or maintain the market price of the common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The TSX has conditionally approved the
listing of the common shares offered by this prospectus supplement. Listing is subject to us fulfilling all of the requirements
of the TSX. The NASDAQ has authorized, upon official notice of issuance, the listing of the common shares offered hereunder.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p14"></A>TRADING PRICE AND VOLUME</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our outstanding common shares are listed and posted for trading
on NASDAQ under the trading symbol &ldquo;ONCY&rdquo; and on the TSX under the trading symbol &ldquo;ONC&rdquo;. The following
table sets forth the market price ranges and the aggregate volume of trading of the common shares on NASDAQ and the TSX for the
periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-size: 10pt; font-weight: bold"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>NASDAQ</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-size: 10pt; font-weight: bold"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>TSX</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt"><B>Period</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>High</B><BR> <B>($)</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>Low</B><BR> <B>($)</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>Close</B><BR> <B>($)</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>Volume</B><BR> <B>(Shares)</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>High</B><BR> <B>(C$)</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>Low</B><BR> <B>(C$)</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>Close</B><BR> <B>(C$)</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>Volume</B><BR> <B>(Shares)</B></FONT></P></TD><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 28%; text-align: left">October</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">3.39</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">2.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">2.67</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">11,269,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">3.49</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">2.31</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">2.78</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">2,665,900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">November</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,758,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,936,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">December</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,457,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.66</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,096,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">January</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,358,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,673,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">February</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,967,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">918,938</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">March</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,113,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">907,737</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">April</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,638,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">893,221</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">May</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,907,935</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,315,417</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">June</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,548,126</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,380,819</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">July</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,649,708</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,111,594</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">August</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,096,653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,133,162</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">September</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,634,290</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,873,375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 8pt Times New Roman, Times, Serif">October 1 to 23</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">0.58</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">0.40</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">0.49</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">6,462,623</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">0.64</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">0.45</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">0.55</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">3,367,278</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p15"></A>PRIOR SALES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the twelve month period preceding the date of this prospectus
supplement, the Corporation issued an aggregate of 4,807,779 common shares, the particulars of which are set forth in the following
table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Date&nbsp;of&nbsp;Issue</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Number&nbsp;of&nbsp;common&nbsp;shares&nbsp;Issued</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Issue&nbsp;Price&nbsp;per&nbsp;common&nbsp;share&nbsp;or</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Exercise&nbsp;Price</B></FONT></TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 64%"><FONT STYLE="font-size: 10pt">December 4, 2013</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">35,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">C$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">1.6500</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">December 5, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">C$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.6500</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">February 27, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">292,793</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.5540</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">February 27, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">612,223</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.6640</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">March 11, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,884</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.6733</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">April 3, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,944</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.7267</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">April 7, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,944</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.7267</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">April 14, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,734</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.5399</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">April 17, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,760</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.5633</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">April 22, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,734</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.5400</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">April 25, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,723</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.5300</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">May 1, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,633</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.4500</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">June 2, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2567</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">June 3, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,408</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2500</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">June 5, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2567</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">June 9, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2567</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">June 11, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2567</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">June 13, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2567</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">June 17, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2567</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">June 19, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2567</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">June 23, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,464</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">June 30, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,430</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2700</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">July 2, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,423</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2633</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">July 3, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,423</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2633</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">July 22, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,588</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.4100</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">July 24, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,565</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3900</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">July 28, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,486</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3200</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">July 30, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,532</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3600</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">August 1, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,430</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2700</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">August 8, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,464</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">August 12, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,464</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">August 14, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,419</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2600</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">August 18, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,419</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2600</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">August 20, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,419</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2600</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">August 22, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,441</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2800</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">August 26, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,445</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2833</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">August 28, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,445</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2833</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">September 2, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,445</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2833</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">September 4, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,445</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2833</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">September 8, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,453</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2900</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">September 10, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,464</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.3000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">September 12, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,430</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">US$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2700</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this prospectus supplement, the Corporation granted options exercisable for an aggregate of 1,716,000 common shares,
the particulars of which are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date&nbsp;of&nbsp;Grant</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Number&nbsp;and&nbsp;Type&nbsp;of&nbsp;Securities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid">Issued&nbsp;Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 51%">December 11, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: center">1,416,000 options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 15%; text-align: right">1.74</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>February 3, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">200,000 options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">1.69</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>June 18, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">100,000 options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">1.46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p16"></A>CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a general summary of certain
U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition,
ownership and disposition of common shares acquired pursuant to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is for general information
purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations
that may apply to a U.S. Holder arising from and relating to the acquisition, ownership and disposition of common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, this summary does not take
into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax considerations
applicable to such U.S. Holder. Except as specifically set forth below, this summary does not discuss applicable tax reporting
requirements. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax
advice with respect to any particular U.S. Holder. This summary does not address the U.S. state and local, U.S. federal estate
and gift, U.S. federal alternative minimum tax, or non-U.S. tax consequences to U.S. Holders relating to the acquisition, ownership,
and disposition of common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each U.S. Holder should consult its own
tax advisor regarding the U.S. federal, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership,
and disposition of common shares. No ruling from the U.S. Internal Revenue Service (the &ldquo;<B>IRS</B>&rdquo;) has been requested,
or will be obtained, regarding the U.S. federal income tax considerations applicable to U.S. Holders as discussed in this summary.
This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary
to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various
interpretations, the IRS and the U.S. courts could disagree with one or more of the positions taken in this summary.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authorities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is based on the Internal Revenue
Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;), Treasury Regulations (whether final, temporary, or proposed), U.S. court
decisions, published IRS rulings, published administrative positions of the IRS, and the Convention Between Canada and the United
States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the &ldquo;<B>Canada-U.S.
Tax Convention</B>&rdquo;), that are applicable and, in each case, as in effect, as of the date of this prospectus supplement.
Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such
change could be applied on a retroactive or prospective basis and could affect the U.S. federal income tax considerations described
in this summary. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation
that, if enacted, could be applied on a retroactive or prospective basis.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Holders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this summary, a &ldquo;<B>U.S.
Holder</B>&rdquo; is a beneficial owner of common shares acquired pursuant to this prospectus supplement that is (a) an individual
who is a citizen or resident of the U.S. for U.S. federal income tax purposes, (b) a corporation, or other entity classified as
a corporation for U.S. federal income tax purposes, that is created or organized in or under the laws of the U.S. or any state
in the U.S., including the District of Columbia, (c) an estate if the income of such estate is subject to U.S. federal income tax
regardless of the source of such income, or (d) a trust if (i) such trust has validly elected to be treated as a U.S. person for
U.S. federal income tax purposes or (ii) a U.S. court is able to exercise primary supervision over the administration of such trust
and one or more U.S. persons have the authority to control all substantial decisions of such trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Holders Subject to Special U.S. Federal Income Tax
Rules Not Addressed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary does not address the U.S.
federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including:
(a) U.S. Holders that are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred
accounts; (b) U.S. Holders that are financial institutions, underwriters, insurance companies, real estate investment trusts, or
regulated investment companies or that are broker-dealers, dealers, or traders in securities or currencies that elect to apply
a mark-to-market accounting method; (c) U.S. Holders that have a &ldquo;functional currency&rdquo; other than the U.S. dollar;
(d) U.S. Holders that own common shares as part of a straddle, hedging transaction, conversion transaction, constructive sale,
or other arrangement involving more than one position; (e) U.S. Holders that acquired common shares in connection with the exercise
of employee stock options or otherwise as compensation for services; (f) U.S. Holders that hold common shares other than as a capital
asset within the meaning of Section 1221 of the Code; or (g) U.S. Holders that own or will own, directly, indirectly, or by attribution,
10% or more, by voting power or value, of our outstanding shares. The summary also does not address the U.S. federal income tax
considerations applicable to U.S. Holders who are (a) certain U.S. expatriates or former long-term residents of the U.S.; (b) persons
that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the<I> Income Tax Act</I> (Canada)
(the &ldquo;<B>Tax Act</B>&rdquo;); (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold
common shares in connection with carrying on a business in Canada; (d) persons whose common shares constitute &ldquo;taxable Canadian
property&rdquo; under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S.
Tax Convention. U.S. Holders and others that are subject to special provisions under the Code, including U.S. Holders described
immediately above, should consult their own tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an entity or arrangement that is classified
as partnership (or &ldquo;pass-through&rdquo; entity) for U.S. federal income tax purposes holds common shares, the U.S. federal
income tax consequences applicable to such partnership (or &ldquo;pass-through&rdquo; entity) or arrangement and the partners of
such partnership (or owners of such &ldquo;pass-through&rdquo; entity) or arrangement generally will depend on the activities of
the partnership (or &ldquo;pass-through&rdquo; entity) or arrangement and the status of such partners (or owners). Partners of
entities or arrangements that are classified as partnerships (and owners of &ldquo;pass-through&rdquo; entities) for U.S. federal
income tax purposes should consult their own tax advisor regarding the U.S. federal income tax consequences relating to the acquisition,
ownership, and disposition of common shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Passive Foreign Investment Company Rules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we were a &ldquo;passive foreign investment
company&rdquo; under the meaning of Section 1297 of the Code (a &ldquo;<B>PFIC</B>&rdquo;) for any year during a U.S. Holder&rsquo;s
holding period, then certain potentially adverse rules will affect the U.S. federal income tax consequences to a U.S. Holder resulting
from the acquisition, ownership and disposition of common shares. In addition, in any year in which we are classified as a PFIC,
such holder may be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other
IRS guidance may require.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">PFIC Status</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We generally will be a PFIC if, for any
tax year, (a) 75% or more of our gross income for such tax year is passive income (the &ldquo;<B>income test</B>&rdquo;) or (b)
50% or more of the value of our assets either produce passive income or are held for the production of passive income, based on
the quarterly average of the fair market value of such assets (the &ldquo;<B>asset test</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the PFIC income test and
asset test described above, if we own, directly or indirectly, 25% or more of the total value of the outstanding shares of another
corporation, we will be treated as if we (a) held a proportionate share of the assets of such other corporation and (b) received
directly a proportionate share of the income of such other corporation. In addition, for purposes of the income test and asset
test, &ldquo;passive income&rdquo; does not include any interest, dividends, rents, or royalties that are received or accrued by
us from a &ldquo;related person,&rdquo; to the extent such items are properly allocable to the income of such related person that
is not passive income. Under certain attribution rules, if we are a PFIC, U.S. Holders will be deemed to own their proportionate
share of any of our subsidiaries which is also a PFIC (a &ldquo;<B>Subsidiary PFIC</B>&rdquo;), and will be subject to U.S. federal
income tax on (i) a distribution on the shares of a Subsidiary PFIC and (ii) a disposition or deemed disposition of shares of a
Subsidiary PFIC, both as if the holder directly held the shares of such Subsidiary PFIC, even though such U.S. Holder had not received
the proceeds of those distributions or dispositions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we were a PFIC for one or more
prior taxable years, and based on current business plans and financial projections, we expect that we will be a PFIC for the current
taxable year and for the foreseeable future. The determination of whether we were (or a Subsidiary PFIC was), or will be, a PFIC
for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations.
In addition, whether we (or a Subsidiary PFIC) will be a PFIC for any tax year depends on our assets and income (and each Subsidiary
PFIC&rsquo;s assets and income) over the course of each such tax year and, as a result, cannot be predicted with certainty as of
the date of this prospectus supplement. Accordingly, there can be no assurance that the IRS will not challenge any determination
made by us (or a Subsidiary PFIC) concerning our PFIC status or that we (and each Subsidiary PFIC) were not, or will not be, a
PFIC for any tax year. Each U.S. Holder should consult its own tax advisor regarding our PFIC status and the status of each Subsidiary
PFIC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Default PFIC Rules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are a PFIC, the U.S. federal income
tax consequences to a U.S. Holder of the acquisition, ownership, and disposition of common shares will depend on whether such U.S.
Holder is eligible to make and actually makes an election to treat us (and/or a Subsidiary PFIC) as a &ldquo;qualified electing
fund&rdquo; or &ldquo;QEF&rdquo; (a &ldquo;<B>QEF Election</B>&rdquo;) or has made a &ldquo;mark-to-market election&rdquo; (a &ldquo;<B>Mark-to-Market
Election</B>&rdquo;) with respect to common shares. A U.S. Holder that does not make either a QEF Election or a Mark-to-Market
Election will be referred to in this summary as a &ldquo;N<B>on-Electing U.S. Holder</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Non-Electing U.S. Holder will be subject
to the default PFIC rules with respect to (a) any gain recognized on the sale or other taxable disposition (including a pledge)
of common shares and (b) any &ldquo;excess distribution&rdquo; received on the common shares. A distribution generally will be
an &ldquo;excess distribution&rdquo; to the extent that such distribution (together with all other distributions received in the
current tax year) exceeds 125% of the average distributions received during the shorter of the three preceding tax years or a U.S.
Holder&rsquo;s holding period for the common shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any gain recognized on the sale or other
taxable disposition of common shares of a PFIC (including an indirect disposition of offered shares of a Subsidiary PFIC), and
any excess distribution received on such common shares (or a distribution by a Subsidiary PFIC to its shareholder that is deemed
to be received by a U.S. Holder) must be ratably allocated over a Non-Electing U.S. Holder&rsquo;s holding period for the common
shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess
distribution and to years before the first taxable year in which the entity became a PFIC, if any, would be taxed as ordinary income.
The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary
income in each such year, and an interest charge generally applicable to the underpayments of tax would be imposed in respect of
the tax attributable to each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid
as &ldquo;personal interest,&rdquo; which is not deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a Non-Electing U.S. Holder holds common
shares during any tax year which we are a PFIC, such Non-Electing U.S. Holder&rsquo;s common shares will be treated as equity in
a PFIC, regardless of whether we cease to be a PFIC in one or more subsequent years. A Non-Electing U.S. Holder may terminate this
deemed PFIC status with respect to common shares if we cease to be a PFIC and the Non-Electing U.S. Holder makes a &ldquo;deemed
sale&rdquo; election with respect to its common shares. If such election is made, the U.S. Holder will be deemed to have sold such
common shares on the last day of the last tax year for which we were a PFIC, and such U.S. Holder will recognize gain from such
deemed sale (which will be taxed as discussed above). After the deemed sale election, a Non-Electing U.S. Holder&rsquo;s common
shares with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently become
a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">QEF Election</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a timely and effective
QEF Election for the first tax year in which its holding period of its common shares begins, generally, will not be subject to
the default PFIC rules discussed above with respect to its common shares. However, a U.S. Holder that makes a timely and effective
QEF Election will be subject to U.S. federal income tax on such U.S. Holder&rsquo;s pro rata share of (a) our net capital gain,
which will be taxed as long-term capital gain to such U.S. Holder, and (b) and our ordinary earnings, which will be taxed as ordinary
income to such U.S. Holder. Generally, &ldquo;net capital gain&rdquo; is the excess of (a) net long-term capital gain over (b)
net short-term capital loss, and &ldquo;ordinary earnings&rdquo; are the excess of (a) &ldquo;earnings and profits&rdquo; over
(b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each
tax year in which we are a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by us. However,
for any tax year in which we are a PFIC and have no net income or gain, U.S. Holders that have made a QEF Election would not have
any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such
a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject
to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &ldquo;personal interest,&rdquo;
which is not deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a QEF Election
generally (a) may receive a tax-free distribution from us to the extent that such distribution represents our &ldquo;earnings and
profits&rdquo; that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such
U.S. Holder&rsquo;s tax basis in the common shares to reflect the amount included in income or allowed as a tax-free distribution
because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss
on the sale or other taxable disposition of common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The procedure for making a QEF Election,
and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF
Election will be treated as &ldquo;timely&rdquo; if such QEF Election is made for the first year in the U.S. Holder&rsquo;s holding
period for the common shares in which we were a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF
Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A QEF Election will apply to the tax year
for which such QEF Election is made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the
IRS consents to revocation of such QEF Election by the U.S. Holder. If a U.S. Holder makes a QEF Election and, in a subsequent
tax year, we cease to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years
in which we are not a PFIC. Accordingly, if we become a PFIC in another subsequent tax year, the QEF Election will be effective
and the U.S. Holder will be subject to the QEF rules described above during a subsequent tax year in which we qualify as a PFIC.
The QEF Election is made on a shareholder-by-shareholder basis and, once made, can be revoked only with the consent of the IRS.
A U.S. Holder generally makes a QEF Election by attaching an appropriately completed IRS Form 8621 (Return by a Shareholder of
a Passive Foreign Investment Company or Qualified Electing Fund), including the information provided in a PFIC annual information
statement, to a timely filed U.S. federal income tax return for the tax year to which the election relates. Retroactive QEF Elections
generally may be made only by filing a protective statement with such return and if certain other conditions are met or with the
consent of the IRS. In order to comply with the requirements of a QEF Election, a U.S. Holder must receive certain information
from us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will make available to U.S. Holders,
upon their written request, information as to our status as a PFIC and the status of any Subsidiary PFIC in which we own more than
50% of such Subsidiary PFIC&rsquo;s total aggregate voting power, and for each year we are a PFIC, provide to a U.S. Holder, upon
written request, all information and documentation that a U.S. Holder making a QEF Election with respect to us and such more than
50% owned Subsidiary PFIC is required to obtain for U.S. federal income tax purposes. We may elect to provide such information
to U.S. Holders through our website. Because we may hold 50% or less of the aggregate voting power of one or more Subsidiary PFICs
at any time, U.S. Holders should be aware that there can be no assurance that we will satisfy record keeping requirements that
apply to a QEF, or that we will supply U.S. Holders with information that such U.S. Holders require to report under the QEF rules,
in the event that we are a PFIC and a U.S. Holder wishes to make a QEF Election with respect to any such Subsidiary PFIC. With
respect to Subsidiary PFICs for which we do not or the U.S. Holders do not obtain the required information, U.S. Holders will continue
to be subject to the rules discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess
distributions. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a QEF
Election with respect to us and any Subsidiary PFIC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark-to-Market Election</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder may make a Mark-to-Market
Election only if the common shares are marketable stock. The common shares generally will be &ldquo;marketable stock&rdquo; if
the common shares are regularly traded on (a) a national securities exchange that is registered with the SEC, (b) the national
market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or (c) a foreign securities exchange
that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such
foreign exchange has trading volume, listing, financial disclosure, and other requirements and the laws of the country in which
such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually
enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded
on such a qualified exchange or other market, such stock generally will be &ldquo;regularly traded&rdquo; for any calendar year
during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">A U.S. Holder that
makes a Mark-to-Market Election with respect to its common shares generally will not be subject to the default PFIC rules discussed
above. A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which we are a
PFIC, an amount equal to the excess, if any, of (a) the fair market value of the common shares, as of the close of such tax year
over (b) such U.S. Holder&rsquo;s adjusted tax basis in such common shares. A U.S. Holder that makes a Mark-to-Market election
will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&rsquo;s adjusted tax basis in the
common shares, over (b) the fair market value of such common shares as of the close of such tax year (but only to the extent of
the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a Mark-to-Market
Election generally also will adjust such U.S. Holder&rsquo;s tax basis in the common shares to reflect the amount included in gross
income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition
of common shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or loss (not to exceed the
excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over
(b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Any distributions we made would
be subject to the rules discussed below under &ldquo;U.S. Federal Income Tax Consequences of the Acquisition, Ownership, and Disposition
of common shares&mdash;Distributions on common shares&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Mark-to-Market Election applies to the
tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the common shares cease to be &ldquo;marketable
stock&rdquo; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisor regarding
the availability of, and procedure for making, a Mark-to-Market Election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although a U.S. Holder may be eligible
to make a Mark-to-Market Election with respect to the common shares, no such election may be made with respect to the stock of
any Subsidiary PFIC that a U.S. Holder is treated as owning because such stock is not marketable. Hence, the Mark-to-Market Election
will not be effective to eliminate the interest charge described above with respect to deemed dispositions of Subsidiary PFIC stock
or distributions from a Subsidiary PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other PFIC Rules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The IRS has issued proposed Treasury Regulations
that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not
loss) upon certain transfers of common shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate
reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which
common shares are transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In any year in which we are classified
as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations
and/or other IRS guidance may require. A failure to satisfy such reporting requirements may result in an extension of the time
period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of
filing such information returns under these rules, including the requirement to file an IRS Form 8621.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain additional adverse rules will apply
with respect to a U.S. Holder if we are a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example, a U.S.
Holder that uses common shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having
made a taxable disposition of such common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special rules also apply to the amount
of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes
paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules
relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should
consult with its own tax advisor regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PFIC rules are complex, and each U.S.
Holder should consult its own tax advisor regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax
consequences of the acquisition, ownership, and disposition of common shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Federal Income Tax Consequences of the Acquisition,
Ownership, and Disposition of common shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion is subject to
the rules described above under the heading &ldquo;Passive Foreign Investment Company Rules&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Distributions on Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed above,
a U.S. Holder that receives a distribution, including constructive distribution, with respect to common shares will be required
to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld
from such distribution) to the extent of our current or accumulated &ldquo;earnings and profits,&rdquo; as computed for U.S. federal
income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates. To the extent that a distribution
exceeds our current and accumulated &ldquo;earnings and profits,&rdquo; such distribution will be treated first as a tax-free return
of capital to the extent of a U.S. Holder&rsquo;s tax basis in the common shares and thereafter as gain from the sale or exchange
of such common shares. See &ldquo;Sale or Other Taxable Disposition of common shares&rdquo; below. However, we do not intend to
maintain the calculations of earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder should
therefore assume that any distribution by us with respect to the common shares will constitute ordinary dividend income. Dividends
received on common shares generally will not be eligible for the &ldquo;dividends received deduction&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable limitations, dividends
paid with respect to the common shares to non-corporate U.S. Holders, including individuals, generally will be eligible for the
preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions
are satisfied, including that we not be classified as a PFIC in the tax year of distribution or in the preceding tax year. Since
we expect to be classified as a PFIC for the foreseeable future, dividends received on common shares generally are expected not
to be considered &ldquo;qualified dividend income,&rdquo; and thus are not expected to be eligible for the preferential tax rates
applicable to long-term capital gains for the foreseeable future. The dividend rules are complex, and each U.S. Holder should consult
its own tax advisor regarding the application of such rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sale or Other Taxable Disposition of
Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed above,
upon the sale or other taxable disposition of common shares, a U.S. Holder generally will recognize capital gain or loss in an
amount equal to the difference between (i) the amount of cash plus the fair market value of any property received and (ii) such
U.S. Holder&rsquo;s tax basis in such common shares sold or otherwise disposed of. While gain or loss recognized on such sale or
other disposition generally would be long-term capital gain or loss if, at the time of the sale or other disposition, the common
shares have been held for more than one year, the PFIC rules discussed above may render such gain ordinary income. Preferential
tax rates apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential
tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant
limitations under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Foreign Tax Credit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed above,
a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the common
shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian
income tax paid. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through
withholding) by a U.S. Holder during a year. Complex limitations apply to the foreign tax credit, including the general limitation
that the credit cannot exceed the proportionate share of a U.S. Holder&rsquo;s U.S. federal income tax liability that such U.S.
Holder&rsquo;s &ldquo;foreign source&rdquo; taxable income bears to such U.S. Holder&rsquo;s worldwide taxable income for the same
tax year. In applying this limitation, a U.S. Holder&rsquo;s various items of income and deduction must be classified, under complex
rules, as either &ldquo;foreign source&rdquo; or &ldquo;U.S. source&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, dividends paid by a foreign
corporation should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign corporation
by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an applicable income tax treaty,
and if an election is properly made under the Code. However, the amount of a distribution with respect to the common shares that
is treated as a &ldquo;dividend&rdquo; may be lower for U.S. federal income tax purposes than it is for Canadian federal income
tax purposes, resulting in a reduced foreign tax credit allowance to a U.S. Holder. In addition, this limitation is calculated
separately with respect to specific categories of income. The foreign tax credit rules are complex, and each U.S. Holder should
consult its own tax advisor regarding the foreign tax credit rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Receipt of Foreign Currency</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of any distribution paid in
foreign currency to a U.S. Holder in connection with the ownership of common shares, or on the sale, exchange or other taxable
disposition of our common shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange
rate applicable on the date of actual or constructive receipt (regardless of whether such foreign currency is converted into U.S.
dollars at that time). If the foreign currency received is not converted into U.S. dollars on the date of receipt, a U.S. Holder
will have a tax basis in the foreign currency equal to its U.S. dollar value on the date of receipt. A U.S. Holder that receives
foreign currency and converts such foreign currency into U.S. dollars at a conversion rate other than the rate in effect on the
date of receipt may have a foreign currency exchange gain or loss, which generally would be treated as U.S. source ordinary income
or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method with respect to foreign
currency received upon the sale, exchange or other taxable disposition of the common shares. Each U.S. Holder should consult its
own tax advisor regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Additional Tax on Passive Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Individuals, estates and certain trusts
whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surtax on &ldquo;net investment income&rdquo; including,
among other things, dividends and net gain from dispositions of property (other than property held in certain trades or businesses).
U.S. Holders should consult their own tax advisors regarding the effect, if any, of this tax on their ownership and disposition
of common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Information Reporting; Backup Withholding
Tax</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under U.S. federal income tax law and Treasury
Regulations, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement
in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on U.S. Holders
that hold certain specified foreign financial assets in excess of certain threshold amounts. The definition of specified foreign
financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts
maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract
held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders
may be subject to these reporting requirements unless their common shares are held in an account at certain financial institutions.
Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult their own tax advisors
regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments made within the U.S., or by a
U.S. payor or U.S. middleman, of dividends on, and proceeds arising from certain sales or other taxable dispositions of the common
shares may be subject to information reporting and backup withholding tax, at the current rate of 28%, if a U.S. Holder (a) fails
to furnish such U.S. Holder&rsquo;s correct U.S. social security or other taxpayer identification number (generally on Form W-9),
(b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously
failed to properly report items subject to backup withholding tax, or (d) fails under certain circumstances to certify, under penalty
of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified
such U.S. Holder that it is subject to backup withholding tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Backup withholding is not an additional
tax. Any amounts withheld under the U.S. backup withholding tax rules generally will be allowed as a credit against a U.S. Holder&rsquo;s
U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discussion of reporting requirements
set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder.
A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess
a tax, and under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting
requirement. Each U.S. Holder should consult its own tax advisor regarding the information reporting and backup withholding tax
rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p17"></A>LEGAL MATTERS AND INTEREST OF EXPERTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The auditors of the Corporation are Ernst
&amp; Young LLP, Chartered Accountants, 1000, 440 &ndash; 2<SUP>nd</SUP> Avenue S.W., Calgary, Alberta, T2P 5E9. Ernst &amp; Young
LLP is independent of the Corporation in accordance with the Rules of Professional Conduct as outlined by the Institute of Chartered
Accountants of Alberta. Ernst &amp; Young LLP is registered with the U.S. Public Corporation Accounting Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain legal matters relating to this
offering will be passed upon on our behalf by McCarthy Tetrault LLP with respect to certain Canadian legal matters and by Dorsey
&amp; Whitney LLP with respect to certain U.S. legal matters. The Agent is being represented in connection with this offering by
Goodwin Procter LLP, New York, New York. .</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_p18"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a public company and file annual,
quarterly and special reports, proxy statements and other information with the Canadian securities regulatory authorities and the
SEC. You may read and copy, for a fee, any document we file at the SEC's public reference room at 100 F Street, Washington, D.C.
20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC
at 1-800-SEC-0330 for more information about the operation of the public reference room. Our SEC filings are also available to
the public at the SEC's website at http://www.sec.gov. These documents are also available through the Internet on the Canadian
System for Electronic Document Analysis and Retrieval (SEDAR) which can be accessed at http://www.sedar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Base Shelf Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Dated August 1, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.gif" ALT="" STYLE="height: 85px; width: 352px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Cdn.$150,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Shares<BR>
Subscription Receipts<BR>
Warrants<BR>
Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may from time to time during the 25-month
period that this prospectus (the&nbsp;&ldquo;<B>Prospectus</B>&rdquo;), including any amendments, remains valid, sell under this
Prospectus up to Cdn.&nbsp;$150,000,000 (or the equivalent in other currencies or currency units) in one or more offerings, aggregate
initial offering price of our common shares (&ldquo;<B>Common Shares</B>&rdquo;), subscription receipts (&ldquo;<B>Subscription
Receipts</B>&rdquo;), warrants to purchase Common Shares (&ldquo;<B>Warrants</B>&rdquo;) and/or units comprised of one or more
of the other securities described in this Prospectus in any combination, (&ldquo;<B>Units</B>&rdquo; and, together with the Common
Shares, Subscription Receipts and Warrants, the&nbsp;&ldquo;<B>Securities</B>&rdquo;). We may offer Securities in such amounts
and, in the case of the Subscription Receipts, Warrants and Units, with such terms, as we may determine in light of market conditions.
We may sell the Subscription Receipts and Warrants in one or more series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective purchasers should note that
we are a development stage entity and that an investment in the Securities should be considered highly speculative due to various
risk factors listed under the heading &ldquo;<I>Risk Factors</I>&rdquo; on pages&nbsp;8 to 17 of the Corporation&rsquo;s AIF (as
defined herein). Prospective investors should carefully review these risk factors prior to investing in the Securities of the Corporation.
In particular, prospective purchasers should note the following risks namely, all of our potential products, including REOLYSIN&reg;,
are in the research and development stage and will require further development and testing before they can be marketed commercially;
any failure or delay in clinical trials for our products, including REOLYSIN&reg;, may cause us to incur additional costs or delay
or prevent the commercialization of our products and could severely harm our business; pharmaceutical products are subject to intense
regulatory approval processes; we have limited manufacturing experience and intend to rely on third parties to commercially manufacture
our products, if and when developed; and we have no operating revenues and a history of losses. For detailed description of &ldquo;<I>Risk
Factors</I>&rdquo; see page&nbsp;10 of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The specific variable terms of any offering
of Securities will be set forth in a supplement to this Prospectus relating to such Securities (each, a&nbsp;&ldquo;<B>Prospectus
Supplement</B>&rdquo;) including where applicable: (i)&nbsp;in the case of the Common Shares, the number of Common Shares offered,
the currency (which may be Canadian dollars or any other currency), the issue price and any other specific terms; (ii)&nbsp;in
the case of Subscription Receipts, the number of Subscription Receipts offered, the currency (which may be Canadian dollars or
any other currency), the issue price, the terms and procedures for the exchange of the Subscription Receipts and any other specific
terms; (iii)&nbsp;in the case of Warrants, the designation, the number of Warrants offered, the currency (which may be Canadian
dollars or any other currency), number of Common Shares that may be acquired upon exercise of the Warrants, the exercise price,
dates and periods of exercise, adjustment procedures and any other specific terms; and (iv)&nbsp;in the case of Units, the designation,
the number of Units offered, the offering price, the currency (which may be Canadian dollars or any other currency), terms of the
Units and of the securities comprising the Units and any other specific terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are permitted, as a foreign issuer
in the United States, under a multi-jurisdictional disclosure system adopted by the United States and Canada (&ldquo;MJDS&rdquo;),
to prepare this Prospectus in accordance with Canadian disclosure requirements. You should be aware that such requirements are
different from those of the United States. We have prepared our financial statements incorporated herein by reference in accordance
with International Financial Reporting Standards (&ldquo;IFRS&rdquo;) as issued by the International Accounting Standards Board
and adopted by the Accounting Standards Board of Canada and they are subject to Canadian auditing and auditor independence standards
in addition to the standards of the Public Company Accounting Oversight Board (United States) and the United States Securities
and Exchange Commission (&ldquo;SEC&rdquo;) independence standards. Therefore, they may not be comparable to the financial statements
of United States companies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should be aware that the purchase
of the Securities described herein may have tax consequences both in the United States and Canada. Such consequences for investors
who are resident in, or citizens of, the United States may not be described fully herein. You should read the tax discussion contained
in the applicable Prospectus Supplement with respect to a particular offering of securities. See &ldquo;<I>Certain Income Tax Considerations</I>&rdquo;
at page&nbsp;15 of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Your ability to enforce civil liabilities
under United States federal securities laws may be affected adversely by the fact that we are incorporated under the laws of Canada,
the majority of our officers and directors and some of the experts named in this Prospectus are residents of Canada, and a substantial
portion of our assets and the assets of said persons are located outside the United States. See &ldquo;<I>Enforceability of Civil
Liabilities</I>&rdquo; at page&nbsp;6 of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE SEC NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED THE SECURITIES OFFERED HEREBY, OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All shelf information permitted under applicable
laws to be omitted from this Prospectus will be contained in one or more Prospectus Supplements that will be delivered to purchasers
together with this Prospectus. Each Prospectus Supplement will be incorporated by reference into this Prospectus for the purposes
of securities legislation as of the date of the Prospectus Supplement and only for the purposes of the distribution of the Securities
to which the Prospectus Supplement pertains. You should read this Prospectus and any applicable Prospectus Supplement before you
invest in the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our outstanding securities are listed for
trading on the Toronto Stock Exchange under the trading symbol &ldquo;<B>ONC</B>&rdquo; and on the NASDAQ Capital Market under
the trading symbol &ldquo;<B>ONCY</B>&rdquo;. Unless otherwise specified in any applicable Prospectus Supplement, the Subscription
Receipts, Warrants and Units will not be listed on any securities exchange. <B>There is no market through which the Subscription
Receipts, Warrants or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased
under this Prospectus. This may affect the pricing of these securities in the secondary market, the transparency and availability
of trading prices, the liquidity of the securities, and the extent of issuer regulation. See the &ldquo;Risk Factors&rdquo; section
of the applicable Prospectus Supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the Securities to or through
underwriters, dealers, placement agents or other intermediaries or directly to purchasers or through agents. See detailed discussion
on &ldquo;<I>Plan of Distribution</I>&rdquo; at page&nbsp;14 of this Prospectus. The Prospectus Supplement relating to a particular
offering of Securities will identify each person who may be deemed to be an underwriter with respect to such offering and will
set forth the terms of the offering of such Securities, including, to the extent applicable, the initial public offering price,
the proceeds that we will receive, the underwriting discounts or commissions and any other discounts or concessions to be allowed
or re-allowed to dealers. The lead underwriter or underwriters with respect to Securities sold to or through underwriters, if any,
will be named in the related Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable securities legislation,
in connection with any offering of Securities under this Prospectus, the underwriters, if any, may over-allot or effect transactions
which stabilize or maintain the market price of the Securities offered at a level above that which might otherwise prevail in the
open market. These transactions, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in this Prospectus. We have not authorized anyone to provide you with information different from that contained in this
Prospectus. No underwriters have been involved in the preparation of this Prospectus or performed any review of the contents of
this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
3700<B>, </B>400&nbsp;&ndash;&nbsp;3<SUP>rd</SUP> Avenue S.W., Calgary, Alberta, T2P&nbsp;4H2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS AND OTHER MATTERS</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">SPECIAL NOTICE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">ENFORCEABILITY OF CIVIL LIABILITIES</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif">DOCUMENTS INCORPORATED BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">THE CORPORATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">OUR BUSINESS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONSOLIDATED CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF SHARE CAPITAL</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif">PRIOR SALES</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif">TRADING PRICE AND VOLUME</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF SUBSCRIPTION RECEIPTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif">CERTAIN INCOME TAX CONSIDERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif">AUDITOR</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif">REGISTRAR AND TRANSFER AGENT</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</FONT></A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS AND OTHER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and any Prospectus Supplement,
unless otherwise indicated, references to &ldquo;<B>we</B>&rdquo;, &ldquo;<B>us</B>&rdquo;, &ldquo;<B>our</B>&rdquo;, &ldquo;<B>issuer</B>&rdquo;
&ldquo;<B>Oncolytics</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo; are to Oncolytics Biotech Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and in any Prospectus
Supplement, unless otherwise specified or the context otherwise requires, all references to &ldquo;<B>dollars</B>&rdquo;, &ldquo;<B>Cdn.$</B>&rdquo;
or &ldquo;<B>$</B>&rdquo; are to Canadian dollars and all references to &ldquo;<B>US$</B>&rdquo; are to United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all financial
information included and incorporated by reference in this Prospectus and any Prospectus Supplement is determined using International
Financial Reporting Standards as issued by the International Accounting Standards Board and adopted by the Accounting Standards
Board of Canada (&ldquo;<B>IFRS</B>&rdquo;). Our financial statements incorporated by reference in this Prospectus and any Prospectus
Supplement and in the documents incorporated by reference herein and therein may not be comparable to financial statements prepared
in accordance with United States generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus provides you with a general
description of the Securities that the Corporation may offer. Each time the Corporation sells Securities under this Prospectus,
the Corporation will provide a Prospectus Supplement that will contain specific information about the terms of that offering of
Securities. The Prospectus Supplement also may add, update or change information contained in this Prospectus. Before investing,
investors should read both this Prospectus and any applicable Prospectus Supplement together with additional information described
under the heading &ldquo;<I>Documents Incorporated by Reference</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in or incorporated by reference in this Prospectus or any applicable Prospectus Supplement. The Corporation has not authorized
anyone to provide you with different or additional information. The Corporation is not making an offer of these Securities in any
jurisdiction where the offer is not permitted by law. You should not assume that the information contained in or incorporated by
reference in this Prospectus or any applicable Prospectus Supplement is accurate as of any date other than the date of the applicable
document.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>SPECIAL NOTICE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus contains certain statements
relating to future events or the Corporation&rsquo;s future performance which constitute forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or
achievements of the Corporation, or industry results, to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts,
and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations
with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future
operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related
to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or
strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified
by the words &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;projects&rdquo;, &ldquo;potential&rdquo;, &ldquo;possible&rdquo; and similar expressions, or that events or conditions &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;could&rdquo; or &ldquo;should&rdquo; occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this
Prospectus are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control,
including without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to all of our products,
including REOLYSIN&reg;, being in the research and development stage and requiring further development and testing before they
can be marketed commercially;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks inherent in pharmaceutical research
and development;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to timing and possible delays
in our clinical trials; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to some of our clinical
trials being conducted in, and subject to the laws of foreign countries;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our pharmaceutical products
being subject to intense regulatory approval processes in the United States and other foreign jurisdictions;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 30; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to being subject to government
manufacturing and testing regulations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the extremely competitive
biotechnology industry and our competition with larger companies with greater resources;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our reliance on patents
and proprietary rights to protect our technology;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to potential products liability
claims;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our limited manufacturing
experience and reliance on third parties to commercially manufacture our products, if and when developed;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our new products not
being accepted by the medical community or consumers;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our technologies becoming
obsolete;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our dependence on third
party relationships for research and clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our lack of operating
revenues and history of losses;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">uncertainty regarding our ability to obtain
third-party reimbursement for the costs of our product;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to other third-party arrangements;
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our ability to obtain
additional financing to fund future research and development of our products and to meet ongoing capital requirements;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to potential increases in
the cost of director and officer liability insurance;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our dependence on key
employees and collaborators;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to expenses in foreign currencies
and our exposure to foreign currency exchange rate fluctuations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our status as a foreign
private issuer;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to fluctuations in interest
rates; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to our common shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This list is not exhaustive of the factors
that may affect any of the Company&rsquo;s forward-looking statements. Some of the important risks and uncertainties that could
affect forward-looking statements are described further under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our AIF (as defined
below). If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results
may vary materially from those expected, estimated or projected. Forward-looking statements in this document are not a prediction
of future events or circumstances, and those future events or circumstances may not occur. Given these uncertainties, users of
the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such
forward-looking statements. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to forward-looking statements. We do not assume responsibility for
the accuracy and completeness of these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on
our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking
statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective investors should carefully
consider the information contained under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our AIF and all other information included
in or incorporated by reference in this Prospectus before making investment decisions with regard to our Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a corporation incorporated under
the <I>Business Corporations Act</I> (Alberta) (the&nbsp;&ldquo;<B>ABCA</B>&rdquo;). The majority of our officers and directors
and some of the experts named in this Prospectus, are residents of Canada or otherwise reside outside the United States, and all,
or a substantial portion of their assets and a substantial portion of our assets, are located outside the United States. We have
appointed an agent for service of process in the United States, but it may be difficult for holders of Securities who reside in
the United States to effect service within the United States upon those directors, officers and experts who are not residents of
the United States. It may also be difficult for holders of Securities who reside in the United States to realize in the United
States upon judgments of courts of the United States predicated upon our civil liability and the civil liability of our directors,
officers and experts under the United States federal securities laws. We have been advised by our Canadian counsel, McCarthy T&eacute;trault
LLP, that a judgment of a United States court predicated solely upon civil liability under United States federal securities laws,
would probably be enforceable in Canada if, the United States court in which the judgment was obtained, has a basis for jurisdiction
in the matter that would be recognized by a Canadian court for the same purposes. We have also been advised by McCarthy T&eacute;trault
LLP, however, that there is substantial doubt whether an action could be brought in Canada in the first instance on the basis of
liability predicated solely upon United States federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We filed with the SEC, concurrently with
our registration statement on Form&nbsp;F-10, an appointment of agent for service of process on Form&nbsp;F-X. Under the Form&nbsp;F-X,
we appointed CT Corporation System as our agent for service of process in the United States in connection with any investigation
or administrative proceeding conducted by the SEC or similar authorities in United States, and any civil suit or action brought
against or involving us in a United States court arising out of or related to or concerning the offering of the Securities under
this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>DOCUMENTS INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information has been incorporated by
reference in this Prospectus from documents filed with securities commissions or similar authorities in Canada and filed with,
or furnished to, the SEC. </B>Copies of the documents incorporated herein by reference may be obtained on request without charge
from our Corporate Secretary at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7 telephone (403)&nbsp;670-7377,
and are available electronically at www.sedar.com. Disclosure documents filed with, or furnished to, the SEC are available through
the SEC&rsquo;s Electronic Document Gathering and Retrieval System (EDGAR) at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed the following documents with
the securities commissions or similar regulatory authorities in certain of the provinces of Canada and such documents are specifically
incorporated by reference in, and form an integral part of, this Prospectus, provided that such documents are not incorporated
by reference to the extent that their contents are modified or superseded by a statement contained in this Prospectus or in any
subsequently filed document that is also incorporated by reference in this Prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our Annual Information Form, which is
comprised of our Annual Report on Form&nbsp;20-F dated March&nbsp;19, 2014, for the year ended December&nbsp;31, 2013 (the&nbsp;&ldquo;<B>AIF</B>&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our management information circular dated
May&nbsp;9, 2014, relating to the annual general meeting of shareholders held on June&nbsp;18, 2014;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our audited consolidated financial statements,
together with the notes thereto, as at December&nbsp;31, 2013 and 2012, which comprise the consolidated statements of financial
position as at December&nbsp;31, 2013 and 2012, and the consolidated statements of loss and comprehensive loss, changes in equity,
and cash flows for the years ended December&nbsp;31, 2013 and 2012, together with the auditor&rsquo;s report thereon;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our management&rsquo;s discussion and
analysis of financial condition and results of operations dated March&nbsp;12, 2014, for the year ended December&nbsp;31, 2013;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our unaudited interim condensed consolidated
financial statements, together with the notes thereto, as at and for the period ended March&nbsp;31, 2014; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our management&rsquo;s discussion and
analysis of financial condition and results of operations dated May&nbsp;7, 2014, as at and for the period ended March&nbsp;31,
2014.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 32; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any documents of the type required by National
Instrument 44-101 - Short Form Prospectus Distributions of the Canadian Securities Administrators to be incorporated by reference
in a short form prospectus, including any annual information form, comparative annual consolidated financial statements and the
auditors&rsquo; report thereon, comparative interim consolidated financial statements, management&rsquo;s discussion and analysis
of financial condition and results of operations, material change report (except a confidential material change report), business
acquisition report and information circular, if filed by us with the securities commissions or similar authorities in the provinces
of Canada after the date of this Prospectus shall be deemed to be incorporated by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any similar document filed by the Corporation
with, or furnished by the Corporation to, the SEC pursuant to pursuant to section&nbsp;13(a), 13(c), 14 or 15(d) of the United
States Securities Exchange Act of 1934, as amended (the&nbsp;&ldquo;<B>Exchange Act</B>&rdquo;), after the date of this Prospectus
shall be deemed to be incorporated by reference in this Prospectus and filed as exhibits to the registration statement of which
this Prospectus forms a part (in the case of any Report on Form&nbsp;6-K, if and to the extent provided in such report).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any statement contained in this Prospectus
or in a document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for
purposes of this Prospectus to the extent that a statement contained in this Prospectus or in any other subsequently filed document
which also is, or is deemed to be, incorporated by reference into this Prospectus modifies or supersedes that statement. The modifying
or superseding statement need not state that it has modified or superseded a prior statement or include any other information set
forth in the document that it modifies or supersedes. The making of a modifying or superseding statement shall not be deemed an
admission for any purposes that the modified or superseded statement when made, constituted a misrepresentation, an untrue statement
of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement
not misleading in light of the circumstances in which it was made. Any statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute part of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon a new annual information form and
related audited annual financial statements and management&rsquo;s discussion and analysis being filed by us with, and where required,
accepted by, the securities commission or similar regulatory authority in each of the provinces of British Columbia, Alberta, Manitoba
and Ontario during the term of this Prospectus, the previous annual information form, the previous audited annual financial statements
and related management&rsquo;s discussion and analysis, all unaudited interim financial statements and related management&rsquo;s
discussion and analysis, material change reports and business acquisition reports filed prior to the commencement of our financial
year in which the new annual information form and related audited annual financial statements and management&rsquo;s discussion
and analysis are filed shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales
of Securities under this Prospectus. Upon new interim financial statements and related management&rsquo;s discussion and analysis
being filed by us with the securities commission or similar regulatory authority in each of the provinces of British Columbia,
Alberta, Manitoba and Ontario during the term of this Prospectus, all interim financial statements and related management&rsquo;s
discussion and analysis filed prior to the new interim consolidated financial statements and related management&rsquo;s discussion
and analysis shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities
under this Prospectus. Upon a new information circular relating to an annual general meeting of holders of Common Shares being
filed by us with the securities commission or similar regulatory authority in each of the provinces of British Columbia, Alberta,
Manitoba and Ontario during the term of this Prospectus, the information circular for the preceding annual general meeting of holders
of Common Shares shall be deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities
under this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One or more Prospectus Supplements containing
the specific variable terms for an issue of the Securities and other information in relation to such Securities will be delivered
to purchasers of such Securities together with this Prospectus and will be deemed to be incorporated by reference into this Prospectus
as of the date of the Prospectus Supplement solely for the purposes of the offering of the Securities covered by any such Prospectus
Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>THE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated
pursuant to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we amended our articles of incorporation
(the&nbsp;&ldquo;<B>Articles</B>&rdquo;) and changed our name to Oncolytics Biotech Inc. On July&nbsp;29, 1999, we further amended
our Articles by removing the private company restrictions included therein and subdivided our 2,222,222 Common Shares issued and
outstanding into 6,750,000 Common Shares. On February&nbsp;9, 2007, we further amended our Articles to permit shareholder meetings
to be held at any place in Alberta or at any other location as determined by our board of directors (the&nbsp;&ldquo;<B>Board</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
3300, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two direct wholly-owned subsidiaries,
namely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Oncolytics Biotech (Barbados) Inc., which is incorporated pursuant to the laws of Barbados; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Valens Pharma Ltd., which is incorporated pursuant to the laws of the Province of Alberta.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also have two indirect wholly-owned
subsidiaries, namely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Oncolytics Biotech (U.S.), Inc., which is incorporated pursuant to the laws of Delaware; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Oncolytics Biotech (U.K.) Ltd., which is incorporated pursuant to the laws of England and Wales.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both Oncolytics Biotech (U.S.), Inc. and
Oncolytics Biotech (U.K.) Ltd. are wholly-owned direct subsidiaries of Oncolytics Biotech (Barbados) Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following schematic illustrates our
corporate structure:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 347px; width: 551px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We focus on the discovery and development
of oncolytic viruses for the treatment of cancers that have not been successfully treated with conventional therapeutics. Recent
scientific advances in oncology, virology, and molecular biology have created opportunities for new approaches to the treatment
of cancer. The product we are presently developing may represent a novel treatment for Ras-mediated cancers. The product may prove
useful as an alternative to existing cytotoxic or cytostatic therapies, or as an adjuvant therapy to conventional chemotherapy,
radiation therapy, or surgical resections. It could also potentially be used to treat certain cellular proliferative disorders
for which no current therapy exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our technologies are based primarily on
discoveries made in the Department of Microbiology and Infectious Diseases at the University of Calgary in the 1990s. Oncolytics
was formed in 1998 to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells
with an activated Ras pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lead product being developed by us
may represent a novel treatment for certain tumour types and some cellular proliferative disorders. This lead product is a virus
that is able to replicate specifically in, and hence kill, certain tumour cells both in tissue culture as well as in a number of
animal models without damaging normal cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our potential product for human use, REOLYSIN&reg;,
is developed from the reovirus. This virus has been demonstrated to replicate specifically in tumour cells bearing an activated
Ras pathway. Activating mutations of Ras occur in approximately 30% of all human tumours directly, but considering its central
role in signal transduction, activation of the Ras pathway has been shown to play a role in approximately two-thirds of all tumours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functionality of the product is based
upon the finding that tumours bearing an activated Ras pathway are deficient in their ability to activate the anti-viral response
mediated by the host cellular protein, PKR. Since PKR is responsible for preventing reovirus replication, tumour cells lacking
the activity of PKR are susceptible to reovirus infections. As normal cells do not possess Ras activations, these cells are able
to thwart reovirus infections by the activity of PKR. In a tumour cell with an activated Ras pathway, reovirus is able to freely
replicate and hence kill the host tumour cell. The result of this replication is progeny viruses that are then free to infect surrounding
cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there are no longer any tumour
cells carrying an activated Ras pathway available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following schematic illustrates the
molecular basis of how we believe the reovirus may kill certain cancer cells:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT="paul" STYLE="height: 271px; width: 439px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For both non-cancer cells and cancer cells
with an activated Ras pathway, virus binding, entry, and production of viral genes all proceed normally. In the case of normal
cells however, the viral genes cause the activation of the anti-viral response that is mediated by the host cell&rsquo;s PKR, thus
blocking the replication of the reovirus. In cells with an activated Ras pathway, the activation of PKR is prevented or reversed
by an element of the Ras signal transduction pathway, thereby allowing the replication of the reovirus in these cancer cells. The
end result of this replication is the death of the cancer cell. The action of the Ras pathway in allowing reovirus replication
to ensue can be mimicked in non-cancerous cells by treating these cells with the chemical 2-aminopurine (2-AP) which prevents the
activation of PKR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>CONSOLIDATED CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since March 31, 2014, the Corporation has
issued an aggregate of 2,335,696 Common Shares for aggregate net proceeds of approximately U.S. $3,169,982 as described under the
heading &ldquo;<I>Prior Sales</I>&rdquo;. Except as otherwise described under this heading and under &ldquo;<I>Prior Sales</I>&rdquo;,
there has been no material change in the share and loan capital of the Corporation on a consolidated basis since March&nbsp;31,
2014, the date of the Corporation&rsquo;s most recently filed unaudited interim consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated in an applicable
Prospectus Supplement relating to an offering of Securities, our present intention is to use the net proceeds we receive from the
sale of Securities to fund our core activities. Our key focus is on the progression of our clinical trial program which includes
the trials currently underway or which may commence during the period that this Prospectus is valid. The determination of the size
of such trials, their geographic locations, and the disease indications being tested are continually assessed and may change as
further information is received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funding for our manufacturing program also
remains an important activity, as sufficient capacity to produce and provide GMP (good manufacturing practice) compliant product
is required if we are successful in our clinical program and our product is approved for commercial sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Continually developing our intellectual
property portfolio to expand and protect our core assets, our potential products, and the other necessary overhead costs for administrative,
marketing and general activities would generally conclude the allocation of net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More specific allocations would be included
in an applicable Prospectus Supplement relating to a specific offering of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All expenses relating to the offering of
Securities and any compensation paid to underwriters, dealers or agents, as the case may be, will be paid out of the Corporation&rsquo;s
general fund, unless otherwise stated in the applicable Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in the Securities involves
a high degree of risk. Prospective investors should note that there is no market through which the Subscription Receipts, Warrants
or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased under this
Prospectus. This may affect the pricing of these securities in the secondary market, the transparency and availability of trading
prices, the liquidity of the securities, and the extent of issuer regulation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective investors should consider carefully
the risks incorporated by reference in this Prospectus (including in subsequently filed documents incorporated by reference) and
those described in any Prospectus Supplement before purchasing the Securities offered hereby. Discussions of certain risks affecting
the Corporation in connection with its business are provided under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our AIF filed
with the various securities regulatory authorities, which is incorporated by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Authorized Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of an unlimited
number of Common Shares. The following is a summary of the provisions attached to our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our Common Shares are entitled
to one vote per share at meetings of shareholders, to receive such dividends as declared by our Board and to receive our remaining
property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are
no pre-emptive, conversion or redemption rights attached to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at July 31, 2014, we have 88,146,414
Common Shares issued and outstanding. After giving effect to the exercise of all our options, we would have 94,134,258 Common Shares
issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>PRIOR SALES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed under this heading,
no other Common Shares or securities exchangeable or convertible into Common Shares have been issued during the twelve month period
preceding the date of this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus, the Corporation issued an aggregate of 3,387,596 Common Shares, the particulars of which are set forth
in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date of Issue</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number of Common Shares Issued</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Price per Common Share</B>&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 4, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cdn.$1.65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 5, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cdn.$1.65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 27, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">292,793</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.5540</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 27, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">612,223</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.6640</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 11, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,884</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.6733</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April 3, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,944</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.7267</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April 7, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,944</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.7267</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April 14, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,734</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.5399</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April 17, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,760</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.5633</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April 22, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,734</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.5400</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April 25, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,723</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.5300</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 1, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,633</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.4500</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 2, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2567</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 3, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,408</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2500</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 5, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2567</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 9, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2567</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 11, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2567</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 13, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2567</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 17, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2567</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 19, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,415</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2567</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 23, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,464</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.3000</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 30, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,430</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2700</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 2, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,423</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2633</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 3, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,423</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.2633</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 22, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,588</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.4100</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 24, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,565</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.3900</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 28, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,486</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.3200</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 30, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101,532</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">US$1.3600</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus, the Corporation granted options exercisable for an aggregate of 1,716,000 Common Shares, the particulars
of which are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Date
        of Grant</B>&nbsp;</P></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number
        of Options Granted</B>&nbsp;</P></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercise
        Price (Cdn.$)</B>&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 11, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,416,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.74</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 3, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">200,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.69</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 18, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">100,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.46</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>TRADING PRICE AND VOLUME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our outstanding Common Shares are listed
and posted for trading on the Toronto Stock Exchange under the trading symbol &ldquo;<B>ONC</B>&rdquo; and on NASDAQ under the
trading symbol &ldquo;<B>ONCY</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the market
price ranges and the aggregate volume of trading of the Common Shares on the Toronto Stock Exchange and NASDAQ for the periods
indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Toronto
        Stock Exchange</B></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NASDAQ
        Capital Market</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>High</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Low</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Close</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Volume</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>High</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Low</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Close</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Volume</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Period</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Cdn.$)</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Cdn.$)</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Cdn.$)</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Shares)</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(US$)</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(US$)</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(US$)</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Shares)</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-decoration: underline"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>2013</U></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.11</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.70</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.99</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,049,251</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.03</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.59</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.90</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,087,206</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">August</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.04</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.75</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">912,029</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.95</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.59</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.65</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,057,244</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">September</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.62</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.45</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,864,673</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.38</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.44</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14,156,295</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.49</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.78</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,665,789</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.39</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.25</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.67</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11,257,005</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.83</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.70</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.95</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,936,921</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.64</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.85</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16,759,137</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.99</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.54</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.66</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,096,007</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.88</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.45</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.55</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8,457,220</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; text-decoration: underline"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>2014</U></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.65</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.75</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,673,401</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.92</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.53</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.57</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16,358,045</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.98</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.61</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.90</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">918,938</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.79</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.45</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.72</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,967,943</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.78</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">907,737</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.07</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.61</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.81</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12,113,726</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.54</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.68</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">893,221</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.46</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,638,510</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.65</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.44</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,315,417</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,907,935</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.52</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.34</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.37</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,380,819</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.39</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.24</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.28</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,548,126</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 1 to 31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.79</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.38</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.46</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,111,594</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.69</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.28</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.34</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,649,708</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>DESCRIPTION OF SUBSCRIPTION RECEIPTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Subscription Receipts sets forth certain general terms and provisions of Subscription Receipts in respect of which a Prospectus
Supplement may be filed. The particular terms and provisions of Subscription Receipts offered by any Prospectus Supplement, and
the extent to which the general terms and provisions described below may apply thereto, will be described in the Prospectus Supplement
filed in respect of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subscription Receipts may be offered separately
or in combination with one or more other Securities. The Subscription Receipts will be issued under a subscription receipt agreement
(the&nbsp;&ldquo;<B>Subscription Agreement</B>&rdquo;). A copy of the Subscription Agreement will be filed by us with the applicable
securities commission or similar regulatory authorities after it has been entered into by us and will be available electronically
at www.sedar.com and, if applicable, we will file with the SEC as exhibits to the registration statement of which this Prospectus
is a part, or will incorporate by reference from a Report of Foreign Private Issuer on Form 6-K that we file with the SEC, any
Subscription Agreement describing the terms and conditions of such Subscription Receipts that we are offering before the issuance
of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Subscription Agreement,
original purchasers of Subscription Receipts will have a contractual right of rescission against Oncolytics, following the issuance
of the underlying Common Share or other securities to such purchasers upon the surrender or deemed surrender of the Subscription
Receipts, to receive the amount paid for the Subscription Receipts in the event that this Prospectus or a Prospectus Supplement
and any amendment thereto, contains a misrepresentation or is not delivered to such purchaser, provided such remedy for rescission
is exercised within 180&nbsp;days from the closing date of the offering of Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Subscription Receipts described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Subscription Receipts offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the price at which the Subscription Receipts
will be offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if other than Canadian dollars, the currency
or currency unit in which the Subscription Receipts are denominated;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the procedures for the exchange of the
Subscription Receipts into Common Shares or other securities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Common Shares or other securities
that may be obtained upon exercise of each Subscription Receipt;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and terms of any other
Securities with which the Subscription Receipts will be offered, if any, and the number of Subscription Receipts that will be offered
with each Security;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms applicable to the gross proceeds
from the sale of the Subscription Receipts plus any interest earned thereon;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the material tax consequences of owning
such Subscription Receipts; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other material terms, conditions and
rights (or limitations on such rights) of the Subscription Receipts.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Subscription Receipts that are not within the options and parameters set forth in this
Prospectus. In addition, to the extent that any particular terms of the Subscription Receipts described in a Prospectus Supplement
differ from any of the terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be
deemed to have been superseded by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Warrants sets forth certain general terms and provisions of Warrants in respect of which a Prospectus Supplement may be filed.
The particular terms and provisions of Warrants offered by any Prospectus Supplement, and the extent to which the general terms
and provisions described below may apply thereto, will be described in the Prospectus Supplement filed in respect of such Warrants.
Warrants may be offered separately or in combination with one or more other Securities. If applicable, we will file with the SEC
as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by reference from a current report
on Form 6-K that we file with the SEC, any warrant indenture or form of warrant describing the terms and conditions of such Warrants
that we are offering before the issuance of such Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Warrants described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and aggregate number of
Warrants offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the price at which the Warrants will be
offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if other than Canadian dollars, the currency
or currency unit in which the Warrants are denominated;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and terms of the Common
Shares that may be acquired upon exercise of the Warrants;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the date on which the right to exercise
the Warrants will commence and the date on which the right will expire;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Common Shares that may be
purchased upon exercise of each Warrant and the price at which and currency or currencies in which that amount of securities may
be purchased upon exercise of each Warrant;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and terms of any Securities
with which the Warrants will be offered, if any, and the number of the Warrants that will be offered with each Security;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the date or dates, if any, on or after
which the Warrants and the related Securities will be transferable separately;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the minimum or maximum amount, if any,
of Warrants that may be exercised at any one time;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether the Warrants will be subject to
redemption or call, and, if so, the terms of such redemption or call provisions; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other material terms, conditions and
rights (or limitations on such rights) of the Warrants.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Warrants that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Warrants described in a Prospectus Supplement differ from any of the
terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue Units comprised of one or
more of the other Securities described in this Prospectus in any combination. Each Unit will be issued so that the holder of the
Unit is also the holder of each Security included in the Unit. Thus, the holder of a Unit will have the rights and obligations
of a holder of each included Security. The unit agreement, if any, under which a Unit is issued may provide that the Securities
comprising the Unit may not be held or transferred separately, at any time or at any time before a specified date. If applicable,
we will file with the SEC as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by
reference from a current report on Form 6-K that we file with the SEC, any unit agreement describing the terms and conditions of
such Units that we are offering before the issuance of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms and provisions of
Units offered by any Prospectus Supplement, and the extent to which the general terms and provisions described below may apply
thereto, will be described in the Prospectus Supplement filed in respect of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms of each issue of Units
will be described in the related Prospectus Supplement. This description will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the designation and aggregate number of
Units offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the price at which the Units will be offered;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if other than Canadian dollars, the currency
or currency unit in which the Units are denominated;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms of the Units and of the Securities
comprising the Units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of Securities that may be purchased
upon exercise of each Unit and the price at which and currency or currency unit in which that amount of Securities may be purchased
upon exercise of each Unit;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any provisions for the issuance, payment,
settlement, transfer or exchange of the Units or of the Securities comprising the Units; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any other material terms, conditions and
rights (or limitations on such rights) of the Units.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Units that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Units described in a Prospectus Supplement differ from any of the terms
described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement with respect to such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_016"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell Securities to or through underwriters,
dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject
to obtaining any applicable exemptions from registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The distribution of Securities may be effected
from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at
the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers, including sales in transactions
that are deemed to be &ldquo;at-the-market distributions&rdquo; as defined in National Instrument 44 102 - <I>Shelf Distributions</I>,
including sales made directly on the TSX, NYSE MKT or other existing trading markets for the Securities, and as set forth in an
accompanying Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the sale of Securities,
underwriters may receive compensation from us or from purchasers of Securities for whom they may act as agents in the form of discounts,
concessions or commissions. Underwriters, dealers, placement agents or other intermediaries that participate in the distribution
of Securities may be deemed to be underwriters and any discounts or commissions received by them from us and any profit on the
resale of Securities by them may be deemed to be underwriting discounts and commissions under applicable securities legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If so indicated in the applicable Prospectus
Supplement, we may authorize dealers or other persons acting as our agents to solicit offers by certain institutions to purchase
the Securities directly from us pursuant to contracts providing for payment and delivery on a future date. These contracts will
be subject only to the conditions set forth in the applicable Prospectus Supplement or supplements, which will also set forth the
commission payable for solicitation of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Prospectus Supplement relating to any
offering of Securities will also set forth the terms of the offering of the Securities, including, to the extent applicable, the
initial offering price, the proceeds to us, the underwriting discounts or commissions, and any other discounts or concessions to
be allowed or re-allowed to dealers. Underwriters with respect to any offering of Securities sold to or through underwriters will
be named in the Prospectus Supplement relating to such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Warrants resident in the United
States who acquire Common Shares pursuant to the exercise of Warrants in accordance with their terms and under this Prospectus
and any applicable Prospectus Supplement may have a right of action against the Corporation for any misrepresentation in this Prospectus
or any applicable Prospectus Supplement. However, the existence and enforceability of such a right of action is not without doubt.
By contrast, holders of Warrants resident in Canada who may acquire Common Shares pursuant to the exercise of Warrants in accordance
with their terms and who will be deemed to acquire such Common Shares under applicable Canadian prospectus exemptions, will not
have any such right of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under agreements which may be entered into
by us, underwriters, dealers, placement agents and other intermediaries who participate in the distribution of Securities may be
entitled to indemnification by us against certain liabilities, including liabilities under applicable securities legislation. The
underwriters, dealers, placement agents and other intermediaries with whom we enter into agreements may be customers of, engage
in transactions with or perform services for us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any offering of Subscription Receipts,
Warrants or Units will be a new issue of securities with no established trading market. Unless otherwise specified in the applicable
Prospectus Supplement, the Subscription Receipts, Warrants or Units will not be listed on any securities exchange. Unless otherwise
specified in the applicable Prospectus Supplement, there is no market through which the Subscription Receipts, Warrants or Units
may be sold and purchasers may not be able to resell Subscription Receipts, Warrants or Units purchased under this Prospectus or
any Prospectus Supplement. This may affect the pricing of the Subscription Receipts, Warrants or Units in the secondary market,
the transparency and availability of trading prices, the liquidity of the securities, and the extent of issuer regulation. Certain
dealers may make a market in the Subscription Receipts, Warrants or Units, as applicable, but will not be obligated to do so and
may discontinue any market making at any time without notice. No assurance can be given that any dealer will make a market in the
Subscription Receipts, Warrants or Units or as to the liquidity of the trading market, if any, for the Subscription Receipts, Warrants
or Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable securities legislation,
and other than in relation to an &ldquo;at-the-market distribution&rdquo;, in connection with any offering of Securities under
this Prospectus, the underwriters, if any, may over-allot or effect transactions which stabilize or maintain the market price of
the Securities offered at a level above that which might otherwise prevail in the open market. These transactions, if commenced,
may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>CERTAIN INCOME TAX CONSIDERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable Prospectus Supplement may
describe certain Canadian federal income tax consequences which may be applicable to a purchaser of Securities offered thereunder,
and may also include a discussion of certain United States federal income tax consequences to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in the Prospectus
Supplement, certain legal matters relating to the offering of the Securities will be passed upon for us by McCarthy T&eacute;trault
LLP, with respect to matters of Canadian law, and Dorsey &amp; Whitney LLP, with respect to matters of U.S. law. In addition, certain
legal matters in connection with any offering of Securities will be passed upon for any underwriters, dealers or agents by counsel
to be designated at the time of the offering by such underwriters, dealers or agents with respect to matters of Canadian and United
States law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The partners and associates of McCarthy
T&eacute;trault LLP, as a group, beneficially own, directly or indirectly, less than 1% of the outstanding securities of any class
issued by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_019"></A>AUDITOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our auditors are Ernst &amp; Young LLP,
Chartered Accountants, Calgary, Alberta, Canada. Our consolidated financial statements as at December&nbsp;31, 2013 and 2012 incorporated
by reference into this Prospectus have been audited by Ernst &amp; Young LLP, independent registered chartered accountants, as
indicated in their report dated March&nbsp;12, 2014 and are incorporated herein in reliance upon the authority of said firm as
experts in accounting and auditing in giving said report. Ernst &amp; Young LLP has been our auditors since our inception in 1998.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ernst &amp; Young LLP has advised that
they are independent with respect to the Corporation within the meaning of the Rules of the Professional Conduct of the Institute
of Chartered Accountants of Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_020"></A>REGISTRAR AND TRANSFER AGENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our registrar and transfer agent is Computershare
Trust Company of Canada at its principal office in Calgary, Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_021"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC a registration
statement on Form&nbsp;F-10 relating to the Securities. This Prospectus, which constitutes a part of the registration statement,
does not contain all of the information contained in the registration statement, certain items of which are contained in the exhibits
to the registration statement as permitted by the rules and regulations of the SEC. Statements included or incorporated by reference
in this Prospectus about the contents of any contract, agreement or other documents referred to are not necessarily complete, and
in each instance you should refer to the exhibits for a more complete description of the matter involved. Each such statement is
qualified in its entirety by such reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual and quarterly financial
information and material change reports and other material with the SEC and with the securities commissions or similar regulatory
authorities in Canada. Under MJDS adopted by the United States and Canada, documents and other information that we file with the
SEC may be prepared in accordance with the disclosure requirements of Canada, which are different from those of the United States.
As a foreign private issuer, the Corporation is exempt from the rules under the Exchange Act prescribing the furnishing and content
of proxy statements, and the Corporation&rsquo;s officers, directors and principal shareholders are exempt from the reporting and
short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, the Corporation is not required
to publish financial statements as promptly as United States companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read and copy any document that
we have filed with the SEC at the SEC&rsquo;s public reference rooms in Washington, D.C. You may also obtain copies of those documents
from the public reference room of the SEC at 100F Street, N.E., Washington, D.C. 20549 by paying a fee. You should call the SEC
at 1-800-SEC-0330 or access its website at www.sec.gov for further information about the public reference rooms. You may read and
download some of the documents we have filed with the SEC on EDGAR at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read and download any public document
that we have filed with the securities commissions or similar regulatory authorities in Canada at www.sedar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_022"></A>DOCUMENTS FILED AS PART OF THE REGISTRATION
STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents have been filed
with the SEC as part of the registration statement of which this Prospectus is a part insofar as required by the SEC&rsquo;s Form&nbsp;F-10:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the documents listed under &ldquo;Documents
Incorporated by Reference&rdquo; in this Prospectus;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the consent of our auditors Ernst &amp;
Young LLP;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the consent of our Canadian counsel McCarthy
T&eacute;trault LLP;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">powers of attorney from our directors
and officers; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;F-X - Appointment of Agent for
Service of Proceeds and Undertaking.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```&X```$P(``!E@```AHO_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`,`#D`P$1
M``(1`0,1`?_$`/8```$$`P$!```````````````%!@<(`P0)`@$!`0`"`P$`
M```````````````!!0,$!@(0```&`0(%`@<``P$```````$"`P0%!@`3!Q!`
M$1(4(",A,2(S-!4604(D)1$``@(!`@0#!00'!0D!`````@,!!`41$@`A$P8Q
M011182(R%1!Q0B-28C-3-!8'($"!)%21H<%R@I*B@R4F$@``!`,&!`4#!0$`
M`````````1$",1(#$"%!42(30'$R!"!AH4(C@7(SD;%2DA0D$P$``@(!`@4%
M`0$!`0`````!`!$A,4%181#P<8&A($"1L<'1X?$P_]H`#`,!``(1`Q$```'O
MGY4,YJS#Z:GF;Z]-6*/N```````````````H)S%G<WH*]W9_`-_%ZHIS=ET+
MZBK)``````````````4`YBSO_P!/6``4/YJRN]T5=3VBWY5W,,YV6M5^FW).
MW,.&#0P9%S+YU_*?[36@NMV%K)"1CEI8<F.$O;V#T1?IYE'W#SV,<1Z&=X[&
M.O57M7^Z>L``HES5E='H*_FSR=M'VKEZ==A3U,H]ZT=SIUMJ=N8]_7@.LVO9
M86TU)VL];EAQ=UU.[.E@^NV0P0]RJO2[MJ;K2=&;Q1KG+%BZ^6:[#7O3T=:N
MY?()OB>?W+VG0_JJJ-I25!&EIPP&_)(AO2VS!#)+/#Q)<`0Q<([)`@PI/;S.
MWZA+QS0;FK-?R>?<FO@]WVZ:L5,OFIY;@CX331)6&J-X=HUQWB.-`FL"/"0R
MHA;D@PG4C8__V@`(`0$``04"662;I/\`<>SV^0+L]/2^#LS+Q@MMP;E17K1T
MV?-N7W'?2%PM$'!QM=C>$I%L)EC27#O;NZ<OLS_Z\SZ-\6_B-_(_Y*AO-&6*
M3M]X_E9===%J@TW#E;(>"E;8[>6^[15.0"P;CG3J5^C;0YNUX_CW.7>T3%3:
M)7>M+5JDVN0M[6=N%P@&D)<;E/,+7.C6J[5)P;)7I/<1,)MM.7_RK=:H^FPK
M*T[ARC3^BM_ZC9031C_T;Z+@XCE4]*-VUIC"W4:85MY++<(9>PUB@6]C2H.'
MNU<GWNZT#,_OB;JT0R-(C9*?W*WO[B/"[FTLYA`BI%Z7&#N\FFFDGN:4QZ%M
MB4Q*!ND4YZ!M@4Q*#6_(VJM2.Y=,=*VZ3@8V)6)M*BG^_P!X/YZ^(NZ#=8V2
M8R['@[=MF#:K@ON;N`8Q2%C[A5I-00#(^282S64EHF)3BYN&E\DI1A$-X>;@
M[`C*S45!HL9!C*MY&3BH=&.E6$LD_?,8MH,G'E><'$BP;.L2ME8=,P(4,+:J
MZJ[\=#OQZR:R+1:G7?;AXAOG'M<7WVB%\"L;@;FKQD8QAV*R0+HP^T$-#KB'
M4*O7&E4A[%5&U@=0E02BYQR@5RWK<$VK$!;*DSMK>&C31+*QU5I8EHQJ^:(V
M>OM;3!-*%`Q\]PDZVTE)O%-F:R9F(`8(&EJ5@N?I)'1__]H`"`$"``$%`A'I
MAG:RYO`4/G@')@.EVY@$#!R[HQEUDTRI%X'(50K<3-7'+L/K/Z)$.@=?@@_(
MJ==QHG$0``='5Q,ZPF7<$0#5=8@Y*L+AQH#CA8Z(>0EI-UC+@HNNF":ZZA5E
M-%)%352.Z]P%'/5=8J"95G1PU5^R/^DWHDAZE_U:(%7;GU]5<@JHMERMTR.$
ME#/4SZGFMNC<AE'<C\_,;\!;D\['?XS/\9Y^,S_&2ZLU@=H#BYDRD'P<U'VD
MY`6S@IBG+P$0*"/5VYY7H'`Q0,`H.&HA(E#!DB#FBY>"0A2%Y?\`_]H`"`$#
M``$%`L!(A`URAGD`.:1%`'X<PD`$(8PF'@`B45.BJ?+K_`OH;\#H"4")]X8*
M0%PP$Z$3$^=J6'3$F)I]_!,A3YIF[E"`3"D(;#)D*)"]YCE[3`E]/:EA""<P
MD2`>TG5Q\0]#?Y_Y54$BA>SL(;M.H05#&3,4$3!VZ*F*"!4F_P`M(_#O'0Q'
M[BWW$?NK?<-[Q-(^$`PC[V=J'>G[B8@(#PZ=</[*?+@/0>]-4/''/&'.])'!
M$3#R_P#_V@`(`0("!C\"4X#;[,KLPM:H:A:-1Q&)>[+3F%*'$%VE.'N$C(6R
MNZ1_E=^,^GB*E8XF?A96*)."B1Q2Y!C$68PIP'_.R9N9W!*C$+FHOO<<""[9
M?V!LA4+`-)%F.R=K9F8C>70)Y49@#>=/07F">VGI/S!U(H"J04;-$IZ@U4R3
M[AN.@)VTVR_<%V]>2D*E(XD[PLI8FX)Y!S'QF%.E6BUT<R#J91,ALUU:XA*P
MU#.X:2DT=0=W*)3_`'%,\)A'T.S:3X8IA8_D&<@_D&<@_=(]MV(1IJ?U'RWL
MY*/CJ.:?DH6_;6*7H"[IO0=SA,WIMF=`?Z#_`!,AQ$KH";MM5/\`B$JM<UP^
M)KG&%KZ*.0E;T\1__]H`"`$#`@8_`A-6_0:&W#6TD"THY!.(W7?0*=JE$;I=
M6/$-9Y>$V9E8I7@SRL^0T,:3%T!U>@6+0?E8AFAB3$(JF$([^00W7\A*)1,^
MYHN=Z"4@AN->02:X-?AX3=@EA&60<YF)`G"=EY!7`Z9W*(`J?N#N5L_OL(&"
M!@I>HL!>-,1J:1C";T&T<<`AQM0AM^\^(4@E2YV8TF1D-1D1#1>\*<>(_]H`
M"`$!`08_`F/>P%)2!,:UA0(+6$;B,RGD(C$<.PW],<?!H1,KM]R7EQ%9?EN1
M#?REC^C)01EY#Q%CNOOS*VK13N)5*"A(?J@;6#IM\.0Q'$V>V._,Q1MQ\D6M
MQ+GW&Q3=VDQR^7A&-_J5CXLXUY=.MW)C@@A^]T*B%N]\;0;'LGA%RF]=FK96
M+D/24&MJSC42$H\8G^\8W^F>%>24%`7NYK2I_95?A9"2GS@%3!;?Q&81Q7Q6
M*K!6J5@VQ$1\;#_&YQ^+7,GG,S]MC&Y*LNW3M+E;4L&)C2?`A_08$\Q*.<3Q
M8_IWDGL?A<KNN]LVFS\ILUT1[(ZVR1*/WHZ_B_O'??==B/\`,WLK%9<S^!6Y
MKS`9GPB)VQ]T?V>T^YT_!;Q'<-5(LCYY6_6QM^X2J3_MX]5IK'I_4;?_`%]3
M3B,7D<>>#*R9)QMEUCK5+EA<Q#*O6Z2A4_0HTCGKKI[..UL7]-FY_,E_T77A
M_1BI/J*:-^WI'U?XK736/EX;9LM!-="S:YS"@06M<21F93R@1&.'EV3VJ[,X
M^NTD%F,GD%X:@Y@?.-;>FS8;M_Y.&5L]VM7Q"!5)C>JYM.209Z_"J`]/7=NG
M[M(XJS<"Q<O9!G1QN+I#!V[C=8C08G2%AJ41NGSGCKCV#CQ5,;X0WNE(WMGC
MME,8\DP[3RZGCQ=Q95K6(SV,DHOX:_$0]>PMAFI@?EN6)^SGQV[7^G3>^O9#
MT.[U'0]-^96#J:=)G4_B/#EX?8G*4^W_`*WBP+_ZIIMDFW05K'YXUO3-AZ=N
MNL[HVSX\N?$]V1D51AQ5O8TOVJVQXU"3\_J]W+9XS]W/A^4/!,Q&)(YC&/LV
M=]G(!!3'7]-"1Z2=OGNG6?#C)9.UV95G&8[J&5D>XJ\L.L+>FML5XJ24$<3$
M[?+C'Y6EV54^G9$%N2]G<=<#A!GMEA)FGOB1B-=.,KG8K1;+&U9L16EO1AL[
MA'9+=C-D?%X[9XQ><*M%0LC7ETUH;UH5HUB]L-V+W_)[(X=VUVQB+/<^;JQ/
MK0KN55Q^/TTB8MWW:@)#,Z3`Q.D\O'EQ67?[(H!5<T0;8I=S)LE6&9^)K%NH
MUM1"/9,S/#LUD0<U2S6E::XZL<]VO37$S\(1.GS3RCA&3Q_9>&FC:4#ZP/[G
M$;;$,'<!%TZ+$J.1\M9X]5_(K_JGJ_3?3?K6.V=/;KZWU/\`IMW+Y=_GIQWS
MVS8G2UCLQ#MGM"9:AAQ[MX1_9[8[?7\=S+=QU&*`?GV($T3.GLDKG^[AB?'I
MTC7]^U$C_P`.,WBLLIU9ZNX+%BA;Z9+M4+$UT0#T[X'42D?B'P*..QNV>YZK
MK-GMWN*C-3-+!K%Y/&OO4Q4YC-)B35".<SS_`$N<<\WA:S838R%%J$L*9@89
MR((.8\`.1TGW3PCM3O*I<[;OXUE@1L6*=@Z%Y;&DT7*MUUM69_%I_AQZ'#W&
MWF=,F]95&]%2(#Q$K3*X($_=,\^.U.]<91=EJ_;MA97\?7B6V(4JTNSUE(C4
MF#,1,%MUGPXZIYP4%I\55]2\NVL_W1H]/)=3EQFN_AQUG&8%E=U6B5U)5GY&
M36E`N"N>C-LBK?)3RY\=AV>FTDU<TU[R6IC>FI;<>9D4+$IY",\"(Y8Y(B@1
MCZ=D^9%.D1_"><SQ,%$&M@Z2)1J)`4<X(2\8F)\.`[:BI:'M=TCFVXT2=&-F
MX-$W:;?V72ZHZ:>R=OAP"E`*UK$06L!@0`!C00$8Y"(QQW,("1E./Y",213^
M>GPB.<\=J@8D!#BE1(G$B43O9XC/...Z`6)&<XZ=!`9(I_-5X#'.>.V1,2`H
MH%J)C(E'^9?XC/...Y?YCHWFX7.V/44NXZU9MQ,:-:T5W>C!FF9AW/7P*/9P
ME%++%?<Y@*%=+'Y*P8RR8B"9`5/@7$SSGRX+^8ZC;N,MG%9J%XU^3&=8DM[E
MH4SI+#3YYTTX8[`=ZY_MUL[C75Q%O+Z"S7D`8]U<P+XOP\=;?FOHOU/9];^F
MC]?^F?ZCTVG7Z.SXMVWYN6[3GQ0_J+CT&[$Y&`QW<J%#\NNT.O.G+5H!$C/[
MP/UN*^1QUA=JG:7#$N46X2&?*?T3&>4Q/.)^U]VX]=:K6637O:4`M:PC62(I
MX9WJY+%]M=M3Z3`@V)CU%I<R0-TG\0D?5/V3L'@C*8$1B2(I\(&(UF9]T1Q6
M3C\WC[#+I,&F(-V^L)423(J2<`-F0$9UV:^'&LQ'+SGRX&[C;2;M0S:L+%<X
M-9&AA):,%'FMH3$^^.%MRURK3!S.DCU!C!O;IKTJZN;'LTYZ!$SIPX<5?JVC
MK[?4I240^OOUV=>L6UZH/3EN&->/5Y&Q%6ONV=4@88Q.TBY],#D8VC//PXFS
MA[=?((B%EZA`%TB%L22S6TEB#1.(\1UCA+\K=314]X542V9_.L'!2"%",$1L
M(1GE$>7'JJ38L(WD$,Z;`^(?FC1H`7+@;&3MU**C8*EG8,%]5Q?*E(S\3G%I
MR$=2X-^/L184MG2,H!J]K(B)D9AH`6ND\.R.1L)ITZPP3[3R@%J&2@(DSGPB
M2*(XJX^;:(NWD.M5*V^.K8K5^EUW*'\2U=8=9_6^VE0LVD*MY.7C0K,*(9;F
MLOK6(2,_/TE\Y]WV6;Z<WC'TJ=P,=;>%E9KK766!JKJOTG5;66#@!B?&9XY"
M,?=$1QZ!65J6+/6]+*Z\E9&+&NDH-J18D6C/B,EK'GQU.@GJ>&_IAO\`^[37
M[+%&\A=FI:42;"&QN!BSC0A*.'7^P&SF\`YDNL=MVRWM5KY)C<,LY<H,)AGM
MB>(3W+VUG<)<CX6#T(:G=^+;UO2MT_Z9XE/;_;N>S=N>2UC7%2YGWRN;+O\`
MPX6[O-D]L]L@R&A@JOPV;.DZQU0W%,3^NWG'X1XKXW&UEU*55<+2A4:",1YS
MYD93SF9YS/#4EKM<LU%IXZ,&1G3WZ3QVXY.2O_\`YBP5C'RL*R++-^^#3<M+
M#>^NR#T,=!W1Q,>V-.$X:DU[JZ7W'BRQMELE=M-MLB=@B.@FZ8CW<87)>JL8
M_+]O6+-G$7ZXJ;T"N(]/:!M:P)HL*<J--)C6-.4\9'N:WD;65SN4I5,;8MM7
M7J(&C2,V(2FE4`$B74;,R<ZE/#ZQZP%A+4%,>,"T)"9C7ST+C$=O4V-=5PV/
MK8ZNU^WK,567"P)LA`COF(YZ1QCD6WMK_2\HC*UR6*V"3T+:L0<MD3!JF&SK
M'+@:4V?4`LBZ4Q756A8%SZ<`KE/Q:SK//GQAKI6;%')=OW#OXF[7Z3.@]JN@
MZ&UK`,KV%L5RT*.7E,<$%_)EE&R6L.*I6I[8TTV].J(C/^/&1[?O,<JIDTBE
MS$;8:(BU;?@WP0\Y7QB^X**F5;6+QE[%@L#DDO3>FK)F[J29;U^DC;MF(YS]
MO;N<>UXV>VSR+*BUR/2;.2JC5;U]1DIV`.HZ:<_LJUE6<E5<C(>ML7:KEI;E
M%1F"S:J.46*^A<K5KTZJDAWKTY3X\3$^$QI/W3PNEA<]<KX-=RQ<'$OIT+6D
MVK)6K"1OFF+?2-K"\9DHB?'[.E_,V6W_`%WZMU^G0ZGH>OUOH&GI=GTW9^7N
MTZVW\>O'_]H`"`$!`P$_(4$)P8J8Q*NB/[V4#=!>0%<TYE,J+$5-T#1V0ES&
M$=OV%`LA(`'>(VC$((\Z<L%!&TI=@!]1P_<4I.8)9&+>Z,.8%X`[LBZS9>U'
MBCZE2!%)>@`5D;:*DMQ9G"[0`,?<0OJ/=X1S*5&@^D&ACQT#8RLCURF/4K59
MSTQ9B"[?8W@KPV0L@H;0'NT@IVGMF*]"FGJA05ADR@/#LH;ILNI32$U`"U^U
M:T=YO:EBM@*YAH`6&*@`K9PEF+2Y0M:E8R*@%H+&J;@JI:D"EDNI?D>%VNN/
M)[A$I&"HX-R54!;IOK6Q$M0*,W59@&IAY,L%QB[';E8I^RWKB("(!*6%`Y6H
MWQ`@YP/9Z1J)^4D^Q#C>^:-,\<1@2X0?<([EJNZTN:88(9[KCX.1UVH![2OF
MS?%+!#=#F>98(/9^P1C]JN"A[N8;/I&\R(C07D,S4.%F+658W&;8O.EN#&JL
M74.&D!4LE8?5RHK91&.0$L@J@._"1E02T^"BWP@;Z#$S>/%2GH+3%L$853)1
M`Z@*)*U3X1=@'1A:467S!+$RRR04`U`K<N:B#RM`%NK6(,067`=]@0K$718J
MJ<HUN7SN#/2#+L;&"80T?TE1.$:`*"5[SOC=1UO2:\9#5!1/6"QW<6Z@J5#W
MF.+?01*ZS28Q\<#\L>SE7+:WYU+IF#@;E`F3*8IE7VE4W!P58H6ON4JY?4W/
M^<77[\$0E0DV!,<"V=-@U_O-@HSHF$CGQOY3S$(@8T;7!F.&-07`"C$6[@8Q
M,]:=+.@6P^TG+[)F%F*Z3U(*#3-VZF(3(!C8>DZ`.8&P5Q&]++JHTY8RK#(5
M5P5:N8>K2(Z.A2@`999&ZF^`A:(DL!V>KL[D,:4)878+P#/#NJC#^MUMQ2$C
M:FB-R1@H"O!=<SY]>WGVB8QA=?NT;7I.*1!*03HED`"@`-!@A_VAO]G'[<`!
M0`=`H_$N-GKS=!N)6J)V[U4^"7/O4U5=VB%T)31@=&=./[SMQTGN97;N`'"4
MCDS'UO\`T*U:IH**JW+5Y,,E"2ZH##RQFZC0DE1AA>GDCG]53B:!0VY>Z!HD
MSN2=U,I5N-.$S0U6Q3#%9,5JK#<PAB99.D7N5&#H2P8:JAH0HU&IH??R$@0=
M[924S6"!2U88B>4$N)])3!&%P"F>BW]`N,IJ&YQ>["K#,'X\96W$1V"H-%>U
M]H.ZUE%HFF'^^J0)2[LQ/"&Y*H1`-CAA"C+SL7-U`0XKP#(FS7F(9!ZE^"6+
M4@@H@U"H8A,NU%U"DQG(QHT@(IGZ1V._#SPV1YD8S__:``@!`@,!/R$!H$8X
M#;UY\U-M^W4O>M,#7GH^?^PX]LP_<--6R[=//:!1H^*`Q49/>5?SSS]QV^/]
M^GBI_P#?Y/AW,H1VO"])T<+>LG^Q$]".JPNRGMME.U6RC]$!9HP;9:4J_+]?
MV+`=];G1X-ZU_O@7]2,G>JS!\;SUZQ:N[.7VA,NI77I4'!UJZ_$QO8W4OLPZ
M@V2.ZP'JRK+GDM7P1=:]G6#;067E^IR?*OV+Z3O]/Y]-":_^?V)7F:@DI:CR
M-1@Y3UUB?Y_L4&J$(':Y1I]Y=DO1K\U+>FY#>[AD-'HC?ZA=5=%X_"=6I9^)
M8UOY.)A.TV%;J95``HP2^+<"B=R5(W%@G?\`J9M$L)?YBY9.@OY,.J8J``O2
MR_2IYR%NMP,K\QYY(:>UXO4HP4[B[WSG\?35^-'C1_\`&CPR71?@G"V9(O6W
M:\_]GX=C_P`F"]&_^_J4FTUV^>_X@(P&C[C_V@`(`0,#`3\A!6C<M1F-<(TT
M0VWZT"K;^X9;HY-^.L`@X"^X8QH^D[>*-9J7_P`-S,]5N`K1N?@T"X.U[Z5&
MW0;9PV\O6'&*:245=4\$.T8CBE'UGM%QMX28F*'2V6>U1LH;\L:,E^76<R)@
M4/+F>G.Z9A&Q])KCH,W[S,F;=YE+&CHU"8T,O")\2C%>Y+JVY3/46EOEVFIR
M_P"IV_D\#>'"^=S<^7/ESY,^7*W9!7D4=TF8Z/>IG@'O7[GL#5[1C:.8U('B
M)<DI2[OVUO@G,0E(6S,`YD*%>NCC.OL[^G__V@`,`P$``A$#$0``$'0]0```
M```````!J!:@``````````"``3%-F@P8Y^F`MP`$S3AJ-ZGE[]Z(@"D=/Q9&
M$`(!8)[)W*):(1`:`!01/__:``@!`0,!/Q!*O'O5E.<`*S(G^"]I6DC`-$;]
M;4:A*A`4R`5'5'85,FF`<X4X@4J=I9VL,!-/)0S`'9_0+`$!$/MVCD(J+0OC
M4-H`14ZHX&E75=111#P4F)IV',!`4HDQD7K(:5X%J`C]PLE?'&&E)Z#0`/IV
M^GF,^"$&GK$33;);<=>7V$:A^>2@470P:H1(NY0B(1Q*ZH7FQQFT#I%"HX"*
MH6!PE31L!R+4V+6*2<F+)%JT'A?/N4K7"RDJ`E[J>!!18761W+%6F932J0;J
MT'D`#U%AR-#Q[8CRB@8D`>+E(*@4\F!T0`D541"2MQ684*R@I8TYV#$BJLG.
MJ52Y.2V4#T36L!E(J,1"F&:Q"ALN+LV],&W;;Z5BT5M>G#X[OBY$"D(8[#/C
M***+1CK;[O/SX:9=J+)LLG<Z%[EI#8>5BD6#I`!]0:]\M`R`W)?T-\!*HG1`
MXD*ZTDL(700HH66(!F]3%$%3(#+9811FRCZ)!L2*1!C3D:\)U[B2[!$*1P&S
MD;U$B@6212K7A,MM!7JC$'**$@5<D]X`L7&]LD]Q@FY5-B9*U'55-^988B&+
M&(*`C2LNBDJ/Z@CG'!!W8H%;XILHU*4@V04-QI%5VF#Q$`LJ]_:M)X`!1'&>
MUOZM`M!:@R.VV1)>.@,%BI;CA>!:!Q-_3S%AO@T!I@(>(93GM1M4*A7]LX`D
M@'-#0%@B(*ZP/OVF:Q9DX\>.R80(ZC8?SZTF/0+$^TS&$JN`:9V"]KUNT0*8
M*8$\7-,:J&A`H+6`H$XRLZY9IK[>%7@JCH54D$B.`(5XY2;>B4T9I4FG:H21
MD`6"KF`/R!H4`?(.(7TJ`H<6FB**A8H'<K%,Z$YHZ-5IVAQS+JTBH0%Q$+FK
MJ'PN]0<&QB!+2M"*HCZV@=QG[`B[A8%`W"C3"4DHH,R@<=PH%Q3`&8>R`%>E
M0@O8G,K1I-R+5D0R=6+G+"!#N(C`0DH`!T`H"9?'O21(\9N&"C(H`'H*`A48
M67^)>'@7NYBVE8<Z634N_:!6WOJ+>B!(.D(HFR`,7D-82BL#"L"JJJK55#E<
ME7VE(6$#"`$&J*8+3XQ6$%:0;E+SRO&\4\-5V`,2<VO604+9X*]QJ?CTHN95
MBP$FB,JSLA5E3)8D!LP>="$&PEP8^@#M,A@RB<PEB*AL&27BZ8M9^,3=J`E+
MBMLS6-B'9^>XS4"_[`AH+1KA06T)]'LX;S82]C`N&GW+=5$TT$=_I=8!'"G0
M-9S"-%U1*$8$+0!B+]G&7/3"+Q8K]OJ^6]ES;5T!.KQ!76=WI54TA-,5,;RN
MKQ(@771/1&?@I<#'A@3\1+7D$,PDY!F6EPY0+!AN*Y*)6E%5N`%1\/,7+7[V
M$?\`_]H`"`$"`P$_$$Z`+5P`;66H<`\.,7@.BVO$'HOM7HJ?J-`!K*O='^0D
MKJ'\M8>Y0.C"+%(9$?N'8)1.-K>A37*B']/[KRKRNU?$:ZTB?KHG#Q$59,X7
M^J1.B^9?V]Q.,.QE'Z/8^D<8.OFF''.U[7+4V(EA;M13DKUK=7>56;AH75-_
MAJ&`$JN`#*L:"`JNFRPGXC8:M51Z59?MB.9HV2N-=#)EYQ.Z7I!7I6-]ORG8
MZ]W%CI+EP\WPV%Z;_#7A3TW,H?193=ME.\9E7D3+R/9O+%?S,=BSE8/7`H[W
MEU%\;6ES:AV6X:XE3RB+<:M,^]1@CL2KR%736^D8Y5F5UE*NB]=('49H]7X.
M]#TWB4VTI$AU1^)@!`0#96CH>K$0#``AR73!>D^,<J_LQJ^:B6?&=LKY#\_2
M&<O!S0.G>'?D(_$'4="10I+K'4TRN.N"@(5[<M^HM,`N%U?%]N(C%J4&MB`2
M\U,:P6S6[@#[RG)[G4!8.3"-9UQ&4O("'HG*)EJIJL!=L\7>N\N5TI`6@7;1
MV@`'9KU-2F46CGD>T02.:-%OH%_&-0V0)0&@-!7$*`KP\[(@R@/VP6%6IZD(
M`G#[IMA-AVH4M-Y'2=,Q:K`IPOEK`BNT;!6YM`:#J^V9L3@PKT&CVG/:O_E"
MLW6\768UJB!QQ?N`G](>\MB>=FDX?$T!;5:`(W4-0\&1^;=&G6>L`-2AR[\$
M;`P`T>':/!!W.@'A1X4.YK4HE$2]Z@&@B<,^<%%^`]GA-(RUHKR$[!B^R)U#
MN=,>=CYM\/K.V0!0^+0.&BQ@]3_=.(!.M!H_[U>?N/_:``@!`P,!/Q``%IQ"
M-%%@W[\^NCO&R/PO?GWA[*C?ZC2F-_PO7Y3TBL4+2/'W`37H'KU_.+Z#'*J_
MCL=O$(ZC##1!A!V_S=]'M]QWVGOKZ7>W'\8_L^74I``L!D.M6XF_+"J[PO7M
M`1JF@ZL%`U+R-/7(?,),NTM>NTF/`;3`$J;7]15_5>TM8'T$ZOUJ[WW[>".R
M<BQ[793+;>?LG6^G>#0!T#"Z7>6:K+JU7ZW&^6TEJOUN&NTJNKKVQ"+:.KJK
M]I2:H6+Z`2]6$P*+_"@ZD65=`;8JM"FL+^4X+L_2KK\3M*_T_2S&%W[Y_D5'
M5;YC4"$'`MP_R!#!=](K/>_\A`V98W,I@2^%(U*9!=4V?B[_`!*>!X6"TJKU
M$*$G42OS<;I-&C916KUS4S&F`7RU%9;CY.9D>Y+W`]+#Y7455N58J;7_``Q"
MQDO&"+1_F4:J?^"%(H4IIZ8O>HG:H.0>VX?JR!I^%[](+=U!K[IK>3!?7^9B
M9AG']>SOL]HJ-12/B7!6T!$5"BZ\#YH]_#/B7Q&^?"V;FI;W\,Z^K4M\,56U
MX!'0MCT8,.DH']_QQT9V=3/^63O1F;_='S+#*%7T>>A[L2!1E\+=>"WEA+XX
1\'+<&M>%^`TW+^FW@M^/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tpg8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg8.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```C.```8_4``(Z,``#)WO_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@!0@'Z`P$1
M``(1`0,1`?_$`14``0`!!0$!`0`````````````&`0($!0<#"`D!`0`#`0$!
M```````````````!`@,$!080```&`@$!!P0"`@(#`0$````!`@,$!1$2!A,0
M(#!0(2(50#$4%D$R(P="-3,D)30V$0`"`@`$`@8#!PT+"@8#`0`"`P$$`!$2
M!2$3,4%1(A0&83(C<8%"4C,D%1`@,%"18G*"-)0UE39`H;&2TD-38W/4U:*R
M@Y-D=(0EA1:CL]-$57541;57$@`!`@,'`P,#!`(#`````````1$0(3$@,%!!
M80(20"(R47&1@4)BH<%2(V!R@C-S$P$``@(!`@0&`P$!```````!`!$A,4%1
M81!Q@9$@,%#PH;%`P='A\?_:``P#`0`"$0,1```!_?P`````%$<`Z>.59S/,
MNFP\)C7(R)KMJZ>1NZWK8`````````````````````````!1'RCW>==6E9;S
M/;)1Z1>(='/M<-?5/TOR]]9``````````````````````````4*1"6CF-U6=
M-:NWK:\J@FZ9```````````````````````````!$%OE\_\`;Y^96WU9P>G=
M,@````````````````````````````1"V7S-W^9]:^=ZWS]W^=*^;H[%ET^\
M6````````````````````````````%#FNG-PKN\_!B_V7YGJX=FDMGN*VB]J
M;^-/1'FG,B<](````````````````````````%#YRZO/^B>+OY1T<VR39,ZJ
M:>4SL*SI+4S$Y*LZPZI'%Z`%0``````````"D1&],\&)V<$-DMG+````````
M4(K?+46BE8G]-.'=/+*J6Q4Y=:V6OY0Q:L;2FO1B3&.@D9"<I.QBV75E2]HC
MSEC)DU+RBFOO%JH)"50```6PXOT<B8LK:DUG5-9GEL`F:@``H!$#6VK"K4U-
M\L)/+^GEV6=XET\\]Y>K:+R7*VQ6MAYQ3)M%U;;2MLR7NM[Q8#Q1XS.$C`FF
M+:GE6]TUIHT"(_;+"AY:ULB=S2\DI?8UF05UF-+^RQ")K(4$1!+9\\Z.?;1,
M3)A$84Z712?Y=$QKH*(H(1NU8IKA&)K'=L\-7;YWG--/:MMY%Y737(3\3>GX
M_?./MZCCO\W]')*9G2TM)U=!,9<S[UCN7/W73(`````%(6HK*L3A36(WKJK8
MZR]81:F#;/-F^=1/,]I'GM+*7N3X6CQ+$5/0\DE<H]:WC%Z133'G&N/C:NZR
MF;TVWE-)C32Y9"M@%(:F:<2Z.6:4UG^&]99Z0$!2595``````````*%L+Y:.
MU(C;**Z91*^?FG.B)]3:4Y=$NI>I4I"MGS1U\&\I:1UTZ-COL*6NN```%(C@
MW3R1R:3Z-;4<TTPZ;COUWG[+K0````````````````*1&*B!;91#3"(:X9%-
MM]%IIEKT'/;(SF^TI!"DA4M14JD(<4Z>2RKMF/7Y*^ZUB/G/JXNC8[=(RZ*R
M``````````````````H4([;.#WRST]-RZ`!A*0>^=J/:5J9'3201<6P^5NWS
M.Z\O9+Z[<<UY>TY=54X*OSCV\/TWP>A6P``````````````````````8DQ$K
M4OK%)C-6V<6VL35/E-?F_I\[L./;\P]_GR?.\TPT[%AW;.)^5^_R/JCS?7NN
M``````````````````````&KFG)M^;$F+*O2+8%\^H8],VIM0^3NSS)CGIXS
M._F?>)[!S=F%%/G#LX/ISB]*M@``````````````````````&*910J`"D.+[
M\6-,:+7/=4OOLM.I9]7SIT</1J;])RWJD``````````````````````````"
MV(X1T\O.=.;M_/U><6Y+T\_4,>CKN'0D`,0RRH``````````````````````
M``!2&KM6#6Q^:_1\WZG\_P!2=9[4..[<L3OG+:7U&E,-/FS[+S=TEBX`````
M````````````````&.>X`-7--I%QP;KX>C8=,TSUH(BB:E`C"M7+BWHD````
M`````````````````41QG?EC]J;>LZ"6ZEJ)BM8F-=^L<^\/OGH=<>G8]=P`
M````````````````````````(I?#1VKN,]L6U,.)Z#6]8M68TJG%>KDEV&^P
MLZ1ET`````````````````````````4ARK?DS*V]*S9>^"IU7+>Y(TS/Y_[.
M/:TOT7/6?Y=``````````````````````````X?ORZ6U-DCRF9/G?JV/4!2L
M:ZT0?7GZ1CU8RN%:+TWI\8C'M%ILH6FRBX````````````````````&KFNTB
M:`K$I``1^<XEMG+LM(+IAJ[QX*[.F^HTQRZ7W%9JGJF70```````````````
M``````````!HIS_/3VO"_2?POH0@DDD@D*@`````````%(A$T*R065``````
M``````!&+9^4-?>NRK:54T2````````````LB.9[8^<QA6JFN36]L1/<M]W%
MJI```````````'E-.:VPT&V616_1\=MY36^T@````><1=*TOB:R%$63%]92%
M4BD.+;\?4\NG:1?E&O*BTEII,\].8[\TEIK*ZZ)```````````"-VSC:(]-/
M1'1:[2"+@``(4A6R(SGQ;HXY]GK"KUF9M<=]!?+-6CEJ[:(RDX\:]AQUK+G.
MF$QRUVB]IS+;FQU=JMT/'II,<@VYNP8=59`````````4ACR*U+UM#;+616^6
M:M)::T*S%4@8*,.:1>:;Y,DKMKJQI;TN1@6943E3/G6N5$QY7?Q?+F4QLZS6
M9Y)MS8TUDU-^:;\VZJK,ZU$BB=#$XMZ?0W'W5F0````````ASW7&%6QQ+QM*
M7U5\8S>NYI?9UT[US]<7OC`[Y=(SWW\:`:.:1NV40TIU;#;<M1RG7#P1J+4]
M49$7LOE),>G)5GM-P!1',-L)AC?.FT6G/>1/A,V1(S8<PWQ[5S]-9D``"AY(
MU)NTA`)>*!2)]Y"A:I<O;%:S-4T+P4B.2='/US#H!(YAIS]/SZ`!!=,8W:D=
MFL_B^IFN(9BLOPZ9.N`!Y(XEMR=GQZ^&]/#::BR09;3:)]:32R>9[@``#$BO
M`.OE]ZUW%=<'3/TI;8UC2:YX43GS7$KIO83S+JE];@```4ARC;DF.>^V3L8N
M.9;<_3<>@`8R-?-<,UNF>52^=!,[6)RHL``,&:\NUQ]D2W/384F%ZYXMDDSF
M:Y[5M(```H1^:ZNV.G5WU==2;.S:4O$]LNC8;7S((Y-KA@3GE1;&1[3%T3US
M'J])D"D.&]/'\V^AYOZ`^/[OB<DZ>2=\_1C329UW$`TPTUJY(1X)S:ST?+HT
M-J8<Q*ZZ5``!0CLYX,UDT:9<6`````&EFL2TPL3AS3WK?:S&537!4GE=[@<T
MTYYSEI\V]O%$M,NF<_3H]<_I;A[N8[X="PZ(3KE252D*B00'QOZOC??7C>Y'
M+UVR>#]GGQR'3\.B/ZX]XX^_@O5R33+6MF]IIT3/8``"R*Z.T;Z+U`````!%
M+9<VVYK5]I2T*VRWD3YU3*FO3<N@#637E6W/6M9KGKI;UTDU])="IML:7_-S
MZ#YO[@\/W[T8<QF1(`%$S3*^#>(G>-FIC1,>O391&QKIJK4TLUVA+J;SC/8`
M`#%FD#O3HV>P`````%()A$XDQC37:5N/$]Y`"D-/:D`URMB)W37>TTNE2&KM
M3/B_#>GB^>N_S_J3S/4Z%AOMIL`$$L&U.;ZX>];UEC6CH6&NUB]$4E=$UD``
M!RO7#I>>N3%@````````````*02J``"B*0)XST<G9N;KNL``"%"LJ(JD````
M#S1R';E[#AUUD``````````````````(K;'736=4Z*@MB+ID````4A2%U@%M
M6DTKS'3G['ATY$R``````````````````!0@%\-/>LMI?%3\$^U\_P#;OD>Y
M5```%$SS'?\`/;W?GOL+Q_8SIM841KU9%76=Y;73(```````````````````
M%("R;75IR?KSZKQ=````NF*UCA_5S=;RZ-ME-LK=K>F-*Z``````!__:``@!
M`0`!!0+Q7I]NYS+B5S*N:=B?"DFS90)#GRU9HQ(4=BF]IE#\Z'UF+&#)=\WL
MJR-<<Y:.Y<XD]!8MJ:8W\FTNH?3RAI"4<FC52%?ZU4^B?>\2:FP++S?`P0F3
MXL)>"%C/B5<1.%)P0P0P7G7(VH3U-$YSREZ-`O'.2<@+[>=V<^=#/FMG8V3$
M6+'AQ_\`8-?&4F%R6V?A-J-;?G?+::+>T-'S#D46M),SFG)B^STF-&)R[J65
MIF15N2;V)'FKL:]M93X)M?)5Y'&E1YC/FD^T3<61$22Y6A33/%[)VTK^0U,R
MV8=H):Y$GC]C*E_#S7UIXQ(Z?ZZ\F6GC[NU3&>AU_P!8=M`-RNN&9<15I7H#
M-I`D!B0S*;^BN;-%37T=*FNB<G=>8I\D0L)L?CEV[R_C#!IYIQQP?L\10/D3
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MYA7!CDO'Y!I<0LN_R2S?IZ=_D=G">7=6?1G6TV95?)W)2Y7(Y#3KG(+!E_\`
M(G]Z5<U4$?ME>Z)?);I!G=RY87!M9HB\5L0CCL['ZE4K-CCM'%"&FV^S_;5]
M?<>:X3,N++C[V>C$M+PHTF5:H4_874BN7,F-/L3+)Z1'GW*VH<RY5,\?`QV.
M1V'0_P`8H)`_4JU(>XFZX'N&SF@B'RF&/GKF$47F<U2D\LKTIC7]++!&1]CC
M:'4_CL93$C(3^+'QT&1^+&RJ+'6G1/9.NZBM"N3*>*7R2R=<*+-GIC\8MR/]
M78=$7CM'",B(N_+GPH#?(9W%.35[7*N.-);>CS&8T=J(Q]?)K:Z:%<3I".;P
MLWTEQ6ZA!Q[E<`V>;3&#9Y=#4F+R"DG#)=VQ8LI4J'QZV0&>(5^\>)%B(\*T
MY.MU%?Q^QDG^J*<!\6D-"953JIVIY)U7<^2.L,O)D\3H9`?X49A7%;V$KYKE
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M*G>8)9:2YW^30%H<H+M#`Y700I=K5?Z[XU5N0JR;23L^E]<1[-/'JQ^*GSFS
MXLXTW&L)+5NGD,A(<Y#*-,FTFWCM3QOIN]WK)ZOFLJ##G-_J%"1\KON#<6E\
M:?3+H>Q;EJ5LG]CC13_-4EX[IR;TK=$"P=LX;U0\E^M\M2ZVM7<.9&)SLYUP
M6OYE7\=A/UU#VX[,#`>C,2`E*4)\M?E6GYJ+*Z23<JUD+1-Y`ZEFWMW5L2W^
MO,MK-PHTV>Y;"[N8U+`XSR9CD44CSYJNWKT*FW;;#[-S6O#YN"T)UTTF$,#`
ML6'9,+@-"W7U/+:1FSJ.)P'JV@\TD\9;DR6J);3J:6!"7\?'K5HX\:F^V>B4
MY$I95UP^EEV\OE]1QF'9P*?S14RR5<IN+5QB2[919-C,=G0J:7-E2^Y+B1YT
M9S\+BL`@\\W':1/AN%^;$U3+C*!SX9#Y".V'+**03)9,-2XKR_*V8C,=[P;2
M"W9U]'>,R8%G$.PKF:*0DXW'INS?&):%-TEB]'L*N2S/_6'&@BC?2BJHG8$C
MS6RA)L8/#^-7]!_M'R#/URKBN193;6H@O?M''A$NZB<[]5G`D<E:<>_!Y+.!
M\+K7#5PFC"..S88.SO*H0+&%9,?4JVPQ`N68S2KJS1^#>B+'8:21D?B;%V;$
M7=V+OK>D\H?AP8M?'%?R&=-;1R1:3IK-RS9$ZC=:DU%JS;P_J9%G`CS#C<7:
MB_#<&":/A*U0*NOJT>%8/.%*:F26Z1FZ<:8OK4WX!\@=2JPLYL6T5R">S$^<
MF_FIMCF2OGIZTQ[ATW$\BEK5V<FD2&X$*&Q7Q1]PSQYQJHA<<>A/TU`U4RNR
M9_\`&Y']*EUI:G'6VFVW6W6U+2E).5<M;L'C[@^'H>HBFJ&UC/=?=4TW"F(G
M1'.1PFX-=9,V)!^.W(!,PF7/_2)QABI6[TZ9`UB24KBU#JEQZ])QTU[TQ-77
M);_!AF1PHAGV7#AHY&_R26TQ83GV&*2]=B\>8Y4^Y)+DED2F^4V3AM7\\U*Y
M39ZVEG(G0/I+IZRCO.S+;\Z?8S%RY$B?#XPS-N.IQYMUB4S%E5")KSJ;HA84
MM;:*>IK*G.ML&+2'VV")CD;H.LQYO%GG8\&(B''[+BDDV$M-"\F8S03HT:/Q
MZ6AQB@F,M1>.28[UE5/2GZ>J77R.[R@G&6&XM>ZT_$C22DJKX)Z5VQ1ZI9'%
MJ"!1JJ8X5=`2+6.B7>^"E:5`K&$IWNN.(:;;<0ZV;J"<[,#48&"&!@8[E.C\
M#D/<OO\`L>Y*M'H]K%MI!O6MNJ?!N+E58Z5_+6C]DDH'RTA^33/N2:SNK2E:
M8LASB3B_\C<3C<UF&CC$A;7ZE8-HE<:=>%)6N5HN+MNL.BK'8+?@/;]%ZTDP
MZY[\AM]Z9;]&-.O7&K&=:*X<J;-:?CS[62TW9VTDH]E*1)AS[A,-Z;:;4CTA
MZ!X5^3M;*5;UZ:Z-*CS&>R^_[#N&TVI:8$1"RJ*Q(M*1BT<CTE9&2Y60'4'6
MQ##+2&&^\^PS):^'M:<'RR/#./>4TI*K&O04CF%`PHY7([45='$K%>%+<9@1
M/G*]3G[!"U<N8#2V;^`ZV[>5S*BL(9PK"Z92"[CW(7YDC\>:^Y\#3*?^&H$)
M173MBOI]6ZE1*3W.1<:B)K^"_P"L>55"TE@GDN+:D\?NY;M?&LHX@7]19N]E
MCR&%`=0[RZ:7Q-^X/B+Y`6?+X:8')(LAX3+2NKBAWE1/5W_N'JBJD&5!1I-I
MAEE/B3X2)\8ZF(F1^ML$B/4PYLG]8C*CKHV7)7P['QB:F*J9V\K<<141HS$-
MBP@*G\EL/S^-V_($U3O^OZK5_FCB$.M\7+\<YD7\UC]8;'ZRV/UAL?K#8_6&
MQ^L-C]8;'ZPV/UEL(_U+;VO):^'^!#Y',D1*ZLJH52S;=?YZ1=RZ*XO8BJ_A
M]),>E<DL*^)9QCY*GCD-NL9IJMB/`Y+&XW)E/1/`KI[-E&\6Y_.^/GRKML39
M=G$36F_$K6+J<\3CUXB24Z[<KZI2W;/MF1&)T9AV\X^BOF\5>LBK*YRS5QJC
M3#LCXDR';"YN4U=;&J84E;C3/*?]B<V.V3;7B4_,7H+D-JI[YB]'S%Z/F+T?
M,7H^8O1\O>B`_*DL7-;\K7PN1$TY&J'6[^3Q_P#*O4\4E-T#G&EE+F\DBM.M
M\9.34*MVRKD\EJ6(]#7/U\/OO.)99XDTIOCOT#[#4EF-#8B]J6TI5W9==`GI
M7PCC"S3PCC*1#JJVO+';+A1)S"4D@N;5/+[2%_K3C_+Z-U5Q=UQPIL6PC]Z1
M%CRV4<2B1#^+Y&@?&<E4'>*,S2AP8=>R,$,%X/+9"OC66T,M>28&`^W^NW?T
MRE$DJC_[EEY/<UQ6E;16OR43Z2=90:QG6;RHVVT-(\HLZ)N6\W8\EA)K[)V<
M=]8V%9`H.=\ON>:_-VP^;MA\W;#YNV'S=L/F[8?-VP^;MA\W;CK.?C<M_P!I
M\LBSXU^ZS'_9!^Q2#'RG(G1^%RZ:<+CE9#=QY=;?]SX!=G/_`/\`GX/_`.+Z
M+__:``@!`@`!!0+Q=/\`"XG5?N&%#"@?]-5#!C4_.$KPT>-B5A98(9]N?:9_
MY_\`@O!H\YQGL^XP/Y\[1DE&TT2C1HCSUA)$#$?U/5/GK9FE;C*!DFT8[-5#
M!C`P,#'FV-2"`LM32>!L1#9(R0R-B&Y`_K<#`PH841?S]$GW&H\AO&01;))M
MTQTU#0$@8&"&J1J0T(:#0:#0:$-2&HU(:C0QTUC5?T&P-1#<AN6%*V/Q]3&H
MU!%@L)",$K8AL0V2-AD9,=1P=18W4-AD94,J&5#*AD9,;*&ZQD;#<AN0W&Q#
MVF-2,:#0AH8U4/7P"+()!&>J<ZD1X(:D-2QCO8,:&"2-2(&9#8AL-C&Q]L9*
M%F\24N%]S(B/V#T'H/0>@/7Z38P2S'4,;D/8-4@VR'3,&1EW,F,F,F,C(R?;
M@QH"0D?U&Q#<R!J4?@?<)W2>JC!Y(]L^09&Z@3@V28PDQH0Z1C!]XL`U#J&,
MF8]?")(-1#J#<$9&#2"\D]1NHAU1L@QA"ATP:%$,#!^*@@H\=U*LA18\IR9#
M<QMWM1H-,%KE.,=S[)U[#(TI[/L:BSYEL-LC/IW%?9)^JW3;-"R4?22@^S^$
M_;R\\:GJ/:/;GV9/M^Y-^U3J%;-)][BMEC^3!><),*3D-KU"GEJ!F2NQ!!:M
MB\Y)8^Y:C4:D04KSS)C<PRTZ\%9)786,>@]![1Z9+!@_OYJR\;2E'LKOEZ>7
ME@>T>T>T82,`DD#QKZF$EL:D:GYK@QCLU!)]>TC))NJRMM6#6>5>:;EC<;#;
M(V/N%_9>'%DCIJ69&KS0L8PD%J83C=9%W2]!ZK["^_9@>HP8P8P/7S8CP:DG
MDO0]BU-9&6Q`S(),AU-AL#5GS8O0W5H4P,#'D&?K,`B,QJH8,OJ_YT&4D.JH
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M1D?@_P`Z[&"(AA.2)/4(B!IP>"QKZ82,$#\-.#&IYP9=J?MW<F,J"5FD;&,J
M&3\'9)CIF8U4-5`FUXPD@:_#+U&HP-1J9#51CUR2>[J/09,;*&2!I2?>0L]G
MY"7.TEMD1F0T41=FAF,-D-D#9`]AC3LP9C4R\'90V5XQ>A[#<&K`W!+&3SD^
MXW]S"3U2G524YZJO_%_+G9L-AL-AL-AL-AD?D$ELSR$>IF83IJ2"4$^KBRP1
M'@:9&<J/VFKP"\<L`M06H/U5A(PD>T']NW[#T6#ZF,J(ME#_`"&-22#/;L:C
MLXP-2&@U(:D-2&I#4AJ0,L!)X!D#5[27A)J]=O0DC?W:^[51FL\GWR^ZO[?0
MYSX.3'44-U@S,^X1FGL:-"5/K:46J#&,'WB]!U!E(RD;C)J\1`/U\G+W)^G^
MR?)T^TS^D]019'HWY5D808P$X,U,M)8U2-4C5(U2-4C5(U2-4C5(_EN,V:=?
M70:#"09H(&HS\N_DOZ>"H-?=7T?_V@`(`0,``04"\7?#S:C4CT'H-DC_`)$I
M(V(;$?G"D;O(VZ9I2I!Y,:_Y<>_'_K_=:,I7YR9X[#P79_'G:RR1/NFE+O47
MYX>P>,%@A((ANL%]O.WDDI#;RAZNK[-TC)#;UR0R0R7FQKRH.!H\DHE*&AYU
M,:F-#&AC10+/UNPV&R1L1F1Y+Z)1X)*<!><`U:*-YLAU2,=4=0S&ZQNH=10Z
MICJCJCK#JCJCJCJ#<QU#'5'5(=5():3&2/Q]1J>>F.F9&@C27C9(;D.J.H#/
M)DI8<2>A)4.F9@DK&@T!M),=!D$RT0Z:!TTC1(U2-4C5(U2-4C1(Z2!TD#IC
MIF.FH=,QTU$-5C_(0W4-QU!U2&Z1DO`6K5.ZM=E8R>"49%E6=SVSWLD.JD&X
M-C,848T4.F.DD:)'IV2W%H#"E*;/^J37KLL>XP>PRH9,95](:2,NDD=(ATC'
M^1(W60)U0)U)C9)]S!#!#!#!=F"&.PU$0Z@-2QC8B:,=,@2"+P#,B"S;625(
M'H,>0&1&.FD&R-%D,N)'56.LD;%WCR"08Z9#&/#4L)09CI$.F-5$$J\EP0Z:
M1T0;:R&SB1U03B3&?&6H(+/9DLC[A:`A1^4FDC'3(:=W(W'4!+RK;"B//<_L
MK8B,$HC<SV?<D'CS#T'H8U(QH1'CU[3^S?W4180V3A+:U(G5J\S,%G/N'N'N
MQA>J>TU:*<4:D-+3J\KVM)U:!GZ)]3\X<((5@G&DJ<3':2"2I)_8.+,PA./.
MC0"/"]U`U#92@E/GF"'3(/.M,!O!I[#VSE0]P]X]P5E(+[>99]>QYDG4H+5/
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M/8380WJ?8?M7]-GM]IC"#&C8)*?`]1MZ(5L79[2'M'M'M&2,>T8(AZ*&I#!#
M!=J_[]0PH_1"_;U1U1U!U1U0I6R?I%&8PO;/JK)(RLPWG<B,C]=@I!*&FH2>
M2[3^V/30)+5/8I.02!J9))!@D&-%`TY-*<=YS[>@,LCVD/8/8/:,),:I!E[O
MIL=F.^G^_<7]^X:L'MZJ5E*EZC<;C<P7>^X+_%V:&.F-#!H"4ZA2R2$$9>%M
MJ1G@LGC*L*-72,U#*C29F"5Z94%&H%X:BU&Q&1&1]JOOW,#!#"0I"5#"1A(P
M7@&61JHAU"(;)&R1U$#*C!(\,_0;#J>NQ#9)C9)#T!J+N[CU&J1J@:J!+-'>
M6V6K$=2.TT+R602TFKL-9#+AC58U6/\`(0)?89D0)1'X.J1H@$1%XIEDM02"
MR22,^F0-L&18U+/:Y]B]`HME*-2#5@V4YZOIAO'9H0T(:$-"&A#0AH0T(:`X
MJE.)+5*_LE.`K??<TK5Z-MJRI19&^"QA)>\DY\%)Y+Q59!FO'N'V22E&,K'N
M"<Y[3+(]4`C;,_:9ZH!FV0V-02G4@](>SL8W,=0;&-C&QC8QL8W,),S"BR"4
M"06QMD:NF>-,'N.GZ;^FQ$2,DGOG]D?U^@^X(B+P<$8Z2!TD`DD7<-)*['B=
M4F.F0D]G"!'L7>,B,=/`U4,*&A@B)/B+,%Z%Y-_17TY94KR=:=TH7O\`2F9$
M/5P8QY2:/7*R!*"C,B;D.K?W4-U#=0W4-U#=0W4-U#98_AZ4X1DOV]0;F-UC
M#B@2"+R[^/\`EX3GV+[?1?_:``@!`@(&/P*]?-Q$TL4F\7QA/]CF.M#<YJ;?
M<K(W+J<L\8:PR0?/'?*1RVX\Z5'47:OB>6.N2W(+QJL)$L;Y9P924&P9QNCT
M)4&6&J$MJDTG"J%;JL/)"J0DBL4Z-B70S6#<5,BJ1\222A(K"=TSQH4CD2A6
M[F-%[RGR9&=IE&VTL2PWN)&4)73H.N"3O97D[#810[B1+H'&LZCY8FX]GV.2
M0G8E2N)L-:D<=J(YPWT)K'_@N(ZV)V&]29RLKC.H\=8/F<?3&IUL.,F/.*BV
M]!\7_`7<GK<2QAAL:G99*,3'3%6BR69T/ZZG>.E,8T)69$ZVY8UI!B4)"^V,
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M*DL0SN\^D__:``@!`P(&/P*];0=?6Q7+&_H+L63#([FUC0W2R-3:FAQRQA[#
MCC98ZZ;#ANECLCNH,@F[[SQQUE)[5$Y91;.&F,\%I!TJ3K![4\`;I>ZL=%/)
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M_P`3;RJJ&Y1/:"[3E!KE[Z45)7/.9R*FHR)(8<9F1RA0E4H4*%"A0G!MQR]3
MDIQ<Y#;1?53CO..RI.MRG12NF8H2L3A_4LQ>=2:2'MS.V14J3525XPV#R\.H
M=<(8U3IOQPI]OD3**2&W)(H>)XGB>)XGB>)2'%-I12BE%*'=+&\ND__:``@!
M`0$&/P+[+;V)6Z35ICL0;HJ?#5#(+!6)3H(FKG4C*,\O6]./&7@6#U6[M0W)
MB0K6HIO)7C*\',Y);`]L\<\,&O92V51!'`,&=(ST'T^I.7K=&.4FVAAS$R`B
MR)Y@CZQ)ZG"/7(YQ&'M\=5Y=5G)LLYP:*[>CE.+/);,YZ)XXW&2W.FZHNO3,
M*(0`OV^9%I-?:=S/D[41$CJ@<H'#,MTH3R4K>[*TF>6ELZ5M.8+(0,IZ<#6\
M2CQ)KEHHYP<XEQQED*SUZ(B>GHP2:]I#FA&<@M@E.F)TR49>L(EPF8X1/VXW
M*O;6[P=KRI]&C;$&B*[C+)9K58C((L`!9Y9XWCRJ==R-^VNDRE6:M1*K[M55
MI)-BBZ!A<LL5.Z0\)ADXW%VQ?3`;P>POH)\<#:_A(/09;>6:U1SID-,99Y8\
MG*VJHVM9VW==NM6`E$URVJC6KF%VM8G*-/-U0&CH9/N8O4QK:MDWN*>^6V0,
M<I=_;BA9IF,LM=PP0S/IG1./.K#5I38V;:%BR53RWFBON(O`2TY-)7,'./3A
MJ*NW+^E)V$JSEA5`+IL#VOAS[D-(^P9Z\>5;::-\JR]BWQ#W>!>GOMK4(%.H
MA$H9[,H[,\!M@-G=-F5M[F5;UJI-;<MI,["I^B+3,M+M43GU%&CC]NJ@V2D/
M&V1J)/3,AX@Q(E@9Q\GS-.0Y\,^'U&WKK.573IU%E)3),,5*6`#F1L:PX$8C
MIF<"666J(G*>$\8SXQV_;V_X\^5777.QSH^40RO[9#T]'ME.&)'MG"1I>5AW
MMP(7XNW2O,BN#M`ZQ84T95XF)]=0&6F>&>-OV[>TIH>"4Z\K:<['-?N2>Z(W
M4VD(+*HDN8K*"$YXY]W[>J\'M-C<]>>OD.K*Y671JY[`SU>C%/:MPVZUL=&X
MY<N8]Z&>-D+54(J`5<ST:!;+9SRU0'#"JM58)0@!4M:X@1$1C*.$8V3=8L?1
M^XT-RRK[@/=-:_!VGD+.MJ(-,:AX\,^W%5S?*F\\QM=+#E1;;RR(UB4DN&7E
ML@"SSC5$3ETX`R`ER0B4K/+4$S&<B6F2'4/H^WE^C:.$QRBL(LR6CPEBO$M5
M8YG\W`2/&?BYXJA:\O[MOOL`E=ZO6.JP@TQI%PN#ENX=#0GV@\<HG&V*WNLV
MA2VY;-T'9K"FIU0LH6J2:R%^.<3YB3T1H6`Y<=7U(*S817&9@8)S05$S,Y1$
M2<C&<S.+"V[C36=5JDV`.PL22UVGE`R)+,9/7&)2-FN3H7S94+ERR%</:2$%
MJY?'IZ,4J_/J37LC>YUN;2H"LRDM#.6?'3F8OZYC+$+9>I@<\O(#LI$IYWR/
M=D\_:Y=WXV!?%RKR3*0!WB%<HR&=)"+->F2$N'NX,?'4]8"TS#Q"I,0K_+E(
MP>K)/PNS`6*KU6$,C,&I,6`7N$,S'VUO^6[E[;J->KNU-=A9V>5=W"B=5=M=
M9*YGO>)LS"V?>9QQSQ`CD(C$0(Q&41$<(B(ZHB,4=SJ\SZ3VZW!TY!#WPU;(
MT6Z;XK@9PFS7SX]$,@9PZRXBD_I+<5<LQE;$+59(4I8LH$P(59=,9\<%7K-K
M*!M:RAA.`B9$MB-$@0_`SCO1PSQNCQ93^?[CM6YA!@?=.@NLIJ63\0XKYC/3
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M)>](SCCP]W`[ESDQMF]L35W7-ZXBG?`>53OZ<_DWA[)OI@9[<:6[[MHE'P?$
MA,\.'0.<SQQ[&^5C/H\-3O6,^S+DUCSSQFFAOEB.J5;+?B)]R7)5&/9^6_,3
M/^$JJCT?+75]/[V.[Y5W./[:YM*OX+K,</+8CV\[?MM7'[W,XXC7M.THSZ!=
MYFJB7^35D<9&ORV$].F?,0Y_O5LL9F_RHJ)Z(+>V%/W1KY3C\L\I?KA_]WQ^
M6>4OUP[^[X_+/*7ZX=_=\:EN\JNC/*8#>S#_`"CKY8[B/+K<ND0\Q`,_=*KE
MB9'9MM?'^S^9:99>@M=8,1GY9,O['>=L;[XYDO5'W,9M\J[U$=<I;M5C^+`[
M@)%]S'M-A\Q*_P"G0WC_`,.]T8^<+W2K_O&S[FO]_P`+(_OXB"WFJF9ZK'-K
MS[_.6&6(\/NNWMU=&BTJ<_W_`$X[A@?X)C/\$_9]R-JP2M6]ONU#)+!<R3VP
M*FH3F(&:\RPL\NG+&VKBS3(*#J#_`)%HFPZDV.9!%$]Z#!W=S]7+%68M*BM5
MWE6ZJJ2+&*5I79%P(EF9IBPRQJTYR(SGETXK&I]+FU=LLT0DZYD,DZ\%P3TY
M^H&C+KX\<.58:H]=RW:UCJ$8BTZ7:2EG6,GEG]GUVK->L/QK#EI'[K"&,3R]
MS1:./YNEKNG,]D16%F--'R[YCM=C#V_P=>?]-9,/X,>VVW9]M'MW7S%744?A
MK0AN7N9XI76^:?+XQMW..O2V^C=WA?BV#*XL]UJ>:Y2YF!ZHSSQI&WYNN?\`
MU?E>K35/^GM0PA'W\.-E'S02^95[VY^8*U5<3-E41\TKCF6<S[W3C,MEVP9^
M-N/F'>MRG^(*Q7G[^."O*-;\'R^R\?#H]I:NAG]S$9;U61_N?E_:T?Q99#].
M/:>8]ZG^SFE7_P#)J#ECVN[>8G?A[S9&/XJN7'#'M/I)W]KO&YS_`)MD<?HX
M9_M+%QG^?8+C@6*VK;VA/$2E4-$NK/OZM6.[LVU<>VA6+_.7..[M6V#[E"K'
M\"L9QMU`?P:=>/X%X_(:?YJC^1C\AI_FJ/Y&/R&G^:H_D8S+;:!3VS3KS/[Z
M\=[:=L+W:%6?X58[VR[5/_`5H_@7&/T33C\`)7E[F@AT^]CA1E?I3<OIF/P>
M79'+'LV[JG^RWC<8][O6"Q['>_,2O^K,='#HX/!G",9#YBW*8[+-?;+8^C5#
MJ4S...X;._\`WSRMM[/N\EM?'Y)Y7=V<JKN>U3]VK<=IQDK;61ET3MOG+=$9
M_B7*\Q'W<3FCSF&G^AL;/OH^]S$B9Q^_CVFXWZV75O7DRPN/QFT+@91Z8'&4
M[AY3MSV%N-O:63^+<K,"/XV-1>7VV@CI/9=RH;M]Q:C6S&5RGO.U]L[EM-I`
M1[I@+0RQI3O.VD?Q)MI!G\1A`>(("$AGH(9@HGW)CA]@M;C6!1M1-;(7:N7/
M.MIKSGHD2X0W/`0\*EI<;ON&TF"%-4TYK[.S>$O#-S?@KY9#[^?5C;"`]KF=
MTM\I;%\RPM:3I':"2$&CFR##+UN(XLA;\'R[6R5]R&4@8<EH;BA#!*3:<,64
M]Z)[N71@=N^82PKY5UW>2[D&KP)W('D0_4+U2O2??GIB<;B*"I-\-MERZG(3
MF(=0MIK,49PWVT%S..0CH*.O`T2&D3V[D-)5HX-%98LVF=S#F@33S9,CRX[T
M:OWL?_K?T?SOEV?E7;ZOY']]T_73XO<*:,NIEA<'[FC5KS][&6WUMUW0O]BV
MZQR_SBR->M'\;'Z/VC:%_P!)OF](AWH^9TN:4S_I,9#YB>TOZ'RWY<L68S^+
M%NV%@,O3G&(RVKS)N(S\+?/,"MI26?;5VLN9`1V2.,_`^5MMGIU#1?N]KKZ;
M%UHQ/W,9.\Q[C`]:Z%?;MM#W(E-4F1'XV>,[7CKY=M[<]P='^KBP">/X./8;
M3MP3'7X54E[YD,E..X`!^``C_!$?4I-J0E^T;C$5[*K"_P`GNUFA80:VA(G'
M.$>,3G$Y8J;IOA#XW<M5P4`N%+JUFY>'0(^M\G&?'CG.&:9F)Y9Y3'3$Z9RG
MWL5K8W67*-FEMYWK3:^9;>]CN6^4P@%F82O*2X3HZ<3R[[VBBEMCQ,*P@-AS
M-Q)=C4)+(M)5.F.F(XXWAA6G5+M67A-*M6/F)6&Y+BK86TH.#YFW][NYZM4]
MF+[O'7&4J5:A*("H#9?%F"ASBR6)D2\HG/H'/C&-AYUV\"?I3>J]@H7&3UI$
MYH19GPXYP0]!9#!8'G$Y4?0[G):->(E^Z#=L+%!CHG^9$.[E'"<\"=EKX_YS
M%0ZL*#D#59MXN.=6C7,)MYP)Y_N/)J$LB>F&+`_\X9Q[39]OU?&"N"C]YBH`
MX^[CYJ[<Z'^Y[M?`?]6U[E?Y.,HWNTX>H-RH;5N(^Y,LIK9,>_C6A&P6"Z<U
M!N6QNS[8/;+HJB?Q<<:^_H&/_C=\H;PO*,^(HW=*79?C9XS===$1'`-\\LW4
M1.73G<VHV5XGT]&(AE+:KH_&VO>ZXM_--TBD8S'9JG$3;J[K0SZ[&W6&*_.*
M<6J\_P`;'S?=*1S/P/$`#/\`5LD#_>QG$YQ/7''ZFA@"8SEF)C!1PZ.$\,9\
ME6K5)YZ!SUS&F3SR]:1X9X@1KI$1F2$16,0)%TS$1'"9QIY"<I#ES'+'+1TZ
M,LO5SZL#[)?<G,.X/=GM'APG!3X=&9ZM<\H,RU9:M7#CJF.."`D)(3D9(26$
MP4AEIF8F.,CEPQZH^KIZ(]7XOX/U/GVXU*Y=2S</.+T`D9EIS[D8SVW9MTNC
M_P#D6$_1=++M\1N'*++W`G'*^FMCVHNNKMB7^:=R]S37BNI13^-B/F7FG>-4
M9%.\;E&P[>4]O@:^1Z/1(3.(E$>6_+X=<;?M4;E<]SQMOPT06?7H+'_,-RWK
M<NU=G<6KKS/7\VIQ63EZ)B<9UMIV]9?TGA5$SW>88D>?OXRB,HCHB.B/K^;=
MMUZB_CV7+2/_`(A1GB=LM6'6D<^O9@ZFWWK8P==D&.1IK,#(XS'IZ)P"IN11
M`!%81=K6J"Q$8T@(E;2D,LL:T.580P9CF)8+`*)CJ-<S'1A5=`Z$I"%K'.2T
MA'0.99SP^T$^+HT[.?3SZR6_OF$SC56K,V\^G7MEJSM\Y]OS5JXSQ['=WE/9
MO-*EO8?=<M%G_P`7&:%;>?3W]FW+<O+C(],5A\93G5V3PQ&@]]4$?!N;?2\R
M)GMSL[>^C;")ZIT%.!7>3M9GE\*Z_9;)>Y3WBJB-4=D,G&JQ1W:L/3S8I%=K
M9?&\1MTVUZ?3.6(BKNE%IS_->(6+H]$I.18,^]]<RK9;YBW@P*-=3:@5L6S#
M!1!`+;K&"UXP,\<C+CCYNK8O+RY^'0K%N6Z93&7>O7!6N#B/O3QS=R?N&]N[
M=TMFY0_V=4.77&/Q9QRZM9%8/B(2M0_<6(Q]C?\`1CTU-N2SPS]_>$O`[.K1
M-/9J8^TW&YK[N?R<%VY8\2NHNE+,BG=?,?\`SC?VYY=]=29\#MV>7J\9CLQG
M9\Q>8VE_4[@-)4?@JJJ`8Q\S\Q;V/#+E7W)W6M/X:;:ISB?=QXQJ"I2'?+?/
M*PRM(P,>MO7EYA2+T]LJU^]BK1W3PX6+@R6W;A3*6;1O`Q&J?!M*9)-D1CO)
M/O=F?VETN2MH_%8`G'W"B8QJBB-1O3#=O-E!D3V_-26/[V)Y6[.L1T"K>JE/
M=PR^+S7+"V,1Z#B<<VG(AEU;)O%_;L_3X'<8O4BSR]76,8^=+?RHX9[KL\MZ
M/]M\OOL#]U..6=`;)]$_15^M8//_`'*]]'[A'^KQ"[-LMO;,Y<K<J[Z,YSU:
MW@*9]XIQ\JOY/G>N/R/]+T_)^GH^S'M"G36K!29N'F"\$Y,I[..H92C+C%N_
M($(S\$8F>S%3>+U44RE4#L6UQPK[+1D=*\@CN%N%A?>8SI'5ICZD+UCK*)(0
MS[TB.6J8CIF(U?5<Z!T^7;E@3W.JN-)[1=-@\G?]L*.*"78REPQTYZNW%G;=
MPR^E=I,$7#`=*[0,&2J[@F/Z.VJ,\NHLX^U.C<-OIW!_VBNMOW)(9F,::%S=
M=M#J0BY+Z?YE>&VB!]$1&/V@/\E\+^BZ/J_'_#]'J>CZUSM!LY*C9RUQFP]`
MR6D(ZRG+ABFU46H4^S24MBA62VE;4384R2STB$>OEQSF,+**=Y2WP[PS'K6$
M.\.IC6Z<F',9<J8X]>*:D@R"N4UW@AN@"A+=6F=&K-FF0[^G/3G&+(&%YTK'
M;!Y:E*)<%N%DJJ27.8',RWU\YRCAE@G"MB978LU6*;EK!U1YH;'=F8F-8<)^
ML0N>\'F'?=PNWI^/L7EU@UJE2?ZI[],S'7!3CZ(>+:KS$2IL>$!6O]W,PJ-S
MTDU.7$)R+$FTP6`\2,R@!B/2191&-PL5+*+*MHVNO2`TL@XYMYQV+$CE.11$
M5P'/ZKJ[PAB7K-30*,X(&#(E$QZ8G&R$P]3DOW+RAN3)Z7^"U/VIQ]I:5=/W
M\_;!CCST*`F'E$E.D(DBR&.,SE&*0U%DNHIP[A4@9()@SDG"4P7>R]IT3T1P
MQ51$V5C38PT2MY"8\X2!H276M@G,3&*&B&R.V#`TQ8V3A6D"5!<>]J@"RZ<,
M>WF:V>#UZ62,3X"QXJMPZ.X[CZ<-%.K)UA]H]1:O;662UTQV03"S^J7X,_P8
MV#5T_P#:UC+^U^DA\7[^O+/%Z=Q4#JJ*S;)07"0*N$M!BSC(E,`AS@HF)C%+
M>O,5S<K=4TJFE4;<=[?3$0=NW&>4:FC/+`8C(8SG/`>8/+5ZS6M[0.LZMADV
M:KMOB8FRF=4<[EY1JD=64Y<..(^C-@Y]Q1<BXYUQ=?:5O&!D_#V9YC[2I@XF
M-(3V3QPKZ0\-XO+VT5(9%>)SX0OFD1SE'7U_4W/3_P#Z#LW+R[?`5^?I_P`K
M/[86P")DSK/$8CIDB641$>[.*R>:[DSM51UBOX@A.I;J!*16"M60!:DLYZID
M,+7>&TRJI[X;8!ED+-H2JQX=C*Y&1JE+,Q/EERR+CT8KY2]TS2LIF',,8K,S
MM'3L$8'*'MY<K6T3C/5WHQ/AOI`<T;()A+FP_P`8&X++<2`]>>CP.K7E.F>K
M`E2+<?$1:\Q)'Q%ES4^#,+1[3+(>P@SAW+T%ZT=?#$DR=QU-F#E>X_*++3WQ
M"-;)$-7I^JNR>L4^6MYW&ON`@)L,=@\P'%FK8@!B38I-C3T=&F<7*6W;!?&M
M86(NL;@Q-!C:T-`K*JM0B98-KZXR(Z^7''"]EE\(W#:M=0JMJ(K/-0,+DF*3
MR+5"YB#CI$L7JD-4S<+M.RBO6A@:LB24,L.X^RK(#.2*>'OXV59SJ:RH%EI_
MTAV/::_?#+ZCK+CA:4+-K3+H%:QDBF?<B,;&+1R>YVY>;MS">!)\;J1M*F#U
M%I;PC^K^V)M%80QNCF,@8@ST>IK+I+3$\/L$[NE'BJ_@F;?O]$8S9<V<]12U
M$1ZUNC)$0]HS,8J;/>L<[FJU;'N^>=7>:,1FH>;T!N5=?=8LN):=48V8ZX*1
MN>YV65+#?#)>#J:JS'/>Y3(R)]<%^S/.)B9Z\'8FL>XV6^N[<C\3'N"F8A(!
MZ,LL0G;]-C8;;#-E1S=+=H:426JA,^O09,?(](3.8\.'U#4,Y^7JM@(W"TOO
M%O5U;8Y.Q;6$?E/,L#$.*.[EW>W%K<=PR^E=W8-FZ`SJ"J`CIJ[>DOZ*HKAV
M2><_;IP[6I-O;K#?$V?+U@N0KQ.OF>,V>['>VNY#>_\`$DNS%,INS=L[:BVA
M.R^8<MIW=7B^3K(=RD3H;H8@K*"X9C/3CYSY=WU1?U%=-\)_!;4>P9C$S5\N
M[J67P[_A=J2/I-MMN<1'N3AE*;!W<NZS9/+1'",IX<K=_,K8%2US\*%0.?IQ
M4O;I*#L4@T[9M]095M6RA(Z---,_*V=$Y$XN,]41'UT)R/7*R;ZLZ-(E`S&O
MU=69='VVY5RK7M+^*]0-B/<U1.F<>SJNK_>UKU^N'\15D1C`UW5/I2VGG1;H
M66[G8L+GD:JC%>,*:C$FV,BG.<HG.,;5=BK7I^,I(M^&JA`)5SPAD`,1`^J,
MY?5E7+W":\;U!\T?R;Z,;M64QGS,Y"+@]&6<%A;%AN-E\[93*XECI-A,7NPQ
M<"OSCT!;G;)+++3GPXYX82AW5==FVV"I`UAS;#<":4Q#YYC)XQ(\K44C$1.>
M`7RMR]2Y5L-!FFLS7M>I#5B+!`!\7T%EK@NO+%==?Z57/_;C!.&N8;HW2+-.
M0S(F,+FR'-RX]&&5TSNSEMONE"TG+K'AYVCON"6V$LE%>^43EJX%BDT#<R#K
MK[]F)%Y%$9'+1F2R/5'I^US!`Q(E%H;`S$RLM(GI/+U2T%$^Y/UK%2]<,3*1
M8,E$2!6,^1$Y];LN[V_5T'$5]TK`7@+XQ&H)XSX=WQZS)ZO@],8VBA:@8L4]
MNJ5G0!:AYJ4BL])?"'./L`<Y0,E<S(24<1SX3IGIC5'3VX@1&!$8B($8RB(C
MHB(CHB/M=;0IQ)7_`-PTZHL&H$S]'NVA+VY%,93HMS,<ST98KOE[F,'9+CAJ
M35TC<MU[;%219#JAHUX$],=.-M!&ZCR+CK!'932UZ%JKI8*C*Q'"2?J[,L\N
MK#2/<'*F:N^L`8H+'2S;KD10R[N>3E=/QXP\Y(`;51SHVWPK9;=1]'BX&JGY
M,99:F?<TZ<;A=K/:TK)^5IU'7DNX;6KN*`2"-'*USGUAC<O"W+`_,3:N8I:3
MK.J[B*'PM9!,_DQ9SJF9F.]B:DVQA*(K$$'79KW&JRMJ98641RHGQ$_B:,OA
M?4?<<0$:UF:*O,$'6S#^:3$P1$4^B)P;N5X*RIK%MHL=#'@(3&3M,K2SE,SX
M3I^VU@2L?DDZ;!<IT@HM:E:)9"]&K6T>$3GQQ2Y3-:9W&U1OY(>QJB1MUNWI
M6`#KDH-$=`EG&%RJU#>:A%A>@&SK399R4F/L_A-G3VC/3EB(?:B3.R]"X56M
M%.:&BLPD!699J(XU%ZOO8W!E!H,LT009BQ3M&AQQ`%&KEPP&#$Y$,S'UEFNB
MP51KD-6NR$01)(@F(.(GA.6>%VK1S=W"PVQ\X<9V.0I5EJUIJ2_4:5SIU3UZ
MIXXO&OYMN"*[75;JIE+@)827*-J\C*LZ(TF/1,3C;:S[4VSY`M@],B*P?'-%
M"XF9/E)@LAU<?MKN+XML06X(Y3!2$"LF0ZNY-EZL^4]Z/#Z(+*"D)F)G`V/'
M2;AW1NZ9E7"`YCZ+:+%Z1G/1H;G''/&VV>828VP'JZH"QXM@E[;W+$ZA^^G'
MTD^YH57=N%@R)?='Z2->J)D9F>X0QEB[#=R;8^D:U5),)(Q,#7:;`9&4^L0G
MQCH^LL!2:*+9I9%9QAS!4Z0GEF03P(8+!?\`=%>7TD%9M'N%(QM,I@UQ.;%U
M(PN9#F')"2\\HG*<7:OE<#6NR#JI[Q>`JR%<.^NLKB]S3CNZLH$,\\5*N[V8
MLW%CD4QD4*"/DT<V(&7\H>&N8C/[:[@FON!GX+=Z:HV^4J)94+&UU++]1POF
MCRV-(A+/AT3C=30^Q.2-JLTY;4B#65A\*N`(<H1C3&>83)ROMQNR_I"T^45]
MFFJ+$)D#AKC&TX1%.4EPX]F-\29V@LUY:CZ-Y$RHDP],U[0,Y.9\T..<%E/1
MEPPX++H7X8VI\!R#B>4/+\)9YLQEI-?7\+/T?6NIVU0ZM862GJ+/2Q9>L,Y3
M$\<55T:4*V^=Q17?$,/*J-YO+\41-DR./$&,3Q^%]1CW&*DI`F,8<Z0`!C,B
M*9Z(B,)D+5<O$#!HR:&;1F)F)",\RC*,:_%5].LE:N<&7,'UEYY^O'9A4#82
M4OC4G2P9Y@]H93QCA@\[=:.66EF;@C1.4ED69<)D1G[F&39L5$A#)!939#O1
M"X;W]6G0S1QT\>[QP2U6:AV/#>+6LK``))G/2Z3[VE!:?6XX$9:KF%`]R&#/
M$AU1`]N<=';&)6FPAIP.J16T#*!SRU9#,]W./M9:>L9AEU@NL3J*=;`2M`EE
M,Y#DE0QP[/L5R@WU+2&*](S,=PXGJD#RF,;4JZ]0;K8!U9E4BR>=S;\UWLE^
MMW"#5/NXO4HD1*W5<@9.-0"3%R(R4=8P4X!K`VWGAL*]L')9&H+*^9,-C4`E
M*9U^B<"=F:!?\XJ;I,+@RCV--==P!!+B!DC#AT<,4Y"PJN2%6Z[K%8G";*UB
MS;L#7Y!#R#!16(D)X$!1PQMJ=PC:C+;KU1G-4MDS<J5$6$#SX8ONO/G9Z>(Q
M.?'%0UHJ68M>8&6X!BFDE*?H9M6?$2"3@)U#&75QQ8"OX/E6ME;MQ<P2U(<Q
M[W1"8@"B*@Q8D8'JB(Q*":@E%<HW29W_`!"V54H7(*G++3J1W9Z@G+&WMDJN
M52G=K,Y(D),FS:\0,QW8[@>G[;6:1->B+*Y7SJS32]4SQ%BF+D2$@*,*#>6/
MN@5+=F5=S:1&%T"6$<T9GU7\8UCTY_;\-G*P,;@Q'B0K93J)6<QGGEISX87%
M^Y4K.TR:8L&`,T%W"(,^.4Y98_3.W_G`8Y%/<:EEV4ERDM$STCTSE'5'[L*G
MLM5N]W`G2WPQ"NA5+/*8M[B?S<"'X@ZV>C&=S=T;6N?_`&VSUH8Z/05Z]S(F
M?P51C5;N[Y=+ISL;S<B/]57)"<OQ<=P=Q274:-VW%1Q[XV.K&>V>8MU5E_-;
MC*MUKSE\&8<"[/\`XN,]WV\+U0?7W#9(81*CXS]L;)6-,=JB/W,#9HV%V4E.
M6H)XB76#`G(U,'K$HB8_=4Z<HGCE,\8B>KAG&?'$V'MVFYO8F\%W&U6H4%$W
MFP4SRV.9P'+LQXA?_:5T!(E<W3;=D03D0:I"<LIQ^2^4/S>U_P"GA9DBDJSH
MCF%66`CJR[_++2)Z,^W'#]Q^[]?8J5&.I[%4>=>[>46BQNSE3I=3HL&=2*BR
MX,='>*>`]<X"K3KJK5UQW%)"`&.V<HZ2*>F>F9^I9M?0S!I5BOIUKM*=:;;I
M6YK<A=:!'.&P,SKU91CS$%JGI/8$JLD-5_BN>AZ6.7'`!D'#RI@HRG+$OD*W
M)GE%7L4[46D6`:O7.4Z1-9IGNE$QT_4/=M@-=+<B[UJN6<;?NT1\"ZL?4?EZ
MKQC7'7G&(LK!B&"QE>U5=P=4MIG0^NV(ZP+HGH(<I_=57;GO`;=^'>&1.<RV
M%#$LZLHX3U].&[87T4JL39-U3Q"%1SM6J9,>:)04%CY+9OST/[Q@0!&T&93`
MB(VQ(B*>$0,18SF9G!KH55U@84$<+U=XHC*)G5)=7V/:*PZH"U=9S2CXM:JZ
MR(%]ZPUQ&'U"4IE.U7\VZ&@1\^NRKN-Z1YD3F,I,"RB8RD9B,<$02:3]JH-'
M,O$'XNM3GG*'HTKFU'#K@9G&S;GFME6/,6R.4%6&,NQ`VW"U3%Q,ZC(1RRC*
M<\XF,;24B@J>Y0!3>3#7UE&YPK37*5S)))FK*&%&CF=WAA=5(UBK_0^X;B?-
MED-EE-E8!6$CW8$N?Z<5++TT(.T%.U"5M<1^#N,0J.$C$@Q9.XE/<ZL&GP]>
M4CN=W;1R,X<1U]OB\IDD62A@_5G&S76B*G5QWP;*#YE?P[4[>IIH?+NB`^/Q
M`H[T8TI&GS!WROMI&</Y95W)!_,@)F#AFDLNSKPRJE"%LYV^,DB-DJ+Z/LZ)
MRSG/F6#/5/4(X68U4@C_`)/+(83.?ENF<3`Y9!$I..$Y3JCZH5*9\NYNUNOM
M:&1TIBR65FP/IKU1,H],812K!"Z]90)4$=0A&7'M*>F>V?J</>QN&TQN+QB\
MVZZ+:1!-BN=UQO9R],S$Z3/A][B_8#<B%FX5*:#A5.NE:64H.%-2$<(&1/B,
MYYXW*Z!CSMU8AEE:5#7JB:%RO6I`3,"QV>9STS/U:%M8Y5/,1_1NX1'JCN*4
MFW;[A??,2HDEV]W]S,`&`1*F!:,%$RN9'5$''P9D9SP;6&*UK$C8PYR``&,R
M(IGA`C&`:LQ-;`%BS&<Q,#C4)C,<)$HG$D10(C&HBGA$1'3,SU1&!MBRG8.J
M)D#Q)3"K@T<C(3C.5BP1Z>O'C'4]I9%@A*++*]4^>3?5GG2,\PF3Z>..5]%[
M3S=',Y?@JFO1GIUZ>7GISZ\"Q>U[<#`*"`PI5Q("&<Q(2A><%$_7D8J-TQT+
M7EJ*9]W*(C";:Q,!>&J`9&E@3T2)QVB48W>_DXD[*;1M0(1K(5+!O-1$SDU9
MK/,9Z\/Y<,`ZQ@MRVCI("-0.#HDAD26R)CZBN9$YH<#U3$Y2+%]'O3$\<.1-
M6HI#%$QIYI"#E[2Y@FKULFSQF9X%.$&I54XSD.>)ICD\E999<<SD(X<.(QC.
MM4V\TN*;Y64S7F)M*8.END>\3(DL^9U3[N*\Y;>.II^$RE$03M4L9R<IR(N9
MG,Y=>$V+B:T.@6@$L)39`6=UH`V.$BR(C/+"U&FBPUC*5+*$D0`.DI4`=,".
MF)RZL9L56$B83<S@(F6D'+)G'I*0X3/9BQ253J2&WQH;P7)K?;4MA+A7&=#*
M[(U3/3T8Y44JT+DU,T0H=/,3ERCRR]=>7">F,:9K)RDS9ERQ]=GRA_A,Z^W&
M<UDS,\OCRQ_F?DNK^;ZNSZOER3B92I.]V,HXYN72R'N_&Y)'EBDT:M<YW)%=
MU;VAZ%\^S71IL%EU19B<XZ9B8Q4JMBJ-^^FR.1&?A8)%8FN@2RAA</5Z\4SA
M(N7MU#9@L]\R>PKJE]ZO''7`:^OC/''@CK)5;(+%<8DF:/I:O;Y1T9G+,HFH
M0OB8XZ..(U4JK!:G<YK@AK)<3]N?RLI@X$"%H]$1WL^&+35KVUE:O4IL@<[:
MGR^S9\.8F+0B5\@N!#,:LXP^&UJ0#2;-.XR;7+$+FE4C(0R(,ZY2Z,N&HNK"
MP35V\K/*WUC9-ED49[*Q<3`=WFQSELZ^B<6A>A"W4MP\L6Z1),CSB]<JL7!:
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M:4<[F^"M!`,+D\KY%>X`)9_>Y_4`[U>7$H9%<PYZI")F)G3R6!D7#IZ<>,V"
MW:>E43+=AW!YV:]D/A>$M/YEFI9R]6-7+F>F,)O5IGE/'/2<:6*.)D6)</P&
MJ.)$HZICZQBZ))"P>F(*QKY<!,QS.*LSU:.CTXK"YZ*][0VI30FQ950-DJ.0
M#E3WGD"PF<YC/AC=JU1JDKW;9!VYT,)Q_/`ED!;Z"[O*;,3U]&%I``&8`.;(
M1Z[8`1(YF>\6>77]6RY7A>6_:T48A\GGS5;CXR2*(4<<OE\(Z]6)=$4QK_2M
MJ["AU\$V-L&EHT<KEZ^;&<]4QZ<4Q6&V`RILUW;I'4P4O>ZQ2-3CTH'N$-69
M+/CJ+KXXVYK5[>V*>Z7[F@LYB$75\.5\V@0:MO5$1&(`BK.U;7<VZ59LY22L
M/)H/5F$3E(EDSAGPC+"VZJIDO=JUWGSJ\0==-'PC((N5GSFEWIXY3BVP>2Q=
MK:_`0M^J.0R&FSG1E$]TH+CEQS&,;DYDJ9XLJ6AT1\X,:NWUJAS8*0CO,:B2
MZ9Z?KJ6[J"3+9;ZKCH&._-`Q.MN&7;IJN(OQ<":TH8E@K8N1&)"0SAJB7U0.
M?>C+A@!L)6Z%EK7S!@M!1&6H<^B=,Y>YBB*JM<M=VOM\"J%CX?7!\N=$</99
M<(ZL^&.;,5-0OEO,]EJBSRN7)ZNGG<CAVZ<=T*90L)+ARYT`_OR73W89TYX&
M952C6`K"9Y7?`CUA&?2>;.,>G%@X53L,G)%DH@&%FJ>`-^^#+KXQB<JE>,^;
MGDL8^6RYW5_/9=[XW7C9MKIK6`U6KWG=R`<OFM$35MM<LOA,ME!#'Q5S]BS&
M8*,YC..T9RF/>G`IBPN6'8;4$..<V4+EK4]&6L%QG]<;6%``L"893T"`1J(I
M]$1@&K*#6P!8!1T$!QJ$H]$Q.!5)1S#@B$>N1'+5,>YG]E\PT(+V%WPN^5Q^
M(=J6U[T1Z)<@3]T_K?*O_P!X7_\`*W'ZVOMO)"?&)YE5LR7?)3Q&XN<N$2BN
M4,CMP%2K30,MW/>U,)MAFF/HZV(M8/=(M3A.9B.B)X8WRK()T5Z="VAJ6$>8
MOOM3E)>J4@52>\/#CZ,54`M1%;"X0$UD#',JK`P3`YP4R^3RSZ!Z\7F!17IV
M\7!9$["X(;"J8VM,9%)D!R>4=SC'>B<"MU9,NL3M45>4<PN)W0#(`?+2"-:R
M7EPF-?HP&VWJX5/%52R,#)ZSL0#B<E=E.:EMK@N"TEQ*)X=&*;G?*DF(.9^'
M(3*^9_I-&?O_`%Q"400D,B43QB8F,IB8ZXF,1M][]G39IVK<ISF-LYA=W;MQ
MGCRZXR6273W8'NEU8*!++6!0)CQRU#P*.WIQ3KG"1MU74Q=N$6GN9<33&P(V
MN6P<DO,G:].<]Z9XXV:&5Z8-V_=JMRX<V7V8NHK4KU74,.7[,F%:B='1';BA
MR?"`57;SK.6+G*&T4;NO<%IDU@,@KD#(ZNF)GLPTD5ZE>6;4NJ`2XVDJU&Y^
M/(N>2]91$3ZW3GC<18JN'B=SMW%M3/>8NTSFB+8Y8Z25GETSA=9*3W#=+0SX
M+;*\QSWY<):PI[M:JOX3#[L>[BQ8NLA^Z[BV+.XO&,E\R!@%5ZXSQ"M55&D>
MWC/7]A;R_E.6?+_#TSH_RL;2-1MF&^'VRPX`K0Y;A=N2JUZ&-)32+0!G,P.D
MAZ<\0RLJ6/#S)O3T+*)@3+Z#NBC.>I;73`Y^G#V4K!OY.UU[Q:ZZA/Q2W";Z
M41RXC4^M!1EZP%EC<N:PD%765RHYM>(62-R&&;;7=`JF=="-0M*.B1SGABW=
M05JON:QC(UPE[<UW5K::)6CEO22\Y$H",QQN;9OV9I4*%!R8BFDSL394WG,*
M(4!R:]`SD.4#GQC%$/&652>Z;[4<[PM>'34K)MMH.GF585QD%]Z!TGGA2[.I
MB;FP:V`I,*FO=/:&.;XD25J8MK8[LK*-!]R8QLM%;+(!RJ=:POPD<KVVU$U;
M.9*C*2!P=.H1B>[,3BJ0/L7K4U]YEP6:RA.'UVS"0C0A4]T>B/AX4*;3)0=C
M90FQX=/,CQ9%%]64JY?LUY%GEF$\,1-IDM<%FXF6D`K)@)M-6HR$!$(DE#$\
M(C['2\QI6QP4%OJ[HA(ZF'M=B08;P".+#HM5!Z>L<\3NWBDEMPJYQ6ESS%PK
MAWID-71GQ[,!8J/580T8);DF+%G$]A#,Q]7RM_\`>%__`"MQ^M!A`,L7JY9R
M,20:\H/3/2.J(XX@P0H3@VL@H'C#+'%QY]K?A=N&0-*O$-C2V(#Y0>9+M)=H
MPTM675.*['$,C7!P0EJ`>J>?`P1Q$R)`V('A.?O8&`JKDHK!4)A]YC4+'0(M
M*?E)@>&<\<N&"6RJD@,%+*)#I!,YJCMCE?!ZXQF*A6?*E(L"(U@$Q(]W/.,]
M,]/3A:5QDM0"L([!"-(Q]R/KV(L*!R6A*VJ:,&M@%ZPF!<)B<3/E^T-BG_\`
M";JPR2N.RCN&1V*T=@'K#W,"K>Z%_9VS\,T%<H_BWJ<-5E/W\!B"K[IM[HGX
MEI,S[XZ\XG&H[U,8[2LIB/\`/QRUW/I!_P`&OM:F[BZ9[,JHL$?QIB,::=1>
MQ5#Z;NX2%G<=/;7V]4DA99=;3G+LPU\$ZW?L9>+W&X?-N6,N@9+*!4J.I80(
M1V?8R9!A57#%1KY4L`9?8`9CECT<TCR[(F<\2@&G#.9;KP?AW<N+-,"-Z=>C
M235@,EIZXC!J&R?-#;T[@=SP;IK0IWJ-RRRS+XN>#2;"UBBS8X*9(D%0=5@0
M/3I)JXGB/3A5OQ$IK-V\+HI?78MG*-HJ%N<QQU$<#`]>(6;#AQ/*K"(0TG2\
M4^(Y?+$)+.4\8[>K`[AS8\(8"8MF"C@90`QIF-6J3G++ISQ7KUVL![]P70;H
MK\Q]0B4=GOH,)RY@+X3,9<<\1]9-/R[2^DC`Y59W%Q$G:*91TP3\M=TXZ-*-
M64],QB0W+S>"&CE!TMG\#1$)/H&2L^*NYS/1WHQX=VZ;B^WIU\EN^6/$Z?C\
ME;EEI_%PUH;M<4""D'/#S`_2DL\M+3.P0++..B<%.T^;;+I7$3X>]X'=$]Z.
M[S9`%7($O0<8%/F2BNO7.1!>]4"-VVRTIX#846=JAJF?6/-?WV((9B1+C$Q.
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M[+S39/LBUMFV,_C2I""Q)0&S;R(Q\D'B-KML]`RUEFIJ]V0C`4KU>SLVY'ZM
M+<0Y?-F.JK:'54M_B',_4B;UVM4S]6'N`#/\`)G6?O1CET]QJ6&?T0N&'=&?
M!1:63]S[#)6-MH/*>DFU$,F??()QJ'9MJB>V*%6)^[R\:4J6H?BK`0C[@Q'V
M4ZK"(`,E%)!ZWL6@X>G[Y>$JFT46)N[ANRUSIU&=I!U;&4?T2AM?=F,&L;#X
M6W;$[6P>Y.I5>?9,B9CNLB)X]N'7%[DZU"F[C2(,P(4&]<5[=:"RU#"2'NQ\
M'%>NVS89%:@K;UG&A;(!#EN0W.(^5`E1[N$W2<R;*K<6]>0Q!D-8JH+D>I8+
M.??G`[5)LE(:=+,XAL$M\6%EG$99BV,%:A\E<&XFU9*-&9,34.JA9A'J`-=L
MY?6$`--`VK="D]ZYTFFM;N)18*#^!)+/3GU:L+JU5`FN@86E*QT@L!Z!&,><
M*5>M6:ZYY9VA(2_2"UFUFX##S*!D_9]/#CPQMPH4_=;%'R?4K;A=2`MO#5#<
MH7:OJ`N^]BEY\.G+CC>W;5X=M&SLMNPMZX`O$$:R(WL/+,WD?K3/>U8KR\1V
MM^W>6E*JU`R_YVBU"39=AD0`.51.-&C+4!<>C!K8`L!@R!@<00F)<)$HGA,3
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MIK19MK`YK5TCG,&>648WUR;UX[7@+=[QD7K7,BQ`$T2K'SLT(&?4$>[IQ53M
M]JW-.GLBY\PU[SGS\]M*0>V,K(M3+H(H%DF<9`49=>#J74@])]11Q`O@L4?K
M*:'4493$XWK:[U\+>Y[4<!M(VG1-S<*]I:YV^'3PES@8<@9=<#BYN]E2MQWE
M=%EVY<M1#6.<I,N-*C*)E%49C2L!R@8PX+VW)!U8U"%NO'+,3-"K(/H6QR>E
MB)9E.4\#C%FM=9+[6T[A9VMEF>FU%?EFBP4?TC*S@U_?9_88M(@X7+7J]I$0
M6JNXTGPB9X:@^S6&;<PUVD#%A<`(&3X04-95TL$XSM+&0B>F)G"C2RY[;8M\
MMZ(J+9*;OS=FV)F11.3EB4CH^%QSSQMZUW-S>V2IVFEX$)@U.NJ"RAQ+JZ8%
M263W8@2&(SF<>9':30P=UWZRB6J.,XEC&):(E$<P"Z8[<#`[C:`6LJ#8ANVO
MFSMH'1;[0U^%KFQ=S<%Y:XU"/1B2&]><*;>R@*XHK77M+L#IOR7S8F@OX4]_
MV<XL61ML\5#E@RB=!M>4$#F0VNNQRVQ[54<#TD/#JSPQVEP<S9ML*V#X&'#<
M*6D(V(#V</BO,9Y</K'U+*X:BPLE-">L2CCT<8G^#$5KR'[[MBNZC<J??W52
M8]6-QIS(S:((X:T\9B.(YXL[G4W`!W2RI=:R-FW90Z5HDI6HJ-PEZ.61ST!U
MXC>1S.]%;PG-BVTE^%U:^5R(9R-,GQ]7IQN%#DRFCNIM.[5"[937,G\7\I8N
M@:T-GUH7IB<;?X^ZB+&TE![>87GGN*>[R]`37:5QXF$Y2'>@NS!5MFJ6-LJM
MC2>];FKDF"RX3.W[>4\\WY>J38$8[)PJE5&86O44D4ZF.:PI8Y[CGB;7,*2*
M?3AK$H*RT`(@0!@LFE$<`$V3`#)>G%;:&;99\JU76TH.>YXNPIC1"8#<6:JB
M]43P(/5SXS@1CRI=*(&(SG==JF9RC+.9Y_'/'[)W/UIM7_KX*N/EIQ/`=9I'
M>-GEH!,Z8,PBSJ$9G'[)W/UIM7]XQ^R=S]:;5_>,?LG<_6FU?WC'[)W/UIM7
M]XQ^R=S]:;5_>,?LG<_6FU?WC',MT6;>W5,>'8Y+RRCH+77(E][#:D,Y#9E;
MJUB.,U[=<X=6?$=>AP1GVQ@*'F!7T1N7!8FZ?^7[@4<.=0N?)9,GCRSD61V8
MO;YXQ3%7:5:G%843&@*S&L6?B.>4',RV<^[&"W5[:[JC-I9L[=N;5UBQ#7B\
MR)DMTS,D.7J=&-R\N!N\G0M`^O1.S6EUC;ZEC/.M+/$!XD4ZIA<SE,1TYXV?
M=*]T*NY;97&E;L!7]CN>WP$"5:RGG9QI*-0%JF0G$TMM&=XW3+NTJ1:A7/1J
MNVN->FJ)Z=4ZNR)QNE3=7`Z_O9,?>M('(4O(0%`5->90FD*A@,^/#/KP_9/-
M,NVJTVJRB=\5F5*\HU\F;E2W"VH63`G.09D0%.%4MG-N^7%K%2*]!4GS"&(&
M"L606%*L,])$11@_%D!WKUJQN-^5Y\J+5J1DEJSX\I"P$![8'[`UI<!4LV%,
M\(B`&2G^#&U:XTFZOXHHGISN,.UQ].3OW"VNX(8EP$M@3\("C*8X<>C$\H2S
M*!B3,S:<B/`1U')3I'L^J1",1)\3G+B4QPC.>O*/KM%VE5MCT964*=]SF#.6
M,_HR%>BO:NUQ_BHL+''Z-U^AUW<'#_$;:,<94:%.IPR^;UU**?=(1@B^L.M<
MKJLH9&1J<$,"?>+HF,"(QE`Q`Q[D1E'[V)7Y9WM&V^S(75C1`ML]/R=_,BK9
MQP]7W\;Y7M"FAN+6HL&S<ZC;ZKZ8&0CE;DBT&>AF><<>G/&K>-FAM0?6O[(U
MESEQ\9VWL6%P`B.G1S<*MTW+L5W1F#5SF,Y<)CM@A*,ICIB?KSKV4JL(9&1J
M<`L64>D2B8P1;1=W/:-4Y\JK;)M7.>RK;\0H8]`Z<>S\SP8]7B-FJ&7OFIB<
M_N8[WF<`C^HV6I!?=:UL1]S$1NVY[MN@_"2RWX6J7NHI"B)CT3,XBO2K(JH'
MH4A8K'HRSF!CO%PZ9X_9!VM$_/=^L+VFOE\$7YE<?^"BD!SGVY86I<9+4L%A
M'8`#`C'O1'VGJOJCHVC?K7A;]<>"JFZ,&9JW4#ZJXN%$@V.LLBZ?W/G,Q$=<
MSPB/3,]6&>83B?!(!U'8@+X:I/YYN>GJFTT-"_ZH<_A?:BU2URIC1@D.CI19
M48MK/'TK<$3C*Q$(W.H7A]TIY]^O:#@4Z>GDN]99=$C/[EY]ZTFLOJYA1!,G
MXB@]=K)^*,3.)BRE^W>7(G\G;!(O[W']>'!E/;_O)B&,Z\HP"UC```P``,9"
M`C&4",1PB(B/M3&X4GGMN[K#2N_7B/:!'0B\F?9W:WWI<1^#E.(#<=C'<<O_
M`'6R64Y,^^FG?95-93V0989![7N6WPN![U]:%PR9^"OE6'3,CU]$8.SMNT6-
MZL1GE4KL2LNB9USS2B2CT#F6$4]UJVJZZX66AY=IBFB;6+#N^(.\U,V!7GJR
MU<<L?LGNWYUL_P#B./V4W;\ZV?\`Q''[*;M^=;/_`(CC]E-V_.MG_P`1Q^RF
M[?G6S_XCC]E-V_.MG_Q''[*;M^=;/_B./V4W;\ZV?_$<?LINWYUL_P#B..=X
M=G-Y7,\+FOFZ].KDZM?)UY\/6T^G`[15V(_+QM>"!L;BN+%@X,]&JOQ\&6>>
M<99X0MFS>97L!2Q8X]MC4TX&(-DY.R[Q<>&.&Q>8I_Z60_YS!Q[/RUYB9V9U
MJ:?_`#[R\L95_+7)F>@MQW2JJ!])!4BY,^]./GN[4-K1/2K:*A.L>YXN]J&)
M],!&/%2+KMWJO;DX[UD,^GDD_4->)[%P/VOV+]`_E,_EGZ8_)V?HW^L[?O<_
ML=C]!_\`6_5_X3_:_B>G%/I_):_K>M\B/K>G]Q__V@`(`0$#`3\A^8PT+BNZ
M6CX"TU,C<NZ'<]`,JF5CPI5E97*%NMP`@R5N`>I'F5/7U5DX'@O,C&27CQDP
MHJA.U-W-E^1IK)"`6,DP1\`VP%<1KM$^DQQGUUV,!SCZP1.>KDI0T85XC+EC
M7V\8>L/$<^:U+TZ4K8-PZ\0E6_C@*Y&2T1J-$)_6JF62Q.A>.HX945I4@W3S
M@714EH>B+(J>1_>U&\,1W!4K?O%:S@<A;?UBG2=B=)9S*?EK;(S9(=`^[&"Q
MJ:=`("I6*,`P.--%.`<SM$LXG8^M";)E93)+A]LPG,);OD?DC<4M^8F^A.-5
M3T-0NT:/(^N58XQSWB^LJ(T:AGQVKK5&V86DYIP``M"UY<P]=BA8)E-)<F`N
M'FK2(!6*B&J`S'(.3K)@--DOGZX*[$:GAARZVBQ<+E-U#G#:FRI0`@SAM-B`
M'(H*:P!C7H<$-H0JHDP`#JS$5LA#$P5?69H(*%%T.'78FTXT6%8;QM$TW!0^
MR>"H&PKR,7%$R0J7%F;`V81M6'EY%L%7'OJ!BP')!V0#DV?5:^W%#.KI(,2T
M'X`2'T;`%!#`&!N:5>!'1"4+BAG=$)T5`RO[QTK@M>18-XF80?*+X-T8P<R6
M2+_EHTN`KIXX:E4$L1-RZ+A!,P)-@!H.=<QQBB`2;R;+E(YFUXQB#A47G-"-
M#+]`?@`[!M_FY`^!H;1E<#(,P'T^W+ASE.6GI,!_..'.1FF5ETB2=BTIDG)C
M@.',>#-F`D'("<)_"N*&:EZ(XI=6K`P`V2&H+:L+V##6"N0X3E1[1#:`<JCU
M6('&QU#RX5!C0D/K6#D:L#,.!*#`KLUL4(MU6X!Z/IYA5"G'6)NRK%I+JK#T
M/5-@;S1[9!WAN$V#=K*>VI;LINK6W+%]%E\>**@>K:J#'U5MSCCG3Q^^_*XZ
MP:D,-#LWSJ-MW1I2M6--08<:L)[L(-=+G*9L>_#Z,4#INN'(#>%0)GM4U^BV
M"N3$V)6%;[6MN#C-%`H7#A.>9YBU"U:LWI/3^S/N2^WS7F`#^$4+$>&N"6+3
M>;D)2>MTS#7$1.WRQ&6A@^Y0J?"X-*CI*<DF?;!;T(?G7/3Z9F^(2I6H`AN&
MU]89`CE^X#HO+,66]-V(0N?0W*-9U>9]+B[JC;PM#;'UPITQ)%T6`:S>B:D\
M]E<_B9.MFLANX:.N4P+CBL\Q4WRW[3%Y"^?Z<=KI%Q\T9BB_P*8JU-*-\KE+
M+-MUOU'\YN$8K#>78&1MN7E+EPWHH'1VZ/OR&6YU5:]>8M?!Y\^7O_1'H4N(
MUB;Z65'Q8#C\$DOROQ?=C8/1+Z]=>@$F\T9G!G-!X.Q9J`ZPX!YJWO0U.W.-
MZ9P*O<@CK:V>$R1D>*[0B_?!#GY%1#`^Y-[HUZ*FN`'(>Q,.](C9=*FY^U.^
M)3:<&MGG#LP]YF6`&VPJX2/<#Q@(MPHZW4T,#GK7]<A,7$LW385_()0^=#5=
MHL9V2K@4,L2%8^VXP6$)NVLCHP,F&9ZHLV'(8I*NVX\DU1=^.J(2H:AU4*,H
MA2/,U+WE[:[G2PT8TB%TO@E27]XEFYF&[7)G"YX:(N[J#+(UJA>6L!=&\GQ?
M'2C'FP./V_-.`[Q*!MO68W:.0BD9FNBZ[!;F$7>*L)6"%%])]5'6;B6^Y7K%
MSE5T4OO5/]U6`4?J@:\I*ER+D&44"SCC3.+[8PA6@%K6LH4&M>E678JSF":=
M!@WXL=I+BI1WRLRV6HBF!J55KQFX=.VQ?6,J7!Y)*EFBAM05,0"=$KHC%5Q<
M(A5',T0&/F94(6U1%R'%R>&X<>7\('<!`9.Y8EFM6:K7:EGM&3Y'^Z;@JF+J
M-P48O.]8JWWE=CF#==:B#@.U]TAYQ=QK:@H55E!;HVXE^:(H];LB=VK@A\7Y
MUU74TYJY>39:=,H*`!8@$ZB*(^"2UQ8JM)J1G083'41EW&R8B3JP\77-G*15
MVV)MMLL+5?"X&$,;F,IYD86+)3K`:NS(&VTF?'QE)R4EG)4^^;T/9J63:`WE
M;JR0\*QA:FATEQ+\@E:)V)3CIQA0#%S0%3RM:R8B';.GJ92UT5WH:.M.)5D[
MZ:`G).Z*O4U7+DPT````!H```E?%W8N!QAV4R8SQ[KT*5D\++;Q``0`#,KFP
M++#SHX9T8I'J3*#!G7A4J5*_,K^0G8\!`;S`]\BBUK7*U>M"OI$PZIS*=58F
M]F9X`T-M<I.I1WG+RM#;P&6SKLLL*9=AC59_,]E8<6"W:(QS`QU4A.1:]$,L
MI'#IX1Y'5?#2_62,O\,WECB8D/[')S5&[F+Z.F7SE/6H"`W0M11N%0.WR5`5
MXS'IR[40W94KE!>D(T".9\AZ6">@SC?!2(;;5]-03D>2W9E^SAVJ'[K]`TH=
M;<%8?8=GBQ%F.$;F`?HB)GVO^;B*MV=B"*2O50/%Z#^%86&$SK$R]8<UK(6V
M92`<O3E7*FKU5=U`(N>&+K'Z9Q@%E4THR+8OM(^Q_-*=_ALUXV=?AR_&JDCA
M)ENW0V`H.052IL&X8;"N(BH&P#JE3%O%^"-H@@'BBE;D32P];6M[&7,JO=FO
M@A]&97W<JYUT-%[LAY,Q$E![?%M.19]IOH_"/1TF*SCUZ#EF>0Y^0FIBH)!A
M%RJ!BA6?<IOC"&3(^3RN*AV;C5T#7(K2"X.#<+/"ILCV>4.3QT<UWA2V@7=%
M3/%@ZC$$R_#<OQEQBP2`=)!6VL`1`J,W9M(P;!Q<LZ^`)(X+BEB0/HNL=)VA
MI%FLS#)]/4T-QAX"BT&6:1G%\IP77$<)13)X3Z6_&:EK0I)-F[8)L8`+XQHP
M\*_W06Q9LFWK8*:+\>#O#YVJ#:8'2/$/Z+4L>#ZEZC:B!N"M*3MX85-04B90
MBBH$E@*@@5#*9)!8;PBR3P-@&6-FM2&FE:L4Y9HU$NY?;KK@ORK'Y9J^GY@"
M']T\2+Y2;C+MT:,GAB*+FJC&:)*)N&NJ5W/K>L75I@"B,T8!+4$"UE%@8JX;
MJ`RP@TLI<_#.>!5(5JQ>L>#J5I#A**>@P45Z@]E2'28!RSFA'"#:3K5J+:*9
M*5TTA!-7I]XH"T$\[8>D<]\FHZ*?@<.8LXH-6]X-:6:MTA]0!8P(,H!P;C7@
M'PLM;BYX$V\W5LU"AC4!0PO2<(RLM!6LXJUS1RL<:-35YJ:KOML#5*Y8Z+@3
M1,=V3,(,JH,MX#EOH1BF<[DN2[4J$.X?!S(/I9M6IL%OZREB=I@$UFM+)\I0
MW7-N+F9RETD2F-S=@)8`]PDOX<3=D"@QOR"C/27W4HC?P7M8!-HC`J_C^T6Q
M<HU`KX>"Q'>&4I4JUIGZMNA%/AV^O!3+A(=WSV(O(F5$8R(P@Q]R$J6(J,J\
MI54U:G@\RPJF@E.+,V&ZY)UOO"#HCV'8&.W'31ZL70!M,1%%3XI#_P#N%7(V
M$H*E27J,&LPS,8)VV3J/H"0I55&>])3C9.UECHI]./+Y*DA)4I'-#+ERY<X;
MN;T3F13HQX8BY=6I%PKB7D=F$ECG#I3`T;R>-$ITE'24E.DOV>`F<+18!=#<
M,=A@]5``:^G&]:LNC1*$;84-IHY(KA0>&&*=-A94C1%:IWP;P\DX@I60;:R%
MR*1;>=#Z[75M(]$NSR>,&U3SP[)PF-F%*B@`4RP%-\LA8@IGD:+7W_D1$T2H
M.<.-\Z065W0-?D%B0`(B.D;'R3'U6AU1:$N&9$L&3@8$$>;2:BQZ!<=8+@ZS
M>0H".@,(J/6TR1&<.5W!I0*+-8S8VGI`QS[OXE._NRDR+Z"CO8_-TS+2Z(YY
M99A%)=HG%R.&+3DU4N:8;04*PWZIC4^JL.QJ!]Z*VB&(IWX1Z%D6TP(7<K=*
MW>$M0%K05Z4:/U)0!((,=.\Q;CL:I&:7!<L#4-%^(!V:"G5AV0AHG.DTPX&L
M%1>_2(`9@[%M12H_M[*-6FEL'3]519TS';:904%@P$K3:1=`K`-Q7SS5RQ]&
MM6UB.T:<H3H-&V-#`67#=:@:C7*DS?P:E?CPPM+)!T1@=E`W(`<IB6XFF?O,
M.7$]*J(&ME"+)MC6A6SHP=XOO#]"GO:HO09-O5<W*+,65"V3='TI@L`ZBZ1X
MJ?-""D;,.#+,TAZ\:MYA8@K,0.OY2)#&=?+)!:&:!6<LHO5X^F/*;02N9P58
M^4$VWJ8LV:I$<)<,*QGD[*(30'J3&;C,),T!<7*N8-]@.*!,HIS!-H&95@Y;
M4%ZQ+6&""^E!7,E'!^%8]1@N&L92X^((JM0))F"X7E>X;2+$`B<%2N`=;C,S
MC$132#DE:![W&XKDX^K:1[:?!5#ASIPRVL:$:FB="*V]P^17\>_.>1E_S6)V
M12:OD$U=T7*%WXCH#9Q-S[2_N"W,Z916UMN?Y:>#Z3!(N<,HEC*_DRJ#S(%>
MA:8:5Z9D8HF=.SET*1=("^HQ89;9+@@I102T"P\H&/8^=8^FZ+:$A>9-<^>J
M\P1_*")4:!H&R*)PLN))"\A6KK4@TW5MN;A[TWEIN)7("Q@%]BF2M-JW-H'R
M;_7S.6\9SQC<$2S3%%+FZ#J]NL&_@00=VKTW+E_`L?O]%HKQ%=`8R%$^RE;4
M#>/>4JQQ5$P;$&AS"\(44G,I1]U2XT<V;"DPJTK9KE'7L<8B1\I`>!G!N:N'
MJ"&!L<4T!*EAD#A_E5_T#H,EQ>'1+YF<A:32NFJUX0VQC.AMLLH#*S&*0Y<`
MI3Y9F.C';#5L];F*TH$VUD0&9$B=;S6;),DMA;5B$ZF.B@LG2X*7-J2)@5?0
MDR6CZ:/<_!4NU$`XE9H%D`T#"4ALXJ8*=-6NSUTTYN7Z=0;00)XM#B9AC*J[
MS4B;:%,4#\OCAC4QO*HEO"IE&U&:`'"0?[_?@LZT)=_T$*'!;41RKH;-HK%#
M<6F6S+9V>Y,23!Z\!(+;P9:=`_&[M)67;8NH;)OYHAU\&QO'[481;E=66;_%
MNH8`X18XV``\0E<T6K'R;5T0)?ISW"R2)A&)N"B#K4P`RPS1C""ED0$`04!(
M74&=HPV5,+-(9DE#5NL*N'M5IT!1JQ&QEDH;?AJ7>=/0MA<JT$WJJ3!RT'#%
MC6(W\<>MZ06P%64UM=VN@L!YR'AR@':#>Z<P#D93+Q0^?H!VPK<2ZTZX9EL2
MN0O!!6\H+\]!JU9;$M$Y.@CH50M,]P4W)-9J+EP=,6]=TA0MBA-!E'@0"@V/
M=XX1?UGP`\\%EY+%"V):KOP).(BBFP2#V[S/KCYU-2*\K]MB!7@"B3;;0-'O
M2%#8Q\=ZY1L,!2$%7F_YG"CDZA(L<U1BG"K8>B!.GL?H.0EFTHB`[QR:-#6V
MW426/_+HES`@`Q&4I8Z%S@BJY1V*#"U;RVB><3!J4,;JEW]J.8?Q*[L?X&.!
M3DTL*9_V>[NQ7&Z)B%E*NZ97C5I<$1ZNEN2;P=1.89Q?T-12$9/-=%QX!=!U
MYNX6-;PY2UWGG0PSJ#$02Z&:0Y$;X%HW,CS_`$Q]+/806>=A*"TMN%O2<N+B
MM8SC1YJQ*\N%?!@]0[H*`[C-*Y=.+E,CFYD&U05/_8,@E<44JZ)9Q8"LP:'O
ME7BNU")KT4[47H5F+4%4K]J.7,IEW&U7-25KRX`,"'@RK@8A92WFXFH+X3KH
MHQD%+R+Y-*^='H='?-S+_*"!*>\27D4A6:6B5:A#YY^*UT3X8>>'>8PJY&>$
ML-,(-)"Y\"_2Z5O$FTCB#?RRLU#@M2X$Z'?%!OAU2V^/496<UY9;%?Z5I<U5
M1`U%305F5SW+L3-W(Y;?0=*KFD:&7%5Z'!Y6T!=7"B#AML]5L5?R1T86@AF+
MK`Q=8:`_DUG0ERSKXV1!-CYSV1VQ],CV91Q=L0--)OIH57<LZS<IT_4I_P"R
MF.T^ZB4U6/3_`"4J5JOZ/_/%BW-TG].LQBSK\)]%_AQ@8\2L_P`@(8E)"[G`
MUBV0K:3>-W8!@)P>^!RE%MM["-'0Z.H@QPF]_2J.^P-3;&9)=%("FD"T&=K\
M27%B'&EMY9,CM2M4S7Q4!<4K.Y8%5+!T5P"O+A8$$'([78#)E=JE$F<``6$#
M9I#B:@2RDEE)G'LA+8@D?,NC-VC1\(S<5ACC8:2'I0C)-N:H)5.M+5XBR"<I
M.T+=;07A%??JRMP&GO)R_DUJ;*CM_J()2V7?4-`2@ZXE)+\)Z'H5K=-Q5RN5
MH.ZBUP#FIB^*)"DB'V@:JAX4J>@0N?*AJ,14G\JK>Q),2\NX@7$!"#X.5CUF
MLM8<Y@57;2!3.`$:#.PS"@,>A;+N/#5FZ!F(<&FP57`YV*M5,6;V=+^G0;NL
M_+4DV#'/1Q&6)F43ENO-B4<;?.J8?SB:0B\X?D-2J*0)%C&BE-A"RJ[&/-*!
M"&P()61I0-$:W,#K70"DL"M;4`<O;<.G=5S*@_='.R?(V*73+JO:JNC`%"PT
M=SEY3]?8<M!\9]+2Y4(3N&4048R\6+3`!\01.LN;=%.<%GM"5CCAEU@8-)<?
MA=607JUH3,Z8X-=V[Y&Y2+!VRD5(U#J)SU,2,R=;-^51\EFY",=N!3(E=%2U
M0OFN[15(;<EQ4X'.XYK(NPUN)PO`Y>.=D5RCZ"H?ITQM+39B67IE-7I@L\H*
M[1"-(Z3L?#+\`UKY*6H(4Z4)7)"KH_KPHZ$P'`;A[WY7T-L18M3,EFK<R$AH
MR;.D1F_81Y<L.I285T$LD1S@427AD2JH@X6E3Q#LM']!TF@@DA@0/9<!@&GX
M$N6ER7H!7Z*W*P1AZL:U0(F-=R1%DP)`L,L`%9QB;_$2$[^^6&+!%5UVBZ%]
M9;3(YQ!9JL-X)A_U3^*NO-D9&GQ<,JX(L%JY^1P^(,&UR-;/!FE*\P]EKIW4
MHZ;0[S2T>22\,ZDN\KVNK#J2T[?*@*2\8*KB$W@J;%U?NL3:T<Z4K+!1LI\A
M`4@CL2Q])UF,'5Y68?`]#GD+PD':'_(3YM3$5,A@V`2OM,G$?J'3;B>D`OH"
M+4;!0&Q&BQ*DA.F\JS-S`&49?'@96J-XS%!#28U!2V!FQN&7?N(E0%=9,2OX
MMX9>JBVV[G3Q8\BTGVW/SZ%9W$*H#7[7+F6\W>.9,I#O15;">7`EOZ$I9/-5
M0!A.:4E9Z\UO,N:)(95GBKFVR+&E2<I-U=2,M/7(,$EZ'2D:`UM#EFD=1CY3
M[T^=.G3X]J'Y1JF@V083`D$@"64X#N_2`R/P`X61O;*G$?E5DJ-GOZJU=%&(
MLWR_TO.0UP;GH>1E:C01RX#%$HV+6'2R@,[7W;J42V6*H+;0=)YQII*:RW+#
M%X-<#E%;@*2Q49/VL04J1.;E6[<H8$D[FC9B8`H.E&V+QI\B<>\`BC+&-0V>
MLZA\T@P2?5-%%`!1*@8)J6+";9I;&0#&LGNEWR&Y&K!H/"JYZ#5%D4;*U(ES
MK`T];E&S\Y>**Y"W)6(P0@4M->`5FBN64QM2;@""":/P6=O[JNHH!L3*+)I4
M(5UZB4NPV)6Z%ME8^IHI68@FRU%]ZV]3:`I]W(61BNP'40;+)!>9@BH;41"(
M);-OLL_2Z);'>_SWD'!A11%J1%,.D-"@N!J:=A5/""061!@"B10V(%WX:27/
MOK4)B(H9^/MV[=NU+2(E]TF71=DN/$-;/'.!U#F:SL36##F6EQU;<2#4?XX3
MZPJ"I97&%&1\&,+=<S'OS`FW@H)F"9'@>5@`0YTZL4C`_03/TH793+`<CC0R
M*9DLLJ/S3XDT-/3"D+E\`N6(X+"M6@QA<ZE1QQH)S8Y^0P8HBQDK@`BSM#6-
MG9P/GT2B,B"Q!*^@6MF3B!FH&P</H:&.=RB41-G@<,M\H'3X:+NLFI@.K2H/
M<7Y3_P`8P6/>D?NX^ZTO.(%HF08YSX[K*;K/A41#PO+C4G`3(ZE-1;T,&;:!
M%7"P#=+07`[JQAY:!E1!LEWBS&064Y"U*!VG2)S2;N%_*BJ$B"2I4J5X]J&!
MJGFO<8GW2B=%TTJX!-()@'>F22-7F]K\GB+`^%/K!:>0$E9],CP4A896+E\.
MP>7&8$4`'0**\CY)UX$Y-XC8Y\*N2`<(?13=A?1*E/M8A_\`7^H@>`4`,E`!
M4<X;+Y_C)A(55`+48`=8'6[,I1EST[*`HKZ.::IMK@&ITY=O"&BSQ9AM+3\%
MG7Y=P>_P+WF89T^,(;XQ#TE?M*#1$4O^?+$IP_S&AD#@!](2X:#V^:DMAPME
MK)':1IQACEQ:4BL8!,*(5IR3)A90--5O,!E*J;I*T/N')M.DLV!1#Y&;MV[=
MNW;M_P!J;"YP'^U=]G1#P*I)6M%=56LQ"YV6SAUW!G$LZ[E?QG,>5'`7NW?5
MF);5P4+H/]H&)8<-^+,IC8W?02%)EP.8`Z_3&=?+PST7M/:>T]I[3VGM/:>B
M/IZS[OS/O],^SK[5[^#Z?P?_V@`(`0(#`3\A^:#T249%>`[$T9P;M>"[$/J]
MRBX\%FN<XENQ4Y^$ZZ"Q?L)90;8HE9T_W#ZO6.CP%K*'U@,&&.G@#&HYW]:P
M!J5"65K>LSSOZX`F989"1>9$\%W&[`KRB4UOZY7T5`;!P2DIBPO2=7<M7>6X
MEI;ZL`>E/*9="5YD02G6`BSBY42[)<"3B928YB%L_F,O%$Z1&P$;+NG\,P"O
M9G9G@CW`C)(@TQ'=4"M?O_C$G!\K_P`)=MA7MORG??:=!?:5[^T]?M/7[3U^
MT[C[1_\`)*=8-_U_SPG0G*KLB6T><IYBU!'POY23^L7Q&%R7*0A1Q.99,?*4
M-P1U*9V8=(1.KOTF+9.\;L4/.XKQ[,IY]B<6:CS_`),KT(\I'MO0CRVCRRZ"
MW67XG>G>G>G>EO"[TO+.O(E^=SR$*:2OFSH4]7^Y1W?XAV:\IUOZPQA^8]J0
M3-"/!3$-DKH\<?`W+E0$ZB9ATF@ZQ?+4)[Q\3/2"0Y*(+AM>T_Z#_(''X1$Q
ME*](]JIW)GJ^'*R9=TA<'K&@\0.42]:2N4*#J)QZR@[RLWQ\[/$SX.86<O@@
MZ7"%G7\2UTGO]F-,/O*-4S;#/3P&H\#.3F=26EO`N#<$U.\$T+/X(I_AF/%:
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M-)C_`-0%^XPO?EPZ7+A\`BH4UKZP;XW"Y\DT$0O@HV8\I3?)*#A]9:S">G[;
MB&`QVE.I*]2`?[?Y`^N`&GP,.H.N(=I"GB/,E/?6!VW"I>(N;%&="U]4J\0W
M/(AX0*?=^&B5X)^GAK:7B)T\SJJ5Q)Q2O[B=P&U9AP1.'&0-S//U4]"#?:4U
M+)S.O5.:AB;Q"%EDX`H_4<'(AO@/JK4IDE-5B<SK,'(S5=8G-^+`TD7>Q"JW
M.(GPKZK;1.-Q#4*TE0$$6/@5$J]B%JN#$RI*?24RT!.9=IF<Z8EI0W],OY5#
M!IJ%FBMN&[@0X%0,;EN[9C"S5>[,0/6;74H)6_JSRLD5L.CIF%NXAF&I76:\
M*#^1Y2Y<OVFU?S+5<'H:G?1_E@-T2U70G"6]YTB>W*-3TG8/.%_EU,<):JR1
MHQ9]]Y?*V%\_,7EX;^&H-_%752V6W@"!V+FI-,-ZS*<$[#E_M_*.D"+MSI:\
MIY/M'N'R1'7A46*[1#MN$+RJ5IZD`F>L#`>)B)Y0XQH7.W<4&N?`"=./)+S4
M6L1:5,*1:"M124UXBS_P0U_&I6N9S7)X=]&PT3#>DLPK\+YG?X:@UKK+U>%I
M2S.Y+YEQX;C9J,`S=\OEQ1*'/AH<J2S$)HUX97=XE.LIQ<LTRK;T_,P)L,.G
M\0=)-?2%,AD1KK%,*2=HK#*+I!M.=RYA:U#0D6CCX##+MIHAD+PQKGQ.CO\`
MU$4>47DFH'$0FN88=H`]X.GQ*UB$_,;J5,2')'1+[IE+Q13*QV)SQ._R=;E/
MCV_@G&9GR\_#^'\)J]DHW=">[?"5NIU<1`7&SXAILG(AA(N86>;^H'YAO'2-
MFXE2M#Y/"97:&7/1+/FC3J5)'(-L`RZ2N^UQ.77A'JS;Y5<Q6K?$1BH\7X_Q
M</'A97EBK9SX74BW\D^ZQ/#=SSYDD<G,78:A\H6BQ+R[GPPT(&9&;\H/'P%.
MB+RIV"?:/!A>SB%^;X>J%,<(YS,<+(@.T\ZC:N?$!</,2G5GPSH%(L(B^88L
M/R6Z&IYD5=[^:Y$+<%=>L:A%I4%:E%&Y<5Q\%%7TC=OAH"CUCKLJ>8.<U8BU
M"*1+1OB>7V3R^R>6/+[)]@GECRQY/9/N$K!%J'K*6.HBWQ!>)EVPGAKVN5`Z
M@:5WJ.[ET&TZ8EZF`NS7R3OYV3,*6%;J4"YBAU'LRK=I7W?`-K(FK#!4R)02
M<J0=):7;1EU;-X<$L$<F5>$[2:7>)V$["=A.PG83M(>ZYNNI9G,BU1B*;#FX
M+25%U/(L%SB1>"#>V7,P%0.C_(&DK:M7_!,-FXK;PKXJG<F>[S.]-@RO#<W&
MI4OQ1JA5M$[PZ,M(HE$HE$H\$YX,RP1GVF!?]1`8$<R*(%:F]_)&>DBM?\RC
MY.IWBNO2%\_QJ747K3N&#Z.\*"G&O@O%\?+SQ,\_`P3`EAUC?F^DA,3=@^L:
M<D-1T1@T=C.QG8SL9V,[&=C.Q\#T65,WF-$2ZCQ;Z^$Y/ZSIIY2K;^E.H>+=
M_P"/DDU-;G_DG+S\#?\`!__:``@!`P,!/R'YC&QQA_!<W/>@V\:X2EE)WX(H
M^L7IHF\]"WU\*.1JS'1RG&$"R#[L-#1!5OU_6*+ZIQ7$'>:UQ-CN#?FE$5%W
MS`#7UH+7#-B$PC:56/KC#TQT"Y>$.&8WRJ%&T2V2GZZX#`5F!E/**&X@V@:.
MG$)0;PC\?5;;#USUAU`EO)'1U47>-K%WI/+B_AW0@K^:+0$JVPI#"N_A>4\X
M88PN3G*EAN5506I!@*P82-6^1B&51]#]LZ'WO.=5'FD0W1WCN?;Y17=Y6_J7
MZ'O+?^IY?S/*>\\A[P[?S/O,^V/]F.XB4ZZ+HX8-=/2&@SRF?FJOUAK.)?K*
M`.A_,O!>9Y3,S\OSB41+WY;E='ZDZL'K,N#T*8LP7R1.9?SF@RA=ERE_A.N#
MR_DS+I.[#_VLT"O65Z#YYG_B0/C\B=J=J=J=J=J=F=E]YFT_,*:(Z#B/![\_
MZ%/]13=O0_J,/MKY-3H^[<\EZ09R1<:5Z9@C2'G%G,[_`(>7Q)5+B'F2\=4S
M[Y(.ZT2ZU7-Z2WP9Z1HW$O*6<O:OW$V4'>=0CNSO!W@]9YWTQ^2`;R\S`VZE
M=!X"R<F&+-Z(H'2(PJMW$.\ZESS86&ZN&OG9C;`KPHY"4ROZGV%&K#F4Z2'<
MG">\"X^TZH0U$EG@@X=3@XG!QXA1OF/K>+9,;%Y,5MZ,P>"WGB6;_#^TNV?F
MW-&#`#17Q[3PG".&9%<0!@U\6/Y!W\-L1WD#E-:E><U'_8!L@5K;R@O)\1>,
MQ1G!`VW,!I-YY^3K/$XM9LOS.JQ)O%_Z(MUI*^B*;BA$\0O;@3@AEC1%JN4^
M5V^"JQJLP02UKQ`AM*&R$9[/I%$`I)TIY_A:3#A9Y&"75&YT$KW5?`-)P_Q#
M5$4-S(XU*>"67-IY6\^/J"@S#81D.P)6W-@5X[/*6[I!S>F89T:YI(7AA=0=
M1W][$<_3]8=>H%VY4I95Q[K?XE_-X;@6NA_$H6B1IZ8%^3/4/A0ID'>_K&'>
MHN_,\H5R-SN<;*M&SR1((->`?6*O#J.=D3-QUEG*4FL>T041ROK@OL/`6M<$
M--A\.(M-PVE7J+WU,NLTK-Q$6;OZIEJ>*[1P8JFP'QN=S3KFL'TXJ`UF!VX@
M[5SJ/@`-\X\,3HN(H;B;>%=7U8MY(@#K4NPW'/$JMM+V\*S<?A,!5G_:.`PQ
M0K?JMK)PDPYYA@Y$Q<H=V&5BO$+3:6'5N-XC66_WZK6V,MW%D&Y<MQ@^!S<#
MB)H*KKPN>B!0ZI#P!0E6V6:<RD"X^F!F_"OD6TYAR_J99W`],E2/$\Q2(PII
MXA6A=Q=XY(L5<<&]?5DK8ENS+?7'AGX<\_6*=^6@ESLH=0_EW1;-2+'<%3J>
MY$.9-Q[SM3M_+!=.J`C`CR88="7;%"".OF&9?Q4IR?BUF"R5#;P%=!'M$R;$
MSG,<E1@M#D_E.<[G($6;:]YV3W_[!:%'R_[0[1;.EU'0.4X+>8XQ4JTEQ;.9
MT\%_J.:HJ%3L40SF.H@-]AFB:+XAG,$+NW\RB[<LNK;\.9<CMOS_`(W:(!71
M+*OACC+%4ZQRY=RR!9'AS7,[?`X)>T:)Z3(>%$;*QF8:$RXEQK$-F4ND835T
M@/@+0QB.IY(#.U*.^,MZ3IJ>66<RQA(6XF2Y!._\0,&1Q%/+$I)5LE0/5@Q+
M1.'9EK7?&;B5VCR<&[GX"K#<N6,L72=28P\7=D7EMF\<2M;!.Y5KOC)GB,V_
MA8&@W?XA<L8ARNG1,,XE=DH[J<*F=B`@.[Y=GS*>%)1\/-15Q:/A_+^&IZI<
M8E/@*L54O+QNJ9%\_$E.Z.(MZC-2$:@=)8<74;"=<."+LK^3PQK]YB#JQ7HU
M"_?66#SB`L.A`J25-+Q3=?\`/#N#BR:_+='J0^!;/S_B>[X`])J!%=/`Z$"O
MC'>,JEUP<LU.^1!I'%U`&'//RE2Y5E2*6X3.Y+KT0NMW*Y^!F$OVW/O,:)I?
MEA7&OA=R)'[7,UB-IC#%C@83N4COQ!CP!;EJ3IQ4UO!&./#;=?)]B72!0H^=
M"X5,HZ5%R.L0F%V15VH!U)QXZ/.`PUE;[CR*A91_ZF!*":2&"+'8E"4SO>Z=
M[W3O>Z=_W3O>Z=[W3O>Z=[W2G7W2Q*1[.6*JFX)])N3K4>!S.\)@]U6":E4-
MD%<S"7U4J+:^1HN>8/GJH>8O?J&959@$>9+GF=/@`4P<=63)08EPSC,/.)W:
MB!<"2J1QAEA2%#1RU.[F30COYW\[^=_._G=S2JE>C<IX)8ACV`=HIQ)B#%%1
M[B4ND4SX9X8/47R-\_&_@H"G4TZODIJ3$P\'A@Z'P:J,)2*)PEQW/W)#H?'A
M19"ZTQ]L)]^I<VHF.->#G<YOGY(5UL-'1]$HE3BN)5>BW\NOF*&X>#FH_1VH
M[_R$:\SX.W/\'*LR8Q`,#Z3TE^#YSC1\I;L)=#;+BSMG=SNIW4[J=U.ZG=3N
MI=*I:K99Y5QZ3M+I2Z&<JY'DG7WSE44?3./`^7^_DL/XH/_:``P#`0`"$0,1
M```0``````I%=KUX``````````````````````````LIW16@````````````
M``````````````G*H^:````````````````````````````(VX``````````
M```````````````````AR]`````````````````````````````Y];)>*0``
M```````````````````````DW/B5GPL@```````````<ML````````!I7-MS
MU9;]D?5=^.G````1F]:;```DH=DSECELM>;?"QW!N)BTF>`Q175"`ONGY"TC
M&W"KCH``````4"HQK4AF.O>^H(FM:P`SR6&3>8``````````E!VV*@BPT^0`
M``#.SC`````````````````!>YC6*`!@M`$JPE?``````````````````$WP
M``17L`S>H$C```````````````````````D>EHLHC"H`````````````````
M``````'/!`$>X^0```````````````````````$```R[(_E`````````````
M``````````````'1[T4D$@`````````````````````````R*U]N\W``````
M`````````````````$@\GHCP_+``````````````````````H]XKPA``````
M`````````````````````K.O'IP`````````````````````````QGD@&,(`
M````````````````````````'1*`#;6B309`````````````````````%.B`
M```(XSP``````````````````````````%ZRR*;``````````';$@```````
M`````$IJ`````````````ST2-````````````J:*`````%C8%G.`5T1N<0``
M`````````%51```"P#PD=2XN\F%6ZP`````````^YAJ(E``'`!)@<:?\]&N\
M7(````````"ZI-*S=`!QX!2WD``%&9X.IX```E\FT)4@XA$`-)`P`&5R78``
MVR+X!````:$2UJ?H````V=`X`#JO,(``%A^<[`````?["(@.:2%`"3:FH#08
M<4@```;(`````&!9P/`WHPI:IQ)9(5_A8<H```>X``````4VJ@`@D&=M0S;;
M`.@C7'8```5``````&*72P`#<YPVM[EMNQ>8,=P```N`````````````%H``
M&RB```6%`````"Q```````````````````:@%`````6`"`P`````````````
M``````'9WS;;;T5V!0````````````````````$B8))))4.'Q```````_]H`
M"`$!`P$_$/F"Q/[J(^!8]RD9V*U$T/Q[0Q$'(2X($6(TF][QR)3ICPN:^5>,
MT.%IJ#5$684P$W,"ZPK;\VM`NJAT0F"!5F+9G0*)2Z1;2L/5;8O!%0,Y(09+
M9N@3*'F8D-^]?5EHN,5`M[A]4+B`])@Y=G"PAP1DIBPW:@)>YBI@NE>/QT6@
M"OXA3OOM7O&BQ`+6T1A[7"R"^%49J-=">UA<JL%-HYI8`/3RMUR0X6FNJE`Q
M#J5#!'U9!*<D!;`>17-_N8JK73C8Z\R6+T,FPD2J*V,I5BA>MEI@<-*,*()R
M?";9`%K(U;*(2E*G0&Q*GZ;7WRQN66RK=P+(+N^6GM;CZRZCC?-TO0KY!%T3
M=3K2"BT!)8@#$#A!FJCM.Y#_`*:^#GGZX&-LD!@$POBN#.Y2U1I*YNZH8!'#
MU-C[>+D+*55@O8XV!%&0&+@X]K2T!(L=`-#D0]`K+`QN:1GZVE]98!C(@ZK`
M(%1PQ2CAX>=*MV%D",^8!,YPB'8E``0`!`T506!6#B&Q&.^Q30-H!EE,FKAU
MRB)!:3<8OXPJEVDU"^;):66=@LTB\`BT&GQH5/95(PH)Q,##XF*!;A:*P.(Y
M0*N`'*JS2LJ@S$>"IDY+,(/U1T\8<](N)/\`9F^H.4!I0TX4-(F%@"@*);U5
MKRBJ-+/O&^RR?*N-.4"D92\63:_6+=(U1J0MIJY+I;P0PE3F9;9>X/Z6)!F!
MN4;49`4!99R)XD[MH%I;D-(P+J:!EP<-\`(CN+]-^F!>(&8%3`H.52$4!PL+
M\+ZE=[)9U/<EG4]_Y%[\P]Z_V!S>MI).N$;?4+H(P#9H:@)H+M+RR`T`.?H,
M`THE7J,6]8!14>:&$(R<YH8%BU*A_A*!:UUU^H>H/@"6F6@PJBA9A--H&K3C
M;YN4CG=F/32-PI(YX?0P.A#4H?+A.4U,O"CI#68.N#.L2A>T(QH`T>4`"9NB
M+EA;6BA5&Q>7$J626-3E?-I4XZCC!26EPAP'>"=(-O!0&Z%V,8"^82'!#XP#
M/CHN9D?<)IHM04*4+J,LD4#;";>Q1?6'(!YG[\/L5/--==<RQ!]CJ*2`&1KF
M`H>R_?SSAW"BH=<]E,H2V$+G2S:.!RE:MCI!1#;XC<?8`09<$'+I4(!WW8"*
MT-XEV&T'RK=JC$+R29\[VZ!``L6CAN.E%`7G"%:6@,Y(`(C5@0],BY;J/S?L
M-05X_9^SPOM!>GR<J=?^$L+#4;7/$C;J[B42#!,QZN*DY"8Z"WL*]CZAD0P5
M<P&AT0`"%6$+.O1F39TE*Q2-%U+L$ILO?'M+>A[_`/);T_/_`"6]'[]/C6NO
MI!OKZQ:GD_/:58P7'6P>"JVZS`'`7KD;\8[!C<%HF`&"Q7#V=<QJ@F['(IX"
MAM67<KT,`*':7X4%4-*H%5`+N+SAS?$7F.T649^[N0-S6GP7$<L,AWD@K$@M
M=V5,I3(0P"D/Q"5(JHV2(<#NZ@&!]-QH\?X-LF8N,+P,6"PT6G*VU9RC>V!5
M'<A&4P\K2=]8MII.V&U<!FRJ^S:OFY0[X.9(HKANFXL:VSAU("DRQUG:JS,%
M:NO@^?/&-N!A`;"ZT+`P+>IU5*!).D<:(*O+:JQ>XO>`HTVLBW:AY$'I&V-5
ME0RH^X1(4=RM19H$NB#6]W,&,IVV@4#60N;A6>@J0K#E&RYZRE;;+,F"VIM:
M'8,2PJ5T.%X29<\Y:"/K46GD(<+(16%EVV@.Z&"B\N0&7C`ZL;`VX!LO)$6"
M\-@ILI5='E@WT2-4J$"P"\`W+:)6R1L)U)[^HJ(JYBK08;\O,V#-.E'#V+%K
MA8N+K\DOWZ6?O7C67N5*@V+<].#+`P&RIFS$RRG=,G*LO;#8-B/$A-@6:*P/
M(7;;8:S67@'LMGS(P!3V3QONV<S1"P:TL9!051S(A"D#N?8O[[CQ<2MU_?\`
MJXD*:#E0/RPO0?IFCF3(9:6@7$@O2F#3F"RXV`%4644>H%1^6`W14SEL=8D,
MV:HN7[@L`P9@+L]%A3*Y%V,7`U7B"(8"#*@Y1:YZ9F-)M,O,A#K1"X;SB?RR
M'AP!0CBF#M%/+*FR(9V@-W`4)KU!'"VLH]$A0.ISG*(9I4`2S),Y=F.\&.]8
M84D."8SKH)NADL1MR`6W%=2B!7(&Q0#6*'#5LF,-,?AX\FVINF(7H[8F+T(7
MW\4XO(.Q9:UH-\1XPK#'3!CYR+H/5K]$;;H\N?.SB%+S?GG^B(]?O\P3&*$V
MP@'O"$XH^3SB`#&F&6ZULIK$6Z!7%YB7$-X(!U!2O*5#9Y5J5%&5>40H2X1;
M))8M^'FWT9JX]T=`;EW2U&E(\;'?LE4VY$J(>J`.#H&&K3*\7+N6"RUU8@V%
M4.R#>PIIDX,!+E]E\HOUJ`\Q([%,)<*%5",W<(H;%VS6(R=`E`<++`6()D%C
M<WTKCDJX($`,%N]+BE,:F62)M"6&*$U%M(U,/1"0.U!I4E3[T/NOQ3%>?07\
M%MPD.!X\"KRAUTA&[BVH,L]!@F<XL!B`;+9+=VSK'PQ%L@A<D1A3.X?'#XEC
M$/(`K#KG;V-=9,TB6$17<H%[LJVJ+%JDRL!MQ#*AXV@*)2[HOK68%<!Y?`H"
MN@M](D,.\33*<*+8=BL>%G@A2M+&$/1RWD)S*@4:E58!XQL5VV&XTA&D'M"+
M0J@&I78QD[?B```"M!H\M2EC19=/)>ZQS&UV#>'N='&2;+1=+>M:O&9I5%&*
MXHT:T0$;?XU=N*_Y+02SR.-9KBO!S\6F8;%E`W=R@]D!(4L]85E[&9LK!::%
M^JSL6[E(/R_J;.J`M6Z0=M$/AL!P-!`4:(%57R/I3-07BU&!(Z)W>Z98)>:A
M50<3]!9RTG.D"6!".2!`VD.'F#?A?@/$`H6NV@J8144:Z*LD7$U9&8C*%*,I
M,`"!FT,LJI+O&`H+"ZN(/1U44Z9M^2Z%`4TX`M?0)C:(4(U7!M)8TM&`2]"Y
MQ&%HL87X/3E,*44`L!0$<(RYXA+(6Q&ZMHV^4(O==Q*@P5PWJ5>*S'8E+/L.
M$;LLPF-\G3Z&F;@!M+OS!BX=2([Q#L5M[%N>Y;@(DU$6JO`:[K*#(+4KPM$4
M*FFJ(M:]P``LQ)K2\F)=',+`%;L9I;PM[KO;'<-?B%@OGPM$VK%!L+:'J9Q#
M1XW$D3ET9S+.IX#M&1QD_<LU?%^GBQ9<6!+3KD@5+J#>8I1RDPAL$%D@U2ZN
M]X*SF+N<C:%D!)"(CE\#D%CL]RO)N7(*?HSU-\(A#"F30OC$5P!<\)I[_OZ,
M+*H;PCTAG:/+MM*S3G$*=^!]D$W8(YW&QFYW%+'O"\<F'XI[Q6UP1L(J%MDO
M"RY0+Z>R-.7,8A46^Z!NS4X0%$HK"E9$MJ[L&,DM613.H?;7`"L812AVPE]5
M0..->*!F@+>@,OX(NA<%%[%&W%OW8:\CHTOQ@8%3:@M$AF*(H,JE1,"':XJ$
MA5K:X,&'OX`M$HU>H<U'@WHKP&BEA(J&HLF.=>?T],`P.*`S0E,`K`UI$C\6
MNCUB`(']$KRVAT3(E(D?NQU531:4*2P&<268/5=!U7"K$#45+B12J1R4,0;K
MK6O"[]@`]YR@B9$M%54=X4B;QY/VVA(55+LE&32VQM)FTX!L1T2Q4ED%+"(F
M)+N[LC0Q`Z&.XAV4L"I0*"H;2PR;QG%^4X[+,8!].'3]I]CGOV^GCU2Y%S%V
M6'=C80UH)*VUTHM0PNODT$,L.>(O00.V##%@!:E14@K\K;E#K3,.W94?`T:N
MP0<O+NRU@!-RJ@\*BLLY'5<WVF/\+(CLSV6-:`/-UOP"M9]A#_)J6Q--:5+)
MDGJ^(!#K&X1!'FTK82M3@\Z)H\C]1?1P5!H`2]W$</=32B%8:%*=H**Z?4!5
M<?G>!H`DLUOPHO-W7X^$6)5]F5Y:@=`8W"ZKCDV-*,3`M6%$HIU,Y@^.,2(5
M,^M/1&N43(\!%MLG@^GKQ$Q45BJL(`A:+1%V\1XR$5`>%QK;!CMI[S;L@'7&
M%UT*_/Y^L=Y$=]<=YJ%M>1`H`6L[+XG(.RWXGD6*PZ1BE!!+BK;8IHN5\.X:
M4>F-G3BAKG"DLI@)F12CFK9K#K(;PP`&A6.=<JJOK<O-9_K[Q%I"G//$6JPY
MZ<><6JPN<UFO0S$O.:.*%U*+H*%BUP^F?JE#L'TB[*BI,IM2MX=8M(=H-9PV
M<`AT@+A8K%=\LK!D#JZY2IM=25'FH!1@UTB2Q>"Z/3N17ULK8[FL`=`$:OP,
M_(@62[%0F4*!0"X0)E7$ABTEG7\J\V0#FK:KE@)*:4@W1AYTVW!!0O"4?<$Z
M2(ER/"+]-+OE<\V$>O@"2F>W_>?24:R9UW[G:("W3V>?(B`<G[XN4?V_."(F
M(%6BR2S)T:]>@Z6>B$\31,(%C6[<.#`=NV'1L@TPP-'@@[-P#08UCKE]5G+2
MQN^;N\O-,K;I=!?8T>D5PF*K:8]'E9ENEW=\VWG\Q:U0765>#`,`)`U'8M!P
MA0``^FLRUR"[B6>VZT!10$X)DR3I"T&+J?<WSHRBAYBO&UJWYX.')1A($`OZ
MQ71FBREIL5:TGNA1PA!BK;>S/H=%)$`A8XU*D+5K4I&2``J\9J_T@Y)XY5Y$
MFDML!\L^Z#D@RF);!OK9Q,MV$)S]5Q2^(^C!7C*`@L^PH9`Q%#-S`,1,`SH`
ML2=)V453W<MXHS&M`6#ZTG^JL[QK:BP*VZ@&2FEE'3\1;;CK%5-E4FN(`477
MFY[KM9;@]E_7VIP&E`$J,P311Q-[UBQ<]`6)O6Y(P!!ZZUR&%0Y25U@/J;,0
M7AYEL:YF+8P:)22DL/4=1=D%U[O)#)%C::ALPB0&;9(N,')7_N]^Z4`A<7U"
MU;`"@@H%H.:7QJ.07X`%"5R==1=]/,*1]HVZ,9$X-"ZO&T#8+IL'^XZK7!%D
M5]5K)RFWAFY5(8K38'9)R963C:!@I4N%QJ"QI`EA4-8)I*#;V859C/\`DW#"
MF1R%'P.5W$7:5UHRI#'22\-H,-$Z'(R@1>N%Y&NR(G"',<<LD71"`CCL>U7P
M)728;+X5ZB!5!8V4-4W++\)3I'0P6)@V5!Z:5785N.,B6*7-8DCN(D,$#!0;
M8[P58V!:,$"$MNM:6@+&AE(E,%6AX+IAA/2K)],2,'4HY^B@(KFWPJ5T:^-9
MB:+'H&#ELXR3;":%3$DS!I90T@@^I\J$(J#6:@+-JE^.[B9J8WWJK;S<$R*5
M-WM')`DP5[`"5?LQ$.L^5K`R)DEC^U`5U-VJ6"&MD"A829,#4TP8*4.,.URO
MHX!%HG:UBO=]5#.JK'#YPTA&Y!3W'YL(^L5*(&VGJ_N)<"M5*>TIZUY0-\WN
M5LP>1*>OW[PHW?\`&O$\GL?WIE+KV3[86X3SP^SF7V@W_+N=-(3,=HC+8%0?
MK6"J]D=UJE/@CM:#)*,I`4:/Y9!:W6!;S>#H$4P(%"VHV'#51I>-ZP[&L*Q+
M8M%2R5LGRTNMV!=);Y:=5::/`L#$ZD8;=HX`LBW;F$`HDE*4XPLLZBS2F0,<
M*Q4]L#!N\)77GR_DLC(/JN<TRXC%FXLD76]N2NTQR$B9F&67*-M8'9L7HEK3
M0=Z`PEU=5Y=-W0J4BR4K2D1X%35_+U!B@[@M:J-TTP58@(G(PY0010I5`4MG
MB";!/,I]1R>-]GVB[)@*R@%5V$]X!UQ]_P!RCINE,9R83S'<OL^(`[TZ]?:`
M7)8`5[]D(P;)WL\>5;+47"MB"+0HHQ7MV@ZJ3'I*^J:JD'3-S7TE="$&+2B=
M01P+G>/<W@6VBT\G&L[*A>+A.E$Z(!QO%AJV;X@I\&)8-_R5O^`DTH6BJMLM
M3-Z,147CQ8N("HHVIW4?>1J0G,A7(`H`+EL'0EBMI49H^2(^`6DCT,,(#YN@
M(TP12T6ANS$B0\SJ)8@N`*:(";%Q.D9HD*(2`0TJ(4528U664$)4*]U;!!$A
M'R*"Z6<X0]8NRW7\31D(;08)!(?W'KTG_;O"T(ED3=M0$@F5P*02_@%'8E``
MW28`E42)'?544G&UQ<;O(%[(S@SB.GR8K(%J38&6M91>(5X/7KI#$O(!59:6
MJMX6O8U!M.[*6Q,=(74U=)'&T[HY85X*+6K#'B:H0:TK>RH'8E_VN">2%8`0
MQ!=[JO\`;_#')M:&N2K``UA"#OM_Y_7\1&S45@R:M#'P16)ABW3`8TPZ.`"N
M"*L6]W]*<Y`1IB)*0CF4:E$`,PM'Y60+B-PNAA.?C35I2%ZBE9T49A<;:6\!
MU=P@:FZBC6&`$;B%6F=<JY:`VT1T@PN<-&VG-%01T\#Z.O@IX5)U0%OEG`6$
M`#78'BZ%642)+!@Y#$K*.@#6;%XK.M;E=5*(*\+VBX@IVU!1'#'(@!5F0**S
MRRP8N+>D[HD'7%2PS\HC$:YE25(1O2TH%9EFU156<38?/0TH$S$"I'<#2.#<
M-<*H)<(HACG-:N%O(M8C^@'@$3N57N"%`&P8P#*.ID(-!+U#?`BAU&MXQ<B:
M4-66DLX>7BA,`#!W^V.GREX3`D-9VEK)0VQ%E:@$HV2E*9J,C\M[GW@L0#0)
MG#=#!Z7?M!YE%<C1JP2('D-4YW"-18?-ZX@#<5]V=B'[.&:<X9H#;-!94J".
MT=DDQVI&JS#9>Z&KJ:BFY@U2;/O[K_$#*_YJ&JB[-6@1`#[]YBI@+#(J%KIX
MB#5&L@,V9B'XU^WET\41?CKXH`*E80:R\]Q:;L7`QP1G==@$\24;!J@A_6_$
MWTC:1!4B;ULR$Q8"//7JQBQ1/230Z."P04:<DFT`0M2HP@IW2V3A5'2R!:4_
M!>2A)].B^8*EBK,7H/@7_(V_5JYTIT4]>(Q:U11>U(+2@R%@(8`#P22,H'RQ
ME("T@6^F:`HTW=8C20>>7"+#`$IUM*#\:":FA=*WD+3R-H]+_92V@RL!KT$"
M$EM<WP@-VQ'2`A-$I2Z!A&9+F<&BNH:?"Z?*4O804/,"3,"Q80GA-XK`728B
MA!*OLQ_=LZ@&P$D?/_@W7G)'!IIF71'U9OI-J<"VM`:*(=R58[2BI;!`&@YU
MU>IS&P#990"2J(VO&T`P`%T94JE`L0>4(!\:]H6ZDT&Z40>73Y"_]]I8YGVR
MH<D1JZ2I=G<S^1"N[*9+IJG4SK)F;,,;R8\Y9U/<\OW+.I.X>YTO]2O`29(,
MR/IP$L/"F0H$,2BQC15Z"I-5DV#<0+0'52L;]HA_H_V+W85VHK>K9ES`1VJV
MH&T*%LS1@Z$QBJ!0`!55P83M4[`O5L]ZE`C(W54RVX49992JL31JW95.7I,*
M@@\^Q5<.T"BOO\8\%3Z/XKTE;05Z%CXI.`6&U+.LOQ)L#!-9.B\7S\-1PO$0
M,):LS[YB1P%4B%38/P*PKE0C5-7RF#6DDZ&)3/N&+[\H+EI6F*8H%-!"ZH=4
M"@,K",3)31W#<.0LRXE4+SANEU4*VX^((XOZ^D(A2$12,*J6Y9K44P3G`F>%
M*%W1)(6\5N5\/9,>:`7@-$B'E27!XAN#:AQ%CU.U#:A`R0`G&H4^"BA/#<7%
M#9::<;3*&U08]CQ`]H&U)E8;U9%=ZU">V%KY,0&3[2V'#8B+82LSYZCIN$)U
M0G@1`BXH,PVC_D2``K%9[T+!80NRH.<97!(]@@4-AA032PJE#(*O/U]VR:S@
MPPPJQF'NNFPAN4#1.1N%O,8]-C?CY''B<3*Z0&H5"O!)155_[\=N.KMJ%$KH
M5"/I-FC8`^48H:+E0>E='-T"L6;$(@`JN,#7`+8`&L_%"\V./D=B4Z>)'/B0
M4!Q`'#L(BM:>T[Y=$K:&#X$%"RY`M8&8X<9UR3-5BQ"`F/.1,5$,0J0I=!`Z
MO1!%^2)B!'1^(&66X!843/W\NRY((KE<N7XT?:Y_-*ZD$@=RJ`BZP=H;T30(
M\E1Z35Q+M,"B`UNV=8Y6(4V8CA###*J-8]8^4G%SMJ"%*#H9E]MYTZ1SE`7+
M78$XW1<MC-P:JY<MFZWQ\D*4-/7[[Q'"XV`0E!(`15)BU.TV]YE-81%=[/%H
M"_,,3;!(?%?C"BF0:4IS66NLE*]1EC6J.:KWZ6;/<E=$A`8^KRM_NE$*Q<:Q
MUG_<C/`VV.A74$@%T)=`"U7`&<2CH8M,&%V^LQ5@M:HJW;K;&TM`4X``M71@
M(()109L7D4FA0VU5[%2-Y&]<78A!^!Q4:TWB35$H7S&;192\"*C1#'[4;ZJT
M%IW$221*8+@%H'12'Y.0$]8""B-GP`*:R)DL1PB.$3<"[E3.6<'69K9F"%^=
M0[^5?8OU1GZY5S1,`!<`3<0[;X^)I7"8CW"1XT\%'=`H\17.`NW8$=`/!@S'
M@I@U!2)*U!`+X/"TL4OAFCHI1H#%PBCD.J8M94+(]E]#@X6K36X.EBO)+:QN
MX&ASS+;!MMA!8YI5>Q*%-?O5&5:FB\9SP'E_?>5RZ@$WTP&N*M1N*X'E$6[*
M@&;@V#U+SOXWAFH('10B1<AJGBLI5NUN64GSN%-"+EF:`O5R`MUGYN!;]F%H
M(.#=SO+RV76!RH*E-\N+7+BIM)AE%-&A((*0`%620L7V=-[\?0E5BK-#1I;.
M'O:X_LXL`7%(R(5G2D.V[C^LZNY5%`!C=J!2.:SE?RY?'%/N8L'$)[`(U*$#
M4-*8`,JJI12HX2)H-J#!3R009CN#_8L&22+(?R@C/%EGD:92'+7A,#,IB"Q`
M=[UXL>R0$1U+,6"S&2.#@OH@Q82O=2U/`,ZL/@*&X>S?\85EFS13JH74+N=<
M2&C,99U/I(;,@B)4PJW<+JY=`XC64K_K--D)?&PB.U/GD>ELE$`=`U'?(U;+
MY+J__P#)=6VLW<EZ,MD>\5J"H*-&<"X#$?</K\,`'79U2VR@U\`%0<_K%VQ$
MI,A*PN.J0VEAC>HV)O`KHY7'-C0D".98?FN>H`W@#\A&36U7RJT??$3((<(8
M(EW-5#4T/FEYM_-:QJ"X+1)7+A8Y._3!!FH^<N86P4HD$NWXIY4/-VB[J/8W
MF44LH]A8U+N$MD@UQ=TTF*?JD?2Y5UJWD5JC(.6#24!JBCX!!U.'Q*>I<*00
M8-::%X:D*(C"$K<@YMK=@5T"N.S2\\^,!75R+C2J-_C*,8P6RL>5V2"4RQ9Y
MB%`L3XP`%JJ'V4T7`T'32W0UB`@[!1SI#D4M1:&8GXHG,Z,>"W1@T4.QV$;2
MY+?/@52!790)KTD0FSXA"A0H4!W16JUO=O<P$AM3:%UC;!B9(9PT.Z(0'S8K
M0L3(076%ERKA%S)+3,]3(AH@W:@BBE5:)35X@#*59[8M8>XP,1VXA922U+"L
MA]CW@VZ"5.1N-1HI#;A,N&Y<@)WJH+Z++8-<AG_GT@&L"%9^(U9%T`1=M@+!
MI\@P\J<BWF[7`1$.^T+3<X(WG'SD'"7K\-GY)04`%WZ]8$4%&=69=OF]=QR0
MYO1`K,ALREK#$Z=CN-@NM%+.2NO*;RUG%N^L6;3/F\Y3>E(%F_P#W"GDTP?"
MN$,EN2\*/"GXC5#J4Q'%BVEB.3,JSK$OBU$<&)*NLBTL&Z6PM&KS<+?V&!$"
M6ME<\S+U%WG>>_-^O@AV7>^\-==BK*E#-;.0EPJ%H*A3JH0+9KS<AU?1(JHJ
M;B`&_)>.5((66H+&$6E\DT1XEI4A;M:`Q:M@%.A*="4Z$IT)01!W]^L17)G:
M]NIL:V!&,!=I@TNJ@J"@@P*R&XW%FVHOF*;0X(9MM;K-L7,,.=KQF^HBU)4#
M^IJBNE76DEHR@O&ZOTU,58FU1:=E'"MP<=E!C&@`*.D`"C7R!#`I2S),+X<D
M2H]1E0"<H8O@_F4=_=_V4?=_%40]?13],`NA+;0`OK5U>(`6.&\!UN[%C<&1
MG')>L@7&%L-!@*Z..AY_'4K[MGWN4?:_,$.[->K`NJH`(]:7J!*!2;RTL")0
M=!]'S^53:2N-4+032R\12@R;.#!R8J!'3?B,8"FZRG.0UCY:`M0[OZ\Y92!$
MLKDKK\%?`Z\_^8CBV%5+:;TQ=4;]:F(/6=5$PD@''M.6T!``#'T@!3?&NS?[
MC7/OKA>%J+5%"!-OILI?#,RYH>()-JYNMY>C!L!1B<M@`^M9EQRCK,MZ=1HX
M,K&GD<'/GGY"Y<N7+ERX+=$GF_72I2BW<D9QH1]:>2:(&[R'`;D(-M1NPF2U
M34"F`JI9P1J@6L@-#BP1XLS.55D(::>WP!'$=#'(AJ\]K'E)U.<P>TF&7"\2
MUIW(`4SB5@A$EI39Y6WZ4ZCJ;'WSS#]'Z\.L6:.T_7R/^SY->LU.[]'7>?A(
MVOOU^Q\[PY=GKJ&SS/X'_]H`"`$"`P$_$/FA&=\D/D%J[I$BTHB&4G'!I'*6
M]<\0M;%N)3QB4*4OVCL]?JS@N`+2`4Z^<-ELCG*=O*87>PJSM0ZF<N[GGBO2
M!KU`/G"S+JW.K34>U-^N/1K<0H`*]%ET%T-L.#`[F^\T^K)>'4`5>F7BN(,\
M#,;%G=WG?Z(RFWYE'DMP`3`6WNP!K(^LU>(R9$UZ._Q*AI;DX^]15M#6F#A]
M=?N"@?,\_KB051A@@YSP]>L2\'=4L"2Z=\<]XYT+8+-'G`0-!WU[_6QJ63N\
M9UG$400/4_'WN78H67/M6O67[,P8H8/Q$D\NT`,3R##<&+='VF6D;\I;PQ*P
M[^J9XW!I:],4,RZ6^;%EA9F`BM!M[Y=>T2!=O:*3`'NW_<"=J(YJV*E4*;\[
MHGHU_G_(@%I@R;QY]8,%K!OLW?K%RW?AC^4JKO$<HUC\QY#1+>:/>4'O#6**
M/O\`PF@M<0Z33*]C+&/%@=HU87+CVB+J9PA8QLZ04N-(8>XJ8CX#V-6>RFN\
M4<#W8GJ.EM^`_,?H]>!YW#@..S_4HJ?G3H_/^2O7V_."82^?_9W/?E.OO_[*
M=??_`-E.OO\`^S[?_L+I7W1^KF.ZY[,TGJOY]?K&C0G<<?D'W"#YHG:7G<H"
M?N_Q&:>Z!'VSB4X-,#:WR)I;]HH98!:E?)LIZ2E%G`]N?.`-H7O,BBE*8FE;
M%]**KUB8!H5O1%"C.Y!30YE?)VJIA5<&T,$Y2_T.V[F?9VBSV'6>LMR.2@HY
M,&H.GG?Z*(`9>@^DR,KO0'O<:L'T6&?2641>N:%.#@%5/5S/N'_9R@/,_=OY
MBOV`/T0O!]/^1T;Z8B8?LQIS1\W_`&=][L[[W9WWNSJ8>;_L[[[P#E\,WH5U
M@_4YJ-,M;]J(4VGI#][E/Z0Q`D6)P,>>W^2_>;[=)8>MS>"1B\A42H+U/SR$
MQ.'U:3\9@%B=Q(/B\4[@]K*-TE2I8<OC<#<.(8\D>+5#;HS43'=<]7FL$I5Z
MKYXNYE#2ZQ<6@V#_`(_W'(\UY\S^U:^#BS,%:5S6CN++0=V.*=@7WNH/R<]@
M]LLP.U3MM]W[N917H,>DS:^MO[B,`/MV_N8<(BO:2YGB<?)ZR]ZP-]>8@J4C
M\L&K9JN8X*TWG/%?["@+PSWK,&K`7?:`BDXJ7=$?83!!:,/?O+#^<,#J88@I
M5IY1O9)HPV]]0&Z7E_\`(!M`%S2G]S&OW"]^8EVNEB18W74#7O4S0WPK]7CO
M$5*C&'_?"U;RAEO26+TS8R5,N66X<B=QE)A8699><`:CM!AE0&\9?8S`AYJG
MN6K-<EKA^W/M'Y7G*/Q+&!>\!%;?*0SMD]8J1EZ/@:34&#T%1XANOO*0#B6%
MEKTB;6P**B6W<\[*[MN`.L7^.%SCP-X]X`:/=4&!@.BGZE96WJ$_"/O`UG[/
M9_V9@1Z6>Y"I6=-G'!.1'E$24B=2!7:XH%L"M%^!I0NKE[2^17?D>Q`5WDW[
MQV*+WN&`S\FO#;4,4VF:.G=X)@'H"C\Y8C95YI?VRZNX*LQ!2E:K;6:\W4CC
M&TV<CWZ^<L.A]#3@XBU<><U%CHYE@4#U&OPV?B&M%-79?-)<B?C_`$]K8U9F
MVD3\P`6QV1_4[+NO7I/M7#6=^*#2YAA9KQWCF5XJQ@`1;H.K'.9O/]^AJ.Y;
MP0N45D&#%\.KKV[P%764_P`@KEP_1O/P?MMP0&ZGYM[=]?A"N\$+`=KF:J61
MK(P2D+.WH$ZX_P"^+3W1IKT&NMM^IB%TMMK-><P(5EX!>HFO.`UX"#J@%R('
MET=AOUN=H?4#S>ZJ*\%W_4MS!M`#7^D5W7CK\YEWA^B:?0=1M"DY(!*-X&ON
M_25H*WWC7>V;6KZ<3(S;XO=<3]Q-*U4_A/.ZQN:?-/I^KSFD%*#V:_4536ZU
MZYUUG4.9J6K?:7]2JU76RXAM0MX$Y@@K\'UU![G['%^40[;==Q:N`%B+>7H?
M;'<1(3%'$>F_/_DT?-^KH%P.!C>_-W[2RE@V<C_DVD@8S6>ESF#T)KSJKGS[
MPPUI#JYR':^>TH/71WMM7[_<?K"Z"TF;U,)^AR1<T+:+/;9$_P#:4YL\LL*4
MIK?5VV?6+73R\OGT.T"OK5&^9L8\FHOL%\C_`"#K&-`7G6.8I2K/13^I1<XB
M;J8OO>(7F@::Z%7ZW*F7(7TKM$NRU0A>\_B`I'8T:K3,T!.PK?V0(AQ]2,LO
M5^.QK.R^D(RF#H(AZ7XT,HJN(%HE&`%AS!Z5$56W?TZZVBBW<"(<?+JO]Q$`
MY4-7%"@O'+SOVF8#MW>L\Q7=!7+IKWW*RQO^KA0Z-WI]_P"IR-0JQ%[?WY2M
M@'9J4,;?5>3M+S'5+UUO<+#2NM3$':XS%;\(."QPMIE_5MU'$@6**<AR\[G=
MZ2%]:Z]`^J):/24]E?U73^YBZ"I2J*(2I:/Q%<%EBBI[CXUE(W"VR4'%U@KV
MYA(&W.#_`,J&/:P>A?YOZK4"/<N%B+RWF`#!NV]>\1?++Z,+F>O&_@<:&F!F
M3FES>"^;!2M2S\<1-;,6'./;RF!0<1@"&&C`>46K7,=H1)8Q],;`=)F7'7>%
M\_$Z#)=RT@WOL])0UNF9T6^K#6.-0(NJ]=PJ&74L%67.KER6K654QLIJ6&FR
M]7O%9@3L$WU@81:]Z[?5B(@'76-@81YTT4[4^3&%[6Q&V[AH>()ZX!I'.(:!
M+E_QE:PN=XWY3ROM!+I[HZ8UU_F#/B0JV_;'E+O\68P(]X(Z_E!R'7B4WQ[W
MGTJ&^]2GX(G@8=L^N&'/3TH_R+WD^2O*)<K=-O<ZP.PP1!.?Y)7,+TNVZ@I.
MD4?TS"^DXA7G7M/^PBZ)Y_,N!;/@&5<2RZ^`2+P0!9KX7)77$"7ANNG=[Q)1
MM#!47/![*2_?M&BXZ9EY3C$0@UCM=I+[E9*Z0;+-?R<7+M[3<CW@)53NM_4I
MS?V>47MB.A7R%HMU#;\&D0EHMKD-<S),@O8@5=A?'$$HW:[5':LX2WI<2H6R
M@^\<L%</>,EC(7N93K'3F-RE>7X@A[0W-?FOJ&.^Z@*WF`:-P%;<'I7R[%?>
M(,!7=,GQSV^KS+()LW+NU6?M[31_$4-RF%`,I3?SQTG(<L%&B<](:A=&?.`W
M[-VQ':M[5%![RE/`@V4T_`98H:=P)7*J%B>'996HOYF'*I\Y<NT?W#8*O?E`
MF]5,@#27.JE1$6NYK-D+\LW!8HOLEUEU""\>=4L$-M-<3/Q*9-[^[@2+AS?E
M&KSOI5W`\-:K\D665YZ<%QINS4U4,_9Y<P;"PGTO'X&+?(7^&ZAC<067^O.<
MN+L[_$!#0Q7FKA(A(9JTU[P"!@7O5^T`,<N;=83MY2IJ`5?7_LS"4L9-]+Z\
M03=E4U`:$FVZ_L9IXNDK\U_D4M[?@8"Z@*14M@U&;#$=6)U\;P&Q?T_[+C2(
M3U'<`-;37D2RL,#VAT%='\0^2E#\W&;I:MY[E>;%_GX=X=0'U@'H:_.#O#A1
M:IP_^Q:[#VE"H]9>JTG%M.:VXALH;G##SB9:X'+U8!YGY**K!G8?#FN99?5!
M'7@9U-;EDWKQOPQQF&2_A0.J4O-@GE2,WKQ=?$CL4FL>E',"%>AW99$Y#V(]
MW-E:_<3%E^_*`2BTO\2D%?/_`+YP%KXD+<-^TJ5CFFO4F&\3H[*K]029!$,:
M77M"V"W8QY/W+8JT98XJJ_N!%\!\S<37H<KK7>`CHZ/W?K\E+@.GM<O;%08<
M,#^(WJ8?C?O*?9$KII;]Z@@%B/Z@8`@?Q,O]%/5!_<.`)]KB%R/[BBW@LKR@
MQ:YT?J$,=?*0HMD,W9[C_93I3P<_^2G6'OX_A?W\-<S'1COR[#7(-1H]6OUE
MO,.?<3)W\>>(%Z^I_9#!8./_`"+(4;BCK\HZERVPNOE#7JP-`XAJ':<_*2MN
M."XQ?OX#DKW46UU2^1@+OCSEB&8C;0GM*+Y^/EN"N+ISZ?\`8$RO/_D/^9$\
M%B!7C?,@*J')5GM4PX5\"A1Y(.V(4OCUW*H2AS]W**#,[B=8Q`I5WJ/TKS7"
M(-<N/'49\N#_`+*=*^6@_P!]9I]X5@G5[+%7,G&_^QK4\DS$U):I5.D+$H/7
MY-.$T[L.O[F+VWYKR7*`*P&^FH`DT^YQ`0A>3WE^F]PJ<RMRYS(J4C*I,5?B
M-@I/J$8*9_Y':6A/G7$0"K:>NCWB7@:-\??ON.J[19<!KRN:U3#FI92@OCR?
M6!P!I!)]S\RWW/[EO^7_`&6=_<\YU98M_P`O^RW_`"_[+_<_N9X@0F6317YC
M"T+Z0%S$5.M1ED)4+P>46<4NH'#V(,U:-\QQ_4`==ZK_`&.="A3=''3I^80"
M@^SY]8AYI=:*W_R&76QK'E,[J]'/[E;C0->?R%:DP9T8[^:L&4"&L5CUS+;J
M)_G_`+"U4I?;.8I6+-!B]_FO>(#2Q]&\$HH5W?\`)2`J[:Z?`V@J9]#NM'H_
MU!58T!8>5:CT@+Q]W,X1`%T7C&ZN$4@SI6//-%_N.M2P9_X$O/?3L&CT@#&[
MD;<THZ'\SF!EY99_LQI82]7FK\Y_[;/_`&V?^VS_`-MG_MLSWE\V!V"[7`9D
MY'GN=4.<<=HP78IYO,2\9;'6W[SN`<0-8R<^LY$!GJ\Q2X/KR=CK!BD!*O[R
MS.(JZ6<]M,JS+7:Y_;QQ"N@4>1KY%P&U_<(/1\Y0-\P*;Y8`:B=$>8U;MB7N
M4@!KX:0#`@\Y@+%S1_D4;OGR_P`BRLW*0*U$!3J(6R2L/$HF9V+4VU[,:PM9
M:I3=/^XAG*UZ#_GEF-1+>F=J=J=J=J!Z(@X=185#I&G">I3[D$,5.RJ)7FG5
M5/PP;?S_`)$,MDL*=0NG'"LB`!1\A6[KO]2UZU??^;:Q\=\0.$HOJ(!,AP\T
M;'KB;C+XZ)1X7\PP=X7_`$AT]X*#I]'\H&SK9#1V:^"O+\LB.N"&O@%0S1F"
M"U[@?ZR[VN\O?Z29LYUNNSF9(1Y/V0=$\F;7B+25RH^A1B'_`"'_`"?^2S_R
M6?\`DL_\EG_DL_\`)9_Y+*3(?(8F)!NV*#.U(&?:ZZQN%):MQ/O+*&5#LM_^
MP!S/0&?[CF+.X_J<`'94:+7'''TK=KUFD?6&\^[^WG.>)[3VGM/:>T]I[3[U
M/]!Y.N\_!?PFVVW[YGM-7G'4]O7Y_P#_V@`(`0,#`3\0^8+*C6O+7%PI-5]+
M(+@2=-/>=K+UDBNCO#$4AEAI!+1C$KZLM%Q5U1%FRS?IN7S&`V(N]FUF$NFQ
M1\KB54TNCWOUC4?43CVB**&N.WE`DN.ZSZI=&PQ:K*5,42M.1:X7MQV^KI>Y
MP69N(-IMJ4FEP"A@:=HGI*<P,'#\1:P\O$7#"IAE@BE^LN"X]:@O=9-2_1\[
M4`,4TWN`(=&/;ZX:1?+$/Q`TI>>LX"/6:#*0G3/'-0A%&M]>\!7`UT[?6[B7
M29*PX_V'4Q3HRM-ZAKGF]^DVMF`EZ6(EH.?OR@%CB5`MAZX^\2I%+9D+*B/)
M%>3ZH=0L8'3;[XKK'&Z'D1$PQT^_O,5ZJ/.!.AT<^<0!0/E15>4?I0[7`=EJ
M3W*_[.:-'X_V!6XRN.,_Y&IDPK[P(``<>&/Y0W?:!T7G\1(7N/`(=M87VE`]
M4]OX2-<F+7VCS<3%9,J]8ZZ$[_W.0S[0L(I;G3UYC,T=-V=G$NS&DT_;,`?K
M;Z&X5ZB$]@?74ZX/.'&WV-^57&<4:K+]AG`R0F'L7O:F/6`MLG8>S_(-=0^W
M28;^QY0+]C]2S@^0G:^W_)1M/(9Z8X]"(P`^K\C3Z,09'S7^SA[X?4*</&<D
MIA2^5GOB'621'H_4H;J9E=97R:H7K%*G:X@Q13L\2BKL^4"0P*KW>D54%FZK
M<XO*>3\PRR8E'7Y+?!<M-*(-:DK2WT"^S]RQ]34#S>(&M#N+/,N_29B1HV<;
MQ/(ABGYO^HP.U/\`SUCZ"BC*W7M'&<<I?[8,T`KBC\DLMAY-!^#!+?K4'M42
M[AK==,)C_8(R'[>LM[[;I?W/^0[RZ=Y3&Q8CK0SLYV<[/\3M/8_R=I['^19M
MC_V$WC?UM^X(HGK`=BRZ]8YL'I_R4:?R-[L:\:5:3^!_L"I"<[_V)&4]FGO.
M]'&1IY1/='?ETQ^XN(G5%C[M$R;^<_$W[X@P+>T`\WB#J#<$T+A3%>%PMWCQ
M=5``S'5H.B+D#I7.HX'[.FI>&^'MFH(!56^*KI,I&2U/%8_,*>(N^-7/T7XK
M4+NP>D6P06U/4?J[_$O4'6\OT%^99$!U9;/H&?Q'GE=&?6Z@S);9T?B__)K]
MV6SZRM4Y-B?;D#TS"L%W&]G#!`T>8&V$RSI`P7T&[^^\"T[BNCJ,<`O/$3$I
MLWLR_P!?F))AHZ.8EO71GJ1%!0:QN64\C>(4Y!C@V_?^Q)*%EY2U;W\ZQJ#:
MIY3J%\XN,!+\4.T;-4]%7N9(NZ!YY[.&)R,,7$#P'E*9HHL<-S6N.S_)BTGV
MYJ-U7G'_`&,5:E^D2%.1@M-PF4"<6&&IVYSUDU%VQ"!0)].HX:=P"PA4K96<
M'NP&O+&QY/YF:'O?]6?3,/6)UR!T&X.WG`V0O_FQ@[0*K3K,0`[2CXMC"(5N
M^T`MB5!4$ZH":!B%&(YA1,3$1;BE4?QUX!*!](YHI[1.4%ZPWP-.#^HXNW[,
M\7$:%YNGVJ6SW.!ZRBK)WEE797PWH6]#![_\A;%#S?/.GRJ7!?---'TA0L5\
MDH%:2W)D)=?KO+1]^3[??:7;$]IO#UB2P+N]-\G'I1*ELM/#_GE^HK?'T.B[
MK,'P+\B(!*5V383R2%%+?#_L-GF<;]+89P'9F5Y1[B?U._Q?I+.GPTRGP4*O
MF67U?`]QC;L)>`&*\O\`NY1!*U\G@96D<E;/MW(BI>V*+CZ-0[C"ORHTY4SS
M=5K[]OAOITC=0#J1`"U,((E&$D6D@=YDB6J=X\5HOI!&%8]D\G;=\:E!JZ+P
M/E![8'>-D48I'>>/7,1:L\*`.H2R5GHG`]T2CI4<-?3\8VG:$^"YLM$`'<#M
MT'X@JR6>%L&[?J&D8"\F\7T]9D.I-]*-D,V/6:OUC[\)??:$W0VN+[-YF/A@
M777G\^`7'=K'<W';>=1V\WZ?M\ISXK_LV(E\>7]3/S.6%'OS$@:7WZ,0#&5?
M"C!U$5EB_P!/[B(7<O&*S[G$#J"*IQW@PHAPRE'V6.X2N@Q=05?T/WS]8K!#
M-!:T(ZA3W-3B(/ZF5+/>!\W/M_R)+-M>4Y.OOVCG6+VXQ!17UA!=S$3K+F/[
M&4!VZ<CU@3<>2_U'`L+KA^<3A%T.GG.3/!P?7$+4^1,^VO.!#9>&VO?B`&#4
M=2SP8(^;QTY@"R.6]V_U4O8,$;3^STE*]+.KN^/2)3SQU4=AM7ZF2\/"V684
M-.2([;AZH`OJ^(!J47?,W+34`AR37:*"2.L`&@^FMUC<2F$C@<5Y06#2[5&[
M_P`S!C0+NC'XE>RJ>#T]X;LZU6_Q*,M3PXK)KC4L[!Y'6:Y/%;_']S-RP<@L
M.8423P[_`#"JPV=?JM(>YE4=9.UP>47(92M^4'"U(6&%H2_*!*-Q8+NS(V(;
MR8I@XF,M&DQ*P2-O6U?T_52W.-CSN!NV5MGK!=2R82R+_,<5$A3Y=H`'`\4R
M(]0B:E8WEO.Y8W9A<1V[!M]2?BOJJ8MSKBNLT51+M:*KOWE9HI@KN14WS_1\
M%0:%;V2A04KR>958M>\!GA&X2@UYQ1E+)DJ\NH)=D<\@FI=">TB5'/TRE6W$
MN$53C7QW=B^?R2\S4G?AJ4932^E2D,-&LCOG<W0KU_4QTS<21!IG=RC#$K@*
M<^7%0SH396LC/((ZCQL!XW=_[]6=-9-Q;:I7"UK/):\R4&I?"I;SN-\07F7!
MMI+E_P`:^N)7.*E=SWF+J\PU;-?RTPAM$0Q^^GAFZ4[?RF)TQ+KJZE5^Y@0=
MMR[-E]'I$JOOD9A%QU7[S6KZM/S4:RU!M2G'\D2%7?Y0FV/*YZ9Q"X5YB_U`
MK/L*_J#VQ#I\Q`4T0*6#44`7F)7BM30')7IF"-UPQ:ZP;X?%:/`+B#CVWVA0
M,)YP-S><-JOMF#0Z>8`6.LN`L:CO7S'3]_\`80:5B?.=OY+N`O!G/M#/!7%U
M][E:4]?_`%!FA&#:T-_)UX64[P&H7N.K#<$U!]H#.IYO::]/U"BYZ].]5"@"
M[;KK&C27WB4T(QVED!MV%"%K^'6<PJ?Q_L%>3JQ`IJ*DFZF:0Q7;G.M2A.([
M$*E-1<'\IM,ZD"15\.(P:[*CP)A7FQW]8UKG^("Z@BTW$B#<](."]!ZP4<`2
MRD:V>4PZ7+K6/ZJ"*,CSB=,K]^%D%E]1\#L8,4,3..`OMS&NZ\8X&D-E(+IJ
ML0X!T/WWEIU&2`6"S$<M=J]=U,&A;`C0A"Z)T@@%(2V`Q!:#<L"VWL1`'F7$
MJ:&.'6ONH4,B_P!@CJ'[EO/_`)-953DBN8F)P7VS*FE,5VJ[FWH0_B,@5MS1
MJ7J4MTXCP&Y3PXXC-!L`NBLW&V`4!7&:@@`0'CU>OG&R&W!TSF8U2JE-UUKI
MS+`(5B`,X*PO]1'<JV-Y\I2A7/X-R8A2$P&:_P#92CBA@`5-'B07C^[B6VPG
MK$(H%[\US*IK;7S_`.3,L*BW*\?0$:-$!^XQJ[K\?"D%-PA:@6'=G_L6=.LR
M0*M(U4*::S[QJLGO9+`='4=8?:"K$,E`N8?G8T/`SM\D1UF8+LKSG?CP<%NO
M%0VA!$$1'P<;E]/@KFX$5*K'P7AP8`59'[EAN6.OD*YY9RZ><=6!?Q.S%?FH
M*N*-^6ICNBIFI"\?F*),-Q@<A\5ZN">^)@6O!@"\L<0.;K,SP-5>=]I=RJHY
M[_9+8M*GK=W[8A=^JWYS$"A@-Y\H[=_^1\DQYC$1Q;]L/8%Q[M02K_2?]N<1
M%R@_M,YPPQN[N/)I4?A3W93[F>M3;('CI&(K+6>S,U9V?W\MXJ:/RSR?\A5I
MWFP#Y?(FFXV6A':(:,EJ]8*J4*E7!!^GRAZ_&16D_H3&@L#>($0L>`+4OL)H
MFG[^W3[N;Q=7:'R@[>H&O&Z]IEFZ'WF#>4OTYA-V41L*9Q,-5:%F&$_V(4Z?
M%0%=0$K)Z\0Q9#V28+M^W29<H7BF.T5M'?.)=`;X:8D7N^#MQ*)U6QS?:**P
M]3*H"%@^B])KZLJC/:"9B1<F/BBY`Y#VAG``RWDG`1-X.Y_V`=DBJ>B/2`"^
M4'%`+BXN04+Q\C>XHJBV.4A7F`B!HZ?-LES"XO*^KN6W/[!F+H5/N)I6Q8;-
MWF"M9_,HA&\/`ZCH+H0/DN8=4489(L*[8-0""T'%^OI`A2=T7=+^_28X$ZY:
MRQK"Y;S+/%8S>]Q61&^/29E@_P#03_U'A#_U$_\`43_U$_\`<2O)80J*KPI^
MF"40Y6V)?4Z/>`^M+>O=B%]1A;0]NCY2X:6!WH,_W"@J67>L\=(EA3=G%YS_
M`-BM&?S!KYP+VW_G/M%872V\_N(73Q6'\?J-F<+GY"CH+CD-?ZCOYJ(T@`7:
M_P#D/56P_P"QN3,[ZXQ,P+UWB.TBTS;+;EKJZW_GP/S'','JNOS$Q0WE+\X<
M"AU;/W!2T-6BAG.KEHX9=J^\N:72B?>934,J][FP*34I_H8LL[Q(4EA\OQ*/
M^7^0%U06G(==3[C_`)/N/^3[C_D^X_Y/N/\`D7,I]^4!5?/N)J.J4M@*MYXF
M0UVSP<>484K56+I58Z>E1K<N[NW#FH%18L,%$=:.].'S_P`EZ@:FZU4Q>+P)
M>:BDJFJ==<RN-4M^0Z3H+!56/GD$IUX5SM<0U"#NOD6RLYZ8%4+\9K]P#1_/
M^PX`"7X:;YE7C6RR874P05WKTV2L'4,KG5DL8^PW_P!EPY;+9;+?$JDG6`XA
M>-!TI_V8J4G>"^%>A;]3R0&RO:O[@E(+;7++@$.2:@!1\E@/3BJ;`>W\RV6_
M&LV[\V)>ONRBRV(GG#3-6Z\LRS'?Y-2F_F"WB1'F9\I%;?T=^H7$>EA_17K&
M.F$/4QSOK\%-Y_+V&]2G=X^"EYJ$<$7J3ZL`-!CZ1Y2P8[7]#:>2,HV8=#?I
MECX^:$;FHU_Y!G9U7[W&[%?R)F9F9$4(\YE-3H@T:DNFZY[?B%2Q2W$_\>7<
MOREF%.%Z]>T,Q'O]+N<ZO=?]0&@A@KZ5S';RG'6N9J_7R3WGO/>>\]Y[SWGO
4..YMS-7<;WOB:_(_KP/6.OX'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tpg10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg10.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```51```.Z4``%)^``!P"__;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`[`&?`P$1
M``(1`0,1`?_$`2```0`!!`,!```````````````(`0(&!P,$!0D!`0`"`P$`
M```````````````!!`(#!@40```%`@('!@8#`0`#`0`````!`@,$!081!Q`@
M,$`2$Q50(3$4%S<R(S,T-19!(C9"8"0E"!$``00`!`(%!0P&!@D%`0```P$"
M!`4`$1(&(1,Q(A26!T$5-=5V$"`P0&&Q,B,6-N8W4%$S)-2V<8&1H4*4T5)#
MLR5UM2;6\&*R-)47$@``!`$$#P<#`P,$`P```````1$"`R$Q$C(@,$%187&!
MD:'1(G*2$P000%#!X;(S\+%"4F(C@J)#8,+24W,4)!,!``$#`@,(`P$!`0``
M`````1$`(3%!46%Q@1`@,$#PD:&Q4,'1\>%@_]H`#`,!``(1`Q$```'[^```
M```````%N+`<W9SQ[!Z&,]#*<NU@````````````!3%3&=8XVM:8W[\9NQD`
M````"QCA<-0W]7NZY]W5OS35&3@``````'N[JF^-WFU2````!JK=E'[T-6">
M%U,A9\_77I:)H4_/````````````````$/Z71S`N\Y5(````%N!$Q$J]%+&Q
MS'RTZ/H/JKX7@7,P```````````````(?4^DF!<YJJ0`````(64.HE[>Y/Y<
M>MTOU(\OG/5C(```````````````"'U/I)@7.:JD`````"(='HY:W>9AWJZ7
MW.HY>5_.[@```````````````(?4^DF!<YJJ0````+(:CLSHWR^BF9<YF.&C
MW\*ZOGYD\WL````````````````A]3Z28%SFJI`````X<$?;L:*\CJI@VN=X
M\-L`_?N_3GPO&OV```````````````!#ZGTDP+G-52`````!$*AT<M[_`#1'
MS0N=#./1X&TM4@``````````````"'U/I)@7.:JD```=>&)93F>,72$+O.Z6
M8GH\QVL9BUJ]K&>KYV9W-V0``````````````!#ZGTDP+G-52```/$P:)L8R
M,T9<N01#H]'+:]S/*RC[6]F-/04YB^%GM3=0```````````````A]3Z28%SF
MJI```'%")]Q*^BX\IB/ZN.L?#ZN9V[G-A9:+<4=O2QTOY_13S<^`````````
M`````!#ZGTDP+G-52```/)P1']&)D4,K]<>+L1=I='+J]S/*S'#A'RH]_P!W
MZJ^)S_8C8``````````````(?4^D[6=;!_5\FYEN>C'M8R!1CIQ?F-GY<%/:
MU3O\39S92(AT.CEMZ'-<T9"S!`GU[WN^;<FYCXH``````````````A]3Z3/=
ME:_T_"[.,['J9:F]#1DT9;BHYIB.6N_([.E$+T8EQYT\TA"NATLQO0YGO1('
M&Q^87N=#/;RN>V7HR``````````````A]3Z3.=U/*K'F<>;-ZVK1ES5YEC7L
MBENS=&HM'HR'RI0]]3&8_E97YJ0B'2Z.6][F>9F!0\]A\\M_3_1[1S8`````
M````````$/J?29_9\_'\-YLRW.KA>[7V<L:Z\LIQCPL<I&9^;!GUDZ/%FF41
M`]G5K3G^LFENY_/L]``MB/G_`+.B^@6'/``````````````0^I]),"YS54@`
M`#IXHE7HEWY^7-L@1#H]'+:]S/,S`%L/EO?]_P"I5'P``````````````(?4
M^DF!<YJJ0``!YV#`[,;+T3=(0M\_IIC>CS'<B0!:0<U]#.'9SW(`````````
M````"'U/I)@7.:JD`````"(5'HY;7^9YXS`%(1NU^CQ6)DOK\U(`````````
M```"'U/I)@7.:JD````"V&L-\:$\[HIBW.;YXS``ZL/D3Z_0?6KR/!]6<:@`
M```````````A]3Z28%SFJI`````X<4?KV.A/)ZN86_G=@9Z``!#;U9T/0Z.9
M-3S<@RT[7SI52```````````(?4^DF!<YJJ0`````(AT>CEM>YGF9@`"W&=#
M^AKMWH_U.@R6Y1\N-P\^4E?!U=W?IVS-4````````"'U/I)@7.:JD`````"%
MWG]+,3TN9[N,@``4@+9BI4I+3MR,8G#0E?HI6U?+VSG6``````H5D`(?4^DF
M!<YJJ0`````A$.ET<MKW,\S,``````6XH^^DC76Z*1UOF^_,`````4QRP;?,
MM?'`"'U/I)@7.:JD`````:YL(<4NJEC/@[:RIW9!2&/Y3D,0`,?F?>QQNF1;
MA/@S/LY:<,G?H&M[\N-_.X_+WRH!X,O<QBZ9%,'@MF@_;TR;\?(#PL,XM5NA
MF#<YJJ0````!Y)HW1Z.D-?K;FFE<"TTXO;E40+$:,V7=T84>]&0H:,B[N3.E
MW\5$53'O=?WCKH^GC%2V9T'%_=F7G^EB%#16-[:^SS??QV`:,F]L)4E_9\"K
M(`````"F#3F^-Q:)KE`M3J#?IW#HV@4B=+VF?XX95HR%NK+4%J<OUZ\PQR0I
ME$=]K;6IF$*RX];05J=GX8YEA(MB=#V\<]PQSW1F!I7=&2:VQXR`````````
M`````Z>N8P>QA=#V=&'C;\[-NKS\-?L:+>Y:6O/L=E9`````````````````
M`````6XJ0OS#BQ<DJR```````````__:``@!`0`!!0+=I5R4^+547'0U&JX*
M&@XM4ILX4BM4^MM;[B+DO*W+11ZPY?#U?R_,>KU@#U>L`>KU@#U>L`>KU@#U
M>L`>KU@#U>L`>KU@#U>L`>KU@#U>L`>KU@`\W;`,OW_+$ZT58RX:EP:_E7!G
M6_=F5=M'3\RLN::KU>L`>KU@#U>L`>KU@#U>L`>KU@#U>L`>KU@#U>L`>KU@
M#U>L`>KU@#U>L`>KU@#U>L`4;,RR[@JVTK])FSI\>T[I:=O.#<42>47-#E95
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MCN*4E%.FVS/N-/>6C,+_`&Z/#4D18LIO)?S%+N7?;D]YI=%N6-=C5LU5D%;%
M43'3'O)N-^K5HVG+;KCK3MN5YYJ+'O."R[1;NG7$X:R3;LIMR_$?"O'A30KZ
M55+SCW-%FV_^R>7U#\*6Q(HG_P"@=]N3WFV+SR([=(DDBY4?#HS"_P!NCPU#
M\,RY"*%G#OMR>\VQDQ69C$&TJ-`>+NTYH3&J?=C*TN-ZA^&?4::JQ$GB6^7)
M[S;;,+_;H+NU<UJ-*KF7F4=RL75E[OER>\VT,R()O2V5E?,J/-N]!ZSK3;R*
M<Y-LP1GT*8WNY/>;:+3Q)CV&MEV_;9IR*I;UNT^W(NM?5"FS[KGUJB6E>L3,
MFS);-'O>V*^O>;D]YMMF%_MT>&M@+^MJJ7)3./,X7/'S.*YT7-G3U2/=N>#T
M<[NSP*GS<Q,TJ)-*XK@ZU9MUQ[SH6YW)[S;;-#SO[:P2R1L<"&!:,"%X6J[<
M[:K<ODBLE_,5JC63<'[3:VY7)[S;;,+_`&Z/#;OY<45<RF6I1:'>I652E'^@
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MNVF:DQ0^SC\"\-"N'#>/_]H`"`$"``$%`MU,<)\'"HQPJ!D:0I*D;[B.(AQH
M'-0.<V.>T.>T.>T.>T.>T.>T.>T.>T.>T.>T.>T.>T.>T.>T/,D2$3TI)4_%
M#DSFF<KC/GM#GM#GM#GM#GM#GM#GM#GM#GM#GM#GM#GM#GM#GM#GM`EI4>T:
M<2A7/C\,A7$\?-$MHXTKL(_K[3`@22(+_JIP\!5$I5,["5];;/=RE>+I&=,/
ML)7UML[\1A3KK+=3Q)SL%7UMJ;+N#I*)8<^&:KGL=@J^MM,>_P`RX29*C?=)
M))#A8H:<4Y3B[^P5?6VSWQ#'`1EX2GVS:?[`5];98'J/%_8&'3,CDX/T_L!7
MUMB7BHTD1>&AWXM#I&I,52EL(5Q%OZOK;(T8H+P(L3*.DV9B2CR"42B!B(ZA
MD&322W]7UMC_`"O'EC^<5!WXM)GPE-3_`.EOZOK8_P!VHRW`499DIO@5PD.$
MAPD.%([L0[B;!>&A[Q/QT*+%*G(ZX#_R'M^5];_M+$]1>5F-COXU1W4@V%);
MT?R'E&3>E[Q/QU/.REJ<;-O?E?6+X^,<8,AP/N!,>1B3:\5I4VY_(63_``%A
MAH=^+5\1@A,??5?6[]'>/[D"=>(<Z01\;H4;BU8'H6GY"?`<48V)1D;Q<6&J
M:OZ[ZKZVR7_9"?AT._%K%RS:WU7UMCA_93BU:CWQ:V+;3F^J^MMG?BUBXL7C
M);^^*^MM2;68>(R7K>`FMO%#+?%?6VI/K),H^:\223KM*9."3".=S$&"4@]Z
M5];;._%L(<CR[J3IY$LH1O$=/QXJ<,:<.7'=1QF"_L6YJ^MMGOB/;,R2CF;T
M0B<85&;2?$G<E?6VSOQ;<PF4Z1)D.-J\V8\TH>:4/-*'FE#S2AYI0\TH>:4/
M-*'FE#S2@<M9%/3BC45];:MM<PIK?EW^-)JQ[]/\ZG=J8C$BT8),&A)'LC/`
M*P(ICJ'(^G'N5];;+)1CDO8X.#Y@^8,'!RG,?F#Y@^8/[CD/&.%XA\P?,&"P
M;2UG@X/F#Y@^8/+O*!DX1X.#Y@P<"F)"@9.#Y@^8,%@V77!P.$/F#Y@^8.4^
MLB;62ML8YG=J$Y@G3@.<?`XZI]S0H)=,@I?$?<.[1SCP4KC5H,<\T@U\P]+;
MIH2HS,M*'N62U\6_*"5QS>+R:A\GG%Y0@:H8YC'`M31A6'%V<?@6.^?_V@`(
M`0,``04"W?$8EV"TP\\.GS!TZ8.FS1TV:.FS1TV:.FS1TV:.FS1TV:.FS1TV
M:.FS1TV:.FS0=-F@Z;-'2YHZ5+'39F/39HZ;-'39HZ;-'39HZ;-'39HZ;-'3
M9HZ;-'39HZ;-'39HZ;-'39HZ;-#D20TG:?QAW0.7Y<CIO&:8ZHO83!?_`#=M
M$^T2$FYT<NPF/QFV@EQ1>'`X/S&2["8_&;:)]H7A2^+S)=A,?C-M%^T(4TB5
M+)"FU=@L?C-K@*>XMF,X\X^<9Q+,F3'(F^P6/QFVA_:%X*\.`UTOL%C\9MH6
M'E.[1$))M(QX^P&/QFVB?:%X""MMI2V6$(E,%%=W]C\9LCQ+07>,>Z`VMZ,X
MRMA6@_">@S[`8_&;(_'3$^T+PT'X0WC-K'$]^8_&&?!`-YP@;KA`GUF7-<'-
M<'-<!NN!+BU-!7CIB?:%X:8*E,SGH$@SWYC\8Y^.[C!X&$D$K)1<1:#"/I!6
M&I",RB8F>H>`IZ6GU?SOK'XQS'IQM.$.4]CWDHN%)*X4EB",E)1]('AJ1/M"
M\-0OZ'4R,]^8_&)=96P3K>!R$&H_*F9E",&B"I/#"!)A$1JCI0#\3T*XN93^
M7Y9SR_%JKX'Z;OK'XS9'J1/M"\-6`3SL??6/QFVA%C$PPUJ4WS7]]8_&;:)]
MH7AJPG&F94J.J(]OC'XS:^`B&7DT^&LR[$ER5]RM[8_&;4RQ%/<6U%6\X\>L
MA2FG4<^5!5#DH#D:0UO3'XS;1/M"\-<R[L#$5Q/E#9;)I4=E(\NSSDQV3+DM
M<I]E<=[<V/QFVA8>4[MGX:<",*(+>@R),A'*D[DQ^,VT3[0O#<'37*IW","&
M!#`A@0P(8$,"&!#`A@0P($7>6JQ^,VU.;<?CO1GHVK@OAU,%'J\*C+O,(<>9
M#4EUR*,%\.I@H]5*5*,O'225J#'XS;1WTLCSL7RW-A#FPAS80YL(%,C%'YL(
M<V$.;"'.A!,Z(VP3T$QS80YL(<V$&I<9I'-A&.;"'-@CFP@B;%8;YL(<V$.;
M"'-A!F7&8+FP1S80YL(<V$&)T2*LG8(YL(<V$.;"$>9%B.KE-%'+=#3Q:OB"
M+`M/<$EJ&1:N`P(M0R(S(B(]*DDH$1%O_P#TK$%Q$6)XD1\*DJ,?]=Y_^&?_
MV@`(`0("!C\"[MS/P5!,%202C:)%)<G?DNF)Q.)Q.)Q.)Q.)Q.)Q.)Q.)Q.)
MQRR/9I*)46BEW`#:2:0KC_)1MG(34*?")Q.)Q.)Q.)Q.)Q.)Q.)Q.)PA6U]*
MZQ,H>U-MQ2'^F;4*4`B:TW3`JH/IYVDTCSEX&6*W2!J7P2@NKA%_!%9(>ZA'
MI\#+%;VGA!'=$&*7^)YP\CMI<X0Y_`BQ6]N/LHPG.:U2F$+#`AGG;X$6*W4B
M;L_;Z4LX)KR1Q'*%&!2$#JD_QT."0LIE+X$6*VX0Z&?QNG^_D0YD4Z3G.E"-
M!M*<Y`_I_P#IB$_(\J/EX$6*WMQ]K.EB2P(SD,.AD2-)QYK_`("6*WMQ]I/:
M:?5P08[3^+^,[YFKG+B0_`2Q6I`C;!N/M22<1H!M_C)O,7#5S!4.?P`L5K2F
M9/$HP!\59&$N.4BDSCEF=*B[)D"EVQ2B+0?#3S'\+C<1G>P^`%BM>U<[%*<2
MAN.P4=)%:6P5)IGA-QG]O`"Q!$'\4X;-1>2EAEH_<&TRL4[',NT"S2)]8;!N
M.P,A_P"M$)W,)]+0@*`5:@1YR(TTZ._EB[*4%CZ.`CGR!*$0D*20_J<47U@M
MS5(.8<TFE=5C1;^DLF%/-;!N.R:<8R>39$,FWC:2H1'(N@;7?BQ`U%85C0*V
M<PBFA>8<1KA*].,`H.O=DHI&[90LPDF[6X[)+@:;2>3Z1K2_V]^+%V2$01"0
M7!)="K+V4G3]JDE%/J]Y]M%$C(:'>E*7,I!8!$3#=(HVDLD=,X\R7,L^3OQ8
MK5(#.*2&1?;)8-QV;6*9Q*9_;OQ8K52ND$<<GE>Q++8-QV;'Q#,H1&II/WXL
M5O;CLUA)2PASF;,.F>;OI8K<I%(&M.=;.00(Y/5K8:'(4AF]Z$,/?"Q6XV%\
M9DFDC\AS7SF=HBP(L[W-,OZ5UBC#>T]ASKMSLG[T6*WMQVESW538;>(D&USJ
M60--O.Y=V1NL2\_^W6/\_P#;K'^?^W6'GTW,-S&&Z6B)I!2+NA8K>S';SI-I
M->U)T$D-/ZO00VJTS?#ISWS"W>YEBM[<?<2:9,.B2$K2/[B7EF1W*#/^(J0>
M!NH5(/`W4*D'@;J%2#P-U"I!X&ZA4@\#=0J0>!NH5(/`W4*D'@;J%2#P-U"I
M!X&ZA4@\#=04H<%=QNH=-&HM89LN$1+*EB6*W/=^AJXY2)-(Y1RT77!1*=`E
M@EL0Q(5LE'3,*=C#(^(W6"@L5OV1S%$Y"L685BS"L68<U16+,*Q9A6+,*Q9@
M3Y<UP(\T=B%8LPK%F%8LP*6Z)72XA6+,*Q9A6+,*9F<F`(9RXA6+,*Q9A6T`
MD/0$,R45BS"L685BS"?96\-HY\`K%F%8LPK%F$Y)B%.)/W"C8T;EB<.X;3;D
M.7R!QGUW6%$2V!,04K"0C"HB26%$KHP6"%W_`"BE$+80O]JZ%!\ULBW,>H-,
MRV$-<=S("*C<:N-=K0-AKE1N?\UQG,"V=O:TD/XR023>'R"7MD[S_]H`"`$#
M`@8_`N\?6+[^`NY35HDIBII+6*FENL5-):Q4TEK%326L5-):Q4TEK%326L5-
M):Q4TEK%326L5-):Q4TEK%326L5-):Q4TEK%326L2,DQE?6^"V)C.Z5TUOWP
MM#26L5-):Q4TEK%326L5-):Q4TEK%326L5-):Q4TEK%326L5-):Q4TEK%326
ML5-):Q4TEK%326L5-):P;WMV2.W(.H.,TS83"F1:V$..A%E_<W4&]1"-W,-[
MB2Y)X''WF>=OZG<;[AAE^X;"?$:9-C'L724I_`X^^SSM_4E(6PV?>"7CGRB-
MT=PUC+A;<'U=E\"C[[/.W]3N-]PRF-@B<?+?/NF$_$M7@4??9YV_J=QON"`F
MF3C5KBDPM,.:XDE\"C[[/.W]0]E:@WW"G$K9"^PAQ7+1:\CDK9`WK8;E@1(C
MVD1UJ12FN?P*/OL\[?U.XWW#*?8^BUNQ&I&=TB,I,AB6?P&/OL\[?U*_H;[A
M)V=2TV&XW0RE*Y1OX`=X_`8^^SSM_4[C?<,I]D3FO<UKH3BRWICD#8G/9S#D
MHH[4.53;$D(Z39I?`(^^SSM<G8G9U#(:+0;.9%^6$47ID,CNX.V2<0HM$FM.
M`R:_?\`C[[/.W]3N-]PRV'4='$=1;$:UW!,))N_Q]]GF(9LK\U_V8-HQ*84C
MD$YB<Q.8G#EN.+L_J;]K#J=QON&>P:\DY;MDUEG$:*U'0(;SE)&S74G3O\??
M9YB%?YK_`+,$O8A`COV#\9674I^AON$MA+,'=+$:1OBL,B=^DRVET#%)]8._
M1]]GF(?_`)7_`&8*IRX!1HFN(Q*2&0)MX*<WH,)290I!^,K+J=QON&4[&DV1
MP@QJ;'&<+\;_`.[#WZ/OL\PV#$I[+S.0BNIJ!%S(\GU?%(XL>E]?N"F<5<1:
MQ+S,S=8HGS*.)NL?Y)368ISRA%B)B;K",.(AG+(W78TBJH.HYR\N@V9%K81_
M\]*A^Y/*R*+,Z`ZCOTI5R(7?H^^SSM_4[C?<,IV4=D-K#;R5VIU[]'WV>=OZ
MG<;[@ED[IJ-*)&AN:5Y3+OT??9YV_J=QON&4[)D2,1FPG2H#@OG+OL??9YV_
MJ=QONM$.'U$,BF(S5SC1I22*H.]WR/OL\[?U)L1:#;B_EA%*(BXDNV?.AR1+
M]T=2YQD:.)5178O,$1MGPD#IL-&HN7O4??9YV_J=QON&4[0A"5%$>!%BMAN<
M;:)&TSI)BF!/YS*=Y':@U(\,UP/D_M'+Y\.BDZ/_`.(,SCLDP.U"GS6TKR&O
MV'*<CI%4NZ1]]GG;^I7]#?<))K:MWLPWQ2H/:2$2$93W\H=!O=SC[[/.W]3N
M-]PRGW#*&QW,AD91DI-6F<GY7R%VVG8Q]]GG;^IAP26)RRO%,["/Y2L::;%)
M-"V)F1;))IL3-I2$#(A2AO<1I<-!U+HT0C<[EJ1RF<MP[B=AN:2D2+E-+'9)
M4:9V*-E!V",)7"/OL\[<@<Q[:4-Q7T!=+R#Y1/-U>53(BO8!\+N/T'PNX_0?
M"[C]!\+N/T!]-R3Y9N6O*LUX?"[C]!\+N/T'PNX_0?"[C]`_IR@[+T7;EDFN
M#X7<?H/A=Q^@^%W'Z#X7<?H'L9!-'M0]O+>'PNX_0?"[C]!\+N/T'PNX_0/@
M\DZ,0I=N\9'>'PNX_0?"[C]!\+N/T'PNX_0/H09'LHGMW,P^%W'Z#X7<?H/A
M=Q^@^%W'Z"DR`=(VF4K[ADAW+P^%TG[\WXCX7<?H/A=Q^@^%W'Z#GL@G20RE
M??R!T"!#-K7H9[2S9"[VEIEM4H,[I^7@JM!G^0+>"8`>3W$8DF!K?_T9_]H`
M"`$!`08_`OBR4SNTEL.R@FJ*/&(5&1I,@L8!7D1-":S1WIEQ7AB.QUM7#+*_
M^N%\L#2%S(\34&Q7YN5[Q.1OZ\ERZ,`:^WK6NE)'=&:LP&J0V7S>RN`W7F5L
MCD/T99ZM"Y="X*D*=$EJ!=)4CR!EY:\?I:'+DBZ5X]'#$HU<=)`HDX]>5Z#,
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M;*K%D+'4TIU1F-J*?_`UO5;Y5XXASVWU\<U='C0H39%!N9P@0H<6TAQXR-%M
ML2N:P%N9,U57KPS5<L/6MM;7K1H\%B&VWN9W(@Q'$?'BB4>W1/<P:F7B]7O^
M7%@X%O9KYRL36<CF;;W6[]Y.,(GZ/^!II'H`W),>EI_=C=?J3'I:?W8W7ZDQ
MZ6G]V-U^I,>EI_=C=?J3'I:?W8W7ZDQZ6G]V-U^I,>EI_=C=?J3'I:?W8W7Z
MDQZ6G]V-U^I,>EI_=C=?J3'I:?W8W7ZDQZ6G]V-U^I,>EI_=C=?J3'I:?W8W
M7ZDQZ6G]V-U^I,!HZFV*>UD!DR`Q#5-S7O(&(C%DO8ZRKX@W()'IGDOE^%V]
M,A2)(_-MPR1,$R84$8L)T*8$JFC,<C)I&%(S2U^:)Q7IQ7ODL?*AQ@11WM6E
MP[_N6Q&RU0ERT[GM0"<^2$F@BL5^C)4ZC<_`Z"*?$=N./?605L;(,B;#=*9M
M&R0SI`@R(DJ0UPT<Q%0C'*O67RIAF5[LGM*O?S7KMN\4*CR9R48/[2-(U[5U
M:EU*B\.C+C:^?X-4"MC16]AF5K#"[1-%:VE=-&X4B=*,T;&P6.;FUOT^E?T'
MX9>S7B#_`/';WP_@S[77?\HW.$_IQ.J)&VKV%?QZ.ZC7-J1JLJAH?=,N\JHD
M@2#5G:I%5,&01>9FYF;-'#5^@_#+V:\0?FV_\/X03'1YDM`;KNG=G@1B3)A,
M]J6S<@1A=<JIGFN70F:X:]S7#UM1^E[5:]NM,]+VK]%S?*F(%X&;**+<42@C
MS*U'C!$8&TG?9PAY"O0FMD(<)#ZT1CD5=.I&YYYQS",WHU"(TC<TZ4U,5S<T
M_07AE[->(/S;?^'\&?:ZZ_E&Y]Q)UW&"(@[C;,1EJ*JBV-B(1=Q0=,(:F)'>
MV)+(305$)DC'N7)W0N\H\4`8L:-XC[Q`"-'8T0`!',$U@1#8C6#&-$X(B(GZ
M"\,O9KQ!^;;_`,-E'EDD/5XVA`&%-))E\Y):C?"CM`I98G)`,NIB*B()RKCP
M2F1"L/%E;HN)$<P\U84+]G6[QO;GDO%J^Y(EQY=;`6):4,D\NV8`D$,,%S"+
M,<1LF/*'K[,UVCJ*Y'Y99+QQXD4\6T;-@$LZO=E6)W(0NC=L#SK.,)&-:<L3
MF$$C5=GI3+RK^@O#+V:\0?FV_P#"N;T9HJ9_JQ'D1)]@"9!Y?8)C.P\V,C!S
M`JI6+!45C(,&>5KS24*9R*G6SQX+[8-'<6H9N2SA\CGG$]X(^TK5[-4B,^.=
M'J0:.<K53-?DX8+#I8CHD<QUD$&Z7-F9E5K1ZD?.D22-30Q."+EBZK(HX!I,
M^LFPP!M6$)6%+(CO$QE@,/UKX;E=]8B<5;BFVY<U-7&N3^'R4Y2[?,1]2C`2
M"640[72X\>8Y$AUO*T*BZ%R1'*U/T%X9>S7B#\VW_A_!GVNNOY1N?=K=P@OY
MU-95^R-S&VT"-5))C2[RMCSILQTJ5,B'K='FAJM<S]M]%4R3%3-#90[*2ZNK
MW6)(9XYD'.-"">0,S8[E;'+S'KU.&7ZOT#X9>S7B#\VW_@E>]4:U,U555$1$
M:BN<Y57H1$3#4;/`NMS6,=FK1$<]41C1G<B`(KE7AD[CY,9^[X/I7%BAF_:R
MYY!)H"R8K7?92VU<X`)$0I$T9]!&\<-YJM<_2FM6(J-5^765J*JJC5=T)Q]S
MP]-YSJ(<:1N674RX5G%0SK@=G5R6I#@&6,=8\QO)S3K"81.#E7Z*[RVX6L%'
M#N31O&ID121V@2OA1*NA)')$$UJ@.LQKG?T?H'PR]FO$'YMO_!2'M17.8`SF
MM:HFN<YHW*C6J?ZC4J]&OJ?KX89;V\D\>*U>2D99BQ8A6]FT-*6$5G)(QY'_
M`.'0JF;J3J<,)[O@S[777\HW/N[>)5TD&\E5^[]OV!!SQ1B+!@!E_P#$+&$L
MDP$%-C1US8YKM7R+C9UT+;6YJ<ZW:;3=-=9[??5[@IB]NLNP,BAFFF"+/DQ&
M/8XG*1J-R?EA+(E1941$G3X!:ZV&QDL98$E\8COJGD$\1'LS8YJJUS>*?H#P
MR]FO$'YMO_!+K1JMR7/5]'++CGGPRRP_LFTZ&?!?,."-90I=3%LRN`5[#-A5
MIGE)8DCL"XCG-('J#543/AAN71Y,/7CP:J]7IX<>&*P*PX4%]PR/(CFED>L:
MMCEC6<ES;1X#N:V3JK^2UCG1R*15ZF2<?!#=,Z+-&$M]8SC1(<.79S&=IVC9
ML1D>'""67+^L)FFAF>CK999X++@"M`B";L[VVM/9TI^8C6O561[2-%,02H_Z
M;45N?EX>[M:50B@2)>WMTP[Y\:QF$@`D`C0YX%$DD46:YCU=)3_`N-]4=M(<
MLRFW[=!:$UCYP47:],X\2$=X(IY$*&8JHQRL1<EZ$1$_0'AE[->(/S;?^"*-
MGTGB*QODZSAN1..;<O[<`:QPV#?,LX0#!BEC0I<Z,R1VV-$7M9!.(%PB*Y$;
M_@=A/<*Q8<56'?S)#%C`5AR>0AV:-)2(OE=FN/!E$X)]KKK^K_M"Y3)/U)E[
MQ<\;DO:JK/;7%5NRL"ZG"KXW_;^[:2CJ9NXNK!.LL5=,BKGDYJ?2S7AC^O+X
M_P"&/LUX@_-M_&YFW5;&LV0]J[0=&9+;S6`=(L-U(=PF*NECBH%N:^72F)D.
M1LV*3L2G&0T:OCE$LL%<MHZ&BK(9]>L1,TU:>/3DG'!8A?#IG/#+DP'HV/4J
MQ)L2C;N*0#7YRR^KJW9Z_HJ]-/ZL19T?:].H)D:/+"JPD8[DR1-.+4U5X.Y;
MTQ]U:?\`RC<?=6G_`,HW'W5I_P#*-Q]U:?\`RC?].-GPJZGAPXEO1;ZBV<:.
M/0&='2-1LY4D:.TE:C3O3CT:EP[G:.7I77S,M&C+K:]75TZ>GY,1I,6?K":X
MO0Q6C%":(Q8[+3G`'"BR%+"CH!6_7O$UI.S-5/VV&_T>[X,^UUW_`"C<^\RQ
M?;FC=@EU[-K0&OK^WWE9;))VQ-L+V.6MET['$YQ"D1K6_P"LF-JP+$IH.X[8
M'(#6%%<RU(^(LAC==S+B<F7*?%AJ0JN)JU9Y\?C_`(8^S7B#\VW\;N]DME_]
M2W=@A9-WLA\K4YI7GL*1Q^8UJ@>A'/)KUHSJ+GQRX84CMR[-<]7O*Y[K>G5R
MD>#LSR*Y3YJ]\9.6J]*LZO1AUA!:.1!#7K+C=A<)0GBBCJ4*1'(Y`*QXF]3)
M=.7R8"TPK(<HD2$<L4<1990'G5:7`(.B,XA3270W9YL:K,\D5R*N6*Z'"BRR
MLL(MI(63JB:83JPD%CX\M@Y)'-*7M[53RIY?D]SP]_Y3OK_<[>]QSBOL!3?.
MM]RW\V&6/8#UR6MB/L$GZIT:)'36R,R.TD=S$1W[-55O]'N^$$&:-319.Z[E
MAA(4P5<B;4MB)]:`@C,R>Q.AR8:QB9-8UK&IFJY-8FEJ9KFJY(GO%Q3;JVP6
MTJHVW-SUME<P8=E='9.@3;,+90Q1BV2PXR<XRO=DS)ZNR\N)Q:MTK*MFNKIH
MIM?-K9,:8T0CJ`L:<,)VN0)VK]'R_'O#'V:\0?FV_C=^?1]DME_]1W=B0@K#
M:AW1F%D2D%+IR.CB$[(QI"->JB&)R]9SLD1>G!)?G':2Q1$8$DGM=.L<9BHY
MPPD-S.4PI&M56M5<UR7!)G/B^:FPW27'&HWP^PM"I'E:X>8G1^0F?5X:<1W^
M9S,589&Q`K0RDD/JXT-CR2HX%#D2!&@RD;K3BQ'\OIZN`2JVN*=S9<@=>6)5
ME3M)S3H%39DA2BH/M.ETD/-75UQHF6>7!7ZIKF,2S>KAUDQ_[M3&[/:3M#6*
M_L,$ZZ'$RXN^CGCM\=JM"LJ=%;J5%U]AFGAJ5JM54Y9E!J;_`.U<>'O_`"G?
M7^YV]A58W6_)=+-6G4[+@BNR72BKY?)@$%^W"`ELLYY!31S[-\,5F[SFLPD7
M,<:/KD$@RFN5N2.TOZ<^/N^#/M==?RC<^^>*5'#($],GB.-I1.1%U)J&]%:[
M)4SQXI[3\TRZF%!W*M]`;.UI))&N7G`'1_LWP'!K4<!R9KI=DO1\>\,?9KQ!
M^;;^+7<%/YC/'M:>DJWQK.3812A?42;>1S6NB0Y32,/YTR\BIH^7!U%LWPQ&
MZ4,@93ALDC62$RYF#(5FWDYPBJG6:[-'>7!(B;,\,$B%*PQ8J,DI&*82*T1B
M`3;O*>4;7*C7*F:9X2$.GV.R$@>SI$9/MFQ4CZ>7R$`VD02!T<-.666$"NW-
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MP#;G%>V+'GM%.2`2:FT+-#K*=#5)!,AZDU,^D_CT8-]IO,?:^=]1YA[>D;L^
ME/VJ6&9>=S,^CJY9>^OA(>1*C;QV5&N3#5%0%8^FEBK8HT_:(]KVL>J+]7DX
MJ\%^/>&7LUX@_-M_X)Q2JC!#:YY".5&L&QC5<Y[W+P:QJ)Q7R8C1:J?+\VRY
MUG.DQ)1@CB:+&-)M0K7,982"$D2"D0Z!>)CN0Y29-3I3W?!GVNNOY1N??+C8
M>Z;1M]%J%BP:6+*JVL=!F6\B?9:*VU:\XE)'Y1N9DU'*BY+\>\,O9KQ!^;;_
M`,$:+(9S`2!$`8:_1($S%&4;OD>QRIB/("R20T8YY0GR9DB2O:SQ&5[I;N<]
MW,DLKAI'8Y<]`N"99KC+W?""8=LEX@;LN7/;#B29TE<]J6[/JXD,1Y)N+N.E
MJ\..&O;GD]K7IJ:YKD1Z9IJ:Y$<UWR+Q3WS;*&9@TV_N&@O90R,>Y)4>%8#;
MV=$8J+DLDPW+FJ)DS"+\B?W_`!WPR]FO$'YMO_#^#/M==?RC<^_W95P"!#+D
M51"C+(U\IJ0BBG$U:&D<BJ.,NGA]++&V;493D*E<&!-?+(A)+Y]=^Y3"%=S"
MO=SCA5[5<NIS%1?COAE[->(/S;?^%X^3"Z+1KU^K48V1IKC2F&60@S00-C*:
MPCN[(7ZP"$9D->/#'@G*B&9(C2-TW!@&$NH91/V=</:1CDZ6JQ<\?^OE]\\9
M6-(,C'#(-Z(YA&/32]CVKFCF.;P5/*F/%VKH=TA@7H;&PG;?I["!1554X;8U
M&CKSM#H,2$$4)"NCHWF-#P15:KN.(RN*-SR!&[-KVN1ZZ&ZG-5O!R9^5.'QS
MPR]FO$'YMO\`PKDSRS3+/+/+Y<O+ADXE[(E7(9G;0W,B%&=,U]EEP5`5F?9W
M06Q)CVC`-HA#=UD3///P5VNJR_-H]Q6D+,$V7!F*,&T[1[7I.@%C2A$<0>;E
M&YN>>71PP6+6NL'",;GO\XVUG<&YFEK.I(M94LXQ:6)U$=I1?)Q]_0V*[2+N
MVA'MS<-/;5PBU3&N=92JDT=I16LR&(HOW)RKDJY*F/#PDG8FY=K"'&NMN5$2
M+Y@+2Y7LVN0KY2U]A+<'D'74UO!7:G9(N)I(]NKQU<?M,URUMN-0@0B!UZ2U
M['E^L<B9,1RX$*JM02#')(%'`1DB')D/B#&:7R(TX,8YFQQ&:KE:U6HB_&O#
M+V:\0?FV_P##^#/M==?RC<_`UH*8T`,ZLW)27X_.2R&PR^9Y7:>0]8HR&;S7
M(B9HF$SA[#__`$MP^JL;4W`'9FV[^PITMHD:36[CEQ(U8&X'$CRR3H]E'BNE
MHX3,V\K-6Z%_6F#P'>'FWF0A/D-'=?:/.$=`C>X3V1FHM@ULMS4:S4-%:KNM
MDF)QB^&%)$+%$)\:*7<\=Y;(CRHQX([PO>$+Q,ZZJ56-5.CCADM/#"E=+=)>
M!U5]IP=J$%HT>V<XRO2&H"/70C4?S$5,U3+&UAW?AY6K%W%,BU[TK+X!9L.P
MDI)?YMTR2`C/E,#&5^O7R,N&K/AAM:NR+A*Y3<OS_P"<:#L*,Y6M#]E\Y^<N
M6K^I^RU9^3+$._B1),*/,+/"V/,Y7:!OKYTB`5'\DA!=8L953)5X?%/#+V:\
M0?FV_P##^$'F[LG;?M7==G[=SEB:OLI;Y\Y(ZH;+1GEEY<-YBHI-+=>G/1KR
MZ^G/CIU='P71[RE[-;$I9=%=@O(<L4./._>8\:5&8QX)*H)S-,I5_JQG_P#T
M<G=&B_TXW%6,W)0SYVU=W759)L[NFFF[57CB1+`?)!6SX+F%&64].LKNKDB=
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MR:5.9SO>^&7LUX@_-M_X:IB10A+*N9I(('RC/!$`H8$RQ(2008ROZPX:L:B)
MQ<['@CNN>P\*"6^LIY6<F1,,!LC:5FQ&H*(`L@_UA4RT,7-..66#!IK%),B.
MWF&B&CS($U@E<C4.L&QC1)?9E>[3S='+5W#//WH:MTF.EB<!)8H*F&DI\0+V
MB-*8#/F.`(I&M<[+)%5/>QJXTD`YTUIWPHI##9(EMBM:^4Z,%5YAFQFO17Y(
MNG/C[V'%DRHX)-B4@($<QAC--*(3CE'%&]4<=XPL5RHW/)J9XRR_MPT%[45E
MN$;VE&&QAAEC81B.1KVM,UV3DUK_`&X\,R5NV#!96)N:/'FT[!1:JD!(K5=R
M;(#(SM0)A2.Y*(X:-,JKQ]R'&D2`!DV!'A@1RF&,TTHA*<PXHW*CCO$!JO5&
M]#4S][$%+D@C.G2&PX:',,7:IA&O>.)'1ZISI#V#<J-;QR3WHG3Y4>&R1)!"
M`^488&FERG:(\8;B*U'G._@QB=9R]&/$Z3*B2(X+'<U;(@&,-S!S`#V]7QWF
MC/7@4;3#5JJGE3WBR[&7&A16O$)9$LXXX4(<C0A8I"*UJ/,5Z-:GE<N6/#'V
M9\0?FV_\-R9L<,L*JU5!($PP55JYM51D:YN:+C:=A378J";M*SEV4)Y*IEK'
M*Z76'JG`?%[;7Z1MCR'99.P^Y3Q0I/M*2D'MU8Z['3D]B%(+=,`@_M'EV_ZU
MQ-.O7RN.G+CC\PJ/N"G_`)3C\PZ/N#^*<?F'1]P?Q3C\PZ/N#^*<0K@OB74?
M::)1GIPQV;#<X#*RSELF*XXV;A<T9"GK^HYSV\&KPQ^8='W!_%./S#H^X/XI
MQ^8='W!_%./S#H^X/XIQ5;FD^*U`^SV@6SJ8W9MEL(P4N]B`[7"DQ1;C,8TO
MLH&O:QJZF)FJI@,J+XD;?/&D#:4!A;$:091O3-KV/;NG)S7)C\PZ/N#^*<?F
M'1]P?Q3C\PZ/N"G_`)3BLMK'Q6V_V[8EBL@;8^RQKV.==Q"U8@SXX]RE(XDH
M)U08^#E<J+@1P^(E(X1FZAJOAZX2JGZU&3<S'M_K1,?F'1]P?Q3C\PZ/N"G_
M`)3C\PJ/N#^*<4EI+\6=ONL-HS)LJN:#8^3'2)X"T<A.4FXGK8Y<]19!5=)N
M'3PP*5"\2MOR8QV:Q&%L-'#>W-4S:J;I\BIDOZEQ^8='W!_%./S#H^X/XIQQ
M\0Z/N#^*<5BVGBUM]IMJ7+-PQ4%LA!HVPK&$@O:]5W&1)38ZV6@HAKK:]S47
M)<-D1_$6E<)_T7.\/2"5>.7[,NYAD3^M,?F'1]P?Q3C\PZ/N#^*<?F%1]P?Q
M3B/77?BIM\;J&W@;A:QFRFQ^7/HB#G!0A'[D>,K1<QKB";U]+DZ,\<^#XET$
M@2$>%5;L')1F&N1`E8[<S2"*/RM<B.Q^8='W!_%./S#H^X/XIQ^8='W!_%.)
M&V;_`,4Z,0^=#G&&/8[8I&$J3"O`_O#]QO$CFMA<US/IJ%%7HXXHMZVF\XE^
MVBK[FO@QH6U243"MNV0E,9YC6LQY4:D1BMR9IZ>/Q!MEVXW);<_:'L/)'EYY
M\T/I>?VG]IV;L9%7E9?M..K+J^]%<K+<)PY-?+5HHL=DK76M>P0&63&LEI`.
MTB\X+M:/S5$5J+E[TMG$F/A3?.L:WC*V*(L:,<5.2D(Q0?5\\<B*=ZKUD5'K
MGB!4QG$>"!'9'&\N7,>C>E[]*-;J>Y<^"(GO+"5SF"?/)3F418,27$0M.264
M3CQCLTR$D$EJK^+7HK45KDQ'KQR"'&!3N0AE3I.<LAS!M^B&,%Q=`AIP&)$:
MG1CI3'2F.E/[</L9-XLNQ9/%-KYA8`4=7=F.\H*\`&2$BMK6M(J/&Q@WE=UW
MO5Z(N(]:$KC-"L@CC%TH\QYDH\V232S)C4))D.5&IP:G#WD^5/M^VK)>[L3)
M-7%**I!VN/,9#B1WO=#[,0L9O:%Y2'D=+B9HW)8;#/.CI,J4JN:@QC=+,\[P
MQ8[<V1887/R$).#&^\61-M96@:O?":*/&:>(K^0_L_:$;^\5[),=I>4]N:O3
MB]4R1)JND/ERK*R/:3CJ)`,?*.,`?J@M5R"$,$9C43-R\,U7C[Q#2K20T`^:
MZ.!D6&\L5QX)($@0I!A$1\&4,FHHB,?K=PU:.KB9ID<UTZ0R008H[(<(+AQ@
MQ42'!$YPHJ$8!'$R^F15=\><(S$()Z*U['=#FNX*B_(N.32]FB6KKG<<EY^>
MU_[C(^T3Z%J$D#.G[J29%ZN63&M5O%$R68E;<_7*8S8+[`L4X11G[>$C7D$.
M&-72$W$UZM7CI&[_`%>KB\#+D*2R*1[JYC7"[6.ORB\Z)SQD(U9AFM/RGZW*
MU7MX\.$@E=9FCQGMW#V"(I8@F1Q]AAIM0+ADA/*SD2V$Y^I5<N>3]2<$`G;T
MCL2PU3RCD0>2:N?9P2!'6`6$\D.0"L:9A5=]-R\%551S-<JPDN!YRJ'C,RR8
MQPZVKO[@RHHV!&U9IZ>4!'.T]=6JCN/'$=UX=+"N4,EEBQ"1T1H6BG,'V5L1
MK#RYATY.I%&WK*Y4)_@Q6BMM2SV1D:?F/0A6IK<H!F(BKS#BCZ6O=FN;D5<_
MT?Q_OQP_N]WK99?+\9__V@`(`0$#`3\A\JH$MB@R4#/W440(WI$-0R3L+E&>
M`N[R4%Y"_F5@RJ("RM.S<<=F9V$9%1AHTIN<@I)A:3*%_.S7(\J=?!.!FAC`
M#>A,+ZM:&)XS;%BQ8L6+%BQ8L6+#`J,0]I6^)M;3`VI&SC[67P#3(EC)NS4`
M1/YRMUPR&.CF%G7%IHPDM!0+&\YAF_D+%BQ8L6+%BQ8L6+%BQ>28&%*E66RA
MDGQ"T<*[6$9<!`+JD$K<S;7C!%3HTFY'=A:$/4`%-.">Y8K!&`E1"PR@_:Q\
M"9;M^"P98G"<*#[Q1CQ(-<#[JR+_`$J+)YXMGXI%*+,&LDCW@:*3\B[>`9<(
MX#:I@X"HB89CRKQ+A+C1!`H4(61K`7!2.9KCOZC`M,_DG<PS[JE&5I&0Y9"I
M*BSHY@U[@X#'X]V@8)CC$]=*79;NY/UW1E`*8^R<`\()MP34&K9/^;U9>Q2A
M4/[O`XPZ6T+<L*OO!7+^.=PXRWQ(B;(R5#WY?#5C5T"Q+9X+L^!UV#IN:)RX
MD.T%91;9B5J'!.KK8$C+`5)[[`#CF;/5"I02S^1=Q/1UJ4X)X:]*!369B\<K
M$(I0F7%N=:%:%CQ@?BW9-S?AH0%RNA4TD[LB(<RW&J`@DZ.3GVHT0SNM(*2#
M1C,$-@FH#,KJ)%!JUHYU<^>6U0(04J$%+&C;2'*58)EN_BW;XJ?B60!0D!=Z
MOXS09&M@N))5<QIW9@DTO+)N!1OB@K;!4K]@U0(V7GPZNLQ%>]S,%I$1_%.Q
M:T3%NK=S6FT4FW#+>I0I6J%6*9#1%M+6TIC9I(!<+`P*Q4<^8P.,U3!V]#L[
M=4-E`HLL@(-:&C15_5"60)79A12)J1+F_EJ!H72WK4[AHB.,?@79X,0E\%&$
MB7.SF9IY+`VJ4^W24EB:^/O/S5P;T-N1`:*C$2$&]&K`($`+`(-A5_IOVD=-
M%_>IZD'^/VC$/=:^PPI`F&,-S\`"6GU^#V`.1-QBD>L")Q\1Q`6R!0%:(AY`
MA&U=52Y=A,7)!I1HUZU_=>M?W7K7]U#:TNG(!P1B,A9!EI"$HN+2GA7KK:JL
M'!SHG-..C#>Z;M>L:/6";/[>V:W5:O,0]9#M3(6Q3R4Q+AQT-3\L_``BD?UP
MU<+R,R#WCB':U'XC@??\W/4M-#Y=BQ2UT83D-"(9`PV66,O`*C*?8I:'X`2,
M!)I`&$DF')SK)V1XTJ;^.EE+42K*8IO0?SMC+%J7508F9$-E*9,XV2B82)57
M7N"$VDR7CCKBK8+V6O1EY*=SB4FE/@A:QY//@KAA"].FMM0-JPC!$9)I75#X
MMXZ$H7@-`8:;,'E)81Z2D\+5)#X)><;H:8`5(-0T>]BUWN>WI*%D&*F@96Q"
M!K)WNF9^4M:&;]D>+720,R=&#&#JAJRHZW/A1PQBR%4"F'A&O<F>CKW,T)#@
MO4!6,)+).:>7`D-4W8S<%?/E2U/0"T`Y:7>J/C9RI,&69B)#15]?A8A5`-`D
MM;Q57%7!V]'$4PNE`3=H\#&CP4D6:89&0/;C0BH'Q.8D,]$(UB%8M[GSH6#2
MU`4O*\2EU20[EP>VL=*7TH-ALT`T4=4^<))$MT&KVY_-IH*"DP4*%A24)IK5
MF?A4@LJC-$6^:-3Q"Q0#N:XD$@VSDCGSYJ>[DY/U5W6FI8!;>PDR?B';S0<S
M#I(26%VC1T"FU(Z<%8*<_;UGP9A\!^JL7_N13$4!D,#^(=E2YK9.)LUAH6LG
MY'>\B*[X1`&G:=MHN&3:!0\DK"U&O*X$D-0W`2R=W)R?JB9B82(+O?&EQ7%A
M,)@.O/\`&N\A%@'+NN'E3+_]$ZX4I3!2C-"JVH.YK'N5"?Q3L!5`)>5(%RT-
M>@-JJ6*:")!6TS`K+:@2+SFXEE&IN=Y*_)VX>M*!$AI[7!;H9_=G-4K%I*R-
MV;H#))A]:_B':$R.()DM):#I4)+C,[TDX-7]TC7H9[!%_P!-E:-L(Q!-++@%
M,0*[ZBQLSV9KP`42'S)"25<:=PZFGY5IN-6$S$7H::CE</:?%EH9)_(.YAU5
M`<#.$>C)`$U-D2^P\*6488<G:EV,R"ELB86/!9%!)-+)B^R7LDB,)MHA<R%/
M6%D\0;JW`%ZT;1/M6<ALW=1A499DSJ5.0@`@RT(XEFOX-V'+%\)+ZA#,F,VF
MO15+ILKKQX,&Q6>R^;9H"P!4&Q7`-L4[W:>D!96F;BU:2"2DP:QQT!%7`%6:
M(V>%<GE6XI#\6S6'C)-_PCN8-)&RO1MV_BZ"HW+-$+$$&.:]]&MI2P3!5B79
M1XGCQX\>/'CQX\>$R9^'$J[2C&Z78TG+Y-V(,IWH7262+0:?8#SKG8&2EM2B
M==0/202`%(+"`SIVMBFAK).RP\&'EE.Z=7*HP#0H0&R:&2<=JQ1OF$IADTU(
M5BIVH-F<#6HH;`:QC8CI*F#V$PX6>W^+8["#SA!02DBH5CNNRO0H`>3*:L6:
M4)B.U8K7.[I*^1XL`T(7_+PC@>`QW)GB2#!NBZ2"5BG*1$I#GQM9+H5NK=\,
M25=@.7(5%6,P1:D0L>B^H[B]+H:?J-J?X&O^!JF+\&KU%N7B^;#X@IFO\#7_
M``-?\#5N&'@5]JBRAK!.6.):),`&AN4GS&1*_P`#7_`]E*5&15-T.%1@&U%G
M(VO,2/QA%?X'LY/\+6U_1X[QS$Y$JBV0?+L2RL,@B"5_@:_X&HBA"ZUZ0KX5
M18)$,A4SKV!9);HFA-?X&O\`@:O_``M;YZ>8KZKHWB`G,YJY(>["4W+U_@:_
MX&O^!JA1EPLH?:99^\)7-VWHEEF3#*C'C-$HDAS;)+?`)1!IVB4$3&TTO>LL
M);%"3(!W"'(5?MTY&+%C=L,",\90]]OTA`$P$=L+5):C"NA7)"$JG+,'0UE0
M5;[B50Y]PK_4*8NCAMBA1>TVQU6AI@1E=@]7`(YD`Q71V1DWJ:9R^\JVB4X"
MJJA\K!5B990A+GM$E`OPO)M%3?%J)H1N1;2U^P<Q(5W'(\T`K##H>"JWWH+Y
M_$!6<18/.R)I^CH<B0TIX<F\JC\/'<14#!F<1+$(C8,88P>K^R7:P2<"C<K3
M8T#EP#&D%$BUG!J#+OK7I&49]VEL#Q39$2F@FY1.3E\!D)Y;-`H`4,\<3*8_
M'0E9$7LB.,VBHPLC31TCM_@V/G6C!&(M&/,?_]H`"`$"`P$_(?+#._L;47@J
MMLD*QE)J&6L$Z[N5O.H.E7BZBW,<Q[9I&B.?@UZ@_P`KU!_E>H/\KU!_E>H/
M\KU!_E>H/\KU!_E>H/\`*]0?Y7J#_*]0?Y7J#_*ZCD_RA0/`.T;4T)E<BR3@
MX4R/7I=C-N%6P3<LWM=B,NU$4:>UN6W&O0'^5Z@_RO4'^5Z@_P`KU!_E>H/\
MKU!_E>H/\KU!_E>H/\KU!_E>H/\`*]0?Y7J#_*]0?Y6^`GQ2@C:<)3)QI:ZP
M(]WS9%3;%,].7W2B,NO"A,W"M,S?'X/YJGQ%F7,S6#8]?NO4VE"M)?TOZJR$
MO2D^7X/Y;QTA41L]XH'53@O-WR`BE?8_@OEO(4)>,5N4B:R9H7Z9W>0?]_!?
M+>+K%0;F;+H")7J'13F&P.1-*LP-JW+7G*2?BGMQ0HF+3V@CV_!?+>+`LH1J
MC@;W(<+I;:L]CK>U6,@BDQA^5J_X;(`ZTD!_`_+>.@IN>E0N:>S`YRV>E(S%
M'$J`X21^!^6\(9I#3N,PT<]*$T.F-E>/VIWP6NHX!@79DQ^!^6\*RJ`$O'_:
MM[BG/3LA'0S4PL?!F0Z'G*5-,&1^`^6\*+SK0X338D3BZ5/!#SGYI+K2U.9>
MP<1<\*30D$G!Z/&B?9"2U3%%U"8A,)-J-KYF8Q^`?+>$:]*8<[@>CC3B5FDB
M)3K*5-ST[;YP?59^!M!0]XTB9\_\M3).04^!%L1-Z1#[P9>V+\\4)E(_\K@U
MP:X-"-RD(!6<7I,BU9XC(E];&)&E6CM45_H[4)RB4"F2$B,09F9*$DF;LVOZ
MV0BZ2O/_`"U%G-JESQLI.H40WC!P3.IQ-&H#S/S0D@RUW2SQIXQ!$:V(H,T5
MIJ-JL?62&S8>YN0Y`H1)+]HDVOT=PH)/(#3F%@2+Y%0>,F\_7GOEJ$IA;I5E
ME4().HJ=R;UZ9022;V%_:X*5%C4U!"31S'"A@M8>[5GFKW!_=::8U10IZ?M(
MB?<JT[E3GIW6R>53G,`I&/@>>^6J`K:&H=KZX5$?1>U#@+/6U)*HU7VN::-$
M!NY9;YS:^7WKE_YTH1"DB>&-N%798[&+@1/-CTMS:U),D>N%.=RG2]-U*>QU
MJQDL7:8J*%SAWD"2V[O-^F^>/EO"5L"5K'!`M:+%=0:LYM3$(01W*<].ZDD5
M&<C1SC_WSWRWA8"I0'(=NET]2X:M!!!VJ*S^N[,7K?R"HNVGQY[Y;R%.>G=8
MB^*3$>TMFVU$+!&8.3AYWY;Q@)"/CGMFAH@WC3GIWKBBL9TL(DXM2B_G'RWB
MI>K`<L'4#HR):AY5[:V:L!/?=()4F"3?I'*HQ06ED$73-7#-*@7/FOEO(4YZ
M=^-[U<TF]\AZ:4)'8O!&>$UA<65P^%+0_95Z!5ZA5!%H6B"-GC5R9^W8IFB>
M4^6\>5JGZ>#!W):*688.US<R<*83H%SVY*'>MXMRS.VU0+MXR1[ORWD+<]/'
MN(J\1`2CH?F:0\1(J#8\15:M6K5JU:M6K5GME-<IG/CSI-R.[\MXPO(`_%7'
M+D-!.%C-PVS1+%@T[B6":MDO'=T7NT,]K!#>E`.M&O"D,%J![_80P-E[M@E=
M:U3;M@4DRTI@_>!^HQW&$F]?+>,69*BE0S4EE,0VM6JET_[4>@_=1Z#]T2>A
M\T\)D8M]U'H/W4>@_=1Z#]T2L2>F],P;!9+-$]&G!#D;CYJ/0?NH]!^Z/2/W
M3@J21!K24@>CC4>@_=1Z#]U'H/W5I`<#;6]0K^CC7H']J/0?NN$].=+@I+^D
MT&Q#A_VH]!^ZCT'[J7T/NM!P#;48JY1NDI'H/W4>@_=1Z#]TV%IZ?]4*206@
MCQ[BBW&\1-&8TJ"H*@I+%RY5!4%04`N9J&#?G,%\BB$))?K]5!4%:3$L4AE(
M+MFV?6:"3)XUT5,9M%;FI5B61[[\Z?05:K-&7&*3@0G3.V<_JKP'R(UZ[U!4
M%,!B:9!H^*)%H%05!44T1\M*^/G@L1LJ0)C6WGZ'7%-`BYZ,??[T+41X'@'1
M;G2%5'RGV:*/+A278RW$$=*L((9=`^:3Q.-ZFF"R]`!!C\=+B58W=KBAYC__
MV@`(`0,#`3\A\LH9H"28_P"Q]VKB9GX9>UG.I)C7S\5=0=,Q,:O9%/CQD"""
M""""""""""7U%);.Q]VCCR!Y/\E!MZ.0:`%<^110000000000000002$@0W&
M%Y-#./$G"E.S1!;.4!(V/.U&M''3AB_\5+9/>`P$8)=_P83WG]]#Q9:N]1;0
M'F^E)^`@*RDW7A?FE/X+T7>AXUU4;B@QK4ANPPPJT*1'!X\4HY-1]'O^"]%W
MH>-ZQMKU'%H-HVVH(ZU3&,B8Z/1^"]%WH>+;6F'J;:^Q^VH#KTH9&?+$4@2$
M;YD`?G\%Z+O0\5E>F%@Z`Z-$2I`C)TU'0!2@EAPF>&>=J:'C(H7AN"?P7HN]
M#QO2-M>HXM7,,P_5644)9$"S=UH.G^!]%WH>%'<U7&ART="7[>QL]@E\BA0^
M7*KBXA.&D?@?1=Z'A!+41;M]8VUZCBTDT9&@35%E%QK;K4VC"S\Y26RWQ,5$
M!HDD]E[S^`]%WH>%:PKG0E1'--7P+E+U05Q[>8M4G:HD"DPMS8SB7%_`>B[T
M/"C#F%.>WUC;7W/M[1*-RA0`,ZN+8F6B803Y_P!!WH5E*9I?UZA5"?W,?309
MLB3UT[G=T/*I;W0=EDWT+^T=OK&VON^SW&=(6M@HF&R&LT3(TQEV$KCBWG_0
M=Z1L469M8TX1;'ZQ]M"Q%$P5B!3[H^)[,*]>W[`TYC[$5`6,=JX_\-%RM7[>
MY8MFF$RWA-[2%A5^`4I+KN?3SWH.]);.(K_#4#JMU<"TZGM6`B>)[C07<GM2
MQXW_`$_5(O.3V"4KBFKU[?L<B;T]OK&VO4<7N@2\&>5,.+DB`%GBD^>]%WHA
MPFY)8-4=&:"QYR7+.YIJ3;&)4F-INBDYYZJURBRA?&6G2^A5Q9DJU;"\25#@
M\-"6P*[!.>+LQ5EV<BYUO4T/,<)Q0W==N9>Z<5BJU^KX9A?SWHN]#PLRG/;Z
MQMKU'%[L3:I'514`L3T+\O/>B[T/";L]R"^B-'N'[>[,7I%0I5@6T],<?/>B
M[T/&]8VUZCB]WEFI1Q,$NC7/&-YQYWT7>AXJES0$6WZ-(]S]O?@P2!9S=66P
M^U61$#J)'/;KYST7>AXL2*3L:P:.EE3*4G`U-"W?.V/3A1+W!L3:WWH^>:<'
MW5BRY6M-#'*:&2?,^B[T/&]8VUZCB]^:TYGA:I(11-])J&E]Q9H:2K+E.-D1
MUH3<V/<4$5BE]"A?JH">:MA;@OR!\TZ8(Z*^G/RGHN]#QN!_T:+.,_;X,M(-
MG#0&'9K1F.2IR1"W1:_'VZU<[QE\=Q$5&_!ID7K'D_1=Z'C>L;:]1Q?'MK4$
MCJ!+I?2F?F6`_P"IO3&9A$3G7%<9KC-<9KC-<9KC-<9KC-<9KC-<9H"5ZS[K
MT7>AXN":E(3!,D&J"@HAON)+>)%&)W[ML7:;M*_2.Z"<;YYD_7<":))+KP,3
M3N`BG'39D%Y*L<2%7;>>9FW9.EZ,_0SW1:($.`1]SW"H`R">AEZ%.QW'>0*]
M5WH>*W-E$0-#DLS:S4H5$;R+VQ`@BN%]NFGL25OR(\,(7T\.ZFFF_=);EF:Q
MTW6=Z`D@[FFGGD@M2M)9I9,UG$'<TP\PM$"5]@C3=.Z6FFF)+*DE<BQI;%^Y
M&FGQ^MQ,+N76CO)AT;U;!8(]R)II@%AF)`1MST\(F/%$8,UAXX!CNS+6A^NZ
MH8U/U?\`=%L#M`J(6H00*BHJSRI%R6_I^PZQ4';!5QPHQ>TBK`"PGO:H8=Q@
M0T)!IYXJ%#I-75+U?";HK"8A/*/[I1MZWK:H/-GZH^!K%$B&]'*;?^,__]H`
M#`,!``(1`Q$``!```````````1$:```````````````/!))))))!6+A)))))
M)*$`````(7JVVVVVVVVVVVVVVVVUH`````=7!@````````````````X`````
M``<`````````````````X``````+_@````````````````X``````9F`````
M````````````X`````=\F4````````````````X``````590````````````
M````X```!A@,V0````````````````X```#R@+AF@```````````````X```
M!!XFC]````````````````X```#K$Q@0X```````````````0:6UP&`4`3X`
M``````````````8VO%I(@6@#Y```````````````659R)QC3@".`````````
M``````=<,(L)\]``;@``````````````X```"&@+@`8```````````````X`
M``#^@;@`30``````````````X``````0@`")``````````````X`````+0``
M"<``````````````X`````;3```4HH````````````X``````+@``.+JIB@`
M````````X``````<@``#N1WT=))))))8``X`````!#@``````35MMMMMLP``
MX`````#VD`0`"4#?DJ4`%@,H`88``````3<#``'@!$3S?@>`.8`+$``````/
M[^7_`/&_5VT3]J/_`,O^8``````````````$B28F````````````````````
M```,!T```````````/_:``@!`0,!/Q#RLZ0,JP%0(\W;MRY=LK0XPR/3QLPV
M-*(@OX=FV>9Q8$I,A:J24K740M*0O_!RF&I@HNQ><027L2T@U%%`$H1,2F].
M,2@3]CYBVP:E;1F`Y8<Q3R(2Z8/&)4J5*E2I4J5*E2I33=C,7Q1<B=KP7E%F
M$@4=/H"E.T8=1SL#/5&::S_;4H+O1J=M6S!EPR_U"3!J&1X$I3Y!*E2I4J5*
ME2I4J5*E2OX"4G&!(A01*4!`29LQ-E'"F3Q']2@3:6&%RB)BUYG##@SUDC5&
M[`AVV64A*-`=E'OC+((,>LT<N"MJ-PA(`W58Y^[4<_=J.?NU'/W:CG[M1S]V
MHY^[4<_=J.?NU'/W:CG[M1S]VHY^[4<_=J.?NU'/W:CG[M1S]VHY^[4<_=J.
M?NU'/W:CG[M1S]VHY^[4<_=J.?NU'/W:CG[M1S]VHY^[4<_=J.?NU'/W:FI0
M($B1##`^U&`*L3=YOB*I27FF.37J,LSF9S0&"%)<R2)F9F*@1PK50%S,_#,T
M&4<0DGP$L`RHYO<&&))O#&I^#&&.K]OC(W+&[M/Q"[+M04P_HOY:(0T;E%)5
ME>D+#S[235$Y^`G%":P$7/X,88ZOV^/C"Z3##A=HQSH`-530`&F@<HD0SZ.)
M&``'X,88ZOV^(PBA((*M:5I3[T">#%M=R]*@2QW,CHM*<BXP!`0NVO<5"C4)
M%&.%,V!W?9]F*$LKH"Y7BB!D*!!?P<88ZOV^).:4B;E#`22(B-Q&](<I7.+@
MA(,%:[EB:\"L/7QKD:`ZF/9Q#K4)A4]2,U.3P1]XU'`Y<VM#,2/6N$U>;%[L
M:&"/P0PQU?M\;UO:_=*XV6?=5CDHAJ,,7:C0RPI2VIE^."UC6?YGV^GS8``_
M`C#'5^WP4YO,>`&4F`5L+09T&#X8$$;M):L4$L(0*0!0;=LIEYSVJ79#I*"H
M0)ZE\GD"(I>B(.AVLTR:(L8Q)DX[&$UZ]G0X0LT5U_`C#'5^WP2"SU^S5\D!
M0$6D'*WMPPO,(QJP$RNE(,I`P8Y'<Q_8_;00G1GXBE:<$U!$6X1/6(`1`;T9
MYAH"@>DHZI=6W`>/P`PQU?M\$#0CC$`O9.&HFU!M6POAJ*%+K36R,(;VU"#1
M8M0GM@C>>@XA)=H,6*^':DT$PJMVDJ;X!N9>P4"?#XT.LI'&*4!0_P`^HIZ:
MHZ10G#KHP4^33%`[KTE%^!9&8=7[\$<$)NI3&,[9.0/&RPUJ=?P!-I9[^ZZ6
M;EM/M0!!LA2/CB40=:`Y#<)5<%$6*.-(&((``%-D566ZKJW[0C*);`&>D33U
MB.3&NYYDSNS`I-9+WHI;\`:`VUOAL@M`@D,)G]Z'7RQ(`2CBDV](O('H+U,A
M4J!A=T@)V^3;N4:-$#"VPP(H)8,QCC4)GYFYN:*,D+R@[A#(TH#<VY-DUA:L
M&/9`L244P"N`1\\#M"@"LT`K"C;0"]+C$'T6Q[=HK:,[(B-MDJ73')\2F2!1
M;:'D0#1&`#BPA+SYI#PE0)5&`A55BL+A;,L/9U`-C`_\K_\`\6'D<C3-"IZ2
M74\80A3=^.XG%/HQ3+/#4FZ"O>:FZ8"%87"8@I,-?4^SL>(10(B(@B)")$(E
M%-C5)2W@@WP$K)"ABV[#HN=I]:H#R=KU<@PFXLD6U[MC*4JO<-<A2`2R`0*K
MXH7WG>*!QQ;*5*2U.0HX&Q:C*#SQIQ<S("LN#%\K&YBBKC.3'9XPT%2DX&?R
MW2*'<C!V<@T^XG<6Y(G$=<]N(&#VGJ]<2XRDAEU(!4=B%81_'(CFIHE))GO;
M`?.)$CL>&==FM0R,1(.!"M"F&>(5!SVE#.DB#(7#)!%RL9J3<O,7+QGVIC$C
M9MPG]J^Q^W<0")(V2C>7"\'>H+"%@CZV-/)6V@9H#SN5LGP_N@/O'^%:8,LY
M*"%OV9;UT$B0!H0WL$6(,CO0&\4R?.16:-:=-3OOLZ3\.9:``9=-[-3E8E+D
MPYFU&1@K#0)H'$5>PG@]4$A`+4=\>0\*32F"@4MQ;J2%!18%FQ#0?`,\6([Z
M0"@"',$!*L``#>+U+%9<FL65L4%#`U)%1"5ZJ!:>,K+14D,A4=J6DWK.PJ`G
MED2@M[L2.Y>ZI)2KTPB7@,-J_/##'5^WP6>1":*,2P!@!:MY&$>3'2#0NF[=
MUF6[=RGN8_L?M[O&<-!RPMAIS1MP!QWS\,5PPQU?M\%_"NV%`)1C21"-Z"Y:
M'ML4DT(Q6C*$$"W8-V"7M@^VXW/OP_@##0+3,3R#)D`(G=`BW$G6RIJ0%A>F
M\8-R!0(&2+(P,*`8\\&&.K]OC&YK'.L,QR8I-G$LBPL%M#NW`95QTH>FCG/'
M]].8+%#:)_E$AT9I$+@[^=&&.K]OB2O`6%@9;#20$/ZI^_`*,,E?;3<%2P&K
M@PP,`3+,1L&6V;=YVQ::A&'.0"*5$<L@&?J#:TIM<V?>38_6[<0PE`4D`BB2
M.+`3S@PQU?M\03[U@C$<STK.&B7:J(-Q?^0)QH?#MY9S-#%`R/$C_,76Y@O>
MG,`GF6EC<F)@J=[U]R5!BF)2$)?BUFFA*S1EABL(=;3F=C%0J*A$DQMYH88Z
MOV^/C^Q^WOPW]W_*!SZL`0N66HI&*B)[H1Q'*98H42;^M;E$/(Z)+US7<^YP
M4().H&N,Y%YZJ%7&SCB@T0B2$5]Z$V#X:A@#H@KRT"+^,+<*,N[;3))@`P\)
M#R@PQU?M\8+9E8`49$:,JH(,"X(1,MFV'&;^!!L5_@%+29\D)L"[G!0D$V`/
M?>I\R.L$_5>QZ&,QC$TRJ03"K"AO@W`578CD2P&&$:V>M8`0UK%^F#V"H<G=
M1B%:9Z"\,'BW`A+@DEY=X88ZOV^/C^Q^WQRI`3?AQWH=^MXN09Y`%:U3&_<]
MJ'(HDZCD@/*A%*@@0C"/B>_?OW[]^_?OW[26"&4+`=B8TO2T''QH,Y)Z\P=X
M88ZOV^*D"-/P,O7/U)X'<\*_%3BBO2I:A!GCMD+FB>WXM-TX6MK?M4C$P3&]
M!$+B=S6@(%`/<2YL@[+0SC4!,4B[19[8LQ/"AJ;B?ZG[QT$:G3V`)41N"&2(
MSF@Y+S0P0D#`U%IE0(&C\5=%4;86C'O\+"H;S\$09!W!]R>X&<79W,4F/R$%
MD+@4?KM@+$\*&<@TRXG)%L2M0ZS"EU"?-3C(]Q9&[>M\C&'T2D!6(0):$R)1
MCJ_;XK?2)<U^_+D8:C$$=(@T]"#!!2"8M8U.9):&&A7"$01GD8C#VB!#T$!5
M5L<)35RZM_:?;)9,.X%"!$T(6)U`X)TJT4@NV[.4"V:F1L"ONYZXB/:($.KP
M(;[I@<W,T.$E6`4X,5[TQ()(9>(:6M2K\Q8L1V]U,#?LV$>ADTTV_(/Z/5&O
M@40I`'P)DE,.L`("<)V`0/4U0L&L4,,99L.UW=^F@8`K$H+SQ9(21%[!`B#9
M]]G>\*=34JV\83RG)4.Q0\@QE_L8)`7M$"!4NW/C@MIM#AJHK&8RY8&82N(G
M"<WTC5T\82:3HQBK3K4$1R<0EQ"0`*\`2EV-7G4&Q[%0;'L5;(2!8!34$7WI
M%3:*K;J&$#H-CVJ#8]BH-CV*"A!(P@W&1Z5$(TD.S/>%Y:6Q4C`A1!6Z$4`J
M#8]BH-CV*-BTJP%E@P1>:$[ZX%`?=#H-50N"Y:/$9%8%(A"*`IBL0$N6:3%1
M!14P1A%G(U(*8R%$53=.4^*?]3%(*?>2*F)X2(%SVM!(@*SA,]I)_M0;'L5I
M7"!+1)N)FCD&.Q<FIB0HQ2FUL;J/H/BLJ#8]BH-CV*A`M<;&U.JC"B@S%PQ2
M=/T\+82?(91RH-CV*@V/8J#8]JNLJ\2Y\CK))0<6J^;*(R]2I!%CSLKU`#%8
M3L,H:7KE(B0&Y@4*XMVKZXY7HAU)53C!FKZ5#)+2H7&UU8&J25K31Q55E&U>
MO"UC!#1WA]Z:S6$BQ8:%^E\M`FJ0FX1@(]Z`5A0@"S!G'X[CK>\OV%?2,M]B
M.7;SNYZ'&-D]*A@6,%D6B+1'F/_:``@!`@,!/Q#RLH`%5_35^!M'>(\4@CR:
M.E1)PX@9Y0CUH8DI=A@QGW/>H*\()(E;QSC3-&%!0HD4#NE$\'SIZMW(,TBZ
M`*$,P9]I)YE$5B*&97!C)J5F?@_RA9@.9]#XSSSSSSSSSSSSSRXQB8WT2@4S
MAW[W5]5+/@7D`H69<3SX5&P,@0)+!#0<K,;,T9ON?#)A"B;*Q&=B@2`D`<.V
M#UGJ&1X_//////////////%FO`DB3<,_%<_$R15P9"$R`UT)H=FS);,I&0O\
M"I=J$+L$D@RNPWW"U`DX,X!<6C>69VH"H\P(#$+1*#5X_@Y"S_@U<SX@0K`.
M80/MTH0(!6SQSOEF<T3$*C=BR)9:=E!!<6G_`%>$5*2-G62ZKN5[Z8IB8/P7
MIFS3XQF*CL$N-J2S'#4VA^&I*S0H2P!@*?$N59R$"B)9)/?/X+TS9I\;Y/ZJ
M)31OSS4T.1%)1$,),7R<I*,TE2JJ;8OG)SOG\%Z9LT^(,UA<7@9^".=T;?Y*
MV4<&WU2CJ!1D2`9NA9\(#?3-0&MH99BS`9*)6`6/P/IFS3XES,UM5BA8!&)"
M+8B43-!'+S&Z)>(A@TC?-ZT^)B5^YHKI@.;_`*I#D*2S`S;HG3C2)MB9X_@?
M3-FGQ@5M*^JQO#1N8QSH<4BW(&,B024;AJ0J3/K,LA##+D:C^!],V:?!+&@)
MN.E#)/;,H+\\C^4(/+^Z4P;U)*YF(1E##BS;G5X;J2WLQ*(R#:(:TG\!Z9LT
M^"X!B:<RTNHLZI9R)+%``,>_[?OM^3^JQ\O8#%2C?`#,D)<BVE/D,@DG&<S)
M&H&*P&(*00Y;8=(_`>F;-/@PL42)`$D@F%.6(M)>DS!#<(#]J@$"C_M2)@AR
M7?JALQ`XT5)!7DP21L,<TK`$G8BF56YU9$C1>7WVSI7(YPZ0,M@M(H8_`>F;
M-.?!"%TM/P2,13D.34;.;,"B4AVJXGBH4S>;3:F5;(OJL?+VDF;%X!%>A+3`
M4#$!U;S,#:(2\VHTU/G_`$[9I'@!#I<,?72L&.X)/-+.^.,TL:1=N)H-"2(&
MW$H0AA;<53>,C7I_[7I_[7I_[4(A*LU69=*F%4.]>&815@[`5=6H(6+'^=N)
MS,?<H0#A[8`"[,7$_=-TKS/-P`"181+116DU;,]&%\!N(Q#Y_P!.V:1J8(G7
M&.MJ2-S+Z&9!`:#(T<>L`T>R0:2U]ZAMDNG9&9:VE6=JD-8V`.%4%K+I,-9K
MWAE,`0M"EQ<O1&32LJ?L^FH&RF*1,3?"(+<L`<!0!MD(7<O:>,?Q2D/#W(23
M3O&@0I"A$7&3((R4AF+)&XR(GSWIVS1W2+)X#'6_.H7.\7^:>FLMU"CC'W2G
M,ZZF4MXOJ6=YHF#XI0,B0L.`LHSB:C+<#(DL?/!#+#34X7V;WD@"X7,%VCEN
MDQ,V;/OI^SZ:ER'A5F@"L*C"B\!&+B+6BL\&%DP[_/9(6U:1U/U5YC;W4O="
M(WFH7H(E1$LW4A6(\]Z=LTEHB,YM&P_/M0JHG;4YT7FD,Q+$\JG`0PA;<J!K
M4+%>1(6R`CD<4Y6`ERE)DW-1ENWH,@8VU>(Z=*LI\)5``,-`9P465$G?.G3L
MO!T3`@*+$P;7@U632!)@1#J`]BA8I`XI9,M\,ZK>80&+ZG\XJ8$`D2P7^(Q4
M`8)B<1'&.ZXI6#,OS=<W$PF4\]Z9LT^"50=`%33$6`9"0`!$Z+TM,^6PX:/)
M+G![?D_JL?+W58L*1.TZT;=!B1&7.S/1Y[TS9I\&UT$@-NI%.DBV$)&2+(=0
M2L6HRQ';?.)ST*-QUAW23@O19'>Y2<@1*PRK-6TQYWTS9I\8BO']4V)I'NE,
M,Q9-S4ZTT@+$"X)&I"D-1UT&2!0-*40B21-*&2?.>F;-/B2#"PM+Q!*D(+$K
M%P+IDIP2Q8(ALT;'2!W4DBAA"F5!-PSD%DF+7H1CF!.)G6QQVMYSTS9I\20*
M"&]0+/69C<)+(5+6IGJ<L`@P%BQ?=OFL@E!NSWTW<EH%,"RP0BZT2I)4%T"3
M-J%C2R34D<;L"G1B]$/C4(9M20IYGTS9I\;Y/ZK'R]_C(V8CZJ(X^"P$NF)'
M*<:L%$3.Y)3&TWJ08;AR26;6\)4%`-DZ?_>M0J.'/?9UQ^2HBH`W)$"LLW<(
MJ]DSLBY)!LKE3$6Y5C)L<^I\IZ9LT^-8-3SC!M4).3P`#%*72]%L5ADS0IBN
M(U=&R8(0@R1"K-#5[XA`H(.!!.@<C>2%A`B:@75PBQ3;V$/:_JU25)4E25)4
ME25)4E25)4E29THP$9)Z=WTS9I\50RTAAW?58^7QR@)NZ1;C?_:>U(`RG;:[
MAI3OP@_F@YV=N-9'\O$]V[=NW;MV[=NW8W3%(&&;RTX4S'BI!%*$F8P-I+/=
M],V:?%(LHEO.`:#*S-A::%'7O[<PV+P&L+25:ZRC.(G-%R+`3/:R`E-*)R`O
M1W4"47+;122DB%/;7M8PF4<J<N%0<Z=Y6^TU`NIO3W:#<TXTL$E-F@<.G=8H
M!81^ZEM;+.]NV*864/>HP"4=48.K8H6VX$`B-+%VM^Y"!`P_4UH_0-/BIP"^
MCVO[U87Y;BQ!)K!;K2Y>3D`&T$V9;M2$2WO[5EB!6I""(4UD<7*6[EEE@>?-
M$QP;#;NO6T`NBA24>VCTY<,)S[;+$-ZSCWV6&I-SKUI.%TM;'/N;#:9<\)M`
M3*+FA/\`RHL*:$&.S++`M[$3HON@)@O,MC6\4N#J^8_..VRPSHR]$3**,DDB
M9PI":DXIX>X('!%\>[J/<LLL@Y`,R8;:LML:T$-`&`[E[YVJ9O$>,6`S5VJ]
MDPHO#)FA$O%7`*X!3!B>%3^S`$V3%XQ)!#7`*X!7`*30!<*F62%K+P\`G":)
M$AX03!AR%<`K@%"(+H#LN'XHMA@BHL0=&/V*4W4"4,N`S=6V\T*))"3IC?E0
MT#!%Y(NP>[8XTA8"*YJ3B=IIDN""""@N;RCK!PH@L(^`/HJ7M/2B*2$H2EHM
M&*"TKE7+J%P38P-*=8(+#3B>[J6:X!7`*X@6BK+^]+8DI!HWB=#%#(!B)FQ^
MZX!7`*AL4Z3+,X6XBPR)I&*,L,C-UNS=Z]//"D3"<@UH*6F+4`..,#F;40.`
MR19AFUF^V<TEE83"NFEQ9PM"<U&M9&X2)Q#;.":;E`E9+([X!MM%KI0)R9J'
M1)<IVK8Z1+*TSDS-BT:+42XK@03!,&RRFQ:H%P,?CK[H]R4^)4H)S'F/_]H`
M"`$#`P$_$/*R&;7CJV*R"&)Z4F<0@\%A.;8XT,""+'&/W`>RBAH$AI6?/#=2
M*D@400"@+"LWQ`9:GF,8R>2=3.=*+`%X)].N+J<74XNIQ=3BZG%U.+J<74XN
MIQ=3BZG%U.+J"D.S<I&@N6(N=*EQ%6LKA_TTJ#)P=:1..`M(5@I\15XNIQ=3
MBZG%U.+J<74XNIQ=3BZG%U.+J<74XNIQ=3BZB'4?9&9+6O\`$T`G"7X8\26$
MUOK4=*!E=6?U3(&T..)[AA%QJ1"!,!3.*Y$B(EYFR4_=*(PX&6;!8FP5!4%0
M5!4%05!4%05!4%05!4%05!4%05!4%05!4%05!4%05!4%05!4%05!4_78F6VS
M6&OB2T%AIHW%++`*V$F1O&S[\:,JI"R64B`(X5H+4P9S/X/#AU?OQBM:.(:,
M\3ZIUUF:EB-03`T#)XP2!0;1+4!`W#L?]%^#PX=7[\A5R7V'8"-9"3>Q%W4R
M"RD1E,JR\%Z-OP>'#J_?BEEUZ+1N_P#!*8"!$2_&I826<G-AN);DT!`@"E2C
MR"?@\.'5^_$-Z1$F2@]DA;=G)1U*6QTR$C_(%(&Q'$"R;,@'<5$%JN<NH+;E
MA+!C\'APZOWXP6/2E%2#+)Q1E96*#UI4VTSF!"!9+P4X0A`^3/4N</P6'#J_
M?@Q1+6U)#':@G(;/%HP69CM2"PQ-X]FI?I&`9(`:I(#=)=J>#H)+9G$6C\%A
MPZOWX/&F85S3)P=VKD"'4:(`;*P45"A%BQA4^VRA4XR326X03%2G40,`8EHS
M%_P.'#J_?A%H=R6^\7I5OE4D+)0;-J_K[J-RBZ&MM\64F`DFG[J\`8;LN)M%
M^P8N4S\003&I*,26DIE(L#+J"0&+,3$A^!PX]7[\'2G!F_N$4.H+TI"DQ77L
M`]Q6;8E#HB/W1C8*Z(PNAN,!]BH0B1&':S^`HD7AH2XO::4BS6$PFG7>@@Y@
M<7['Q<J;'G&Y*3[HZ=S,Q,":3.,E7Q4R"R.<<O;L*:&UK;^/V:4D\7[[G7=D
MWB.VF/:/>U"7JHB26Q"(1(-&9DYH)DR(@IQ^`HP&+KW0H784GM40"@DZ,I=/
MDJ6H@X0JG05>M`P0))CBPO2MF[I<DN4-+"&]?8?9VY.;,[;,3I2EDNU[85$F
MV&>:-#,YX?<KN+5&4?:'VJ5T\IL!"0"\E&!EFEG$7`2#G3EJO._GZ,P"P8!6
M_>$GO<I>[Q*4KM:_.L3B@-'>(,<9X4$;%41)-@)'-YU=6+$Y;EG&DT]BN#K,
M<MD^;0!9%;?"0E`LD)]R>S(H!`6G"LNUE*YNX0Q<JT*(A2RDF'`WM2=XF+&&
M"&4"YP\_!B0_&@;"@RCA:V*?>8!X`$6,$T$)X&3*8*"5XF)INZ2H%XJFH57*
MTVI$^*E)%`!4"`#I`Y!4B]L;$O:`74I)G*ROF>NDL@L"!<(2@E)0FS;LET2K
MG4V.=2;Q"<AERLGHIP1M^598$@RPD\;4)%-!U9_LEB<=V$IQ%&-7\I,+\1DL
MVD'S^'#J_?A)MXB>89>C@RZ5G\&KE"]8;5&:5P`^T3<:MDS1QSY[#AU?OP9H
M0+(CU+#S"VVY2RRY[7!09[L'5I"I&+YAVN[Q=KVS:I;.3>@&1L%$Y3PI$8<G
MGL.'5^_&P]*73[I,Q=&BBSE!RA1;EQAG8BI*9A%HN0N9,19T\]APZOWXIDL%
M'^'"M*(#-_W[TWM0:0MXE<@(1$<12#!DD2Y@D7<%)AOYW#AU?OQ8(,,T:=G(
M;P1W9+5&P!M>I9!WVGCVW:2'$3?_`)3M`6`5E;$L0N(TG-@$G6DC;&&:98-<
M(1!4F-2X\*")CS6'#J_?EJN4^%3D;)$D%K%M;YG+05(+DDP\)QTJ19#$YP1$
M22D0$2]"\MJUWDJLES'&FE-`1<DKNDYQK23*+L%]R9X1QIW&P*CJ6P<[\(NA
M5M3+%C7`F6);#H30G33$BW1-_*X<.K]^,&"33YG1G>H$2;=<\;P):XC0#<R<
M:.@@4`,A>H/N:^]+0":1V:2[%!;)6QF089RTJ;@7,)`,N@"))THV@@B*D&$0
MF',1-LCY3#AU?OSU7*%P4N;A@0RI$N-^-$4)HHC"34D5D$7H.=I",93A=!K_
M`&7^U_LO]K_9?[7^R_VO]E_M?[+_`&O]E_M?[+_:_P!E_M?[+_:_V7^T>"GB
ML?=+D=[#AU?OQ7FI]7H<JWED4B+&!9="A#&J4"29<@)"6%":2(V3MY9IGC6@
M4(N^QU[I@1BX$P=DNXCPH9)[9$8IK!I3<).$H=:Q`&A;BO#A2_!*4,2"XR$N
M4MK0-#4$L-(`7$@%NR7VYAL+M]#@O20QW'-@9J3?X72+YH9G@I[=HEBEZU$&
MQ/(D7@5-H(D=S<^NXR9$H,H77H3/*I7LTN'5^_%R5(/1L@$"6289BT6J4`67
M*0`8;((S*S4Y#$UO_7MUUDL]XIGX@NHX,,%F%V^AW-==87)2^L460`,L,!#"
M,14YR=DD6Z=9[===AWIJ[U)9P9CB0.#:1+M`+$U)\.SJ!:WZ'3IV*YY_<!.,
M97[#(QJTAVO+J;W6@/<;"@X78KK21>AE"V\?KS[==0[\A;5.VWBGH(@W$L$&
M(J;+V$;C?0O&='8[FNNI=*`%U`&\*+V884J\%R%6Z(73F9-JEGG_`+XQ\5(0
M"H*@J"H-,U!243M.R:@J"H*EHJ0'F8)5N6MHG+A0(ZA\S^Z@J"F9"*@027;+
M_E0,I=J&X/BN2B*2&$]/Y5Z!4RZ3!G$P=QJ"A9L4@%X"H-JD;A28"W-4H$NR
MQO4%04`R@T'6`5)@,N6:B*E!8O(CYTWJ"H*@J!A1LBP/;SR`3<IF.`%>$-:]
MV#%J*RP0G6&"=+Q>D7,S+B2=7C$2&<U)H'UEOPWHY)6=XGIV&&[;+5XASO\`
4,U$N(S<R2X6BU7<Y_)6GS/\`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tpg11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg11.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```8T```1`4``%\2``"!Z/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`\@&I`P$1
M``(1`0,1`?_$`2P``0`!!0$!`0`````````````(`0(#!0<&!`D!`0`"`P$`
M```````````````"!`$%!@,0```%`@,%!P0#``(#`0`````!`@,$!081$@<P
M(1,4%1`@0#%!,Q=0,C0W(A8V8$(C)"5%$0`!`P(#`@@)!P8("0T!```#`0($
M$04`$@8A$S$B,I,4%38'0$&1T=(STY6V$#!182,D=2!0<5(6=J&Q0D.UU987
M\(%B-)0EA29&8/&24[/4-65FAM8G-W<2``$"`@4("`((!00#``````$``A$#
M(3&1$C(00$%1LA,S!"`P87&!H2)R4'.QP=%"4N(CD_#A8I+28,)C%/&"HA,!
M``(!`@(*`P$!`0```````0`1(3%!46$0,$#P<8&1H<'Q(+'14.%@_]H`#`,!
M``(1`Q$```']_```````````?!!XWVCO&<.<8?.6[@VTP`````````````%,
M*>>?(9]N.1O5AZ79C6,@`````--#''K'EYRY'[O&?I_&?6*TMAZ```````-W
MZU>Z>NOJR`````.7>TN";'RYGHND[]&IS?81[CI_3ME[4```````````````
M`"'5/HYD7^:NQD`````6^:F,Q&K=%+2[R\>]QF.6JZGNNTYJ4FI`````````
M```````0XI=),:[S-4@`````!#RCTLHKW-;Z.(GUNCUG3\W*/1R]%A7(````
M``````````"'%+I)C7>9JD``````(B4NBEI=YO-B7(*U[R5KR\UO:$L=#[5R
M```````````````AQ2Z28UWF:I`````"W#1,Q7I=%,&]S69+3^?IQN5WP>]U
M<MN>G7U5R``````````````$.*723&N\S5(`````6P1!W&.:Z3I9<XT_4?>G
MI(>O%5WV]S6Q3W>9[\OB_P!```````````````AQ2Z28UWF:I`````"F`B)2
MZ*6M[F\Z6GA../EMY36-+R_WQX7;><BM%Z@`````````````"'%+I)C7>9JD
M```!;@!=D(>:_I)2W>;WTV/.(=4>@D1:TWN5:'?0RF5SLKIX9```````````
M``"'%+I)C7>9JD```!J((LV\2WJYS2"(E+HI:7>;SI48QYS#:KT\S+/+Q:W4
M-SXSD9J5TL@````````````"'%+I)C7>9JD```!\T4:+>),T\Y,N1W,Q^UG0
M38L\W]"8HQ%>ON936=+?B4.M_"8?.SNF`````````````$.*723&N\S5(```
M#700WV2:&OSEAC@VPQPK5=/)WTTW5?6D*$3Z^ZZ#[4J9ER;=T?<^.>YZR.^P
M`````````````AQ2Z3WEC7?5.G\6<[?S?3D`.8Y]Y<M?BEF#.W\ISZ;USR"(
ME+HI:7N;SI`8&/EQZ?-F$1Z73][VG-\=W'GU'5.M5<_<````````````0WI=
M)[[VJUOZ2AU&$/4>4ZY??$(RXM2:5L1"_<QF=II?1((>4.DE'?YST#``&-'P
M,??B57>2-O<]X'8OD\L]KHX````````````AO2Z3WOO4V^VT?R^CIFIS'+9>
M6R\\R=U\_HS.-F;4FY5;,(FWL2PUTLOI@1$I=%+2[S>=(``8LXAI5Z28EKEO
MBS[10Z',R.<P```````````!#>ETFYL^.HC'XL^_1\TN,W?#26%WEX=$\?35
M5+DU?76,>4$MQ&=NEGESB-.VAQ?1]/*R>FZIZU```//1G%SPWG?_`&T_$.DI
MRTY[U````````````AQ2Z28EWF:PE7(``4DQJ]ZQ"7:XFMI99O3'F/6,5M?T
M4Q;?._9F0```UF)\.\-M#W<><X*^K[-7P```````````(<4NDF-=YFJ0```&
MG\D9=EB5FMEF]<"(E+HI:W>;S)````?+G$(:'6>V[#CY8<UZW3``````````
M`0XI=),:[S-4@`````!#RCTDI;W-[X````$=JV[XGUFBG3RF?LL9````````
M```AQ2Z28UWF:I``````"(E+HI:7>;SI````#EGE<CM?].RXUW=ZV0``````
M````(<4NDF-=YFJ0`````LBA[M8\RTW2RUSI^N^M0````8$844.P]EU?(2IY
M_+*Z2N0`````````AQ2Z28UWF:I`````"F!B(=3HY:W.;^A(````6HQ3J=+Y
MK::W26)>!LPFGH'P)&#'U,Y$?@S*[&:'V9\V)?&EMI>74)T+D@``(<4NDF-=
MYFJ0``````B'1Z*6=[F_I2`````P,ZS!B<:=MY;YBC-,R9Q?C#.<;-\<4R9Q
M=C-N,1TJ=%.[QYSU<67$@`!#BETDQKO,U2``````$/:/22IO<WN0````````
M````"/WM8YDN;C7["6-OF:8SDPNSD"'%+I)C7>9JD`````!;%$2GT4MKW-YT
M@````````````/E@\S[N:UMC]>(:QZ(^L@K&H`AQ2Z28UWF:I``````<VM9A
M?5Z/K%2$L+&AR2```<B\-AU>SK<T9```<?\`/8=<GKLF<@``<;\;_8/?77XD
M8%N'-<7.FRJ#D4+O%JNWFE>Y:J0``````\G#UA9+:=OKKXQ``#..,V<]AKLL
M0``MQGANU>ZJ>?NJTP``.,VY;Z'ETBM-D`9,"/NPET_RJR^:ZY(``````,/.
MX>@+I```/.Y>@BNR`'A\OM/H@T>,I^>VE+2S\]U#U]+Y,DP&HPLQC<2Q<D``
M/(0SL)8WXR``````````````'DYN4;#&NEY>KKSTEF/S^,KY0K6E(2K/)G(`
M``````````````````````LKK[`4'FKZ````````````/__:``@!`0`!!0+P
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M1D2,B1D2,B1D2+Y2DM3BVV`UL_QN&_4ZB56NVM2KKOJ@7A+OZO4J1]!OK]G;
M?7)QMFR*?4(E3CGY:@S*[;<O5"7_`/#I=3B5FG_0+Z_9VWUL_P`:GS%^4^I5
M.SX]98N+332JZ;;EV?\`0+Z_9VV.J4]*M97VI%DEYBH9N0TXXRK#K+$=K5;Z
M!?7[.VIA>G=15-U-HDFE:<T"B52E/"I8=.TP)M.G]=LVV[F<O>S+;MMPO+QU
M]?L[;ZV?XU/F*@1J@:55>-*M875;%/NJ!I-4)]5T]\=?7[.V6(Q(8X]NN2E-
MV1`DNRV`K[:-6D4F^[=N*EW/3C3F3IG%G6]5_'7U^SME-4E$:GR6*G5D?;V:
MV?XU/GV88#3FOQ::"\ET"\Z7>5%N>XG+Q\;?7[.V3K?%0=6HE)J3?V&>`_O%
M!XNK%5BU>Q2^[MN&I*I^H*?M%;DR*!JX7C;Z_9VRE.&TQ136Y5VBP;,'I]1^
M)JU085.T\MZS;9M=[MU)>;@A.H]B'3Y.I%B0XM^S4S9;VI=+BLTRHQJO3O%W
MW^SJS4+DD7HJ%>#;F2Y@U3;T>3T>^1T>^1T>^1T>^1=TJ^[5M[`.)-28+=;:
MO-O[.S6S_&I\^U3;:RY2(27(L<RL6J6Q2:G=SK+]EV/?EDQ;-^1+"$:2Q+8\
M3??[-7^U:_8$:OU7X[HY"@T=FA069,>03LEACMU=_786G,FETR6=S-_9V:X\
M7^D4_J'+]TR%5H%"J9:7U&!_0.ETPQ==,IR;7TY_P/B;[_9J_P!JOVQ6GI']
M3KPI<&3`B/::+6MK3];9M+0I).MFO5[]=@S))-T2;_84%E3V:V?XU/GWC3B-
M1K=M>E6YG)(F1F*A$TWIS5#NOQ-]_LVK5>FT75!FXFTU.-7E-,4:\+?A053:
M0:&TT40NA1*?;%7MJB2]3KLMFJ6/Q$APD&FG0E_WQO[1)U)@E6=4[@;J6GEO
MWG:MT/=^ITJ!685WZ?692[$MG=;MMF[%U9\3?7[.V&`R)"DI45.AM0KU;^T2
M*+2)2]88,.!8J$(2K82XD>?&^-;'@4W3B54*%)MV](=Q5+Q%]?L[932D'&IE
M%N==61N3V:V?XTO/8O()Q%Z6K$M*S+<W:L8EXB^OV=M]<4&Y9$",Y$C[+5B(
M_,T\U5MZFLVDT7\/#WU^SMOK9_C4^>RO:W6;LM.I-7+?FC]K7=(KM1\/?7[.
MVIA^[J^J=J35ZA.TTMRXYM<?V3AX)TPK=*H%#M/]E@SP\-?7[.V^MA%_34^>
MR,:@R(=/KE0/1.N+>@:#1XJW[!M35)%\V<NHQ]1+%EM_(EC<@]J)8L:,]?ME
MQYC5]V;(GQM1+&F,_(EB\B_J)8D5AV^[.8J+-^69(FL:B6+*CP[UM*H(+87U
M^SMOK9_C4F6;9K;0XGI\/+R$,RNJW:ZJ\2FWF2BF7D0YN\<G-WB9'-O,U%-O
M,E)EWBDN<O+*<R\5$<V\C64V\TJ*9>)%J%6;@IJ:%5$UFCI42N_?7[.V^N+:
M'K)A0XE/8\7J;1:?6++M&RK*KUD4"/28&J68AG[M]?L[;8X#6L\;-3Y^+>99
MD-4R@4.B%4K3J<NX&[<N!%5C6M<[#.F=5DUFT.V^OV=MKI9GOTO4INKQ-,V;
MPNNCW,4E@<S'',QQS,<<S'',QQS,<<S'%SW>Q0)J93`YF..9CCF8XYF..9CC
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M7TYH,VRK7LMFK^`D4FFS'\,-A,I-,J"B[M1N&F4IWK=+)2:O35"H/43FH$R@
M0V.M4HSA77;]1=ZU2S!'CW'X$.2N%3H-.:[YT&C*FP:73Z8CQ]2I+-2=E:<T
MB6[(TPHLF;6K3;JTZ1IU2GPC3:D)6C3BE)CQ[%;AQL/^'__:``@!`@`!!0+P
MWF9I4E650RJ&!XX8*\=F(9DCB('&:,<5L<9H<9H<9H<9H<9H<9H<9H<9H<9H
M<9H<9H<9H<9H&\V.;+B'/:P5/Q5S2<_%:-7&:'&:'&:'&:'&:'&:'&:'&:'&
M:'&:'&:'&:'&:'&:'&:!+2K;,J0EY"XA*DY<?_)E;:-]2%9E8$,"&!#`A@0P
M(8$,"&!#`A@0P(8$,"&!#`A@0P(8$,"&!#`A@0P(8$,"&!#`A@0P(8$,"&!#
M`@O<YM321C*0=W%Z4YUIF6AF.VZW$)TOH+GN;>1]F)*3@06DFRIIEQ%)6A?T
M!SW-N_\`9Z!XC-MA>*ZFR[S?T!SW-L>XGMZ?0*^UO$T,.&=,\B\>Y[FU]6IG
M#*:X;H0C*05]K/MH>=:*"I;P3Y>.<]S;O?9Z`_)H_P"(8D.1EU-"&YOCG/<V
M\GVR^WL)9(6E9.=E3_\`9:3XYSW-D0/!)%Y=C_V>G:VOL4Y%?B.16412\:Y[
MFR]<CBD)/$O4F75"2E21Z=KBLB^Q"B<IQ>7C'/<V7J>]`Q,C;DK;$M1NI2DD
M%VOEOSH&X03;RMP'#"DJ0YXMSW#/?@8WC^6.\;QO&\8&7:O(;"?+L?\`L].Z
M1)Q;-*38PYB=%D\^<62,%)/Q+GN']Z)),F4Q:R<=XR\!AVJ[5K)+9>79(]OT
M[RDD:6S_`(9W2$5;AR9GYWB7/<\UH=0DC>;,.?=S7\$25)'VF9X!7:IQ&5/E
MV/\`V>G?6@C($:D',5Q(OB7/<_[8C,,R<$NLDKF6,5/M*4Z\A;1F7:HRX"?(
M(B+<;E)X:4J2HN_@1A2$DA)8-O93IOB7/<&!#`A@0P(8$,"&!=Q:SX2-R02E
M$4@]WD6P\RX:`TI#U-<86TGQ#GN;(_N4;)$@L"['_L]-DZE*&Y)ET[$O$.>Y
MMY'V>FR=+%NE.*<D[S\0Y[FW?^STV2TYD4J03,A]DF4>'<]S;-MM&)I)0"49
M[/#$(6E*9)80,?#N>YMW_L]-F]O"*DZRCJ<L<WQ8&9(S(&9`S(&9`S(&9`S(
M&9`S(&9`S(&*=BY[FW?^STVF"1@D,*CFQP88X,,<&%APH0X,(<*&0X,(AP88
MX,,<&$.##'!A!R.RXM:.$KR[[GN;=_[/3Q;*$N29+"4OX%Q^\Y[FW>^ST\7A
M_)2W%@T8GD4#2>#9GD[7/<VS*FTN3>&LC6HE'Y]]3A)/8*62"V"UD@NYN!$1
M=I[DK^_;J(C)$=I1<-L<-`X:!PT#AH'#0.&@<)L(C,J+A-CAH'#0.&@<-`X:
M!PT#AHQ9AMNA<=*"X:!PT#AH'#0.&@<-`X:`B*VM#C#:!PVQPT#AH'#0.&@<
M-`X:`TPVXE;2&_`XJ+8XF7>21J&"LN_',L?S!$9ED60P4,>YBH;SV!9R(\5?
M0$*-`YIS)S;F#+ZF4MS'6@J2XH'+=S<3$_J*O/M]?$__V@`(`0,``04"\/B7
M9C]";:==64&88Z?.(<A-'3YPZ?.'3YPZ?.'3YPZ?.'3YPZ?.'3YPZ?.'3YPZ
M?.'3YP*G3B/ID[#ID_%-,FD.G3<.GSAT^<.GSAT^<.GSAT^<.GSAT^<.GSAT
M^<.GSAT^<.GSAT^<.GSAT^<%Q9#:=MOPI.7F<M.SET\26$LIWC>-XWC>-XWC
M>-XWC>-XWC>-XWC>-XWC>-XWC>-XWC>-XWC>-XWC>-XWB)OA;>F>_@1F>Y+I
M,OP?H4/\+;THL9*D*;6(7"?;<(R/Z##_``MO3/?+S$4VRDRV%1Y*/+Z!#_"V
M]-]_U"/OJ!M\\98*^@0_PMO2L"DO.MNF$??4,W/^N/T"'^%MZ9[_`*A)X*J:
M%)E`_)!XI\=#_"V]+_(PP/L=:XT%^.[&</>$;O'P_P`+9[^Y3/?]>V='4I(W
MXX[_`!L/\+9[D]RFF1/>O;'3Q(79_P!O&P_PMFKN4E:FY+LEZ0?;3<3(H<S$
MH<Q1K2ML]_C8GX26D%#SMF,S8S-C,V,S8S-C,V&>"XKL5Y]M,]_U[F96)K6)
MC4AY"B-(]/%Q/PO_`,M19PHOX$6'=C^[V+(S'EVTO#F/XX]T]X2^^V*FDSG^
M,B?A;NF>N/9E"B,>@C>[V'W*9[_KWX3\I<C[?&1/PDI6Y3N`LT&QO7%>-:H<
MHT\G*P3!F$10I9*9C24+R*[%=JCRJI1&N2[&DQS[Z5+0J+)D*F2#),C-_+Q,
M/\(MCPT=A]I[Q2R(G_78$9I-4Z4XY4$*35/$P_PMF?<IGOEY['UBOJER_7Q$
M/\+;TO=(QQ/94Y668K*1^(A_A;>F>_Z[*._RKT]E+<A._P`1#_"VQ^5(+-(=
M92ULS%19<>?_`.WAX?X6WIGO^NR,0$FMDX4K'D99F420HN5E8<G+'*2\Y1)9
MGRDL'%E)2J)*2?)R\2AS#!19)HY27AR<L*C/H!;"'^%MZ9[_`*[/'`8JQ)2B
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MHZA-'4)HZA-'4)H.H2TDN9*>3]`]-W8>[LS%B/7NX=_S^A;L#01F98C+OP"4
M$D\/X_\`#__:``@!`@(&/P+-H!7#B&2I0%:IK^`5A5JM5A8@L06(+$%B"Q!8
M@L06(+$%B"Q!8@HAPBC,BVE`-A1]L5&+8*^7"\KQ<%B"Q!8@L06(+$%B"Q!8
M@L06(+$%B"Q!8@J.N_4PW3_)?J"/HH]T#3:@9(I@V/:=)6%L4&2JS&/@(HMN
MB@P^!MS".F*"OSS!D'>;3J4'31%Q)C!T/H3A*FM<YK"ZIU0\/@3<P\4"J5?^
MZ`GZ"^0X"RI&6^L?`6YAXH9##4I9T4*?.NNW6]-,-=7P%O7Q4--[*>Y`FM<R
MTWL;?K4*?@#>O+81!!\P6Q\T'50:UO?"B/>JR<AR$2S`%36S3$-D.-0T0[.W
MX`W,/%#+=TY#NR(O%T]QT)[)8NLHH\!G[<P\4,KHQ*HR2N?%$^9?#M7I``S]
MO5P5)Z'BAT+A$'9)?+S[XW9?4&_>0YJ077;]RG7".C/F]7%%[6Q45!4!`.HJ
MZ+3KRND#&R9?\(0SYO5P5[2,G8C<HB"#W$00+ON@-\!4J.@TUC)70IS+S07R
MZ(F&D(2V/E$DPQA.E.Q-,,\:H*.C)"/1KRDBNYY]#Q0Z5*,:*5++?QA3RV6X
MMWSJ@=:I8\>!5UU>=-7@H4%5#&YW]PJ\(*]`#J(NQ;L#P[!K[>AXH=,Q`0I%
M"Q.M*E@N=C;I.M3A3Q'?3G35X*!E,=WWOJ<%P9?_`-?Y*]`-:L,3Z:>X*[=H
M+2+52J>A=@Z%T4=NOH>*'4>.0/;6"N7GOAOG7[QUTYTW)B5:I*!-2$&B$*>T
MPQ6TPJ4=$2@QM8/V?9T-%Z"IR7VD?^`7?4FWS0X-=:J#'J*4;HR<N16'3!YC
M.F]9!GJ%T>&6`-"O:8JCJ8:%4I<IKVAS7NK[4)L06.U'.6]6`10B&1CY=GA^
M)0->7Q0ZOTZQ]*Y?7>F?2,Y;F'BAU>M2N5?3R[C5!4UQSAN8>*'5EO8I?,3J
M&L*ES6N!E3(Z\X;U_P"H8&!\@3YIH93$-/='0JNLN.H*Y6&J9MD9PW,/%#K!
M'78A*;,%T=@=](6-O]K/L4S?.;OK[-#1KU*DTJM5JM5JM5JM5JM5JOJFYAXH
M=;4%4$^7.]+BX0HC5XKC._;_`#+C/_;_`#J&^=^W^90WSOV_SKC/_;_.N,[]
MO\ZHG._;'^2XS_V_SKC._;_.H[Y\?EC_`"7&=^W^=<9_[?YTR7*>3%X^[#ZR
MG-.AW4-S#Q0SR4R8(LWC4]MV#=X?I1A^'IMS#Q0SR\*'+]1SG=ZO`P*Q%8BJ
M>@WKXS*6W76PHL-*&Y]/I;&/XM)\4UIA`KLZ@#7U/CU,>E1EBFYA3DJ6%85A
M6%85A6$(F@$*H+"L*PK"L*PJ%VA!H@+SH5=D4UQ`-]M[S+?]JPK"L*PK"L*P
MK>"Z(/8T]SHT^2C0YF@^,%A"PK"L*PK"L(43`#N46YC`5=31TC#0KT#!0@:%
MZ(UJD'^-&2D$0,%5T?2?X"@:NHA&A4_`'?U)K*(-AY""`HHAY""`$*"3_<(*
MB&&'D6_6A'[H`'@B_22?-7C7_I#_V@`(`0,"!C\"SC^-/P/=RFES^Q1$I]BX
M3[%PGV+A3+%PIEBX4RQ<*98N%,L7"F6+A3+%PIEBX4RQ<*98N%,L7"F6+A3+
M%PGV%<)]A43*F?=T'1'[41NID.Y0$J98N%,L7"F6+A3+%PIEBX4RQ<*98N%,
ML7"F6+A3+%PIEBX4RQ<*98N%,L7"F6+A3+%PIEB+GL<`VO,/U`2T2WU>TH&]
M/NPU#Z+R-,^Z/Z1_DI;Y;XB8R/:*8?`^:C'"W;&8.^4_9**@W0I?,RH-=*%Q
MPTF,:?@?->UNV,P(T[I^R5!]>1W(F`G3'M@[50[2B(X7_`N:]K=L9@[Y3]DH
MY&&:V]+O"(UC4IDHZ''Q[/!0T_`>:]K=L9@[Y3]DHY!&J*F!EZ[?T_`N:]K=
ML9@2X1&Z?1_ZE>B6UD-4=7:3D&BE3+SP_P!9^A1^`\U[6[8S!WRG[)1R`K?7
M6ACR2+K@ZKNRQ.?\U[6[8S!WRG[)1RR9DMC67&NO>ME\^"W<X73]J@H9_P`U
M[6[8S!WRG[)1Z!YR23,Y4-8TN.@W:M>6&G/N:]K=L9@X_P#$_9/1FPOF:VZ?
MZ8:8]V6.?<U[6[8S`N88.$I^R5^J8P[NA/9?+29+Q`5.IJI5P2GQAJ/V(M;+
M>7BNBI0>"#GW->UNV%_V'5[V[Y16'S6'S6'S6'S6'S6'S6'S0:0:1KR_V]!W
MRG[)1Z$=*O1]2I)BI-UMYVY;A$;>U0-#L]YKVMVPH_\`/_MR7=*\>BW+9T'1
MJW3]DHW>GZ'N;2*C7V*8\2W-C3"O/>:]K=L(_/\`]N2M=J<=)<B?XKRMZ;OE
M/V2CU!.\_4,LBE0@5VYWS7M;MA;MC2X[\:.Q0_Z[[T=:!;RTR&FFOR49<E[6
MVJ`8Z/<L#K.U4L=&["K3>)C90B;CH=R#GRW@#L51Z+6ZT6MI<93]DK]9A:#K
MZ@/88."E1F7:81($!%/ICZR(ZU=TYUS7M;MCJJNC2G?*?LE'J8BL%-F.?ZVU
M4#[%.'INT5=V=<U[6[8S!WRG[)1ZJ.I-$R6UXNNH#0W[IU:JT8U9SS7M;MC,
M'?*?LE'JV1,!&%H@B15_/.>:]K=L9@[Y3]DH]6WF/PE/E2W7F#3572H'..:]
MK=L9@;Q#?TGTGVE>F8Q_=W=O6/YQF[=+@";AC"B%.K.>:]K=L9@[Y3]DH]9/
M8QWJ,ML&_B]504#+?'N*@)3X]Q5\,=`*]NW73V%<-]A6[W;[T-11`EOB.PJ.
M[?#N*O&6^[W%`;M\7=A4-V^/<5`2GQ[BMX);KO<KV[?`]A7#?85!['`PC4:M
M?4\U[6[8S!WRG[)1ZR(K5Z)CWG[5>!,>\_:H`F[JB5=-0[5_-1^]WE=_:5#Z
MU=^[WJ)K]Q4=/>HBOO4!A]Q4#5WK^:YB\Z'Z!\:0HBHKTD'I\U[6[8S!Q_XG
M[)1CGF]D.NS(=A^D+>LF0GN%.@'P@I=^%W>N[XPZ?->UNV,P=\I^R4<^W#I;
M7TQIO46$*[N6QC7%T=I`MY=E&@%U-KD93&W&P%'>(]#FO:W;&8?J1W=Q\85X
M2IDWE=Y"5"-X"/J[E5TZE,=2-W++EIZ=2==^Y+<ZR'4F6(Q#;RBJE4JE45O'
M7HY*D.6;B='R7-`_A;MC,+S"0Y<69#O7%F6KBOM7%?:N*^U<5]JXK[5Q7VKB
MS+5Q9EJXLRU<5]JXK[5Q7VKBOM7%?:N*^U<5]JCO)D.]<1]JXK[5Q7VKBOM7
M%?:N*^U<5]JXK[5'>S+5=WK[W>N*^U<5]JXK[5Q7VKBOM7%?:N*^U1WLRU0F
M/<6]OP&.3LRP[(^<,D.C'3\*AD\%'M^J&0'4V'G%%NO_`$A__]H`"`$!`08_
M`O!C2#.1@HXB',[]00F*\CZ)55RL;B+("IQQYC1/BGF19$(<@9H[Y0R`=*&+
M>-6.Q7_4F/NUTMTCC*S[";&+QVB4ZL^S([C(%,]/U=O!@CNN+7E"@E*[K")0
M2'1%`I%WO$0R+Q:\KQ8CG,1Y6RU<D9D*/(GFD9`/DO<$4(9WO8R.-7J[@1J8
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M"W<\X,MDJ`@`L`P-A_9[<;HD!P2H2$]RYMVBHY4IP8BP!:\ALZ#<0W2+*Z7]
MN.2*SBL?&RQ!C*Q\`5%14Y2JJ4V8MNGH_>)$@6RWM8)X(\@:I<H[!N:D2X9X
M=21'.=F>-F1K^!U6<7``)K2QJ@`C"F5VY;0;$8F4(@,$-M$Y+41J>+';.S<\
M_P!GCMG9N>?[/';.S<\_V>.V=FYY_L\=L[-SS_9X[9V;GG^SQVSLW//]GCMG
M9N>?[/';.S<\_P!GCMG9N>?[/';.S<\_V>.V=FYY_L\=L[-SS_9X[9V;GG^S
MQVSLW//]GB/9[1JFU7"YRU(D:#',YQS*$3SER-5B5W81JY?J3YZ(MJE3P'CW
M6T'(*"80.E1&7.-TT4EY&YECI#WBN:QS%?2BU39A5&MXHD^Y/OBCN64=SM+[
M]!-;8^GVK-3H,H5C81BY6@7A:KLSD=AK)F=TUW>!IPMJ%<BO*0$`FM8K[+%N
M4ACY!".#'R(1R*1Z-V554P97V_NZZ3G'N$;<=2*!1U?OU,];3G0FQN2B4X:T
MV89=)=G[OI#'7"V6W=Q[CJ'-O[M/#;X[_M;6)NZ&0Z*_;6G`F-26^;;&09>F
M+P*RR2B(XL2<=UNAS2R(6]`$C8Z/DY$K5=E?JQR4\B8Y*>1,<E/(F.2GD3')
M3R)CDIY$QR4\B8Y*>1,<E/(F.2GD3')3R)CDIY$QR4\B8Y*>1,<E/(F.2GD3
M')3R)CDIY$QR4\B8Y*>1,<E/(F.2GD3')3R)CDIY$QR4\B8Y*>1,<E/(F.2G
MD3')3R)CDIY$QR4\B8Y*>1,<E/(F.2GD3'<M1$2MUUK6B(G_``J3P")^^>A?
MBNU87]..A62&D^>*]:>N+8CI((F^#:[S$G2&M/)<P#'J$"TJO#BYV>ZZ.N4^
M1K.Y7+4&G(2ZELKVVRTVF!;8\J%O'G=&`O2'9\J/1%S[*K7%F'>]"S[9&O-\
MMUA#,Z^L4UHIES(Y@'/!$.0RC3(JK^C\Q=ROXIK7X4)X``Q7(,0M7Z(*5Z\#
M!CU1;'O>OU-:E<"G03,DPY+5>`XZY"-1RMS-JB+2K?DC:XAYYUBTOI^_DO&G
MA2"`D7>5*=;V6YP/L#!58F4CJNVI78BXT;>.C2WQK?K;2M]N"18LB::';HS9
M,F7((&*(A5'&&O&7+B%=;>130;C%#-AFRO9O8TAB$"3(1&O;G8M:*E?S#W*_
MBFM?A0G@$3]\]"_%EJP[Y-1PK1<%M5R/:9*0[DTAA.AE8W>;YI8WVXW(UB[6
M[<.OD3I'1[IHZ7+%TEK4D*A+2;:5&O(F=7)]*XT=98M]M4F[@TO:FFM@)H"3
MA.BP`))0D5CU,Q0+RJIL_,/<K^*:U^%"?/G8LR(CHK<\IJR0HZ*S]>4U7UCM
M^MU,02@(PHB:RT(HRB>T@WM75=JXS'L56N;L\6%^2=NU8C^AR<BER[I';E^5
M29^)DKPUV4QI1)I+?)D+9(G2"VWH;K85^[XZQ.@-9!6,[Q;I,GT8[O=P`(<V
MG]<5W0F#S<6RTKD1*\/YA[E?Q36OPH3Y\DSIT)'I<9ER&CQR'BF/DWZ#?6Q)
MD:J`AQD?!1A%#F4R\=R;*8=#)*W<F;W@:=N&_B-3=03W?6\.7D@#.US=U`<?
MB9VT<Y*JW;3$HEPU9>=1M*UK1"ND6R`;%<URJX@EM-KM[W.(BT7-5-FSY)^8
M;C-Z%*J)JJCBIN'U&U4151S^#&CVAMY[2)+'"0=ME$(:1!;D7[L8QA`*0C/I
M<QJ_5B(:^VL5P+`:=D,CR2!/CMD[OI#6.C&"ZA=TVOZ,:(GV.WK;Y9>\32T,
MIA3;@_/%/(.I@N::60:C)D2NS\P=ROXIK7X4)X!$_?/0OQ9:L.^2:C7/&JQ)
M*(\;7/(Q5"^CF,9QW/;XD3:N(%F23>9EPTU#@VRZRKY:+M9IIY;@;QIMS>!M
MDFWK-M:O_3\D>'<"SHZ0+C&O$.1;92PY0)\#>K&,,Z->J9%(N--S[G,D3YT@
M$SI$R4_>R#J.YS1,<5_\I4&-$_Q>']ROXIK7X4)\YPXV;?E`]HWF<S5^B'H(
M>3>%5NJ+8Y!#WCF#SD5*)F5$JNU<#.6%)M[RHKG1)G1^DQUJJ9#+$/*C9ME>
M(1Z;>'Y'?H7^+&L8%QN%]G%OUVM"V>&MAU&>VVEHK.(1(XKIT,MF&,Y4WCG,
M(UB.X=N.M+.=TF#TF7#WK@'C.Z3`D$B2QJ*2P94W4@2MK2BTV85/I1?X4IC5
MF@WW-]RM&D1Z?=9WFB1H\D;;\*X7.6PSXZ)O\IUXJKM1/#^Y7\4UK\*$^;,]
MSD:U@BO<YQ-RUJ-$Y5<I?YM&IMS?R>'$=L2`H(:J)LB9(GWM)ZF4#RKT><V9
MD-O.(HT<VAA*JK3@PG^'C^6)^^>A?BRU8=^1^QEYB"L&JY%RU1=@6*-;94:.
M>UK=I4@4\4E$-`*21&(TI*&SYG[6I6F$_1C56H;&'3<V'J45@9NKK<KG!D1G
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M36S5.GPZ+B3`EC_=[NRX3KVO2`/*T^XZ&#E-:O&7P[N5_%-:_"A/FRO1:*T9
M'5V;,K'*BU6J)1?IV8Z$<W2`W"?+DSQ&=IQA+@D@<@KH]Q%"M@S3H[=[3(K^
M!K:[$PB)P;:>5?D0C'RQ;F7)GV]HW1F=63IER#=I$J*Y(V\,Y\\".RR'&8B*
MJ(FW"6Y$)(%.UQI61/?(>F]FR+MK"`6X$,H6A:W?N.NQB-1J;$I3$HUAM0[<
M26Q@I#AGEEWK!JKF(J2)!D3*J^*GY&B[K)ML*5`MNM;;)NEQGJ1@=-VYD:<P
ME[4S#`&!P".:S,3,/C\G@PZYIJ[3W5HY+(+YW6<?HS9CAJ5D9Q<^3?.$F:GT
M8A396K;`&)<V%);Y+[C'0,P<<FY.^.3-0C1%3*M.!<=WMZM(95_@V76#9UR6
MP1WW<T:(^Q7!C"/!"WI.,Z4/9PT<F#2)-@UR"/'&\YS%T=>F#$$35>0I'+'H
MT;&I55\28@W2$YSX=QAQIT5SV*-[H\L+3A5PW<9CE&]-B\'AG<K^*ZU^%28!
MIRSW:%:(B:7)?#%/9^M2E.EV'`0;:SX2"&@W5\>W#0DU]9V%>BJ,3]*1VD>B
M<*L8M_S/1*>+"?\`V-8-M:?[M0]N6N:G^\.W+E6OT4PT@M<VL@W)F81FD1/&
M]J\#F/;?5:YJ_5CMK;?[(#_KW';6V_V0'_7N.VMM_L@/^O<=M;;_`&0'_7N)
M]_;JJU3^@.@KT,FE6QVF9(N,2&1JF9>B.&N20M%HNW'*7^#S85&NRKMHZF:B
MTV+396BX&(_2W_[Q3I!I:LW<Z1#44L"C-D`1K+"S[$@AJ6F0@Z*JM<U$^6)^
M^>A?BRU8=^0J/8QZ+PHYJ.1?THO#C*D6.C>'+N1Y:\%:9:8IT:.J-Y"*$:HV
MO#1,NS'>2CI@[.\G>'<NE]<W"WQ1RIH[9:=Z2V([HR]":)6;'9G(ZNW&IS"(
M,P2Z7O9!E$]I!D&^U27,>-[55KVN;P*G#C2D:3J[34>1'TW9`'`:]6X9@F%;
M8[""*-TA',(-Z45%VHN.VFEO?UM_[Q@,J*84B-(&PP#A>T@3!(W,,HB,56O&
M]JU14V*GA7<K^*ZT^%28;_\`SPOQ('"7,MUE@5KK:]H1C$Y!/MA"/;NG[*-D
M(54)F1[OU5:E46)QD^Y@TF`:=#B<G2<R1-!_-;.GDD4-3Q<&$@`,XH6'FF9G
M1K<J39TF=NFM91B,"LG(VG\E$PK@%$9J$(%7#(U[4*%[AE'5M4SC(Q6N3Q*F
M&[XHA(\HP,4A&L1YS.1@@MJJ5*1ZT:G"ORZA_P!D_P!.VSY%2JM^AS:51?I2
MJ.2J8WK`S)$6+JV[R3'^Z+1R!E1R3I%Z!$$R0%YWY>KDHX2JB+ZO"?X>/Y0;
MG)OOVOT1NM[F42%_:FU[M2HQ4>H]Y3-3;3`NLUB.FY5Z2L%I61%?5:;AIW/,
MC<M.4J[?RT6Z6:TW%0H1PUN%LA3=TI:9W,Z2`N3/E3-3AIBP#G:EM-[?]ZMZ
MW`,A&1I3DG2F@A"%+%%*C@QLHT$HVK1NQ,M,?^'P?]$C^SQJ1S8$)'-L%Y5K
MDB@16JENDJBHJ,JBIC12?^EK'_1L?PKN5_%=:?"I,-3Q_P!WA?B0.)!AZ^U-
M$&4SR#B@BZ94$9CUJT`5/8C&48DV)G<YU.%<?_HVK/\`0])__',#C2KG,O!F
M;QRW">R&R27.]7(CV08\2*B":N5*,38FW;ANZNSHHTDW@C!`B[IK$NMY=>>E
M`W9V[J[`5^ZWZ*E1HFQ/&3/.CO!UO:[P&.:W])&.1;+H6X*XYY$HLTSSC,H]
MI*,X4_5Q5JU:M%:K46CD<E45%X'53#AH]JD8C7/97CM1]<JN;PM1V5:?HQJ'
M_9/].VSY*JJ(B;55=B(B;555^K'6UOF:5*4MYF2W4E4)*MQQF04?HH(+V"N`
MZM5\AKG/?DV\I<(GRQ/WST+\66K#ORUKP+LQ;&@TI%<!FMM*2V1K+'!;'@GF
MO,0'6JOC0C+]@SUNQ-X-,JN1,.7Q?I3$F#(;GC3(YXLAF96YP2!."5F9M'-S
M#>NU-N.\73L$TWJ>R%TD&TPY=PFSV0`GL;S$#&=-.=XA.>O)1:>%=ROXKK7X
M5)@,BZS8UOCET"4`CS"LCA>?]HPOW+2DHUQ=WQLO#3!91N]W3QK8XDI16E;7
M9Q*$9&D2*/K%L]3EZ(YS5JK4WF7;2N)[)/?-IR4<\9!P9#;+9(_5\C>M<Z2H
M67%S9B.$BLR.HFVOBP,%WU_8+U-:I%)/1\"V(5KB*X;>A@D%$/=LXM47;2N)
MB?M]IUYC2M\^6Z_3FDNT;K9)_5]P`R7T:"%(?W;.!'.R?0VK%E$/WDV5Y2RK
M4^&WKN4X%L@1[C,/<K6%'S?O`9-NE]&1[TSN:Q,W`E.C)K_3J.##TU!C`'>I
M+(BQ;+3K.(Y>D[R,&^HQ-XX:9V_Y28N4N;KC3\Q;@"*(8VW-"="'&G7B4.(P
M\HY#GC1@W)HAJ[C49XMB)>H%MOMKG39+K4T$2),#(DF<EZMKU001.<0BHQJK
ML\28Y3/^FF*$IE\>:E%3QUKLI3&<<2Z/".\SB]8Q]XMK$!'7'H\4B2BVP(AH
MQ^1>C@E(K6BHM4<]WE_C^279H$=DX@&PPADI,`,$BYRKT*QDAY$WLA@8,DZ*
M4V6FQS6(Y4PL^2-L!+9K_3<"XYGJ0("V76D($TS#JP>]B?=U<U^5JY>%$5,2
M0Z=OUMO!8K&%DC@G0S@C(Y6#>1$X&O<U:?,2+;<X[)D"6/<RHI:[HXJH[(^B
MHN6J8U/'@Z1!)CC@3KP.T07RPFE7.'`.R,^*4#BR!3,KLC',1RI7@7&GONY(
M?^H[2B0S.*0L7[@#[N0A40I"`1,JJY$<JIMQWCPZC>&XVC1][KE<T@GMCS;5
MN:YE:YM(F;@\?A7<K^*:U^%"?-<&*.1'(O"B[45/H5/'@IYO7$`TF_7($"-$
M`$-@GL7IIXRF?+=(,622+5SD#NN,/8F7">+_`)_D(23;81B&C]%*0D<;GOC[
MYLC=*_+FRI(8CT^AZ5X<0(L*,*-''K+0^00F(UB9]6VQSUIXW/>]5<O"JK7A
MPY48U%^E&HG\7S)XDH>]CR0ECF9F>S,(S%81N<;F$9F:O"BHN+K#BZ>"R+<@
MMZ>!DJX?>DBJZ0!%>LIQ&*TOZN(-]'HO5QK3=-`::MT44,8[K*ARH%PO19$6
M<>?(MQWD&R0WC.8B[<76T,M=\M-QLP8!YL6]1(\4B"N6_P"BO'N)<M'YTCN^
MCPGN5_%-:_"A/FS=%1BRMT7HV\KNND;MVYWN7;NMY3-]6+7<+C%VAF!=)2:2
M&<0V#M16W&XB8`I4%<I5UD9(FZRM'$:N>BNPE?EB?OGH7XKM6%^:5BYJ.JU<
MBJCJ*BHM%3:U=O#B\R;1J:_V,QSV&-UE==2:FNX(85U!;E<P`GR)I8SYB.4.
M83454)1RY:X[QT_\DT+_`-A=OH\?A/<K^*:U^%">``&A'B5^K]$,WHE:A19]
M4VMJ$$KVO9O&*M4JBI7`XQ)<F<X**U9<Q0K*/QE7.=8X(P<^VG%8U/F]3BB1
M(DZ:R$.3!CSR!%$6;$EQY,4AGR#QHZ(`XD>F=Z-JW;C4&M!,EQ-5);K&C[K`
MNERAN>H9T*.Q"`B2Q0S-$P[T2K%Y6&_H3^)/".Y7\4UK\*$\`B?OGH7XLM6'
M?-W[3AW/8.[P"1<S";IR/56O%]JH9&[:I6)5<CJ)XL28_4/5FH[G"$%+(61D
M03K;>Q-:U9,IH$:AX<+>(KD3E8U!99MADV.XZ:6TI,!(FPIR$2[122H[A&@O
M>+8$55V^/PCN5_%-:_"A/G[@VWS(LJ!%F-@S9+K;N.KM]>(D-Q[;'>99MQ':
M8+R.EG*UL924W:JB.3"3)P72"Q=?Z=#%Z.%H2WB%;];1!098`D>T;"7,04R[
M4&JK5*-7$H<K2NI-.-`QKVDOHK8,<I7N5N[C+;[G<%5XZ5=FR\/C^;5<6/1L
MN-J>SS$DW"+;5U;9WVHMVE2)UQN98\(S7GC2R!`Y7<1WJZ>/9CO8_P#8O]`'
M\([E?Q36OPH3P")L_P",]"_%=JPOSG=[<Y]N:6WV[4%PDR[R8TB-#TT+J*:Q
M;I,,-6Q6!)FW7WC[.KOUJ8FZIGW32LS>GBPI]Z;?]T%9+098460>-/$'?)&'
MQ&KMRIB).//TN&'/WW091=3R&1Y?1G[N1T8KKHC#;@FQU.!<:);9[G:;9%G6
M"_OFLZ[>0)R3TM?4#GI+FF;FFM>_H_\`UE5IA]F9JBPONX7G$6V-ND19PR16
MN?)&^,A-ZUT=C%5^SBHF)AHNK].2`V\"2IY0W>&1D.,K]UOY+FDH$6\6E7;*
MX==$U?IQ;:R4V"^>EXAK$;->-3,BN.A-VAW";F1M:TQ#FR=7Z;CP[BPI($DM
MXA#!-9'(H3OC$<5&F:$J979:T7`+=(U38`SY2171H1;I$9*.DY$6&H@N)G(D
MI')DIRJX+:@:HL)KH!9*'MP[I$=,"L)KWS$)':12L6*P;E?LXJ)MQ-DQ-7:<
MD1K:%DBX'#=X9!0HY"($9Y+VDRA&\KLJ*ZB5QUG^U^G.KNE=!Z?UO"Z)TS=[
M[HN_WN[W^ZXV6M:8AR96K].1X]Q"Z1`.:\0ABF@&]1$+&>\J(8;")E54\>`V
M@^I["*ZR%BM!;B72*V899S6.AH..K]X]932-5FSC5V8/;0:JL!KA%22LF"*Z
MQ'RHZ0D<LQ3`:3>,2*C%SU3BTVXERX^K].'BV]@B3I(KO">"&,[]V%\DB%RA
M:0FQ,W"N(A(&I+',%<+AU5"+&N<4K)=SW6^ZOC.814-,0/&W:<;+\SW*_BFM
M?A0G@$/]\]"_%=JP[]*_P?..8]J/:Y*.8Y$<UR?0K751<*SHL;(JU5NX%E5?
M$JMR9:IA&K$C*UM<J*`*HVO#E:K*)7&E-362QVZ[@LMKO\"7$DW`-L>Y]S6W
M]$(,CXDMKD`D5WBV5V8S_P!W5HWFU<_[6PMY5W#Q^H<VW#D3NXLR(Y*.1-5P
M$1R?0[_4'&3"L_NXLRL5<RC_`&L@Y,R;,V7J#+6F&M7NXLV5J4:Q=605:U%V
MKE:MA5&U7".7NYLZN2E'+JR"KDR\FB]053+XL9T[NK0C]M7IJR$CUS<JKDL.
M9<V'-;W;V9B/Y:-U9":CTX:/1+#1R5QD_NXLV2N;+^U<#+F_6R]04S?7A$7N
MXLRHU*-1=5P%1J?0W_4'%3"$7NYL[B)2A5U;"4C<O)H_J',F7Q?1A7)W<V?,
MM:O_`&L@YUS<JKNH,RYO'AS4[N+,C7<I$U7`HZG!F3J"CJ8TK<[EW9!*"R:F
M;>A+;=3;[H9H5JN1'3)#85F$P8&@:Y,QOLLRHB[:8M=W03@)=;;`N2`5<[@-
MGQ1R6B<]$:CU8A*5HE<;/R^Y7\4UK\*$\``(K$((NK]$#(QVUKQDU3:V/8[Z
MG-7`X<*.*+%CHK`@"U&"$U55V5C4V-2J^&:E2X@20R%8KS/C-4AAH.7&M<QP
M3?8D'O-VO\EU6_5C1\>1;X%P2%8+<;=,G2E=&DW*%'D3L_1YB/8XY]JH[@7@
M1,:CA0C31R(^B-+L?;-VG5<:&*7<0131SNE$,24]H\KT4:;&IQG+7\ON5_%-
M:_"A/`(G[Y:$^*[5AWAA0'&PP#C>$P2L:011$:K""(-Z*UXR,6BHNQ4P9+-9
M[9:4D*Q3I;($6"AU'5&*9(PA[Q69EI7@QUY;]5S[)FC0HDF#$M-@D#E@AG*;
M(:9.MY[A0V]5*(2C?Y-%P^<_6]X/;W%.]ED=:]/,BB:5CT$))3;<V>YD5SD<
MVI%<N7;7$]A^\.^37RHVYB&)9],A?;#;YK^E@0%K&PY,B9,I<[*+6E<0)TJ]
MNU$=TN[`?=W6YMJ=)Z'=9<1&N@L:QHECH'(JHB(_+F\?Y'<K^*:U^%"?/[NW
M;Y2],M[Y(HQNCRI-M%.CON<6*?>!W9Y$)'M3CLK6E4K7&66Y4E_W@:=):Q7(
MSC.B0"ZVBDLD2X2&%.]ZQXZC0BHY[FMV554QINPZJ!I8S-5GN46#+TY.N'W`
MMJM[[@9UP'<PHA&&&B-9NU1<W#C_`#@/.C]+'KP\ZSSX]>'G6>?'KP\ZSSX]
M>'G6>?'KP\ZSSX]>'G6>?'KP\ZSSXTE"072EU1J(=@0HY0QI"4D&9-Z41JM?
MOFMZ)ER\7E<.-L@/.C]+'KP\ZSSX]>'G6>?'KP\ZSSX]>'G6>?'KP\ZSSX]>
M'G6>?'KP\ZSSXL!=VDUM[U/9],Y121#Z,^\$*Q)I*H_../NMK=E:\.-L@/.L
M\^/7AYUGGQZ\/.L\^/7AYUGGQZ\/.L\^/7AYUGGQZ\/.L\^/7AYUGGP*ZJ)+
MBA;Q9;3T<4H07-6\7`%O:?,K2)DCJ;.J4VHF/\X#PK_.L]+'KP\ZSSX]>'G6
M>?'KP\ZSSX]>'G6>?$>U%F6DA`R)YE=;(@;5#I,G2):(R$PYD8]&FX[LWVCZ
MN\>/7AYUGGQZ\/.L\^+KJ11)<4M;([UA!E""0Z'F1X=&D5"(S(LC-P<"8[DW
M,(Q];CK-RY'M=3-I,GT+X`^V7VVP[M;B/&0D*>!DB,]X7H03W"(BM5PR)5/H
M7$N.G=II22*UPK?<K@5T".,O1KG<WVP+(`TC%21)8X+G.17,3@;PKC;H/2_^
M*TQO1QV#TO[IB^CCL'I?W3%]''8/2_NF+Z..P>E_=,7T<=@]+^Z8OHX[!Z7]
MTQ?1QV$TO[HB^CB.U.[32QXK84ZYW.<ZV!4=KA0BQ1*9X`1Y$IZ/W[W9FMHU
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M&%S5<)2.FM3>D5B(O`B\.);)/=[I6'<;?)'&G0.J6YXCRQ02Q->IHXD?O`G1
MR*VK5:OTU3'8/2_NF+Z&.P>E_=,7T<=@]+^Z8OHX[!Z7]TQ?1QV#TO[IB^AC
ML'I?W3%]''8/2_NF+Z."`7NMTI/C@"648<:+%)<^@QX1I<JY.@LBD%%@QGB0
M68Y1*5[N(B[$<>3"T+IJQ7RS,@2!3K7&$]1AO=O(8:1Y2QHQ!G0.<96TY.W@
M=X""3*@1),B*[/',<+"$"[,CT4;WHJMH]J.3Z')7&SY@+YT")+?'KN'R0#,X
M696N<C'/:JHUSF(JIP*J)^5%!-=+82:;HT1`VVXRT/(49BI'8^)%,S?*(#W9
M:UHW&4DV,%V\4620<4=^\;1'-09WC>JHJTX.'`,L^&J2G*R*J2XRI*<U<JMC
M?:_;JCMG%KMPL>X,@N-)MYD+TI@ES6QIF(5)!'HK&0]^1O+5&N>NRJX4%N-:
MPQ@C=(<.%(AH$8U>N\D$W9*-8I*YGKX^%<#1+A"7?(C@??(OV[79J.!]M]JU
M58[DUY*X&&'=89R&C1Y@4:8?V\>4IVA>"KDWV98S]C:JF7;@5)L=[3RFP1$&
M5AA.F/:KV1U*%SQC*]&[$<J579PJGY.\D18YWK'-$J83"5BR,BR(ZYT6H3J-
MN9O`[*E<;B#$CQ!9E>HXXVB:KW417N1J)5RHG#]"?,$N2VR$L\N3>S-PSI!M
MTQ1CWQ:9B[L:Y4S5HW9AP[?"C0F/?O',C!8)KGY49F<C$2JHQJ)]2)3\P6DI
M2%&ZT71MU`@\M"&9#F0T&7,U:BR37+LHM43%T,63+5UU60I:MBNW72;S%O9-
MSFCJJ?>8C6[:\3ZZ+B1-=*G(LR3(-*$CA[IPY%T6[]'"Q&HT*#E.7C455:OT
MHBH<Q#*D:?;H,">+(CGJEKNS;M`(!7H\2)O'$85KFKF:J4X,/<DJ4%ZS[O<F
MN$R)Q9-WNUOO+L[7`5A@QY=M9E8^J*Q51U>'%T,^7+))O!;=(F'R1&*A[=>W
MWQKHK&1T;&8:2_*YJ;,G^4JN58[I<IZ;JP1V.W<1',!IVZGNL)B?=\OVKSJ,
MNSCL^NN.K(\^1T`MSM$XH7,1H(P+,]AP1;8$=&1.D'CLWJ\G+R6IL_Y(?__:
M``@!`0,!/R'LS#2#;;8(D-`K4)/[7\PL'.*U*+/GRI"U7K4'G3R[CBR$&NE$
M;0=.2%#]>4;Q:"]8F$W_`%=)8)>3M]DI.#/H0$"G65!])WZXB[KKJU:M6K5J
MU:M6K5JR*ZV.3!*J1",UO/T?CL(9"9%)$ER&5L%\WC0N@#FV<S$8ZP&O9><V
MR+0TJL3##'2<:(Z`<`.P*U:M6K5JU:M6K5JU:OBR#<&5T)A(-]:&U_@U=.=5
M`+KTST?J+(7;$BX%`:#LVS23+4/C<B!*2ZC5P,:TPD%.P4TMC47O";:I]HW2
MY%IW6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W
M6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W6^)W
M6^)W6^)W6^)W6^)W6^)>FH2#6N@7-'6I?&5Y^L%+N:OA?,+6]S_R/Q;Y\!IP
M*&D3%]DA5C':(XN<"[V!/RH8.)/\.:=>JLYZ>QV=7(C(T*6?/"8R&D!:*V$Q
M!D+SV`I8QFER6EE1@6$0BV=+2'NB%Y/\*:=@Z^ZZ,V[0::@3#"6&/:D6FGB*
MU?>LP`"&^1@"I?6&0>)_@S3K5J7.S(E6`YNB,Q_GM/`XDXDF//7HK8+R0,33
M7SC$)6/:Y6'LVM=%333!P4]M[5>EL,`!@HFO^!-.MT/AI=>^I#6!&*0<05]`
MIV%$J28_R:HZ8<CR/IPSX`,P4.@L5`O-I4+@@HLQZ]C_`#=766XC:`K]H,L=
M5NL72B20'"5G*H0`<_V_X$TZZNCK[KH`:<R`6"C>2%&8OB-LQBI4L:RW?0!'
M<#B1ERJUJ*V;31<0;=\/\!-.J0:H>,0+0'&\>L`+0.(V=*CQG"^@QV-R@S&#
M5,B70K-H1T/^;O=LX9FCDA+5@2]37FX&%H1&<9`236D`7XF'K*EB3%MS!,$P
MKCV^:=4P+UH958:IB`X(F/@1X+(,Z@B"8U:9Y;O#\.ONNA+$XE0Q9:-K8MGB
M8I^/::N;!6G$/J0Q_=IJT=)@@.+#D^)IH_7D"JYT=NFG5#0*0Y%U1L7BQ)3_
M`#P+H-"6@UHF(VTLMU:64%"T%"ZMV+YS*7XVP:5&-3:C!%[2I`T03"66(KV$
MO4]WG^#)5`)0X8N1X]'N;@=%-CF/7;"\`@<:W=NFG5#&+U02H(PNPC>.:_?,
M+R:+K8K"$4H4!FCC6P7?A'T$M9QE/,#)*1!AW#"T0)1\0)E+4H7-GZ2L_@?P
M07AD!"U5*AB[CTUBFB]HN*O93]37V70U*FL4^,MV!DJI(/T,MTV5U8"V'LDY
M`F"J<RQVT&.8`UKNE:UO!"H60_4GN5HHI@N'N\OHR;EZ,#DL%`("QPI'\2Q8
ML6O2'V!<JT"H$M_PF#"NT1>$:"EUO*S4M+A5O@U#$[Y6UO/'+G\.ONOP-*='
MWC`4&(9B4I.@I3D#$LD#@25ED7Y2V&ZJJM"$*LM6H@.1#F6F%"#2(Z=FBHF)
MP#,2S;W>.!]6^H(#9919VMN!FUV8']"R:/,O/0#'@Q<7BNJP:%-"L<;JOL@2
M^$$UJ.]T!3<Z'#DF2Z_(1:E`Y7$QR_"G+.1V'(9I<EB69$BY46MN5M#?'Q69
M^;^W3QG63@!`.`S/680`P,O&8/Y$9?E9<IK+\<'7*L40+NI1<#$Q=@BC*^Q[
MBO>#XH1ZCJQA-(P5K[I?3HG:V[LCP>^:N=14.]L+7^O5&1S*-/.32&(/6+I6
M@OZ664R5+8N@(N+E?2D9'.NR)#;AIJJ#!&T(A2T-PPP<(1&&Z_-Q*;5ITDN#
M$H`!04`#,PKZ\["RU]WM5&B&+TTRW^'7W7YE4!"PF$WOC<5=S8B.K"NY:*S;
M%'765>;&?EGE>70JP&HQ<&ZLO_M5+$*H.UH[Y^]1%P@-"UW51SM[:290C&(6
M4086*-MCB9Z]B9U+ZO0*98N9EFS-";](14?HLDQ`-N*+>99D4!D8W/'4PL:Z
M6&BFZ_7T%4+3$M@@9ZA@6>10%V.W0XDR8UT(T.3>O%1..[)/$:<X8HM'-YW7
MNT>$5VX3*EY::A<2W87"M#"EOSE)=9P0/JD3T`J1:-=0SN=D0PVT;A-)=F4&
M[(%E*P:B88\:3+S0\%`W&X4QUUZ^UZ-UV[7-#RO73:5*E2I4J5'F3PKTTG)Q
M$<D&(%*,!&"A=:&,OJ@Z6K4HU%,X\WI*BJ4,*V=;F-@F@,M0;<]?\+,M9*KF
M>MBT5PL'#J<\YSISN"BD[)-51E04B)8H5<V8C72V"C?:L%2L2TRC=-5T@VT*
M[5-.JJ?#V$4]<U53-VLQ$MK28K#ZM/GB4=KK-Z_AW]_U2O`4`EI0`P&1R1ID
M]\,X<%4`DAIM`TSHYT19OVF:=>2K2X`$3"*#(F)=K1=XT2#88,=7=CA@&\@F
MLBQAK)"QXF=/^DG&!Z_E<ZF>TS3L'7W75U)V^N``B.?7*)7#L;6^@.XQ:M$7
M%1%!;%36^TS3K4@UP6/1!&,@5:2I!*1>MD'-;E-F%5/42^"`W$"A3U;D97[+
MXRJ!A``M+-:*:P:FG.=%^E+90MQ!L'B=FFG74<"`J!P0X?Z@-/=]W/KU8LI+
MG&#3!BX@(HU!]<N.E&A',X-X$/V*H*($SW28_P#3^V*<6P1DRO\`!>^UM,;I
M72$T4'9"VMXUE2U=Z"78KR;3=2YR"X*78A#&YA/6PK/QC,-!4(_*'BF`6BRT
MJ-UP_;C3I)'6LW7KR5^A_MTZ1UO*F(YSLP%0D*B&GW4Y53E<6`3C$0JFIFPE
M]^O:B]G^@P15K#&[66EU=2JF[/4S3K_7?MOB.`<T>K/H]9RF=AT0;S)LB!0"
M4)86C5D>.X+&6&]K1F`9I;T4/.E6HI;*YO*-58-SDN<Y@.3TH5UA+,TV7%TD
MJ+(452.`U9%T2E#E!:R-5;/%26P37('&T5OUT\"45`YSFY@=,%)H#!E2)<^(
MU*N1N"XTX2D3:+5'8J!_'&@!:P!NY(`9CGO(AJ<[P,,@8-6!(+2[J9*1)D\I
M?NU$5R"T/0:Z\0I=$M[W33AU&D\1ZB:=>-R/Z)!NR/)CDBGI0<L[1Q[8C5ZN
MT[^I$7=2VDU0V,]UJB0F(A]$G62$=N.N4[UP#LZU!O\`&:=<C5X[[0J>?FG[
MKMCM\E#RCB,HI@X-.8%'("NV8.)I4D"/<1GD(J\\481F1!B!B["4R]15X3`B
MN@92G6AE(JV)H`_%-.NWI+I"@3EV6!J"M3%6T-V1G7LT?RY*>AULUPJ8-]1Q
MV[=NW;MV'"[:L4`L15EX%MV4:UNH.W;MV[=NVV;5E"6N,+;2'NQX]0W;MV[=
MNW>2;(Y&=:@S"S65$40,VX:]Q^%N7;2CV[?CIC,LJL!9\+%*AB=#MW;:HG3W
M0:MVI$,>J!`NZ'7C5'QN*(KZA9+PQ>S^P%U%3HNU&T<'"GZ]1%BQ8L6+1"-D
M<$'.0FW6!%=9XA'-2_,BQ8L6+%I*7&G\R$I#J^\&OC?Y:,B1@%P5;!B]Y/YQ
M8L6+%BQ0,&\]A>0A*&XSPX%WQS3_``R4/SB18L6)%BF=KVM1`H)`I!1`C0W!
M5@JH"T0T[!5*#W^.#L&@#(,``%!W_?4*9U9$@:\38DL(*\*K\3860'$S)&+S
M51&:Q*ZBBO0)M6LLP>MJJ#MK%AAK&T.J]Y",U%,V+7X(3HKUZ&WR092KF>&X
M*B&A0V86()JU,2NN7Z&++U[ST[B(-7!8$=C[?#^"-B!BFI-2?:#1$"F<;J(F
M2UM!H$"K_-B=ML<?!EB@E,1*M'2Z49I71#`'^!A2BAPE*9GJ2K&@@!.QS*ZH
MMJQ#$7)HH!L34Q+6X!M@@!7D+0YK![]`A%M16Z$&N.E'9H*+HLE+\'C6V-*P
M7"T$DW:%.YC>394IIQ7>\WY_Z+KTO:__V@`(`0(#`3\A[,#O"T11S:(91J9Z
MM?A+,*O&+H-=NV$K!772:^P\8CE$-`>O;,S,S,S,S,"D:>-S)FNOK&5EYG,$
MJ$RDY7='#--\JEZ=9K\QT`-,]@S,S,S,S,S,:!:]<%0->GBGZ,PCT#6E*W@A
MBJ8I7T$H/%VAK]QY0UA#)M9YM(*@[+PN])R"<@G()R"<@G()R"<@G()R"<@G
M()R"<@G()R"<@G()R"<@G()R"<@G()R"<@G()R"<@G()R"<@G()R"#"CUNH\
MO:!*FJW\^D-9V?W%\2X5P,6EJ@-!=4NHI;T2P`!NT7-1-5W%Z@_PO<1Z_`O+
M``TBF@B!:C$(;6R2[PM\0G:U?&&G^![B/7_H3Y(Z3<#:$5W$@6W-0K)X-X-Y
M_P`#W$>MWJ7OC5AIQCP+P#RFSET7Q:VCKFIM\3*VI,[C=/';>#B"JC_L$<FG
M;_<1ZW!9@8&#P?-`*N<7H#A@T<G,:Q"U''H]@RE:TJ;P5E">.1E-!/Q\,'=^
MW^XCUM%WO$N$,."?)T&V<HSEQUZ%2P-RZK5\:-*@]RQ%T6V]NK?;_<1ZMQK-
M>D6/#+9.@UF*$N*(%>9$MOG&$EO($AY:P42[[;[B/58O%#9+RJ.\NG]"?)TW
M,U;-I^_[-(B[HMEX5JCMF_*(2:`@[C)*J*R]^V^XCU50TTO/3OZ0*C<MP3?*
MB^=!:^`"K!1T;',=$Y)O"D5M^!4A#KT;B)]WN]NO<1ZH?"FD#36_]EWF-C9&
M4;<U(1Z/K3%-M&Y8A#I>GFO[_#0R#&S*W!>8+72M'(XD=J;,[>TJ9RF;R:]L
M]Q-\IJ`Y9BKZ.>4H6>R5Q^TKC]I7'[2N/VB*WV3/'H.GDX'8>)ETY,5F4.LH
ME#RI\GX;5M*(K`5++B'KP_DNKN)YF\4F-+2J]9"DK2!XI_PTBB%'4W.U>X@'
MF_J8ALSG)B41&\#&"#P9`VMBW0/#D!\7&FI!NA,2B9C*)IKF-L:S-'"O!<-.
MS-#8KI-TY)Z]?FN:35E19,,8_D.&^]HQ:#G&SBS'6,]]]]J]Q$:##N\Y<V<<
MWM/:;->#\U*M9#H7\\85`FWR*'R=8<$7[E0-/Y%/%5YP:\7?YF[HSMF.*PC0
MG%9S7+0@0WKT_H3Y/SVJ889IRFIJ3&21'F,HQEPW%1?+M7N(T6NFHT<BH"D2
ML,`E@TV1Q9AJA/!SF!)04RV!X'*B'IU-MOIZ2K88WQ@[?HSLU!`:^LX,XOWJ
M6U+;B\(FQ%V/!3S2AS9CD!-VLP>8:\YC53J$5"YK$2HKE,WO"%6^N>U>XC4)
M<@G()R"<@G()R"8X3'0G&"YXN&.'A!08\IK+="U^<1NVH`.CJ4L>J`8-6-YB
MLUJDP_=1#/*,FFO:?<1ZJBB;YF1GU\VGD-VK$\\<W=\^&W3^I/DZHSB*+!Q/
M!!FI2SSH_P"0=`<NG:/<1Z_0\,.KKBPT-/)E86L`X3GD?.&K0"KPOM'N(]?^
MA/DZM"-501L2[XXQ(N(:#A\.T>XCUK>T-WH.=(>8`-8E;*!Q"WQ$)I1U>Q=8
MF4EF+-7E-?/$X$]@GFBNUPT[+[B/7IRWIUH+ZQN_:#R:(@+;:LJW+T2<._#I
M%+P!X7[S+0>:<MZS#=*\9N4]9R7K+&J>LMR#UG)>LY;UF2J7XS8IZSEO6#%B
M5?4^XCU^EX.MO'2?13Z*7*J4'"U[(5[O@GZ[%EM/AG%H?#'U6#^90<49?KL?
M3X59!5;]G'U6%H-%=7T/>7(L0\[J):G7\_<1Z\V?##!';"H)O(F=<1A(:\N3
MQ0L$Z,>;*97">/X>XCURU'?D3Y.V8!D$R<H[:E[KC6+DS+F5M\/\C+*V_P`/
M<1ZZI[15M9C]#R1;&%L(TO%GPF/&.G?260C%DLEDLEDLED9^^HT8EDLEDLED
MLEDOKJQ9=WAEDLEDLEDLED(<3&I9+F)4"5HEDLCSG>.W.,>OH69+:A2_%S7*
MXG+3EIRTY:<M.6E^L%@5%'&^$0XTY:<M.6G+3EIRTV#`'B8*I6]H>`JXJAH/
M.T^"<9RTY:<M.6G+3EIRT6,MH'"CR$8@9M&B"W>$$R43EIRTY:<M.6Z,QH6+
M<>%>[-!\KM6F.P.8#MA,WU!J%3/XX%QK]O[+*4@;V6%XX]ZF,<&&-G/\@<$K
M'GI\N$M@/\>$;W'!.<FFZ=?P1$0%&KQJK]L0!%'WU',/'K;_`,``&05[C\32
MMAZ:W"_&\RZEML>;XV'K+DB=9W`:2NS(,S8<^*/S!E/I5(*P$+K5SK$8EQZ*
M9:!+%SK_`*.CX?@Z>U?_V@`(`0,#`3\A[.AJRRPW:_CUIKC*)9IW/A@V6:3/
M;Z@-4%H7@+8&*B7KCK/7S[_/OL^^S[[/OL^^S[[/OL^^S[[/OL^^S[[/OL:.
M^2L`WE>5Y0I7`H_E<T!LDXSTM?VL<8CQS%\V??9]]GWV??9]]GWV??9]]GWV
M??9]]GWV??9]]GWV5;BR-+:/=EFW6CBHE@.L%EU+@I634CH0T?+38\[BLT*J
M>?6R?2:0+/,4<O#XE\3+XF7Q,OB9?$R^)E\3+XF7Q,OB9?$R^)E\3+XF7Q,O
MB9?$R^)E\3+XF7Q,OB9?$R^)E\3+XF7Q,OB9?$R^)E\3+XF7Q,OB9:U55YT@
M==<3+,@[X(*$16*\96">AE;H\)Y/^&L.OHLM5^,DI4_X1F5":&@L#"A].,&&
MR<['P_X:P[`N]P?HZ/4Y,&?-*3+O?I;TQB#_`(18==4-),*YB_!T4U&#3QFJ
M<;KO2\WF4M?X2PZYO:,/%E73M-38$M3O#H%\+:F>&=9==&H%7Q1S!1'_``%A
MV!<>X?HZ+)K":M'F['/:+D+8`!IT-[>(.I_@+#KS>8./)P2)9^CH2RC7OQQ$
M2H5@5>>Y7O6-<A8^9DF"#X9'MZPZN[43._X+CW#]'3BJBDC`,(&G-IB&2YC<
MJH6L[>6'5KD767>>BL7&)&T9Q_A^`4+0);@;;/%4+K.O0'H2J[<L.K6D=88;
M-8EWSC?J"P>;96!L<`_"A"ES<@XN)F&'"#)&D5D>Y=0E9&B4Q-W;MBBYT%UB
M_P"TM89W<IS$<_\`B[NZA%9W8Z6Z+U_;,W\_P7'N'Z/PHLV-.4W-S7GU@%<`
MUEX110';.+-+\5RR-#9PDVK!./;-E9=S.;!JI93BFOF/Q[RLWG)]:QY5[S&F
M\Q,='MG]/21CC[=92F^/3OG@Y.@.IKX?D-F$AJK4-QEP'&%.V:]2C-EZZS"6
MTS&P1[7L6E99\DI$K0RF^4MI!RVTEUTDIX,L68K^I3AN/ZAG2>R?T]-VLU'\
M%Q[A^C\TX:]ZB+MOJ(%U5Z\(-E`7>EN9C1A[7L<+FA;5FNLVM]5LURI_<O(#
MHN^JM>\QJ73/N8L'\2%X;V_V'MB59G%-X\"CBLF=KV@6`M^2?0=`R1UFT-S:
M^T.]$@%YE>FS9RZAV[+Q7S*>Q6X`LJ5F`-;5!A7A#6G/*%EM&>UK!2O4'//3
M-L=>@"'42@@G6MG$_1U)G3">)HP86XIJTO`#,82RT31H\>/:UAU>RN_UM'EI
M^&[W!^CJLT%6KSGV=81!:DJU,+YG"#6FL4'/'[[4L.O=J<Z(&33P.K%]FD\D
M7LQ.%V?0PEB6:=I6'8%Q[A^CJ]%-;)?M+*D*IE3;;OC6'@J[2L.N=6(11'5*
M.)42M%3?P=6T:*WL7+;3HWHL<:M8:NTK#K\9<>X?HZL65".@%!:KS%Y$+5^'
M)^H6$G;-^HD:Q.';C+SP\X'P:B&N;N:3$5VU9*XU6D1^U=B^.,08IWAPE<JY
MG!G3-;Q9W6#(^&,SV6YOU%+7NMHWJ>]JQSJ8*JBG`WI6-XCAN>YI+H7L'!Q,
M8.>D%=2L.P;CW#]'6"6PB]W0`X@1FJ[U5RIT+!9^(ZK;F_D4RH"KVO*%X%O5
MO>L"*:>+^3B?F?\`)C,HTV?67_*?R?LF?R:B3A[I`30:9?QBN74YOY*Z\>EO
M447&#\QYDV<&L-]0L.OJ36<MM5GZ.V:R7!H,\1(C0`,J@5H!$0WM=VT+LK26
M[C<\/R6'8%Q[A^CMM^LQHE"PIX4O48`PX?8ME.^(#P:J'Q6>,<F:Y7H_B6'7
M;H'?@P8(8O%^,LVT.<*0K/2MX;A?A.0^DY#Z3D/I.0^DY#Z3D/I.8](,GS8I
M#YAF*I?#D3D/I.0^DY#Z3D/I.0^DY#Z3F/2%UP6YP.`^G*<A])R'TG(?2<A]
M)R'TG(?2<A])0<3Y"+*#3-VWI-^U^$YJ7PJ\J!G.A1[3D/I.8])<*'3E1?B7
M"8&!UX`ZW,3/57B?V??/[/L4^Q3[%/L4^Q3[%,N/40=5ZS^P-3ZC^S[%/L4^
MQ3[%/L4^Q3[),KWBFGW,TKIK6\_F?8I]BGV*?8I]BGV*?8HZ@O%++N2M/L4^
MQ3[%/L4^Q3[%/L4U]O%_9=ZS17`H[5C\7$*>`1079,UJ=^?B4=<6O9?T2S]^
MTO`U?2_I-KV_$\=)68`//\VM4P8-/\!S`"XFY8-I8*:!'K6?::M]0^GV1*`[
M7[U_(!-SU9(WNN'I.'+_`,?_`/_:``P#`0`"$0,1```0```````````YAS``
M````````````$W$(``````![2```````$(`````#'4TDDDDDDDDDDDDDDDDA
M@`````'Q>7````````````````%8``````!/QV```````````````%8`````
M`&D/Z```````````````%8`````&00.[@``````````````%8`````#`H@'H
M``````````````%8`````$]@Z'P``````````````%8````SX!0G8B0`````
M````````%8````8("@.32X`````````````%8````4-)@%)#0```````````
M``%8````]7MP$!O;`````````````!V5_P#P\@`X`,):^0```````````![J
M93[O,`@``./HP```````````!U)!BH)D`H``!.U````````````!0C(O,%2G
MR```&)@```````````!5R2251_KZ```!-V```````````!6````"L`0````#
MZ@``````````!6``````!"`````%P``````````!6```````H````!Q0````
M``````!6``````F6````!OL0`````````!6`````!G(````!\0G%ZJ+V$```
M!6``````!P`````(&;W9`K5X,``!6``````!B`````````````+[7P!6````
M``$8`````````````'_A@!6``````!@````0```%@```YF3`)&```````)/_
M`/\`8G__`/</_P#_`/C_`.OY^```````.P``!V``X'2;``AP``-D````````
M``````!ZO-K````````````````````````,!V````````````/_V@`(`0$#
M`3\0[,(,83099F(4!<1\WVJ6"/FB-(9F2&VP#*=<JT`83=7`8A.G7@I@C,QM
M_6]/[XQ>$J7;E3Y(./4!$.VJ#7*_*)<<Z8RO`XQ@\YA6YJXDH:Q2D-7A+.(X
MI>/'$Y=X_N"&D\\K\+-O77[]^_?OW[]^_?OWP`8]]1#@F!1,($G9M47&^$C0
M#D<`6SF(*J1:;7JVZN_&8!IHE0';`+&@Y693@.)74,$X%P%`.OOW[]^_?OW[
M]^_?OW[YN[Q$J)N_2VVAFP2E$2D1I$ZU_>(LG>72I,C%`PAN.I1,7_E>"8HS
M;TR7$=AQW-BX!5I'1=+`QS*MA=7R,'HDHD7\4GQR"C_AI\^?/GSY\^?/GSY\
M^?/GSY\^?/GSY\^?/GSY\^?/W"2'%5-#C>\U`E%ORK^]:*M1IHIHW+6]5K=K
M+UIVN!GU*U?!)I5*$.]"<.Y->.4-;"01`T%PAF9?W!-#+DK6`4`V$H)-=P.4
MKH/^%3T^?7J;L,-_6K3G),&H5MS&1/`+(P$Q1H9U-(`."[A)M4URCA=!4RS4
M&,Q!0L)LSC>KU28>@,-#P/\`!IZ?/KTB"B*)A$I1XD2W9S]L'I'2#TIAX*!1
MZHK%PKD>&WNEU99)N8M\V'(+6:*I$`9`1XB6>W^#3T^?6C>Q:%P7I?OB%/=A
MMC!.[+9S&5,Y/G_6!I#]((W3SIOH3`XKPJS)92T-,HNLV04O0*IW`PEC+7;R
MP5A,F@JVZ.((&```Q;H!!`)H^#^K/\"GI\^M%T9;!9=IHKJ.YDEJ$R.;:;`.
M8&*0?&1=X((`HL(;J\]%%>9VL!HL]S;L4X!!<37J8$K8N<WN`C<_DA`P-(*&
MF)>YQJ4+>[RDTL=``::&XZ4:_P"!3T^?6T:RCJ?N`*B+[K^^@[I=UNE6>"DL
M1W?!@$6B,;!`Z*A1%;JC!>95XR,W"9)&,%#$`!_@4]/GU18D+0H+:6CBT1<:
MU;`+0+T%K7C"S3="2FFD4PG2I[&A.+D(?,,`?(<@R-39D383!:7:`W8,@\'#
M#_XX+Q*6E^:DP01&39TA*^D(P$-IMPPIUK,XS,*9HF6@VT5MQ@JBWQU<:7V^
MGI\^J`-Q?=NP<()42SE9!'+'5RY":2F,$=`728*<`X8_!+[K^^@$-$6IA*<F
M28PQ6@`-J&-!W8)A6_H$.)&Z!>`)^Y;J[E05"ID*6!0]X_F;+BO(JP:C?;J>
MGSZK%EV'1\3KY`%B6(:5K*&:GM-`A(-PB<4$JF-8PPJ%`"X#5BHQ.JB+A!L)
M!@Q<SI8^[)MD68%(4:;BA5B%LWK7I='P8`J]LR*#JIN)AVN<KF[SK6#?B'06
M_)<JTDO+F6R7[.W4]/GU2+CG*X6I1`8)B4(CXOGTPVTD#W/9($`4BXSIG8TG
MGE*Q=ETYQA99\MYF:_5J(HQ6-&<\=-E/C0H:+/\`730+"I1TNCX0UN&(`B-5
M),D.>=IS;-&9OX$(8QG8A2>F(A9A[A?XO5]Q'?(,U?<*#FVQA`+A!![K+K40
M8HL[8ZIX'J3!/S^J=QI4>9!2+]WI2=4ZH7)3,F3@9R6Z1.J6.F*UG[:8>U!!
MH_BP8,&#V,B'`G"8T*2SH5/!]WL-^D30!5EW`J&4P"+*KHW+$("1=6J%VTF2
M\RCA*.A+[K^_P2_9Y$"]P&$3$-$)!+#5TTU88T@]103+>-;6AG+F5\@)DV4]
MAZ1D1YCRA).UD%)3'J@-6_UR((!(/Y(.\L#:\H"(YZ+,X)`1$>UY+PW%Y`_S
M!_1C_P!&.H^IG%9D>JH66X112A`^)L5JU+\"<C'`LF3UGD#4X0C["U0@"6%0
M0%Q!>BJPU3GRE'`]"$OHO?O.C@3!/7(8E=0`^!8"4_D:9Q[RII4W:&[UNN`]
MO;IQ59>Z5(L(%#*)P`!0(ZXP4KJOR6@O*-B8P&CMB-AD9HERV#A@%*>_`'7*
MM:R3C'.L5>#6-AWA4>_I*%:-S``P,--IJL5J*/GVO(`ADT=`T@@3O97$A?`1
M5\W2="V24!H%='I=6*U\YEGE(;=8`P%<V@%3`&4*\[3/H5`@T*1Q7X/)V>M9
M02AB.A281C"H2WBAJB$HIM70NMI,\$"FE+0%N(=HC(IN+J)A>#SE#2K(JTO+
MR_!+[K^_S'K-L4"`(@#3>T,NUOZ2A%I4\EFAEWBW4T#G25:P(,6E'5EH(,+<
MLS8<.ZF#"GVKD5PQ3T#*2^>(L5YK>M!A8D,R2\H_W?HY+^ID0^'FH>_NF&@(
M187WU07W\*H&-W;\'^3%61`>3'*'SP=#<,M,6=\W'E9^)/67B1U3PFBBE304
MDC*+(6T+553:N2UXBA/IFGM7/BG!<:W+3P[&SH<H10%Y%VYSPVQ";E?QVJ>=
M]TBS\NUUDH$I@5N0J7<->=JKK3J"TC2W_P"2PIIFHU5LF]B08ZIJ(/99+X[_
M`'F(9!8'^:-STK6W0E[53MM%2&AELU':5XOM_)7B^W\E>+[?R5XOM_)7B^W\
ME>+[?R5XOM_)854N]#&_$&?4G\BO"<DC%;A$1&F/4*S2YVH@2$-,="0*,%AJ
M3*:F^8AU+Q7E!V$#<ZX.55W&8*%[;7<JK?P2$FJCI+22-/3J3+ZPZ8TAWVW4
MP'A?!1BZK_B87#NV7%T8;4@4\U^)Q@RFLM2T=IIZ?/JA/1`Z.`K%*48"5B<!
M:Z]\P*0\,2D&@JJ.7)?3H=T3FW?HA2_B?)T>J5EVU7G(+&%D!EGH'1L\+^H9
M4]%AK;XK"44H8&H5*+>G/-?OM-/3Y]>=2]#1`LL6$93".YH;(SV3KBO5&\N9
M!-#JM;5EKU64ZHM&YHI`$KFE.Z)<E7S[33T^?8$ONO[ZM(.84YV(,E4>AIR>
M.J,"U&!K)9S,(^OJ18)``':*>GSZU@60AC4%-1-NEGE*8PK"CHZ'<O<1U4S1
M3.1'+=:SGA]?JZK`UVOIHE@ED'2LRO>FFP(@.&]&`J_.4RO<+.3]3DOI#*P6
M"T46//$(W("-5A.'9J>GSZU!U!Q62\</"8`P&A11117#$S.2X6<C!K9/!A*P
M4Y08;$<UEX]6"@#6$O(B>C$QY_DS81P=[C3.)=;X#@`BE+0';$+B&!2[%+B5
M;1H6LBUO'FI$-`!78P[H!03'[Q`]W=V=5VNKIII)2E]N"Y07%K#_`(J$>."L
M806/!Z@9@Y,7$M@MDVNCB+585#U1B$3)G)RJJ8`1HKRY(*O*75$2\FPK*ZKY
M(XA/,CS&B`6+T")JU'TT.1(-(99.<RG#)#R:9Q`?`9:&QD04;Z>(SQM.3PZF
MGI\^O>"E1`"Y/)84L0!F'#0<AP.L8-Q$C5:H+$&H;$GYRC8<M!PPW9`<V"5R
MNE;+;$B*#,?LXC"`@C*%9!9UH&M"C<TP`LA`PZ3J*N$%.IK*4,X*4&7JG=&&
M(2!U#F$/4DT``[I@!71$H.CZBW"&I*N[80&0G#&C@!`NKFA@K22UL6:.QQ=2
MRWQ@<^RU$+G6%5,N8#B.%,`82L80@%Z8A9D9N5LU:2KV&L,$+)`6.V6[,>-"
M109JNYEDE6`8!HW:[``A"E4,FIU%/3Y]?M?KVH4GWNA''+-D^BG``KMES)%7
M]]5L4RX$.;[`P^HUA*=,?&([&>8B]BD2LF6L!WHTXL"4L&B^&;YGA<KC6OC\
MA^-/3Y]=KQT<!8U.!TEO<F-3"C4-0GNO[[8JO'C[(<]E!%(09A)0BW$(0@L/
MO$?0BC=E,\S408TNO_(>TPJIR4DF2VZAD+F_4K<#<M,Q/QIZ?/KB2LPW/Q+Q
MD%D+4JYHQ+L>P66A(RM2-ZI/"T2I:.^@Y<8M74%2I4J5*E6ZTJCF62.*A4"C
M;HA/:U>74%2I4J5*D6)@AR6*?`MA1FF+#5V\*71C?4%2I4J5*E;6)8_CN#T0
MR^"7,#O5L%63&I%M5AT7.:,.:\I@YTUXKK1U@2A=8A($[SR]ZR(BNF*E3N$I
M9R5`J8*40Y=:E@:T+:%JYI\^OJ^;ER,:SZ-!(Q$#7N5=:X*E%*3:7;JO.XV<
M?FQ8L6+%CDTBN)[Z8.+K_`;!G+*#9`#V;(*(CJC^;%BQ8L6(D(KL@IS"^!*K
MV,!:)4&V&(`>)2#L\T\LG49BQ8L6+%BI55@IT1:(#`!R`B1'K>ZNRL71/S#%
MBQX,>*FD)ONQ?+5(0`!468(154R@4RUM=C5Y=>PX\4/%98Q0&""R6J"]U77*
MJZ@LO<K&$J%:`488```+P%`'(#\7[5E+$FT$P9<$`##;)$\"Z9`$9`X8;!&I
MP#"+U$33.Q_$@@D"F-4/IT]7>DO*9Y.!+F,=2A4B^,"]IZJ]HI#!"6EK">7'
M(<D00!4%PPUJAK^`2R?GVB'HJN!`S>N``SKU4J!YPCK?P5^>,8ZP+%F\``.I
M56Z0U8"&+2A';UZH[>DP@"S01`&-M26C;5Y!E!D(;"&U+UDD7B&8V48VXW0?
MFZ(2:G@=9C-%+C:,),62-#&DZF$;PZQTH`QDG4"\$EJH5&@21I0M6@+97'%S
MX_Z.CKH?OIT,W->_SVK_V@`(`0(#`3\0[,5:LPW7%'G"4M$!J)J(:)HFS`*.
MU:/&OWCQB5HHNK7N\.3Z07<A:*J+"Z>:$H4"[SGT[<W+<A=;UQC6`.N9X$P)
M*@;!2Z&=V`T9XRXT?.OW$BVCQGW$^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$NA
M7NSL#>CPEZD2%=4)MQ,\#C*R);MA.:W)C%:>40ME:UOTG*&>(-PI._@8;,"M
M:*Y:ZS+\M2R"ZJN6^>D^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$^X@@U%
MFM)R=^NNC=`NE5FB%F&+E.P$77V]'!NU;4KCHYU66QBPQG,1T2Z#J&M/Z1S#
M!!BM1S`R&M[15R=LM7M*<:9PC>T^L)]83ZPGUA/K"?6$^L)]83ZPGUA/K"?6
M$^L)]83ZPGUA/K"?6$^L)]83ZPGUA/K"?6$^L)]83ZPGUA/K"?6$^L)]83ZP
MGUA+C4+K!S._K-76[PNUCFL_>>,MP$)OBB/$AB'E00O(7:@X<HRNBV8T6CPX
M\9BH\;1.0FD''*,+!G&ILE`:+PH674MKL(M0XXU2^/\`A=RYS5UZ0-E]_P!2
MHK@_I81-L"4V:G!E03=X<F\\`JM\<"+(ARE!7JKMP;G0A\&)Q`U'F;Q6'E_@
M=RYS5U^GW\RU9[KA6AK`D>6PUKF(*INM)IDI^(WS7E]V(JX+@`%TEY$?,<G@
MY_P.Y<YJZV_$F2FLI-JHT\;>!:X)2G0`B6'5O9VXZZ0--W?MZ-IZ"^-,PHY>
MDO2+8C<4KADUJRY.$K1#RW=5N=3BP&P>([?W+G-76N19J!DCEFVUK*XN"C3,
ML)LC2%>I"^!0Q+L+?9K?`/EZ.\N#*#"`8=3Q\-(X@VLB72,PO'")8417$L@K
M"M*<%.LHZ5EQ5;NW;^Y<YJZU:T@!3I#?[?&=YX]##:K/:4>DP25;K>>7\Z!H
M`!`-1+8RLF,),ONS5C4K(F2Y>';^Y<YJZH1TB.!!!9ITH`O[9I)&G'!X=%`*
MT7KPYRHMU2I6]//E\2T1HV9+-3Q-X:(R!,<)D6OS0.'10>+2:#>N7BT9\(#0
MZ=M[ESFKJESQFL^+"QSLBB)FX@*MSPX\K.G3[^9WGCT&LIL2^WJ@T)?@RV/,
M\XEJX2B=6*#B7D4;!NTE/!<)E=+0$O6X@H!:]M[ESFKJBL`0]=IE.*-/'0>:
M#1#(N=1I,YPX\L2RA;4$<U4#80TUX0$R]GG6@@K+++9<5,J:D]W]?@%:$FM4
MXH"F[=?+G,V\WH3K!U=6'2KR:F(U-\7]]M[ESFKJE2H:8Y2MBC%F@Y-%<(#`
MW<``*:5GUA68P07+?="^E8:@1;3GX$#7`,NJYNX!8NL=`\4OX"A(W5`YXX,1
M@+9*WX7-&O%B"K93.2;&<7C'C*O@,X9-I2FE^<#\+K`N3(Q\<.V=RYS0Q0>.
MK4R#X!\YB=!]O!X\;B_E5=)/>YROH_LY7T?V<KZ/[.5]']E27=XSP?0B`VU<
M6O!8`A<65UJ@07>XB&KK4*'G5M7KK%U@7PG*(0.`^>=YX_@JA.&APBFH996W
M4W"'(0E@I.*'-MMF.W5,"J%)::<+BJG6CRQ:%+"E56(.4J`4[707DNQJ[1X3
M401#"(TB.$2QU[5W+G-$C3XU(L7&`-"MFUZ5B]&]J;$]-AVIISZL5;*Y"J@!
MM9SLN:LX&\2I8WM"X+P:O@;NA*M6+G()@')1^YRST@(AQ*)@`03)@-*M2[@`
MP:-"BU15IJ\^GF9_;.-5%=75[U>:OC^0Q-%:@6X'7"H;1%!'(8.N[EX8C:<@
M4!X`U!D3SIPU+X,"]86K9>!?<67OVKN7.;`_XC9Y4^LRZG6L\,%OE-[U$1IG
M`:\?UZYW**\*U::F2T+-6K@!\:U:@T>)@FIHDO800##$R,)0@W;CG,MZ5T76
M#AOI"E8%0TTMAK7$>LT>`_?0M,;0D&]MH8EEQ:%-`"KA1?#?6MA\#'3I]_,[
MSQ_-;OT@\U`(@*=4]W[ABI#QX18RV:Z(CY)&,0@0J:"K3#)S[5W+G%:V"#X*
MQJ!+@5[L&S(4XQY;QV=FIC'A;*TFMPOB362XI3B#YA#)*^7-(,"ZJ%]1$;I2
MLM+=UM6T1Q\*JMPE4Y>I`VA;7'CT)N%R@EJ-7@,#45:6K;6P*)JK)9H-W%"Z
M:&8AC5#C1O48(!U$78Q*AL?(&(TL!V',A_7&A6%W[G4.AX;WCT8J+0V7WSZ1
MPBE$VVZD;EP#P!=+R8YK!CM7<N<"P@P>P^,^LGUD^LGUD^LGUD*;)7`>G0B"
MX&Q(!(J;852WF6@!RM`+6[P&NKC6("G280JH*%!!\:4\%('6Z-N<7IG%0I`&
M[H#1Y=260ZAQBHZQH<,7NNX><O)-:H*JF;9FMU'A2K`-;XSN4.NW:>Y<YJZK
M$85C:.S50467!B.HLO1O82EW;:6*@;"M-A#;I0&^^RGO-^J`%-"359>]GKZD
M6RP(R:C1@:<MH(!&^8-4[1W+G-77A:MOVS`FUIUY<>K`(AD$&AU$<59G+B(D
MS<*5=(<`;+67<51A=.<'L9.T=RYS5U^GW\SO/'J](4/:59'IL5L<2[!NB_&4
MFV0%Y5<2XNL=H[ESFKK6*POG*D;CC=[!R"!,KVG&2G0JTR+A&W.L(#04N]W3
M0ZLI<Q6==OG24FO1T9L<R^58BN+MLJM*#P$UJEN66X>F&,+<BXU*W=;]E[ES
MFKK4'648Y:<H8!>;YRWUOWU8TW#H@++:H%Y(AFB]KO:7V^+J8$*TT5:JYE%*
M)$UK>#B[!`'`&'#R-W)\T'/K+-/2?V56YM72O6ZB883IAGPSF9J;O!_84A'E
MECS@12#6@UXYQ,5XO!_8AG%X/[$;2>VKTNYEU!R;><$R>D_LO#.EV:NVNKL:
MR[ZCN7.:NO07;_O@-GC^^L02@/`Z,VCT7\GUJ(&:I[,E5595ZUI9*`2Y*_6O
MZ)P8![LMV7%B!&G_`!$W,D32WM=]BY*.KZ,\$B#;PQ6-0T_MG[QM36+@00R\
MJ+FX0<'%%WFM[=;'2K%E;I<?`87Y?GW+G-77^$/VR@BC/MVRPZ,[1JMDI[XC
M+`;X9`Z-@XPB@TVMHP9NMM#)JZD2U$EG&3Z3)HK\.Y<YJZYM`L0;$_O.\\>V
M%QK!*1R$>4HR"16MZA>@[RYA%+3(:&1T@%DG#'\B["*O"-,Q<)B6^-?AW+G-
M77,%L.K#39E>4+$J44\K%K@G`VX)E?GJNRF[>:8#MQQG,)S"<PG,)S"<PG.)
M3$KCDA<KEBTN<PG,)S"<PG,)S"<P@VE`:]\<8HR*BC8X^LYA.83F$YA.83F$
MYA&(E`<\M7X<6(5DR#.<2O$BLI2I9BR6)K76TYA.81LTKV+@@5A'8\R:NO6A
MR8#"H#5Y%EFS2OW-(38<?>=_)W\G?R=_)W\G?R`-=Y3,](:NV/!7O%DNOPV\
MYW\G?R=_)W\G?R=_()=S6):H6KH0*:YRL9<LQC)EZ,"%8!LB._D[^3OY._D[
M^3OY._D.08Y%2K&YH;O.D0R`;631JU7U4'M/!._D[^3OY.\D[^3OQ%%Z4$-&
MEK5:S@Z6[44.J5F2V06@.W]BWGEUX14JN'J6Q$#SZB_NMK4U6J^7XW]'5[!8
MOPL$`%G@:''ZUVN(602<`%C=Z7?B.&8`1=G'-7SIF+UUJ4EH`V-#05JW>&Y;
MEFYNDK/$;6F2E$WC)854W"WCBN-/*:U8"WPX\8TY`V\./X+TA!"4FE:F)U+Q
MK`)AHMZJM=K5EX`T/S5`BQ,:6WC-3#5#1=8"%/;Z_P"R7L:+S.O&%AILX-(<
M0$\3%TNSM2EY!*/$[LO^;-2Q#G.*_$MUC"%Q@=#&V3&@&2!-)D%-,"X5K.G"
M$'@#88X\#1U(DC95,I:[O'5^84&PM.'+_1YK[=)K.\T[5__:``@!`P,!/Q#L
MPBT91J4B`-5G6]*\8@E!B&ZVJ<?2#5TPM(>/;5_8/$39A75\1I$&O;[,RI%0
M"D:T*/-Q#8&%91:O2]8=93N[2]H7N\)WI^)WI^)WI^)WI^)WI^)WI^)WI^)W
MI^)WI^)WI^)WI^)WI^)WI^(@:UO`*X2TOZH/RX1V,,$SBUPV/B)A51HJBXUM
M08-6^^0.EKW]IWI^)WI^)WI^)WI^)WI^)WI^)WI^)WI^)WI^)WI^)WI^)WI^
M)WI^)WI^)WI^)FQY*8UPY+#PU8(MKIKS.M`=,\8.Z*,\/#C!6'T0E4'P-=XI
MKM33:H.\RF!.>AN((5;":P%\3IBK8NAV[%-3`<642FZ8M^XGW$^XGW$^XGW$
M^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$^XGW$
M^XGW$^XGW$P9*;18=.^LT[K>_P#RNM%(,X1PF!TY8/O(>LG$$*0(TWKV@HUC
MU9;A@TNK12Z$4,X._/\`PWF_Q>O=J$@:U!>A4=>P0$2MZE+@L?7TS!6Y<+O"
M*8E@B:=!'VYE-2U3G/,PS"6?X3S?XO8JC(1.9J2C<*%#&:.,!E!`1`CC8PU-
M'"X]14T\W^RDPZG^"\W^+UQ;E-YJ>2!7@>W1%CO+=5+KG6G."P)VA-QK45G-
MZ[QG4NGNQRV_X+S?XO7%5P:QT/*A#<`UX-RWKH/&!>\UQ5/0@QX=9%2ER-9O
M;0(J^`+KX_V:YJ1@YI[P4U_@/-_B];<MC6WI3D0A#J!J1I<<18&7!`>0I@"'
M%`4O^7T6OM%CPJ-I;'/F\/\``>;_`!>KIB(TZ]-2XAT$*&JLK;HF=D0A57GA
MN<+QQQ%P2*B*XGAC(XQ-'0\VT,)2D.0W+8+0)?':YE>`\R_EEK[>\W^+U3Q@
MRHPQ!S?E4Y()3HRL4:.;<"Z12Y+.`$5A`MB`&B0&9&M5V\.<MM(7RK2"..';
MGF_Q>KJLK+3VB'31@7@UE+IT:J(`Y/D.YN&NT%KK&-FA6)L,^%^/2Z1MM?8)
M$F33#XG$J(KH6W=O&Z+\:+X="BVM/3,S7Q[<\W^+U6T3%JJ#3;OZPA0TG@)4
M-)NW;&`!A2CK9$]2!F:_I:8Q_P!S^!5K2`0T<0@T*4U*)N$L4`#!D<S'..50
M%133Y!'0UB0:A66VC^]&,<$-M-/F)7;?E"S`P"\T'*#/E+P.*,K.-2/NO\GV
M'^3F/7_)S'K_`).8]?\`)S'K_D5GPW;""C7,!5[W*\>_ET:@H>&74>":\36+
M:\7[ZBI2`(`*+<.4':W6M8I=XN_9?O!&U?+%,+1N[TC4<FH,U3DU5&JN*7$B
M"@U$01'4J""(>*?,6X"^)VSHYIQ4KS8J1$@QZ_,/4"@=;R+UT9KNXY<"4Y.P
M:^"VC0MQFMPHTFXFH\S<UG%B:+Q4HF=\RWH(!,H:::G''OMK*@*5/DJGMTH5
M4ME9H.8JP=11P[&/3\G!;8,92[`Q@-=+TKCBD?6D0C%I2:Z+E;S<*P!M>?\`
MIYRCI'D1?H[7TT4*I98-2FM8Q%7$"6;4&+E+7(%9?`"WRB;)#5E5F:::\H^K
M*:BGSYYBG72`K6T#S$A0W@?'5Z<=)C7('/X'!H%.._A$KG7JZG(&D!8;WL^$
MN8BYN@*M;170TU.:S"BG)5V7M6((;`6:WKBFW@S5R.U]'P'-0#*A,%M-.#;*
MIC468%3MKIIIA+..:C;,X8`+7+C+2+'*EW/C-!PX1\$T6H]$]F6G<!ONK/!"
MK5+A[6JKRUYL5H1$&HW'7`=GJS.D(;%9UJ?8^@'*Z'U#5(XMO<"%15\+'[OG
M'S`J3H-2O%Q*Z[4H7C5.F3.^.'44^KFS-5FCBEE]0R==0S-^0:;RH,.ID2(4
M"V&AB,I29P0SI67M;PM55[LMELMELMELMEB]!X[>E3DNAY.V.BVK:#D((<AJ
MZ]"*=AU0?`NZ>93"S5JB\UPNI?:F*AI[H1,/$KC#PFI34F0'<HL-/L@C:T7A
M=G+F_")C;M3S?XO5YM`A[\;Y\/6(7=0\7F\W?GTA:^K0E6AA%`8\CP.LNWVT
MZ\:5B+)W;1#41LBC`O`</`92=I>;_%Z_"(UA='B<I>L`*P.KF:C&*F)`7*&"
M\QQB%IZO61E1=AVEYO\`%[74Y.<)&E!VIW7?S&`W)*H9`"D\0+QH#;0O'M+S
M?XO7(^H3`MC.*M2O"9`1*U.)0;'#6_5VH#0`!6H&%"C5;P6QF3DP0=D#0--Z
MF8G)I_SHJ^SO-_B]<@X=)H.(F3N4HZN!T7_S)!>M?2J=8/-KE<$).:'A0M%J
MR1LH`0HO)@MF.HE0K%4E"A&[O(\X$M,.&G1P4=D48F!U465NM&_$$)Z&L[51
M!;8LQSB!5`C-2F+R#%U<0L&[2HK6W'%9X3$,"Y75"U;6#.=H/?0:YJZ.6!H3
M4,:]@XUGK$8&T@J.M(7T;B(%]E3NO`53?"#"3"5%++%+%5=WB(@^D)+QK?&Z
MD8390"&W%JMBXM[;SQOJ7F_Q>O"UQ"VNG6$7=$L1I$X(B>(G0^Z?VNO)A13H
M*TFUI3-WG)QF3@`2H&AE2H7;HN$,*U4ZU5>>M[><"Q`O84TT*U;J'G%J9W9@
MSKB:+[-&@\F1H-#YRA"]U3@X*QPOPEHUN4N3US]XZ='P)]0/O`[`7=6[UP7Z
MGTB(-(!:@TUHJN,9&O0OV)%E$HT`35;06@Q6-X+S99>*.BF3S(&H"*JB:C2Y
M-SJ'F_Q>O32"(Z-CD=LDR0RS*:!0W-S%070CW18,--#6#2*U!Q<34-*[&VW&
MA::)^"F_'32*<3S1`\5*(-FWDW^+S?XO7G&=M3E:1W48><HU$"D`N<-'($&>
M"FX%V[U;#+!22_M.PA#$-+P9(!%PB[0%#17'*C7/XO-_B]=62#:(K*X<61,X
M;:U&C(EF<4%"O)5:,4-$\7\GV;^3[-_)]F_D^S?R?9OY/LW\GW+^2R?+1HHL
MUID>>-QR3"EVX_#G/LW\GV;^3[-_)]F_D^S?R?9OY/N7\E>FG3@*;:F:\=Y1
M1O$W<'+C<^S?R?9OY/LW\GV;^3[-_)]F_D^S?R68&L.CDVUK[<2Q*S6'C6,:
M8F?4^+^11MYI_(&V6^#$5*%[#_S]S-UXV6]-:``Y3[-_)]B_D39\5)D&V]CQ
M9N)$35"9O\7K]R,#;PLS!,*&QGL#VCHJ$W<;YG<;YG<;YG<;YG<;YG<;YB81
M=[C!+4S?#\A[RR5O3_=.XWS.XWS.XWS.XWS.XWS.XWS,6!.]O'@,%L)=,:VX
MM'+`XR8R,Z1W&^9W&^9W&^9W&^9W&^9W&^9W&^9:UG8_M!T.EVNING71I])D
MK)WMYW&^9W&^9W&^9W&^9W&^9W"^9Z4+!YTAXHFQ@YS;E\8]3K=]@OCU)6\>
M#7\16WA&HI93`+S<Y2JHW3]H0^`PV=1?<Y9A@M`35S`_N"%M0K2EGG^F]XE9
M;4<<1+O;\#-F>R4SALO>MB(J*JW_`#05F0!T1_@)'.I4V\KZFO)AC;$O24@;
M_L&CQ8M<T--BVO.[U;S[4`O*OVCY6Y'<]0'%><MK0K.8T..)6`Y15\?]0UFW
#:O_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
M1TE&.#EA8`%5`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````!?`50`AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`!$A8B4(D2""!A$>++C0H,.&#!]*A*B0
M(*N!#"MFW)B0(T6/&CN*_#@R),F3)E."7%F2)4J7*EO*?#DS)LV;-G/"W-E*
M4$^"/WTN#$ITJ%&@1GL61<I4:-.E3J-"G7I4:E6J3Z]JS<K5:E>L7L."';M5
M;%FR7\^J3<LVZD6!"#'"+2BW;MR[`UG=/:B7KL6^<P/;]4M8\%[#A0<C7JRX
M\6''B1]+CDR9\63+E2%CWJRY\V7/F2=WM>BV*NFB2A>>3JJZ==#5I)O"=MU:
MMNG;MG.7UOT:]^[?O7G7!CX\./'8QVDC-\Z\N//ESY5+7SWWHD6,U@]BW_Z7
MH*#OX`4%_PJ?<"!W[=?3HU^?O?UY]^KALW]//W[]^?;SX]\OO_]]__H!R-]_
M!`98X(`&)LB>66W]--X5@5@1X816='&%(!<&,AM:#';(X8=K>1@BB`V.:&*)
M*(J8(HDJ=KA7=M4-II=W@01RQ8U76)'CCCKJ>*./@711T&<ORFADD4@2!N-Y
M,2;9I))'0NDDDU2J]^255:Z'I959+LGEEUIV&>6688+I98@;'E1CCSQ>P<*.
M,NSX9H5LRE`C4(@TM^*)+;+H)Y]_[BEHGX`6.FB@0CT)GWG98=@FFS\^*BFD
MWP'(*(*8"JCI@9LJV&FFG(;JJ:B@CFIJJ:@*F%J#741X19QTYO]HHWBLC*>A
MK1AVH2.LK\K:Q:&&$@KLL,(6B^BQP2)++(?6%6B0A3[N".%XJNF55[,TVBCI
MA7VUURVIGX8+[KBGBELNN:FB:VZZYP8HU*KOQBL(FW,&B51J^,:[*H2[YJCK
M=ZA9!6^^]PIL<,`(LY9PP0OKJ_###$/L<,043VPQP1?'6S'&'&N<\<`>=PSR
MR$Y9BRVCK/3D*J7H<<?HR]CVY2B;$K9\\LTPYXSSSCKWS////@<-]-!"%TWT
MT48GC?322C>]L\.HU<BKA+]*3&*K<^I:8\,=+YOLUUZ';2S88XNMK%O7\M4=
MACU:4?.,:J<]H]PFUYU=A&[[VU"W?/__]9/=<<,]M^"`#]XWW=8=3GCBW2'N
M^.*/*RYYXY!7/GG@EQM.>>:%=\XXYIN'#OKH@T.=IT]2\P@PU*SGZ[J\=6[=
M^NROUT[[[;;GCOONNO?.^^^^!P_\\,(7O[OF:;?)+?+,VWWM\X;/K'<K,S(.
MO?/-6Y_]]=IC[WWWX',O_O;D?S^^^>6'G_[YZJ/O?OOPYZ5[(+Q>8=`LQ.-^
M>BL#16IG_L8+(``'*,`"$O"`!DP@`HF7IQGQ3R\JB]3R4N9`^5D0@A=,608?
M2,$924M">=J@"#%(0@V6D(,H'*$)5YC"$ZJPA2Q\H0Q=2,,8UA"&.)RA#7>8
MPQOJL(<\_"%&_Y2R/X/0[%[[>U<1B<A$GRS1B4VD'BOJ5)`H/I%_5LPB%+>(
M12Y>\8M:[*(8P>C%,))QC&9,8QG7B$8VGO&-:FRC'.'H1BU6CWK4DQZWI$A!
M//:Q@W_DHQ\%^4<(PBU'/CH((?UH2$8&TH&%?&0C`3E(2#JRDI-<)"4CB4E)
M>K*3H.2D*"\YRDV2\I2F3*4F5VE)5;:2E9E\I1+Q^*-_^21E4$PB%I<80B;V
M,I=R_$Z/+(3'.OYREV@\9B]YF<QF,O.9OG1F-*$)3&HBTYK+G*8VJ[G-:W8S
MF]P,IS?%"<YQFK.<O32EC7HTGE:X\Y&5C"<\YXG*>>'HEO+,)SWWJ?_/?O+S
MG_X,*$`'*M""$O2@!DTH0A?:3WP*0E==8,%X9J%,I>`2F1=-9S0S:M&.GBX0
M]7)H,4>J46!RM($;3:E)58I1EI:TI2N-*4QG^M*:8O&D)+VI2W4J4YNBM*<\
MI6E0?9K3GPH5I12TIXX"X<YXOE.A4.WC.G.D2(9:-:I8O:I6L\K5K7JUJV"%
MYRUGH1<)#A*E:*4>1?'8P+5J4*UI985;;TK605ZA"W&Z@A_GVM:X\A6N;`7L
M6^7JU\(&EK"'_2MB!ZO8QAJ6L8^E:V3[FMC)"E:RE<TL9#6+V<UZMK.@I>QG
MF]H*;5'UJ:1%+1Y5FS+6-K6UJXTM;&<K/7S_NO:VLGVM;G$[V]WFEK>^[2UP
MA_O;X@K7N,%-+G&/RUSE(G>YSFTN=(&[6$'`:J*#W:ME%QO:RZ*5K/BCWZL*
MHMCNMJ*\V_WK>=/+WL/J-*[O=2]\YRM?SHHVOI^]KWZ]6U_NTC>[^P5P?_';
M6-A2+U(^2:V"%\S@!COXP?/R49YB^^`*4]C"&#8PAC?,X0Y[^,,@KK"&0TSB
M$C.X@=>`5H[T<@T*MIAZ+V9%C&?LXAK#V,8RQG&,U^K.879!K3BNJUPI*&0:
MW_C(.4;RCHE<8[(:.<E0?O*2G<QD("M9QUB^LI:CG&4N;UG*70;SE\-<92^;
M><EC1O)K5Z9($[LY_[6M79F&W@QG.A\7Q'>FLY[W_.$17]C#?C9QH.'<XBF^
M2D@O;D6+9Z%HN3::T8M^M*0C36E'5QK2C@;O>>4:I+RJ5=*:#G6F+4UJ*IMZ
MTJ7>-*/!.V1,NQK5KLYQK#4=:5JG^M*PSC6N=WWK7K^:U[_VM:QEK6M?/YK8
MP&[T-93-[&0G&G_2&C2?\8Q@#C,:P]>>-I^SK>UN/YC;WNXPN,--VAQ;=[R(
M8#0VSEOL8+N[W?"^AC"IBFQV+WN,JT9V:^5-UTG;V]**5G02D0CL*&]:9#*V
M][\AW51^.W'9E%8XP^OZ+H!//.`OKOC$.<K%UDWXTA<5!*N7'6QWDAR7T/^Y
M\<43G7$'U:I20F$XR27=U*DRM:GC9K>"<\[S!?=\P5/]L<Y32U8;V4A(#+YV
MK>[ZJP7?.[4M-HBC)'BC&@&,Z`P6#XYP!"1J<7CJ"6[PN+5^HS;G?-D8TM;-
M29LK'%FHZF['D6G#3EI&UTI;(F]XA;^S)J[#O9TX5[!>:O2CO$7KKN!Q9[:S
MC0TCCA?CS4YXBR$N^<I3_O*1Q_SD,\\_6!V$\C)W9Z3>Q%3+![P5.GJ3(-8-
M<<BWOB?V?-.;(,0O-^5H()J7_'=NE#4)U5[V%F+QIC4O>MM?0>:2=WVC6\%[
MJ@HB]\LV-*Q2MOE93/5-<9J3[5,OI[O:>MG8$$__ZC^??,WO?ONRJOWXRX_Q
M\]?K0NK??D%:__KBZXCNY`8QM'WDX!:O;$="IV#7@`C2XA,YIWCN-%6(!T'O
MY!T7<GI8UQ.ZLB.!,!"I=7Y`XF@,MFS:8@4&Z&%3)2$:&'AZ1'T*YA%3=R,=
M<1H-Q@J1LG8.QC9NTRI5)47?(2035G?K-8$54H&]Q7=&EVY.IVCB`2LFUPJL
MAX0!EX1,N(1."'Y/J(10.(526(7KAGJ]LGI1>(614B&SMVI5R'RRHH5-"(5B
M.'O"MVYJR&QK2(778".>]WQ*V(2E)5XR\!U0J&XZ9U96N(60)X;9]WG,9FC\
MUX=4R'H$`2MYLH9MV(?A_P=2*Y9PC!APL]!\'H@(K<>(CE:&2$@0(=6$:UAD
M2JB',^>".Y)P"'B$J@B!3]>*>K>*K@B+KRAP6V>"L,@*/-B!$D):E.<J]C.+
MW+9U5V"+0T=RLQ"+&.>"B21CQSB$/:$Z[)9M,\=F^S:+R'AOZ^0V@HAVA3>,
M@2>+JJAB>9>*K*AWIGA_TOB*,L@MU]",JPAI[GAZC"8MPW@-,^>*LQ"/Z:AN
M;),C1]B(G!B0?GB(`SF'8<A.9&B0]_8C=](O0F>&-R(#0C*)2?B&O6(%*0.0
M!<F$!,%]6DA_?2B&A0B*Q1<G7<!P%&F0%5F25(4(ZT:(-W*$(+F2X%<KN^(3
M)/^9DH]()XNHDDCX4#?)"MC`?C3ID^MV;A6B5\E7E)-HABT6*>QWCQ)'B50I
ME2LWE599E8T6;9"'?+Z(2R]X7ICV=A[8C"M'@.RD?$<(AJUW<6*((XH&DG+9
M$VR2=U+I?VF)CUJY<HP6@K<4*0^YE^5X;=6FE6U)E2)Y(1?'</\GAW<IF(\I
M/363$/MFCPIWF.#W4$9HE)RIDYWYF9ZYAEA8(0DYB8!X(4<)*:]72Z5ID*Q0
M/U`8FIU9A&YR$+*IANN$5SBID(HF0;$)FCYYFAX(*>YTFTYXE-BWF\;YB'$B
M`QD9G+%B!<4)G+)YAMLW(?:38)YY;\L&E5<XBE2Y;A?_)Y[A.97D.7/GR6[I
MF8]#*2V*]IVL=PU#.8&*>91AV6A?J9YZAS]Y\X"'"9_ZJ8=Z>(X00EK?B9YQ
M.47]^9YZQX$]XA-F")[K"9[W)H-L<G/_*7%F>7I3)8<"6IX,1Z!R.)T0UX\Z
MHH33.9UZJ*(2&I?XHT?&5W4)5G],B`@K,YW+29TZ:IQ8:"="R9DBV2IK&'LQ
M>5Z\-Y&<B0B\$@@YN:-`&5%,M9R:69L_:IH1>5>_F:-M:"/:IU?RN:-SV)&U
M":8[Z28]:9HT@Z-D"J1J@B'2,WNV&9S=N2//UXR-F(G*QY1YNJ<SB7''V(]Z
MY9.MYXLX^:72<W,K(V-E^*?0_SB7`AF;<PJ7EDF0X,>?=/J>L]"$;/:9;KB%
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ML_+YI80ZMO4*HU:`B6&KN(9**969A+`WN!G;COMW?ZUUL#I+/8TIGX0+N6EY
M@$T5MG3[KQP(@'][N6J(N(1;JUNW>CI;N+5+NHGY?(J[LV0E05>WLA7Z>;O[
MN"HS'IMKF60U,R=JC\&[M"-+IT1[O=0)J.DJFE?*I$#:+W'_LJS!>5?<ER'B
MD79"&YKSQ@(6LCHO9XG?(9O5>UWP9W2TAR%JZIEFJR'8:[;*29VU(GMGRJ9$
MFB$O)R2\-QX4>;5P:L`/8H<VDK]S^+A*A9.[>\%JB,%(J,'MFL$>O,$?W,$@
MG*GR]J`@?,(B/'>TFKRU:HJ22K,LG+,#J'4*RP*&!R$`@\&H&[.F-7MNTI\/
MB,(8?*KV1'71$BU"V:XY&\*U^G8QR<%0[,'VV*$=',4@'*FHN<-"W*[<B"/:
M9\-`HIWRB;>XFC<R8,;]^7F/2[H4^5"S5YS1@+UR_+8>&9KR67$T&YSO`IK!
MFW$V^E`&`6-%ZR#@H2&WI*4AISLY_XHO@WNMC/RKJ;&]G8ERN')+DBR:*8,K
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MMPS2,+V[._]K5G4[SR&\PK>;NCF=MU<`S"Q,MM,;U,",TRBLTT+-Q#N=U$SM
MN#Q]U$OMU$UMU%(-PSD=U59<U52]U5<-U5,=U=*,A56WT#-=UF4MKD]LUFJ]
MUFS=UF[]UG`=UW(]UW3MUBC<$]BGP#?=U5K]U%:]L_UXAW/(P5S]U4U-U(6-
M#=+@UXG=V(S-UXYMV'U-MEF-V(\MV9$]V9K]T,P')!1=UVI=6FD)VJ1=VJ9]
MVJB=VJIMU]@@SJF,(<U9J$KMVDJ]Q;8-U*EI>V18V;6-V[?-V[_-QL&]Q4L\
MW+A=W+Z=W,"=W$BMW+V]W-`-UGR=U<W=W#K\T:9U(62]VG1)@=O_O=IO_=W@
M/=[D7=ZG+=Z?K;S-^LNTS=(FS<S`S#_]<@7PFLL=/-`_"7M[G,S3O,00!--C
MW,&XM#HX&N`E[4Z<G!`W-\ZWC.#Z72O%&=%%?85MJITH;<L.;N#AMX@R_=$B
M+<M*L;,HK;R*%,PE_M+#O!#AX<$P3:##N,3@7<*UN-:F:"WGI[LS#:TX/M-B
M*"]E5];OY"@PR.-E]^"?K=*PMT>)I];5N^/K]BI'3MINJM;]F,2U.B]1OLS/
M>'6=N\R+;=LP":ZX3=M:W.!FKL&(0)Q7W,'M#=2M\"9A.B_*&<7R.2O+W.:E
M6W5YC(6KM\MKKK/06IP87,5K+MKYZ^>W_PR77HW;90[H,J"F/7[F#-[*?R[%
M.E[I9"["<O[C\OGC@Q[?E_[<`'ZL#\C=17Q[XJW1/5[(!6K6<N[J:4W*T!JE
M9ATA+AG:,KKD0![K<(UWX0&7JCWEL.X396>/^`O3D<[C=Z[I4V.;J"T>VB?F
M,UW+S-=.0N&F./[2[6KG0"Y14?YV`#ZD+)#$J2[@MK[?%T[H__/>/*[C2F1H
M62[7C\L*:YO2E([E\OEVR:[2L#V['8[D>M1.I?V,AW?K;>TH%.V"9UONX7>V
M9DV7%BS@-Z*H9\WM#__$##_.;AKO0&[Q[>J"CQ[LJ#GL'3QUTIGC!;K%%MVN
MBZW!I_G&(N[!M/]-VUMLJU?J:96^TAO\Y@]X[;HJQ2+M\<B.[:F!OX.=TB<<
MZ&9MJ&>K+SGOV\R'O]?NY#J/Y>/,ZW`=T8A0[^W^\WTKM53?T;M'X%[ZUF\9
ML9;[UN'5A:T.UP[^5JT+Y!'_\`@.%._)UG$?VB%NH&OMX!:N]Y^=]Z@M^,@N
MZ")L^#RNWWP_Z2K]N/+V?SC/XHR_NQ=AB6.8]<$\P>;]R1E/Z:S]Z7T_\.7-
M\=RMU&:?@OW)O"8WRZ?'=[IRP]RR^;(_^[1?^[:/VG%,Z(FI?1()?[1R*VX:
M?_43X5X.Y)*N\EJ.]\Z-_"1-^CKOW,\?Q0^?_*!_^U'._!T=W'0M;Y+*.2G>
M#RD5V/FW/_[D7_[F+]?.C^2PQWV\TIRVY_YS\AWJ1MK_#M[I?_[X#]KWG_]X
M'T'"2#,`<47@E4""6K7"EE#A0H8-'3Z$&%'B1(H5+5[$F%'C1HX=/7ZT*,TB
M0E:M!+$Z6?"D080(&[IR*++C-8<T0=[$F5/G3IX]??X$&E3H4*)%C1Y5Z!+I
M4J9-G3Z%&E7J5*I5K5[M"3.A36Q<N2K]JM"K6+)8*<IDB-;L6K9MW;Z%&Y>M
54KEU[=[%FU?O7KY]_?X%'/AG0``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"`%;`B<!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/?Z****************************************
M************************************************************
M************************************************************
M*******************************************************BGN8+
M6+S;B:.&,'&^1@H_,U5_MS2/^@I9?^!"?XT?VYI'_04LO_`A/\:/[<TC_H*6
M7_@0G^-']N:1_P!!2R_\"$_QH_MS2/\`H*67_@0G^-']N:1_T%++_P`"$_QH
M_MS2/^@I9?\`@0G^-']N:1_T%++_`,"$_P`:/[<TC_H*67_@0G^-']N:1_T%
M++_P(3_&C^W-(_Z"EE_X$)_C1_;FD?\`04LO_`A/\:/[<TC_`*"EE_X$)_C1
M_;FD?]!2R_\``A/\:/[<TC_H*67_`($)_C1_;FD?]!2R_P#`A/\`&C^W-(_Z
M"EE_X$)_C1_;FD?]!2R_\"$_QH_MS2/^@I9?^!"?XT?VYI'_`$%++_P(3_&C
M^W-(_P"@I9?^!"?XU;AGAN8EE@E26-NCQL&!_$5)11111111111111111111
M11111111111111111111111116'XBC26?1$D170ZBN589!_=25I_V=8_\^5O
M_P!^E_PI/[.L?^?*W_[]+_A1_9UC_P`^5O\`]^E_PI?[.L?^?*W_`._2_P"%
M']G6/_/E;_\`?I?\*3^SK'_GRM_^_2_X4O\`9UC_`,^5O_WZ7_"C^SK'_GRM
M_P#OTO\`A1_9UC_SY6__`'Z7_"C^SK'_`)\K?_OTO^%']G6/_/E;_P#?I?\`
M"C^SK'_GRM_^_2_X4?V=8_\`/E;_`/?I?\*/[.L?^?*W_P"_2_X4?V=8_P#/
ME;_]^E_PI/[.L?\`GRM_^_2_X4O]G6/_`#Y6_P#WZ7_"C^SK'_GRM_\`OTO^
M%']G6/\`SY6__?I?\*/[.L?^?*W_`._2_P"%']G6/_/E;_\`?I?\*S?"Z+'8
M7B(JJHU&Z`51@#]\U;=%%%%%%%%4]7)&BWQ!P1;R8(_W36+H_A;0)-$L)'T6
MP9VMHV9FMU))*CGI5W_A$_#O_0#T_P#\!U_PH_X1/P[_`-`/3_\`P'7_``H_
MX1/P[_T`]/\`_`=?\*/^$3\._P#0#T__`,!U_P`*/^$3\._]`/3_`/P'7_"C
M_A$_#O\`T`]/_P#`=?\`"C_A$_#O_0#T_P#\!U_PH_X1/P[_`-`/3_\`P'7_
M``H_X1/P[_T`]/\`_`=?\*/^$3\._P#0#T__`,!U_P`*/^$3\._]`/3_`/P'
M7_"C_A$_#O\`T`]/_P#`=?\`"C_A$_#O_0#T_P#\!U_PH_X1/P[_`-`/3_\`
MP'7_``H_X1/P[_T`]/\`_`=?\*/^$3\._P#0#T__`,!U_P`*/^$3\._]`/3_
M`/P'7_"C_A$_#O\`T`]/_P#`=?\`"@^$_#N#_P`2/3__``'7_"G>%?\`D4='
M_P"O*'_T`5KT44444444444445BZ_P#\?6A_]A%?_14E;5<1X;NKWQI8:AJ4
MVJ75G#]LFM[6&S94,21MMW,2#N<D$\\`$<5GZ/X\OM/@FL=;A?4+J#7?[%CN
M;8*AF9@&C9E)`!P<''I6W'X\L3:W1GLKN"]M]173/L;!2\D[X*!2#MP00<DC
M`SFK<GBJ*&]M].FL;J+4KFX:""W<`"7:F]G5^A0+U/KQC-<CXN\4?VKIUG%9
M/>:??V?B&TL;N`R%&&Y@<$J<,C#!'K72_P#":)OU:'^R[G[5IMW%:O;;TWRF
M4C8R<XVG<,$XZ'TJOH_B_4M6F\01/HLD$6F74ULL\<\;<HBMR"<[CNR.,=B:
M-"\9V]]IFBP6BWNH7][8&\"S>6DGE*0I=\84$L0`!_(&K7_"<63:G%IRVMRE
MY)!%/]FGVPS%9"1A48@L5P=P'3WJ'XD:C?:1X2:_T^ZEM[B.ZMT#1@'*O*BL
M,$'/!-<U<^*[[2SXJ-UJU\UA8S6ODQ^5&M]"KLH8X=0&C+$*"<G&<=!GKK_Q
MC;V:ZN\-E=7D6CX^W-#M^3Y0Y"@D;BJD$X_4\53TWQG<ZIXMGTRTTHS:<EK;
M7,=ZDRC*3!B'*L0=N!T&3^=/L_B'I-["EXD5R-.=)I!>!-R(D><L^,E`0I*D
M]?8G%5]>\12W_@G5+B*QU"R\W1Y[ZTN>@7"$KEE/R/RK;3_0BI?"/B82)HV@
M7=O=K>/H\-W'<3,K"X4*JLV020V2.O7-&NW]_;_$CPSI\%Y,EG>P7;SP*5VN
M8U0ISC(Y8YYYIL?Q$M&,+RZ7>Q6[ZLVD-/E&5+@-M'`;)4GC.*T[?Q5#>W,R
MV=C=W-K!>_8);F)00LHX8[<YV*2`6QQSV!-=!6+X:_X\[[_L(W7_`*.:MJBB
MBBBBBBJ6K_\`($O_`/KVD_\`033=$_Y`&F_]>L7_`*"*OT4QYHHV57D16<X4
M,P&?I0)8VD:,2(77EE#<C\*AFU&RM[R"SFNH8[FXSY,+N`\F!D[1U.!Z59HI
MDDT<*[I9$1<XRS`"JT^JZ?;1QR3WUM''+((D=I0`SG@*#ZGTJY1114;7$*2B
M-I8UD;HI8`G\*DHHHI#]TUD^%?\`D4='_P"O*'_T`5KT44444444444445BZ
M_P#\?6A_]A%?_14E;58%IX6BTN\OI])O;BRCOI6GGMU"O'YI^\ZA@=I/?G'M
M5.7P%IS6>G6L$]Q"MEJ(U,OD,\]P"3OD8CG))SC';IBF7/P_L+P:EY]Y=[[Z
M]34!)&51[>=`%5XR!Q@*.#GO5VZ\*)?-87%UJ5Y+J%A-YUM>8170E=K#:%"[
M6'48YJG>^`;"\0LUW<I<2:C'J4TX"EI9H\;`<C`4``8'_P!>E@TA=1\>R:T]
MG<01V=N+822?*MW)DD/L[A`6`8]2YQP`:M6OA*.QN]7FM=2NXXM4F>XF@(0H
M)&4*S#*[N@'&<<50L?AY9Z;'I#6.I7UO=Z5`UK#=)L+20DY,<@*E6&>>@.:N
MZMX,LM<B\G4;B>YA+(^)0C,K+CE&VYC)P,[<>V*M^)O#T?B?2?[-GNIK>$R1
MREH0N[*,'7[P(ZJ.U8^L?#RQUP:A)?7UVUU?QQ0RW"[`5BC<2*B#&`-P!/!)
MJY/X-MI9M4DCO;J`:O&(]02(KMF(786&0=C%>"1[=QFGVWA"TL-=&IZ?=7-H
MIM8;1[6/88FCBSL'*DC`)'!Z4S2_!=GI6G7&DQWEW+HLPD4:?*5,<:OG<BL%
MW;>3@$\4R+P8(O#5QX?.M:C+826SVD:R^66BB8;=H.W)P.`3G%2V7A""RUG3
M-22]N&ET_3_[/C1E7:T60<GC.[Y1R*GU#PVFH>)=,UQKR:.?3DE2&-5781(`
M&W9&3]T8Y&*RF^'MJU@+0ZE=[1J_]L!MJ9\_?OQTQMSVZ^]:&G^$X=)U*\N;
M#4;VWM[V<W,]FI0Q&4_>9<KN7=W`.*Z&L7PU_P`>=]_V$;K_`-'-6U111111
M115+5_\`D"7_`/U[2?\`H)INB?\`(`TW_KUB_P#015^BN<\:Z1-J6@FXL44Z
MKITBWMBS#_EJG.WZ,,J?]ZJ-SJ;6?AUO$9AN+6?4)8,@6V^6*)BH56'\.`22
M3G;D\'&*X_\`MK5]1OO"]S?0M-J]E>ZD/):%HCD0R"$-P/O?)@\`[AWK0D\5
MZ_\`\(+-JZ:DAO1]E7R/L)$D,K.JS(P91G`+'`&1MSN(JU%XFU\VVIPI=Q7$
MEGJKPQS.@A,UOY088?:4#;B0"1AMA'!YJ?Q_</J/P@FGEMY5N)XK=_)EBQ(&
M\Q"04&<'KD#WK-\5Z$;6--4^T0YU+5M._=6L.(HUCESYF#G<V#DL<#"@=J;-
MXRU]=%NX(9YY]3CGU"&U>*Q!\_R>8BW!`+#H`OS=00`:T;#Q#JFJ>(XH/[7^
MS6?]CP7CXME`,Q9A*F6&1PH.#R,UST'C+Q5)HZW#ZH5N'\/R:AL^PKQ=(X`B
MZ?Q#/'7CBMRX\9ZHVMZ<L#S?9?M=NE\#9GRXXI(2V0V"3\^!OR!DXP<$UH^(
M_)_X69X2=\+Y=O?;Y-OW,K'MR>@Y!QGT-<WIOC3Q2UE9RB47UW=6&HN+1K4)
MLGA?$(XP?G'8]<<5WGA746U2P-U_:4E[&ZIQ):>2\3;?G4\#//;&1TYK?HI#
M]TUD^%?^11T?_KRA_P#0!6O111111111111116+K_P#Q]:'_`-A%?_14E:5Q
M>VUHT8N)EB\S.TMP.!DY/0<>M!O[0#)NH,<?\M!WZ=^],&IV#`[;VV.%W'$J
MG`]>O3D?G2/JNGQH[O?6RJGWB95XQUSS[T2:I9QR0Q_:(V>:3RD",&);!/;Z
M5+#>VUP2L5Q$[!=Q56&0/7'I5,Z_IH:$?:5VS!61R"%(.[')Z?<:K$FJ6$1"
MR7MNC%MH!E7).<8Z^M2&]M5C$AN80A)4,7&"1U%-:_M5ABE^T1F.9Q'&ZMD,
MQ.``1[TTZI8#_E]M\[MN!("<^G7KR*8=7LE$!DE,8G!*,Z$+P"3EN@.`>I[5
M(NH6SW4=M',CRR1F10AS\HQSQ]14#Z[IT;['N</DC;L;)(ZC&.OMUI]OJ^GW
M4<DD-W$T<9`=\X4$^YXJ274+:*+S2Y=-VS,2E_F]/ES5<:[I[%U$KED!++Y+
MY&,9XQVW+^8J5-6LI+I+99_W[YVQE2&XZ\8XJ.?6["W7<\^5$AB9E!(5@0"#
MZ8S4SZII\:;GOK95QNR95Z8SGKZ<U-%<0SY\F5)-O!V,#BLKPU_QYWW_`&$;
MK_T<U;5%%%%%%%%4M7_Y`E__`->TG_H)INB?\@#3?^O6+_T$5?HHHHHHHI,4
MM%%%%%%%%(>AK)\*_P#(HZ/_`->4/_H`K7HHHHHHHHHHHHHHK%U__C[T/_L(
MK_Z*DJYJ.E6^J(B7!DVIG`1L=1@U43PQIJ0-"%E,;$D@R$YR,,/H>XJ.+PM9
M1S,[/(RKY?D`<&(H@7(/<D"E'A/2E^['*N%90%E(QN))_G4T/AS3[>6*2(3*
M8GWJ/-."<DC([XW-U]:(?#MG!)))&]P'DC,3'S/X>/\`XD4A\-Z>7+8EY)(7
M?P,EB<#T^=_SIL/AC3+=$2%)$5``@#GY0'#C!Z]1CZ<4'PQIALOLA24PDN6!
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M6"A=WUP!^511^%=*AW>7$ZAG=R`YQN=2&/XY)^IXJ]8Z9;Z?)<20F0O.P:0N
MY8D_C6!HNH:A`M_'!HEQ<Q#4;K$J3Q*#^];LS`UM?VC??]`2[_[^P_\`Q=']
MHWW_`$!+O_O[#_\`%T?VC??]`2[_`._L/_Q=']HWW_0$N_\`O[#_`/%T?VC?
M?]`2[_[^P_\`Q=']HWW_`$!+O_O[#_\`%T?VC??]`2[_`._L/_Q=']HWW_0$
MN_\`O[#_`/%T?VC??]`2[_[^P_\`Q=4]6U"].C7P.BW:@V\F298>/E/^W5_1
M/^0!IW_7K%_Z"*OUSP\07,/EK/ITS%LYD12%7YR!D8)`P`<\]:?+X@GB?']E
MSA`K,SNVT+AMN#QUSS].:5=>NC&6.D7",K,K*S?W>I''*D<J>_H*@3Q3*V3_
M`&3=$$`H`#DCG/4#GC@=_:I[?6[AX#*UG+)OE8(%4C"C;CJ.OS'T^Z:#KMQ_
M9ZW"Z9<>;YNUX<9(08+-VSP?SJL=?U"UFG\_3I;B(3%$:)"I4;W`8YZKA5R1
MTR.*?<^);BU9S)I4^P*Q382S.0Q7&`O'3/7H15F\UV6VFV1Z;<3+OV[EXX`S
MGIT/;U/I3KK69;:^FC-E,]O''N$JJ<,P(W#\`P/3L:I1>+!+)Y8T^<."JLF<
MLI()Y`'08QGU.#@U-_;MU+#?;+"2&6"W,L:RACYC`L-HP,$<#H?XJAN==U.,
MW"KIK1_.ZP,X)W;45@3C(.XEAU&,>O%79M6F;3[>>W18YWD56@E1C]5R/NG'
M()XZ>M4?[>U7D_V<=@\L@[&R58?.<=BAX([]JL2Z_/:I`DNG3RSR(681*<#!
M('4=\9QG/(K;B?S8DD"E0R@X88(SZTX_=-9/A7_D4='_`.O*'_T`5KT44444
M444444445BZ__P`?6A_]A%?_`$5)6U111111113)8TFB:*5`\;C:RL."/2JD
MNCZ;//Y\UE!)+C&]D!./K5U5"*%484#`%+111111116+X:_X\[[_`+"-U_Z.
M:MJBBBBBBBBJ6K_\@2__`.O:3_T$TW1/^0!IO_7K%_Z"*OT4UT21=KJ&4]01
MD4ZBL_43=^?"D0F%NRMYCP;=X;C;][M][/X5F_VCX@,Q7^R@L(8@MD%BN5&1
M\V,C+''<"HX]0\1QV*`Z;YDZA03(1\W'S'@]CV[Y/3%21:AXADAQ)IR12!2=
MX&02,<!=WN>IYQ3&O?$AO3+'IZ^4H91$Q`$@RN#G/RG&_P!N,=\TZ.]U];B0
MM8,T;S8&<81,*`V,YYYRN>.>N*6>;6$MHIX=/"7*S2"2.,*5D7:VTGG."V/0
MU?TVZU&X9OMMH+<*!C_:..N<GOGCMQUS6G11112'[IK)\*_\BCH__7E#_P"@
M"M>BBBBBBBBBBBBBBL77_P#CZT/_`+"*_P#HJ2MJHKEG2UF>,9D5"5&,\XXX
M[UA-KU]:J!<:;/+,1RL,;;<A<Y#8.03C'<9P>E3VFN74]U';RZ3/"S,07)R@
M`'K@9/M5?_A(+T7"RG3)_LK0!L!&WH^6R#Q[`8['US39/%KP0^;<:7-"K%0G
MF-MSQDDY'&/R^E3V^MW5Y>6\:Z?-`C$E_-1N5VL1SC`(90#GU_&E@UVZGL//
M.F3(XBWL-K':WRY&,`G[Q/'7::8VMW]K/+'+ILMS$N62>%"-RXS]WGG.1^&0
M*2]UZ]A6.6+396B4EI3C@J%8G!(&.Q![].#3_P"W[I97633)@JOM!4,1M(0A
MB=O`^8],XVFB[U;4/L*S6]A(DPN/*>-T+94*3N&.N>!]>.M)_P`)!=K#%(=(
MN2"Q#@J=R\9&!COT'OG.*BF\07[1));Z7+E9%WHP;+(5)R./P^H(([U<OM8G
ML[N0?8W>U2$MYO0%\CY<]N#Z=JK2ZUJ3JH32Y86W[2Q!<<%<]`.""<'VZ"F2
M:SJR2W2?V>0OFR1POM8_=5BIX'.2H';KU/%69=5O)-.AGM;,BY,A22WDS\O#
M8R<<`D#G'0UF-KOB#RP4TACN7*[DP<%L*2,G#=?E_'-=7$S-$C.,,5!(QT-/
MK%\-?\>=]_V$;K_T<U;5%%%%%%%%4M7_`.0)?_\`7M)_Z":;HG_(`TW_`*]8
MO_015^BBDW+G&1DTM(652`2!G@9/6EHI"0.IHWKD#(YZ<]:6F[U)P&&?3-.I
M"0!DG%+1112'[IK)\*_\BCH__7E#_P"@"M>BBBBBBBBBBBBBBL77_P#CZT/_
M`+"*_P#HJ2MJBBBBFO&DF-Z*V.FX9Q3J**:Z+(A1U#*>H89!IU%%%(R*ZE74
M,IZ@C(I:*****Q?#7_'G??\`81NO_1S5M4444444452U?_D"7_\`U[2?^@FF
MZ)_R`--_Z]8O_015^BBN?N-`NFDN9K6\2WDED=P0A."<#<#G(;&0<<'CTJ`:
M'KHDD?\`MMAOSD?,?XLX`)^7CC(YJ;5-"U"^8F+4=FV1)(BV[,95"#T/KSGW
M(/&*AETG7XW>>/5/./SE8@64<@``9..QZ^M/M='U=]-N8KO49!+*@6+]XQ,>
M#GD@]\>N>2,G`JRVC74T4@GOR\@E62!RI/EXR"<$_P`2D@CI5>;0M3:5S!J2
M1QAP8%V']TF"-H.>,C`R/3(J6VTG5HKL2/JK/$)_,V'<<IS\O)]-H_`FJY\-
M74=U#=6MU'#.KRERH8!@[[AP#V&0<]>/04CZ!K30*O\`;<AD#`[PSKD?-Q@'
MU(Y]!4IT/4YK.Z@NM26<31QHJLC%5*G)/7J?Z"I;'2]6M[H27&I^=&"2(SNX
MSCOGGOP?48K=HHI#]TUD^%?^11T?_KRA_P#0!6O111111111111116+K_P#Q
M]:'_`-A%?_14E;5%%%%%%%%%%%%%%%%%%%%8OAK_`(\[[_L(W7_HYJVJ****
M****I:O_`,@2_P#^O:3_`-!--T3_`)`&F_\`7K%_Z"*OT444444444444444
M44AZ&LGPK_R*.C_]>4/_`*`*UZ**************I:EIJ:DMONFEA>WF$T;Q
M;<A@".X((PQ[5%_9MW_T&K[_`+XA_P#C=']FW?\`T&K[_OB'_P"-T?V;=_\`
M0:OO^^(?_C=']FW?_0:OO^^(?_C=']FW?_0:OO\`OB'_`.-T?V;=_P#0:OO^
M^(?_`(W1_9MW_P!!J^_[XA_^-T?V;=_]!J^_[XA_^-T?V;=_]!J^_P"^(?\`
MXW1_9EW_`-!J^_[XA_\`C=9RQZ@?$DEA_;5YY*VBS#]W#G<79>NSI@"M'^S;
MO_H-7W_?$/\`\;H_LV[_`.@U??\`?$/_`,;H_LV[_P"@U??]\0__`!NC^S;O
M_H-7W_?$/_QNC^S;O_H-7W_?$/\`\;H_LV[_`.@U??\`?$/_`,;H_LV[_P"@
MU??]\0__`!NC^S;O_H-7W_?$/_QNC^S;O_H-7W_?$/\`\;H_LR[_`.@W??\`
M?$/_`,;J;3=.33+9H4EDEWRO,[R$;F9V+'H`.I]*N444444445'<0)<VTL$F
M=DJ%&P<'!&#6+#X:EMX(X(O$&L+'&H1%WQ<`#`_Y9T_^P+C_`*&+6/\`OJ'_
M`.-T?V!<?]#%K'_?4/\`\;H_L"X_Z&+6/^^H?_C=']@7'_0Q:Q_WU#_\;H_L
M"X_Z&+6/^^H?_C=']@7'_0Q:Q_WU#_\`&Z/[`N/^ABUC_OJ'_P"-T?V!<?\`
M0Q:Q_P!]0_\`QNC^P+C_`*&+6/\`OJ'_`.-T?V!<?]#%K'_?4/\`\;H_L"X_
MZ&+6/^^H?_C=']@7'_0Q:Q_WU#_\;H_L"X_Z&+6/^^H?_C=']@7'_0Q:Q_WU
M#_\`&Z/[`N/^ABUC_OJ'_P"-T?V!<?\`0Q:Q_P!]0_\`QNC^P+C_`*&+6/\`
MOJ'_`.-T?V!<?]#%K'_?4/\`\;H_L"X_Z&+6/^^H?_C=:=A91:=IUM8P%C%;
MQ+$A<Y)"C`R?7BK%%%%%%%%%%%%%%%%%%%%%%%%%%8B?\CO-_P!@U/\`T8];
M=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%8B?\CO-_V#4_]&/6W11111111111111111111111111111111111
M111111111111111111111111111111116(G_`".\W_8-3_T:];=%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%8B
M?\CO-_V#4_\`1CUMT4444444444444444444444444444444444444444444
M444444444444444444444445B)_R.\W_`&#4_P#1CUMT4444444444444444
M444444444444444444444444444444444444444444444444445B)_R.\W_8
M-3_T:];=%%%%%%%%%%%%%%%%%%%07LYM;"XN`H8Q1-(`>^`36'9S^*KRQM[H
M/HRB:-9`NR4XR,XZU-M\5_\`/71O^_<O_P`51M\5_P#/71O^_<O_`,51M\5_
M\]=&_P"_<O\`\51M\5?\]=&_[]R__%4;?%?_`#UT;_OW+_\`%4;?%?\`SUT;
M_OW+_P#%4;?%?_/71O\`OW+_`/%4;?%?_/71O^_<O_Q5&WQ7_P`]=&_[]R__
M`!5&WQ7_`,]=&_[]R_\`Q5&WQ7_SUT;_`+]R_P#Q5&WQ7_SUT;_OW+_\51M\
M5_\`/71O^_<O_P`51M\5_P#/71O^_<O_`,51M\5_\]=&_P"_<O\`\51M\5_\
M]=&_[]R__%4;?%?_`#UT;_OW+_\`%5/HM[?7,NH6^H+;^?:3B/=;A@K`QH^<
M-SGYL?A6M1111111111111111111111111116(G_`".\W_8-3_T8];=%%%%%
M%%%%%%%%%%%%%%4M7_Y`E_\`]>TG_H)K#TW6I'?3="L4C-TFEQ7<TDN=D:'Y
M5&!R22&[C`7W%1VWC:"UGO[+7HQ:W=E=16[M`KRQR><,Q,N!D;NF".".IK0B
M\8Z'/;130WC2>;)+$L2POYNZ/_6`IC<"O?(XX]12W/B_0K2)II;X>2B1R2RK
M&S)"LGW"Y`P@/OCUK(T[QBT?B#6K/5W1+:#4X=/L9(X6^9Y(U<*Q&><L`"<#
MI6A#XTTVX\0IHL,-\\[1R/Y@M7V#9)Y;`G'9N^,<=:;9^,=.=)C<7*%UN;B%
M(H(96<+"0'W+MSE<C<0,<C!-:4&OZ;=7HM(+CS9?E!*(Q4%DWJ"V,`E/F`/:
MN;\4^,[W0-<N+&.*R,<>EOJ"-.S*797"^7QT)SP?TK3M?%ML;JZBOGBM6@BM
M2UN=S2+)-G:F0-KY(PNPG)!]J;/XZTB*[M+6-;N>:XN7M3'%;,7AD1/,(=<;
MA\O(XYZ].:N'Q9H:WTEF^H1I+&SJVX$*&1=[KNZ95>2,\5C>)?&?D>'Q>Z),
MAF%Q:H1<6[X,<T@4.`<$@@D@C/2NBTS6].UBSFNK&XWQ0R/#+N1D:-U^\K*P
M!!'N*YFZ\7WZ^$H?$MK%`UM>74$=M#*""(9)1&KDC^([@V.PP.O-=--=7<>L
MV5H/(\F6*1Y"0=V5V].<8.[OZ5BR>+B?%,NAHUI;W,4\:"WNW,<ES&P4F6(]
M&`R1@9.4.<5?U_59M"DLKYV5M.>=+:Y4KS&9&"I(#Z!BH(]#GMS)I/\`R&=?
M_P"ON/\`])XJV****************************Q$_Y'>;_L&I_P"C'K;H
MHHHHHHHHHHHHHHHHHHJEJ_\`R!+_`/Z]I/\`T$UB67A];A-'UJTNI+/4(]/C
MMF=5#++$0&VLI]#R",$9/8TV\\$6]Y"Y-],MU-?PW]Q<E%+2O$5,:XZ!1M`P
M.V>Y)JM#X`%O=B^M]9NH;]+RXNTG2-.//QYB%2""IVJ1W!`YJW?>"K>]FU1C
M?7*0ZO$D6HQ`+^^"+MR#CY"5^4X[=,'FJ.J^$BECK=O;K/=OK=PCJ%"QK9NJ
MJJ2!NN$"(W<DK[UIKX3CAUJPU2UU"X@GM;4VD@"HPGC+ASNR.&+#)(]36?;>
M`!97_P#:%KK5W!??:KB?S4C3!6=@TD94@@KN52.XQU-:3^$[>3Q#!K+W$AN8
M7WAU55=AM*[&<`%H^<[3GFFZEX5;4=?DU9=2D@=[!K`QK$K#RV8,QY_BR._'
MM68OPVL(W<Q7US&JQV:VP`&8&M<^2P)^]]YLYZY[5:G\#0RZA'JJ:E<1:J+S
M[6UTB(=S>3Y.W801@)P.^>:?%X'M(Y=8C^USMI^K&5KJT*)AGD7#D/C<`>N,
MX!/'I23>#I[GP_;Z1<Z[=W$=O/#+%+)%'O`B8,BG`&>5&2>35[1/#B:/'JJ-
M=/<KJ5W)=RAD"[6<`,!CM@"LJQ\*-+X/7PGJ7FK#9&-;6\A8`LD;AHF&<X==
MJ@@C!([@UN?V5=.LCS:G(UWY#0PW"Q*IAW8RP7D$Y`//''2J%[X234VC2_U&
MXN+:.[2\6-U7<LB$$!7QE5W#.!ZD9QQ46N:)?:O:6FB3327%LUVMU=W<JJO[
MM)?,6)0N.20JYQPH))SUT=)_Y#.O_P#7W'_Z3Q5L44444444444444444444
M44444445B)_R.\W_`&#4_P#1CUMT44444444444444444452U?\`Y`E__P!>
MTG_H)INB?\@#3?\`KUB_]!%7Z*****1EW(5R1D8R#@UYOX<\4ZI;Z1I$;1MJ
M5WJFI7UJKW-R4V>4TNS^$\;8\?KS6GI7CV374T^/3M++7EUIS:BT$LX0!5?R
M]BMC!8MG!.!@#.,UVB/O0'!!(Y![4ZBBBBBBL?2?^0SK_P#U]Q_^D\5;%%%%
M%%%%%%%%%%%%%'2DR*,CUHR/6C(]:,CUHR/6C(]:,CUHR/6C(]:Q4(_X3>;_
M`+!J?^C'K:R/6C(]:,CUHR/6C(]:,CUHR/6C(]:,CUHR/6FO+''C>ZKGIN.*
M;]IM_P#GO%_WV*/M-O\`\]XO^^Q1]IM_^>\7_?8H^TV__/>+_OL4?:;?_GO%
M_P!]BC[3;_\`/>+_`+[%'VFW_P">\7_?8H^TV_\`SWB_[[%'VFW_`.>\7_?8
MJGJ]S`=%OP)H_P#CWD_C']TT[1/^0!IW_7K%_P"@BK]%%%%%(RAT96Z,,&L>
M+PEH,*P"+384%O(TL.TD>6[?>8<\$Y.3WR?6FCPAX>$%I`-(M?+LV+6Z[/\`
M59.3M]`>XZ5IVUC:V;W#V\"1-<2>;*5&-[X`R??``_"K%%%%%%%8^D_\AG7_
M`/K[C_\`2>*MBBBBBBBBBBBBBBBBBBN0\->'-$O=`M[FZTFRGGD+L\DD*LS'
M>W))&36M_P`(EX=_Z`>G?^`R?X4?\(EX=_Z`>G?^`R?X4?\`")>'?^@'IW_@
M,G^%'_")>'?^@'IW_@,G^%'_``B7AW_H!Z=_X#)_A1_PB7AW_H!Z=_X#)_A1
M_P`(EX=_Z`>G?^`R?X4?\(EX=_Z`>G?^`R?X4?\`")>'?^@'IW_@,G^%'_"(
M^',Y_L+3<^OV9/\`"C_A$O#O_0#T[_P&3_"C_A$O#O\`T`]._P#`9/\`"C_A
M$O#O_0#T[_P&3_"C_A$O#O\`T`]._P#`9/\`"C_A$O#O_0#T[_P&3_"C_A$_
M#O\`T`]._P#`9/\`"C_A$O#O_0#T[_P&3_"C_A$O#O\`T`]._P#`9/\`"C_A
M$O#O_0#T[_P&3_"L[6O#VC6%K:W-II5G;SI?6NV2*%589G0'!`]*LW=I;7GC
M2%+JWBG5=.<A94#`'S%YYK2_L32?^@79?^`Z?X4?V)I/_0+LO_`=/\*/[$TG
M_H%V7_@.G^%']B:3_P!`NR_\!T_PH_L32?\`H%V7_@.G^%']B:3_`-`NR_\`
M`=/\*/[$TG_H%V7_`(#I_A1_8>D_]`NR_P#`=/\`"C^Q-)_Z!=E_X#I_A5/5
MM%TI=&OF73+($6\A!%NO'RGVJ73KG[+X<TM_+9]T,$>`1QN"C/ZU)%KVFS#,
M=R&P0I`1L@GH.G4]AW[5%_PDVD!=YO`$_OF-@O4#[V,=2!]2!3V\0Z8A8-<[
M2K!"#&PPQ.-O3KGC%,?Q'IX@9XY&D<)O\H(0V,`^G&`03Z9&:LKJUHU\;(R;
M9]Y0*5/)`SUZ=*JQ^)+!YG1VDB41K(KO&P#AB1@<=<CIU.>*?)X@LH;QK:0N
MK`(5)0_/N(`('4CYAD]N]+'XATR6142YW%B`I"-\Q)88'')!1L^F*<VM6W]H
MP6,.99I68''`4`-DY^JD<=Q52/Q3:/;EY(98I3`+B.%@"TB$$@@@D=B.>AJ<
M>)-*+HAN@)'.U5VMDG&<=.O(_,>M//B#2U+`W0RK;#\C<-QQTZ\CZYIUSKNF
MV;;9[D(?]QCZ>@[;AGTR*;=:W!:77DS(R@A6$K$!&!SG!SU&,D=<'C/-`\0:
M89&C^T_.K;"NQLAO3&.O!_(^AJ(^)=-W;8I'D*MAPL3Y48SG&/F'3IGJ*L6F
MMZ=?R1):7(F,JEXV12591CD-C&.1WJOI/_(9U_\`Z^X__2>*MBBBBBBBBBBB
MBBBBBBBL3PA_R*]G_P`#_P#0VK;HJ&[N8[.SGNI<^7#&TCX&3@#)_E7(77B7
M6H?`D?B^-;0PBV6^DL2IR8"-VT29^^$/7&">,=ZO/X\TB/4FL9([Q9$N(+9Y
M#`2B/,`8LD=`V1SVSSBIU\8Z2;2>]9ITT^%9F:\:$^21$VU\,/?(&<;L'&:P
M?&GC26T\-ZNFE23V&MVEO#<Q)<0K\R/($##.01DD'N#6\GBRS,L]L+:\>YM[
ML6<D0C`;S#'Y@/)^Z5YW=*S[7QLFH:!H>JB">QCU2ZAAC$T/F;O,SA0588SC
M[QX'I5]/&>E/ILVI`70T^**2477D'RW6-MK%3]>F<9'(XYK1M]174M+DNK0E
M!A@C.H89'<8.&'N#@UP.C_$+4[C3(KV^>U6.70WU*0BV=6B=>NQ2W[Y`,DA3
MD8'/S"NH;QMI5O9_:)GGDMXGABN;I(3Y<,D@4J&YROWT)ZXW#)J*R\=6<^EW
MFH7EI<V4-M>O9#S-K>9()?*`&#U+?@/6K*>,],E:..&*\FG=)I#!';DR*D1`
M=L=QE@`1G=GC-8D/C-]/\9Z[;:G/</I44EC%;$6XQ`TZ_P`;``@%BH&<XKO:
M**Q_$O\`R#(/^O\`M/\`THCIC?\`([Q?]@U__1BUMT444444452U?_D"7_\`
MU[2?^@FH=*@BN/#NF)-&KJ+>%@&'0A00:ECT73(5=8[&!`XPVU`,C_(J,Z%I
MQNEG-LF%1E$6T;/F()./7@5+_9&G<9LH#@AN4!Y'0_6FG1-+*[3I]N0,<>6.
MPQ_+BI/[+L/MGVO[)%]HW;_,V_-NQC/UQQ49T73"Q8V,&2,$[!TSG^9-5=7^
MRP,IEM;60RHP+3MM`VC<.<'C(_E6;#?Z.ES:H^EQ0.)%B.%4F)R$8=.V9<9^
MO8U9O+FULM4=ET^T:5/WD<HD`8.P;(/'!(!QUR3VS6=:ZIILMU96$>B(D4ZY
M4E1A$8%2I&.&'0KT]ZZ>'2=.@51%8VZ!&WKB,?*>#D>A^4?D/2F_V-I@W8L;
M<;_O80<\@_S`/X4Z?2M/NF9I[.&0MC<60'..E/;3[-\[[:)\@#YD!Z`@?D"?
MSI/[.LMBK]EAPNW'R#(VDD<^Q)/XGUJ)-$TN-BR6$"D]2$'M_@/RJ6WTVRM)
M/,M[6*)\%040#`)R1],C-4=)_P"0SK__`%]Q_P#I/%6Q1111111111111111
M16)X0_Y%>S_X'_Z&U;=%(RAU*L`5(P0>]<_%X-TV+3!I7F73:4KAEL7ES$`#
MD)TW%,_PDD=NG%0WG@G3KO4+N[EN[Q9KR[M[MPKH!YD&/+P-O0;1QWQ4D/@G
M2H;+4-/W73Z9?>9YE@\Q,*>827V#JN22<9P">,5%?>!-,U*SN(+VXO9I)[>.
MV:X:4>:(D8.%!VX^\`2<9/<U+9Z"9/%-YK=U`(G,"VL6),F95S^]<#@-\Q48
MY`SZX$4/@73H-+T_34O+_P"RZ=<QW-JC2JWEF,DHO*\J,]^3W-6-/\)66EVD
M]G97=]%9R.7CMA/\D!+;B$&,@9['(Y(Q@U;TW0++2+"YM+$-"ES*\TA0*/G8
M`$@`;1T'`&/UK%3X>Z*=)ATUI[R:&ULI;"`M*NZ&*08<#"XW%<#)!('2K*>!
MM)2*>$FY>WN3"US`T@V3M$%"LPQUPJYQ@':,TC^!=*DL;ZR>6\-M=W1O-GGX
M\F8OYF^,@94[^>I_+BIYO"5K/=6-ZU_J(U"T1HUO%F`DDC;!9'XVE20#C'!&
M1BJ][X%TZ_NM0N);J]#7\MM+,%D7&Z`@QXRO&,#/K73C@8SGWI:*Q_$O_(,@
M_P"O^T_]*(Z8W_([Q?\`8-?_`-&+6W111111115+5_\`D"7_`/U[2?\`H)IN
MB?\`(`TW_KUB_P#015^BBBBBF/%'(,.BM_O#---O`0088R",'Y1TI?(B!SY2
M9X'W1VZ4[RT!R$7/7.*=1111116/I/\`R&=?_P"ON/\`])XJV***********
M*******Q/"'_`"*]G_P/_P!#:MNBBBN,TVX;6;OQ7=W9;=87,EA;(&(\J-8D
M8L,="S,23Z`#M7'>'/$EYI">'[J_OV']I:+#L6XN7ECFF\Q`TC#EEDPX``X8
MDY88KH+/QYJNIV6BM:VVGK<:AJ%U8,)'8JIB$A#?*<C/E].>O6LZ/6K_`,-:
MKXQU:"VM;B"+5;=+F`R,)&#11#$7;.78\]:LS?%-X/M[BWLKF&'3X[R&2&8A
M27G\K!)&2B_>+X'`/'0U"=?'A[Q9XMU1S:7#BTTX#R6VQYDDD0N>3@#(+'T%
M;-SXSU6UU+4M,.FQW,]G+%B:U!</')&SY$>=S,I49523A@WM3VU9?^$C\*ZE
M8%#%KR/%<K'G;(%A,B/@@'*E2N2`<-@]!A-4NI[?XE[8IGV)H,]T(6D;RS(L
MJ`,5!QT)'XUD+\4+^WTQKR]TVU;S-%@U:$0R-A1)((RKY'12VXD=@:[S3]0>
M1-MY<6!=Y"L#6\N1,-N[H>AZ\`G@9SZ:5%%%8_B7_D&0?]?]I_Z41TQO^1WB
M_P"P:_\`Z,6MNBBBBBBBBJ6K_P#($O\`_KVD_P#033=$_P"0!IO_`%ZQ?^@B
MK]%%%%%%%%%%%%%%%%8^D_\`(9U__K[C_P#2>*MBBBBBBBBBBBBBBBBBBL3P
MA_R*UG_P/_T-JVZ***RO[!M1JMS>I@+>(%O+=E#1SE1A6(/1@.,]Q@'H,2IH
M>DI;M;II=DL#@!HQ;IM(!R.,8X-*^B:5),)GTVS:4/O#F!=P;&-V<=<#&:F.
MG637"W!M(#,K;Q(8QN#=,Y]?>HDT;2XU54TVS55#`!8%&`WWAT[]_6G0Z3IM
MO&T<&GVD2,GEE4A504_NX`Z>U']DZ=]F%M]@M?LX;<(O)7:#ZXQUJ!=%A.MI
MJ<K>9)!$8;6/:`L"G&[`]3@<^@`'?,\VE:=<7)N9K"VDG*[#*\2EBIZC.,X]
MJ9#H>DV[;H-+LHF$9B!2W4'8>J\#I[=*?!I6G6R0);V%K$D#%H5CA51&2""5
MP."02./6KE%%%8GBL2-HT:PNL<IO;0([+N"GSX^2,C/TR*JV<5]%XU47UW#<
M,=.;:8H#%@>8O7+-FNEHHHHHHHHJO?P-<Z==6Z$!I8712>F2"*P;"_UBSTZU
MM6TNS9H8DC+#4!@D`#^[[59_MC5O^@3:?^#%?_B:/[8U;_H$VG_@Q7_XFC^V
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MHHHHHHHHHHK$\(?\BO9_\#_]#:MNL>X\16=E<RPW9,6QF`8`L,!0<GT^]BE?
MQ%8(X3]\7+;`JQDG<,9'X`@_C42^*]+9'8--^[*AE\HY&Y=R_F.12CQ5IAE>
M/?)E,JWR?Q94;?K\PIT7B.TFWR(28`4"R>N[<.G48VFH[GQ/;0VUI<QQM)#/
M(R,S'88]N=Q(QVP:1O%5DVW[,DLXW*'*KT!W=/4_(>*B_P"$TTF2"*:VG\R-
MY$5B01M5B`&]^HJ]'K]A(TJ!Y!)$5#(R$'+-M`'K\W&>E1Q^([6ZMKF6R22=
MX$#;&&S?GL">])_PDU@L1EE=E4,1E5)V@;OO<?+]UL^FTTDOBK3H8P["X*DE
M1MA/8@'\B13(?%5D\S12B1'+N(MJ%A(JD`L#CW!([9J6;7PD%O<0P!X)H6F#
M22;&4`9!*X)P?7U(XIL7B&,W\-I<0-#)(2A^;<%D&#MX[$'KQTIU[KC65[);
MM:EP%!1TE')VLQ4C^$X4X]<CI3+/Q`;^>".WM#MEPV7DP0A4'.,=1G!!Q@X'
M-;E8_B7_`)!D'_7_`&G_`*41TQO^1WB_[!K_`/HQ:VZ********I:OQHM^1_
MS[R?^@FL_1M%TI]"T]FTRS9C;1DDP*2?E'M5[^P])_Z!=E_X#I_A1_8>D_\`
M0+LO_`=/\*/[#TG_`*!=E_X#I_A1_8>D_P#0+LO_``'3_"C^P])_Z!=E_P"`
MZ?X4?V'I/_0+LO\`P'3_``H_L/2?^@79?^`Z?X4?V'I/_0+LO_`=/\*/[#TG
M_H%V7_@.G^%']AZ3_P!`NR_\!T_PH_L/2?\`H%V7_@.G^%']AZ3_`-`NR_\`
M`=/\*/[#TG_H%V7_`(#I_A1_8>D_]`NR_P#`=/\`"C^P])_Z!=E_X#I_A1_8
M>D_]`NR_\!T_PH_L/2?^@79?^`Z?X5F7NGV5GXBT)K6TMX&::8$Q1!21Y+<<
M"NBHHHHHHHHHHHHHHHHHK$\(?\BO9_\``_\`T-JVZC-O"S;FBC)]2HIIM8#&
M4\I`I&.%`P,8I(K.V@@CACA01QJ$48S@#H*#96ISFVA.<Y_=CG/6G"V@7.(8
MQN.3A!R?6C[-!@#R8\#D#:.*1;6W1=JP1*/0(!2"SM001;0@C.,1COUI_D0X
M(\I,'@C:.:/(ARQ\I,MU^4<TODQY)\M<G@G:.<]:8;6W)),$1+'))0<GUI3:
MVYQF"(X.1\@ZT-:V[E2T$;%1M4E`<#T'M2-:6[EBT$1+?>)09/;FE^S0;BWD
MQ[CC)V#)QTIRQ1JV510>>0/7K3ZQ_$O_`"#(/^O^T_\`2B.F-_R.\7_8-?\`
M]&+6W111111115+5_P#D"7__`%[2?^@FJ6GZE:V6B:3%*Y,TMHACAC4N[@(N
M2%'.!D9/N*MZ9K%CJZ3&SGWM!)Y4T;*4>)_[K*0"I^HJ_165IFOVFJZEJEA`
MLRSZ;*L5QYB@#<R[ACGD8Q^=:1FC$JQ&11(P+*A/)`QD@?B/SJ.VNX[L2F,2
M?NI&B;?&R_,O!QD<CW'!J>L34O%FDZ1>RVEY+,DT5N;J0+;NX6$'#/D`_*">
M?2M"TU*UOI"ML[2*(DE$@0[&5P2I5L8;@=CQQGK5AI8T9%=U5G.$!."QQG`]
M>`3^%/K,U_7;7PYI$FIWJ3-;QLBOY*;F!9@HXSZD#\:TZP[KQ7IEG9W%],\H
ML89Q;FX6(NK2%MN!C).&PN>F>/6M%]0B2YM[=DF\RX4LG[IL#'7<>@_&JQ\0
M:>NKW&EM)(MW;V_VF56C8*(LD!MV,8R".O8TG]O6[:(=7B@NI+4+YA'DLK[.
M[!6P2`.?4CIFJU]/%=:QX<N()%DAEDE='4Y#*86((/H16]11111111111111
M1116)X0_Y%>S_P"!_P#H;5MT444444444444444445C^)?\`D&0?]?\`:?\`
MI1'3&_Y'>+_L&M_Z,6MNBBBBBBBBJ6K_`/($O_\`KVD_]!-<O9Z9?V^LZ'X@
MMH#=VQT9;&>!7"O'DJX==Q`/0@C(/3KBLS6?"VKWU_?:K'9NLU[J-BP@2959
M+>!OG9F#`;F!88!/&T9J&U\/^)+1;>-K&>YTNWU2[<Z<UXH9[:0?N2&+8.PE
MOE)[@CH*LZIX;U^X75;>);A_-M[==(N3>_-8.JX;><[B=WS$C=N'!JMJ>A7M
MI'XDU2>/[/=#4X-0TZ5I%`N6CCC3RR%)/SE67:1_&#UJV?!\\7BK1-5?2$NU
M2"X^U;9@##-)*DBD;B,JN&`Q^54[?P_XC@ND:?3I[K3?[4OI9+$7BJ6BEQY+
M#YL?(`PVY&-V1TK9M]%UJW\5VUY$)6LPZI(MS-YFR(1;<JX8,23C*,I!.6R*
MK^*/#VH:KXLGNTLKN2S;19;$/;W"1%I6D#`'+#Y<`YR"/8UGCP]XNCN;MQ&H
MWQZ9YR03+'%<>3N^T(@S\@8$8X`(7!Q3;WP9J4VL6E\VEF[TR#5))XM.DN%W
MPPO;[#@EL`&7Y]H/`^N*NIX<\1MJ6MNTES%=S/.VG7Z72^3&CQXC1T^\=A[8
M(R-PYJ&_\.ZM>^`;BPBT6XM]2F^R++"]\LB.8Y%9Y`2V!D*>>"3C([UO>%=+
MU/3X]?MYHYK>":]>73Q+,)-D;(O3YB1\X8X]ZP;71[S5O@]!H%K&B:O8"&.:
M"9MO[Z&578$]M^S(;N&!KL'FOYW6\72Y4:W@D8022QAI9"!A`0Q`Z=21VKE=
M<\-:YJ_C*?4[16LE&G0)"TK(\,LR2.YCE0'+(=P&1T//:NHM=:O([%KK6]+.
MF1PVPEGD:=)%5QG<HVG)'`(.!G.,9KF_"MC>:;HO@NUOHVBN%>=C$_6)621E
M0^ZJ0/PKOZ*****************Y;0-2.F:+!97.G:F)HBX8+9NP^^3P0,$5
MI?\`"0P_]`_5?_`&3_"C_A(8?^@?JO\`X`R?X4?\)##_`-`_5?\`P!D_PH_X
M2&'_`*!^J_\`@#)_A1_PD,/_`$#]5_\``&3_``H_X2&'_H'ZK_X`R?X4?\)#
M#_T#]5_\`9/\*/\`A(8?^@?JO_@#)_A1_P`)##_T#]5_\`9/\*/^$AA_Z!^J
M_P#@#)_A1_PD,/\`T#]5_P#`&3_"C_A(8?\`H'ZK_P"`,G^%'_"0P_\`0/U7
M_P``9/\`"C_A(8?^@?JO_@#)_A1_PD,/_0/U7_P!D_PH_P"$AA_Z!^J_^`,G
M^%'_``D,/_0/U7_P!D_PH_X2&'_H'ZK_`.`,G^%'_"0P_P#0/U7_`,`9/\*H
M:KJ1U*WM[:WT_4O,-Y;/E[1U4*LR,Q)(P``":GGGA@\;0F:6.,'3GQO8#/[Q
M?6M;^T++_G\M_P#OZO\`C1_:%E_S^6__`']7_&C^T++_`)_+?_OZO^-']H67
M_/Y;_P#?U?\`&C^T++_G\M_^_J_XT?VA9?\`/Y;_`/?U?\:/[0LO^?RW_P"_
MJ_XT?VA9?\_EO_W]7_&C^T++_G\M_P#OZO\`C5/5[^S.BWP%W;DFWD_Y:K_=
M/O4VB?\`(`T[_KUB_P#015^BBHI;:"=HVFACD:)M\9=02C>HST/O4M%%8.F:
M]/?^*=;T=[:-$TP0GS5D),GFJ6'&.,`>II+'QEHU]8W%X)I88(+AK9FGA9,R
M!]F%R.26X`'/M4?AC7KG6M1UZ";RO)T^\6WA*1,C,#&KY8,>OSX[=*Z.BBF"
M&-96E$:B1@`S@<D#ID_B:?13)(HYE"RQJZ@A@&&1D'(/X&LC5?\`D8-`_P"N
M\W_HEZVJ**************************************@GLK6Z*FXMH9BO
M0R1AL?G4/]CZ9_T#K3_OPO\`A1_8^F?]`ZT_[\+_`(4?V/IG_0.M/^_"_P"%
M']CZ9_T#K3_OPO\`A1_8^F?]`ZT_[\+_`(4?V/IG_0.M/^_"_P"%']CZ9_T#
MK3_OPO\`A1_8^F?]`ZT_[\+_`(4?V/IG_0.M/^_"_P"%4]6TG35T:^8:?:`B
MWD((@7^Z?:K6B?\`(`T[_KUB_P#015^BBBBBBN<A\.7UIKVM:M::I$DNIB(%
M)+7<(O+4JN/G&>O.:S3X`?\`LV:R7690JZC_`&G:/]G7=!/YADR>SC<3QQP?
MQK9T+P_)H]]JEW)?M<OJ,ZSR@Q!`'"*G&.V$%;E%%%%%%8NK?\C!H'_7>;_T
M2];5%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%4M7_`.0)
M?_\`7M)_Z":;HG_(`TW_`*]8O_015^BBF1RQRAC&ZN%8JVTYP1U'UI]%%,26
M-W=%<%HR`Z@\J2,\_A0\L<>W>ZKO;:NXXR?0>])%-%.F^*19%!(W*<C(."/P
M---W;K,T+3Q"54\QD+@$+_>(]/>GB6,N$#J6*[@,\D>M1&]M1*T1N81(A`9"
MXRI/3(]Z?%<PSEA%-'(5ZA6!QU']#^1J6BBL75O^1@T#_KO-_P"B7K:HHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHJEJ__`"!+_P#Z]I/_
M`$$TW1/^0!IO_7K%_P"@BK]%%8=QX<\Z=I4O[B%BSL/+P/O$G'N.1]<"F77A
MUI8)A'>2^8R.(PS$*&(;;G'.`6X]``*1/"Z",*U[<;=X<H'.T<@LH_V3CIZD
MFDC\+>6"#J5PQ9@7)ZL`2=N1SCD\?3TJ:+P]Y=O+$U_.YD8%GP`QPFSMWQ@Y
M]1FF?\(S&=.:S>]N&!G6X60G+HR@8()[Y&[ZU"WA9HT46VH3IL5E10=H4M(7
MW<=QG\<<]35S4?#\.IQ2033R+;O`8`L8PR@XS\W<'`R#Z5&OAWR[M;F*\D5T
ME>5!M[MU!]1FI+S04OKJ2::?[Z>40L8!V$$,N??).>QJQ8:6+&XFE$[2>:N,
M%0,?.[_SD/Y"M"BBL75O^1@T#_KO-_Z)>MJBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBJ6L?\@2__`.O:3_T$U1T75M-70M.5M0M`1:QY
M!G7^Z/>KW]L:9_T$;3_O^O\`C1_;&F?]!&S_`._Z_P"-']L:9_T$;/\`[_K_
M`(T?VQIG_01L_P#O^O\`C1_;&F?]!&T_[_K_`(T?VQIG_01L_P#O^O\`C1_;
M&F?]!&T_[_K_`(T?VQIG_01L_P#O^O\`C1_;&F?]!&S_`._Z_P"-']L:9_T$
M;/\`[_K_`(T?VQIG_01L_P#O^O\`C1_;&F?]!&T_[_K_`(T?VQIG_01L_P#O
M^O\`C1_;&F?]!&T_[_K_`(T?VQIG_01L_P#O^O\`C1_;&F?]!&S_`._Z_P"-
M']L:9_T$;/\`[_K_`(UEWU]9W7B+05M[J"9A-,2(Y`Q'[E_2NAHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH(!&",@U5_LVP_Y\K;_OTO
M^%']FV'_`#Y6W_?I?\*/[-L/^?*V_P"_2_X4?V;8?\^5M_WZ7_"C^S;#_GRM
MO^_2_P"%']FV'_/E;?\`?I?\*/[-L/\`GRMO^_2_X4?V;8?\^5M_WZ7_``H_
MLVP_Y\K;_OTO^%']FV'_`#Y6W_?I?\*/[-L/^?*V_P"_2_X4?V;8?\^5M_WZ
M7_"C^S;#_GRMO^_2_P"%']FV'_/E;?\`?I?\*/[-L/\`GRMO^_2_X4?V;8?\
M^5M_WZ7_``H_LVP_Y\K;_OTO^%']FV'_`#Y6W_?I?\*?%96L#[X;:&-NFY(P
M#4]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
&%%%%?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$/`;<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`*P4UK5+N^U"&QTJWEBLKC[.9);PQL[;%<X4(>/G`Z
M]JWJXR#PO+J#>)&N7N[*XN=09[:>*=U&P11A6VJV",J001R`10!N:?XBL;S1
MHM2GD2RC>1H66XD5=LBL59<YP>5/3KBKQU&Q6R6]-[;BT;&V<RKL.>!ALXKC
M9+74`?#U\VF7-A%90SV\]M811N8)"5`=%(;*':V"!NPX]33(-)ELY=*U$:=J
M,EG'?W-Q-;3JCRH\@PLHC0```[CM'(\PG&<T`=M%?6<XA,5U!()\F(I(#YF.
MNWUQ[4U[Z'[1%#'+`[-*8G'G`,I"%L8[G&./0YKCI=,O4L[W6K739DF@U8:A
M:6@`$LD>Q8Y0`?NF0>8=OJ03@DTZQT*_@N/#%U-;,;EKNZO=08`?NI)89.#]
M"RH/H*`.N@U33[IMMO?6LQW[,1S*WS8SC@]<`G'M3YK^SMXI99KN"..%MLKO
M(`$/'!)Z'D=?6N&L=*N-+\+^"YGTR:/^S)!)=P11;Y(\P2(3M7DG<XSC)Y-$
M]G-/!J%[/I^J6Q.N?:8)((5>1%%NB"5HCG>N01C!(SG@C@`[V">&Z@2>WECF
MA<962-@RL/8CK4E8'A`70TB47-G%;+]ID,)CM_(\Y#@^8T9Y1B2V0>N,\9Q6
M_0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`5E:3J5S=75_97\44-W:S':L9)$D#9,;C/J`0?1E-:0EC+%1(A
M(."-W0^E<+#%)XR\47]U&1!I]G&MM;W*G+R`_,Q4=!D[2&.>`,#YB:`.NUG4
MAI.D7%X(S+(BXAA!YED/"(/=F('XU/8-=OIUL]_'%'>-$IG2)BR*^/F`)ZC-
M<%K?AZY\+VEKJ5C=7NI165VLRPWEPTCJ6.T@$G:5(<CD97((/&#W5IJ=G>V,
M5Y#.GDR('!8X(SV(['L1VH`MT444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`&3-X7T"XN9;F;1;"2>
M5]\DC6ZEF;&,DXZX[US&G7J^"M<U2PU$J-,D\N>WN-V76,($^=>I"[`N5S@!
M<CG-==K6H_V1HMWJ'EB3[/&9"I;`('O67X?A&IS7VKWRVLTTT[10B-A(L4*$
MA`#ZG)8^[8[4`8/B3Q1;>*/#\>G^&3%J#ZA/'"L[<1)AP6.#@O@*20.P.2._
M1)X*\.FT2"[TBRO'`)DFN+='>1B=S,Q(Y)8DGZU'XIL(X-&FU'3[#=JEH?/M
M3;P;I&D'1>.2K#*GV)JSX:UV37K.XGELVM'@G\EHG)W`A$8YR`1RQ'3MGO0!
ML?)&F.%51]``*9!<P7()@GCE"XR4<-C(##IZ@@_0BN<U?P_?ZEKRW2O;);JN
MU6_CQL=2IXR02P/#`8SD$XK.F\&WS63V\"V4!<JP:-B#&RV\<8()4\`H>P."
M,$<T`=N\B1E`[JI=MJ@G&XXS@?D:=7*GPQ)<W6V\MK22#[6;B24R,SSC+%0R
MXP-H8#J>G8<5##X0N?L4<=W,DTZ*$+F5R"@M_+`_[[`;\`>M`'84FY=VW<-V
M,XSSBN*E\,:W,UPOVTJ\AYF6X*^:A>,[&`7=\J*R@Y[^YK5TC0[C3]:>ZE*2
M)Y,D,;AV+*GG,Z(0>N%;K[8H`Z&BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BJEYJECI[PI>7<,#3$B,2.`6QC./I
MD?G4*:[IC310M>11S2LRI'(VUF(8J>#[J<>N*`-&BLP^(M%$"SG5;(1,Q17,
MZX)`!(SGT(/T(-/&NZ2QA`U*T)F8I&/.7YV!P0/Q('U(H`T****`"BBB@`HH
MHH`****`"BBB@`HHHH`**1F5%+.P51R23@"LR7Q)HT4HB_M&"24G`CA;S6S]
M%R:`-2BLAM=)#>1I6I3`#.3"(A_Y$*UE7/BZ>/>GEZ7;2`A0MSJ(+9)Z;(U8
M^G?O0!UE%<B^L:O<QMY-S@L<)]DTF:3'_`W*K^E12P:]=J<?VXXVXP\]M:J?
M^^`6'7]*`-&^!UWQ!'IHYT_3V6>\XXEFZQQ?APY_X!ZFM^6:*%=TLB1KZNP`
MKC!X0N3'-&EG:0QSN9)1+J5U/O=OO,1E1GA:=+X<@TU%N+VXT&SBWJBN=.'!
M;MOD<]6QZ4`0^"_$FGVWAJ235-=MGF>^NF_>W(9POGN%&,YX&,>V*M2:O:6_
MB>'4-/\`M-S#>K]GO(X;65L%`Q27A>HY0^N5_NUD>!K:VFTBWM!XCFCN6GNY
M!:6IAC)43N"Q`7=CD=^XKJI?#^F6UI--?WE_+"BEY9+G4)=JJ!R2`P`&!Z4#
M'CQ&'=EAT;5Y-H!S]E\L'/IO*U7G\4O;B5I=*EA1.CSWEL@/_D0X_&JT5GX+
M6.`B"S82,T2&52QR"`0=W(Y(&3ZCU%3POX/ACF%O#I:K;81Q%`O&20`,#GE2
M.,\@CM0(@_X3(L"ZQ:6L83=NDU://TPH:F_\)BSVHEC.E-O'R%+N5U)[<B'I
M6K;:YHB7#V5O/#&4**`J[5;>N\;2.#\O)QT[T[_A)=(.P)>Q.7WA<''W`&;)
M/`X(//4$&@#$A\5WTD)D=].!4G<(H[F3\OW8.?PJ2#Q!JDWR[[<L02I33+MA
M@>^!ZUO'6]*7SLZC:CR&"2YE'RL3@`^^>/K5N&:*Y@2>"1)8I%#(Z-D,#W!H
M`Y2;6M=VJT4D2^H.AWC$_P#CPQ33K6ONY,3Q*@QP^AW>?SW#^5=C10!R2>(-
M6`.]"QSQMT:[''ZU-_;.JD-M"9'3=I=T,_I73T4`<H_B'5+:`R7,<(`/)6PN
M_P"6PU4'C"\+-F:S1?X3+87:<]N2@!KMJ*`.+@\9W."+@Z/O)PF+B>,'_OJ'
MK[4O_"<LP5H8]&FCSAG76%4`^GSH">*[.D*AAA@"/<4`<M'XT61VC6QCDE'2
M*'4;9G/KP9!5O_A*"(A(^B:H<\8A2.;GT^1S6G)I.FS%C+I]JY;[Q:%3GZ\5
M5D\+^'Y9%D?0].9UZ,;5,C\<4`,/B:TC0/-::I$NT$[M.F;;GL=JGFHF\9^'
MXP//U$6^>@N(GB/Y.HJ7_A$]#!!CT](6#;@T+M&<_52#37\,6F\-%?:M"0,`
M)J,Q'UPS$4`6K3Q!HU^ZI::K93NR[@D=PK-CZ9S6B"",@Y!KF+KP;'>1%+G4
MY[O@X-[;6T^#VZQ9P/2JK^"90(Q%<:?B/!`^Q-"<@8!!BD7'Y8H`[&BN/?0M
M=A60PRECCY?*U6=.@XX=9`.:-GB>W$:A]2(4<L3:W`/0<\1M[_A0!V%%<@-?
MUBV8BYB?&3CS=+F7IGJ\;2+VZTU/'(4[98=/9@VTK'J*HW4#[LP0@YSQ[4`=
MC16%'XGA?EM-U%4P#OCA$Z\^\3/4J^*M"\PQR:G!;R`XV7),+9^CX/>@#8HJ
M."XAN8Q)!-'+&>C1L&'YBI*`"BBB@#%UK1;C5KN+;=_9[4VTUO.%4%W60ID#
M/3A3S^AJG<^#HKFXMF-].MO;RK,D6`<.LC..3Q@EN<@G@<UTU9VLZ:=4MH(,
MKY:W$<LBLQ`=58$CCK].AZ&@#)C\&Q?9)8)[QI`\,T"8C`6)9$5#M&3CA<XZ
M9)P`.*2[\&K=7L\PU&989[A;EX2@(WJ8R".1_P`\@.<]>,'FLAO`^H011+#<
M120A(_.M_,($S!I<D[E8<!TQD?P8XP*MGP0\L>ZYD$L^S9O>>1F($"HN3QG#
M@MTZ\]:!G8Q313!C%(KA6*,5.<,#@CZ@T^N+A\)78NY/,6!8IIC)=,L[YN@T
MBOR,<%0I'7G/H344'A;6)M2DEO7@6VE>,S0Q3OMDVR.Q('7E64<D]/3%`CN:
M*XW3O#>K6VK6$US=2ND$<8WI<Y"A4*LA#*2P)YZC/4\@5V5`!1110`45S>K:
M_>6-\+7_`$&UWM^Z,C//+(N<;A#&N<=?XJH,NMZGL*IJDJDY_>R+81=.A"AI
M:`.KN[ZTL8_,O+J&W0]&ED"@_G5`>(;><`V-K>7H/1X8<)_WV^U?UK.M/"T\
M;B4S6=G+DDO:6P>7_O[+N)_(5HKX;TXL&NEFO7'>\F:4?]\D[1^`H`RYO$UX
MTJQ1MIENQ;!0RO=2X_ZYQ#_V:HF&N7JG][J\H+<"-(;).,_WMTF*ZR&"&WC$
M<$211CHJ*%`_`5)0!QZ^$[F:0//#IPX'S7;2W[_G(R@<^U:D/A^988XY=8O-
MJ$G9;+';IU]$7/ZUN44`9"^&=((7S[4W;+R&O)&G.?7YR:T;>UM[1-EM;Q0I
MUVQH%'Z5-10`444UW2*-I)&5$4%F9C@`#J2:`'5GZYI%MK^A7NDW:AH+N%HF
MR,XR.#]0<'\*P[_Q1/.ZPZ8AC64'RI7A,LLX]8H@02O_`$T<JOU!S42Z-K5W
M^]G\UGP=IO=0<<]!F*`*@_,T`8OP<\$3^%-&OKK48=FI7<[1L"N"(XR57\&.
M6^A%=]K%G)J.BWME$X22>!XU<_PD@@&N<'AK4X>8Q:,1M(\F\NK<YQ@\[V_#
M(^M1?VIK>C.B7)DQG`CU`J8Y/9+E``K<<"11G/6@9?E\&6T]^M_-<M-=NW[^
M26&-Q(OR\!2,+]P#(&>OX22>$+1DM_+N)5EMLF%V`;:2SDDCO]]A_P#7K3TS
M5[;58Y/*$D4\)VSV\R[9(6]&'OV(R#V)J_0(P8O"UO#M$5U-$(XRD7E*J>63
M$(RRX'!P`1Z&J=MX(@@2??J%Q(UP292P&&!C6/OST0'KUS7544`<XGA*(W44
ML]W)+';2J]M&$"^6`_F8)'WOF`Y]!]36SI]DNG6$5HCEUC!PQ`!.23V^M6J*
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*;)&DJ;)$5U/4,,B
MG44`94_AK0[@L9-)L]S=76%5;\QSVJ*3PS:%"D%WJ-N#CA+QV4=/X7++V]*V
MJ*`.2F\%`R^9#<VK-UW3V*!SQC[\)C-0'1/$-HN8)Y6*@@?9M1?\/DG60?\`
MCU=I10!QK:GXFL01)!/(`1DW%@),CV:"0_\`H%+'XY\M]EW9PY&1^ZN@C$CM
MLG$9SP:[&FNB2(4=%93U##(H`Q8_%NE&+S+AKBT3^_<0.J?7?C81^-:EI?V=
M^F^SNX+A1U,,@<?I5!_#&CM()([);:0='M':`_B4(S^-9MWX(M9F\R*[<2YR
M&N(8YC_WT0'Z<?>H`ZFBN+_X1[Q%8_\`'EJ&Y4&$$=Y(G0\#;*)A^HH_M7Q3
MIP'VJU:5>I,MJ6X_WX&8_G&*`.THKD[;QQ%(Q26Q9GSPMK.DCXX_Y9MLD[]-
ME:L7B?1I)O):^2WF_P">5TK0/UQT<`F@#7HI%974,C!E/((.0:6@`HHHH`.^
M:***`"BBB@`HKG-:\3/I<M[;BU,DL$!N@%?EH0O+#@\[_EQ^-4[OQE-8&;S[
M2)LI*]NJR$&39,(@G(Y8YS@>PYZT`=?17.V'B-KQ-7#K")+)6D18GW93+A3N
MY7G8>GT(&.6:7XANKS48(7@@^S2.T`<2DOYB1JY)&T#&2PX]`>^``=+1110`
M5QGB6_FU"^&F6T:S0QRI"87/R75PPW"-N/\`5HG[Q_7@>H/822+%$\C?=12Q
MQZ"N.\(Q"YU%;F1E:2&R69@`.);EVE<_7:$'TH`Z/2=(BTR)F9S<7LV#<7<@
M^>9OZ*.RC@#@5<N+B"TA::YFCAB7&7D8*HR<#D^]8^G>(23+;:Y#%IE_$S'8
M\H,<L8/$B.<;AC&1U4\$=,XGB;Q'H6KV4=C#<V]];1WL#7KQ@2QPHDBNVX].
MPSC..IZ4`=Q3)8HYX7AFC22)U*NCJ"K`]00>HIRLKHKHP96&00<@BEH`X:_L
M+G0-4MC9!Y3AAI\CN<\#<UFY/56`)C)SM(QZ9Z_3M0M]5TVWO[5BT%Q&)$)&
M#@]B.Q'0CUJCXIMS<>&KXH^R:"/[1"X_ADC^=3^:BJGA.9#_`&G!$?\`1_M(
MN8,'("3(LI`_X$S_`)T`='1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!!=65K?1>5=VT-
MQ'_=EC##\C67-X6TYXV2W:YM%;JL$QV'_MFV4/3^[6W10!B:-H+Z)<2"WN(#
M:RY9XQ:)&Y;L<IA?7^&MNBB@`HHHH`****`"BBB@#&G\0P6=]=6]S$X\I@L3
M(,^82$.T?[1,@P/8GM5<>);"XN/)%C/)=)<F&*%EC$A<!B2`6RHPC'+8R,8S
MFM*ZT>UN[RWN)$&89_M&-H^:0+M5B>N0#VJ#_A&M(W.XM2'<@[UE<,N-V`K`
MY4?.W`P/F-`%"/Q5I,;S>5:3KNB6<E8E5IBVW:`N=S,2X&<8SD9XJ23Q79PN
M8S97AGCR9HEC4M#AE7GG!R67&">#FKC^&M'=E+62G9'Y:*7;:BX"_*,X4X`&
M1@\=:6/P[I4:E5M`=P^9F=F9OF#Y))R3N`.3Z4`4E\8Z:;J&VDCGBFD<1NC!
M<Q.7:,*P#$G+*W*Y`QDD"NAK.70M.2[6ZC@:.4,6)CD90Q+,WS`'#?,S'G/4
MUHT`1W$9FMI8@<%T*@_45Q_@AXUN9%SB2XTZSDVD]T5HG'X%`#]?>NTKSS7[
M"]T_4VAL[B\M=\KW5M)9A3)+$Q#7-NNX$;\CS%XR>0.AH`M^.&DN_$7AG2XU
M'ERW+O/*%!,"E"JL"?NL2Q4'U.>U='_PC6AG3_L)TFS-L%V[#"#Q]>N??K6%
M>>$K'5M*&H>']2FMM0E19(-0,K3^9@AE#AR<KD`XX(YQCD&G;>)?&6H1?8;+
M1[%[^&0P7MS)(\<,#@#.,@[^N0%)X(SCD4#*WA*TNH=2O_#FEZM-;Z;I;&.1
M5VRLF7)C5&;.WY.HP>1D8R:[?1])BT:S:WBN;RXWR-*TEW.TKDGW/0>PXKE+
M(KX"NKJ[UM85L]1D1I=2CR1'+@*!-QGYCDA\`9;&%`%=W0(S/$5PMIX:U.=R
M`$M9,>YVG`]R3@8K*\'VQMI-2A'*6[6]J&)!W-'!&&Z>A./J#53Q1K<<TQLX
M(GN8;.:,SHG_`"\7&08;93W);#-_=5>>O'0:!ILFE:/#;SR++=,6EN95'#RN
MQ9R/;)./;%`&G1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!574-/M]3M3;W*DJ&#HRG#1N#E64]B#R#5JB@#AM
MVJ>&+B2241I'(VZ278?LEPQ/+MM!-O(>YP4)YZ])?"NL/8Z4ZZK:W`GFN9[A
MI[2)KF!@\C,-KQ[N`"!SCITKM*RI?#>CRSF<6$<4QSF2`F)FSUR4()_&@"%_
M$VES0D11WEV&X\N*QE?=S@C[N!SZD5B:CXBU#4)FL+:.6U9A@V]JRS7K?7!,
M<`_VF8GT`-9OCFZ\-^#=-22]MKR]DF=/*M[NYN9HY0&&X`L63<%R<'&<5T'@
M'7+?Q%X;.I6>FQZ?:/<RI!"BA<HK8#$#C)QVH&2Z!X<-DT5W>K$LT2LMM;0L
M6BM0WWL$\O(W\4AY/.,9.>CHJAK<E[%HUU)IRLUVB;HPJAB<$9P#U.,T"+]%
M<6MQXJN)6N4^T1HEQF&W>%%$D;7.WY\C(Q#SV/?KQ41O/$(LD)?5EF\MFN"M
MFC;)]IQ''\OS1[N^",8^;DT`=S17"3W/B>[EN895O;:/R"7\F,'8ZM%_JV"<
M@CS,<L2/0\5-#=>*$C>=T=?*<8@,2JDNZ64,6;J`%\LY&,=3G-`':T5S'A+4
M[S4)=0CN;M[E(##M>2`1,K-&&9>.H!(P??&3C-=/0`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%,ED6*%Y&^ZBECR!P/K3Z@O;9;VPN+1F*K/$T
M98=0",9_6@"M/KNE6RS-)J%L/(94E`D!*,S!0"!R/F(%3?VE8D3G[;;XMVVS
M'S5_=GT;G@_6LAO"R+&HAN0KJ96!>($$O.LW.".`5Q^-5;#P=!`T4D=XDL22
M1O&X5F9U1R^&)<@\GJ`.1GO0!T8O[,S>2+N`R[MNP2#=GTQZ\'\J:VI6*023
MM>VXBC;:[F5=JGT)SP?:L&T\&VEM;QPI<AI(5B3S?*7>-LQF//8G./UJO#X/
M-LL:)=6K7$2HL:RQ,ZR1HC1C>A?D_O,\8&?K0!TL6IV<T<4BW"!9L>47.WS,
M@$;<]>"*=;:C9WB(]O<Q2+(SJFUA\Q4D-CUP0:Y-O`<RO&(]33RA(DC*UOW5
M85R"&S_RQZ9Q\W3BI8O!3Q:I;W1GA>..82%,.NP+-)*I4*P&3OP<\<=^E`'1
M:QH]AKVF2Z=J5NL]M*/F4\$$="".01V(K+\$^&#X0\.+H_VC[0D4\KI)C!*L
MY89]\'!KHJXN/7]3\9V%W#X=CETR-)6@?4+M?F5@?^6<8ZG'7=C&<8R#@`[2
MBN+?Q%?>#+"TM?$J37^YUABU&U7=YI).=Z<%6`YP-V[!QSQ7:=10`4444`%'
M48-%%`$5O;6]I&8[:"*%"=Q6-`HR>^!4M%%`!1110`4444`%%%%`!1GG%%'>
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`JGJMO+=Z3=V\#.LLL3(A27RV!([-@[3[X-7*SO
M$%Y/I_AW4;RV*">"V>2,R'Y0P4D9H`Y^TTC7X4AC)"QLJJ0+AAY(6?>21SDE
M"1\O'&.!46GZ%KNEV$JV*+%/"B&*.6\9XIY0S%C_`+*E6QC'8<?*#45SK/B"
M)8_LAN[D+.?*>2RV&X3<@(8;<@C+]ER!G/K;O9M>748Y%>>2.19@MN(<(N+B
M)5)(YSY>YN3Z]N*!DHT;6899O](DN8XH9!;![IDWN8XE4MCG.5E/7C=^3]!T
MK5+35(Y;L`VZ1SA"\A9TWF$A>2W'R.?O'MS59]0UIH$N(VFGN4+R-:_9FC6-
MO*D_=EOXUW;??(!SR*W-`NKJ[L9)+F5)@)2L4BH5++@?>!`&<Y'''`[YH$:M
M%%%`!7(^#=9ADBN[.ZMY-/NVOKF2.&Y78TRM(6W#/#8S@XS@CTP3UU4-8T>S
MUW39+&^CWPN0<C&5(.003T-`'/>+M9`GTVVTZSEU.ZM[^&6:.V&[R5Y`W,,A
M2<X&<<9S@<UV%8=BVF^';C3?#=M#)$)8)'@?:-K;-NX$_P!\AL].0#Z5N4`%
M%59=2L8+E[>:ZACE2-975W`VJQ*@G/J013A?V921Q=P%(VVR,)!A#Z'T-`%B
MBHA<P%]@GCW;-^-XSM]?I[T@N[=A&4F1_,^YL8-N&<9&.WO0!-15:34+.(*6
MN8OF<HH#9)8*6*@#J<`G'M4RRQN<*X)`!(SR`?4=J`'T4BL&4,I!4C((/!I:
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`/3KBBBB@`HHHH`****`"BBB@`HHHH`*:Z+(C(ZAE88*L,@BG4
M4`%%%%`!1110`4444`%%%%`',^-_]'TB+5XF'VG2)EOU4,`7C7B5>>QC9A]<
M5IZ/X@TSQ`MR^E72745M+Y3RQ\H6VAL`]#@,.E5/%OA+3?&.BR:=J*8/)AG0
M?/"_]Y?ZCH:Q?A;X;OO"GAJ[TO447[0E_*PE4<3*=NUQ[$?ETH`W-4\.KJ>K
MVMZTZHL+PR%#%N+&-F(&<]/G/Y"J$/@Z0W,4UY?I/LFBD9/(PL@3S<`C.!GS
M<X`P"HXKJZ*`./D\%2'='#>PPQFW2%BMO\TI554;_FQM^09Q@D?+GO5A/"C)
M=37N^T2X=(0J6]L(U7RY6D.WGC=N`)]1FNHHH`X72_!MZND68NA8P726\43I
M'%D`B&1&8D'E\RGD=E'K5BX\%SW$_P`TUJL:RE]Z(P>=2Z,4DYY`VX'X=,<]
ME10!G:+IC:5:SP&4.CW,LT:J,"-'<L$`]!FM&BB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BF22QPQM)*ZHB]68X`_&L.3QKX<CD:--5AN)
M%&2EJ&G/Y(#0!OT5S7_">^'U&7FO8U'5Y-.N$4?4E,"M'3?$FBZPVS3]5M+F
M3KY<<H+CZKU'Y4`:E%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%(Q"J6/0#)I:*`,&UU^WP=0N]4L4TN[57L"V8G*@
M?,6W8SSCMQ5!_$5R96\K7/#FPDE0S,3CM_%Z5TE]#-<64UO:77V2X9,),J!S
M'[[3P:J7MKK,DD?V'5+6!%CVN)K(REF_O9#KCZ8H`SK/4-:OV86>HZ!.4`+"
M)9&P#]&KI!G'/7O68L&NC;NU#3VQU_T)QG_R+5FU345E)N[BUDCQP(H&0Y^I
M<_RH`MT444`%%%%`!1110`4444`%%5=1O#8V+SK$97W*B(#C<S,%'/89(K!?
MQC%!%NNK<Q*;IH4F+`QR*LWELRD9.1U(('?%`'445@Q>*K>=(_+T^_,TH#Q0
M^6N]XRI8./FQC`/!(.>,9J"#QK8R6E_,\,VZRNFMI8XQDJ?,*+DG`7(`8Y.`
M#R:`.EHK)U#7[?3H;2>:"<P7"/(TBJ#Y2K&9"6'T&.,\U7G\6Z;:W!M[E+F&
M?R3,(VBRQ``)``R<\B@#>HK&@\3Z?<74-J@G6XE9U$;QE2I0X(/X^F>#GI5*
MX\:V-K8/-+!-YZV)O!"!]\",.54]^#UZ<&@#IJ*PU\5:;YK1EY"8YO*F9(V*
MP-O*`.<?+DC'I^'-7-*UJTUA&>U\W:%5P9(RF]&&589Z@X/Y4`:%%%%`!7/W
MFMW=[>S:9X?CAFN(6V7-Y+S!:M_=..7D_P!@$8XR1QE_B>^N8X+72].E\K4=
M3E\B*4#)A0#,DN/]E0<?[16M'2M*L]%TV&PL(1%;Q#@=22>2Q/=B<DD\DF@#
M,A\)6#3+=:JTNK78Y\R].]%/^Q']Q/P&?<UJI<V%O"RQS6T441"D*ZJJ$]![
M5:K@K?P_=Z;X=\/VBZ/$SV\;&Z:***66.7`Y4.0ISE@6Y//N30!W#W5O'&DC
MSQ*DF-C,X`;/3'K574-%TO5DVW^GVUSQ@-)&"P^AZ@_2N`B\,ZI'H]LEQID[
MW,?VU$3;;S1A))BZ1O$V%VD8Y0C'3@5Z+IZSKIMJMU'%'<"%!*D))16P,A<\
MXSTH`PFTK5]!3S-#N7OK5.3IM[*6./2*8_,I]`^X=LKUK6TC6;36K5IK4R*T
M;^7-!,A22%\9*NIZ'D>Q!R,BM"N7\20'1KE?%5FK![<!=1C3I<6V>6([M&"6
M!]`P[T`=112(ZR(KHP96&00>"*6@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`I-R[@NX;B,@9YQ3)XO/MY8=[IYB%=R-AER,9![&N8CT
M77G>W-YJ'F`L#<+%,RJ<21X"^Q1#D=RS>M`'4;PF/,9%+-M7GKZ#ZT^N-@T+
M7'UQ;BY>,6D=Q',L9F9\,#+N89R<E60=NF,#`J34?#VL7&H75U;WTJ>8MQL7
M[4X`8H@AX'`"LKG'J<\YH`V`VARZS-.MS:-J1A-O(5G'F!%))7`/&"2:HCPO
MX?V@B:[V^7Y@/]K7'W/[W^LZ>]4$\*:C"WF?:!,&N;V7[.\F(XS*9"DBX7.0
M'VD'(^8GL*C7P??Q'['#);II_P!EBMD&23'&7W2QX_B7Y0%Y'#D=A0!L+X0T
M5T#*;]E89!&J7)!'_?RMJWMTM8%AC:1E7H9)&=OS8DFJ.@V-SIFEK8W$BR"!
MV6)UXS'G*C';`.W'M5C4=,L]7M#:WT`FA)SM)(Y]<CF@"W17+7?A^ZT2W>]\
M-7-UYL*ECIT]PTL-P!DE!O)*,>S*>N,@BMW2=3MM9TFUU*T8F"YC$B9&",]B
M.Q'0CU%`%RBBB@"*XN$M;=YI-VU>H12Q/T`Y-5X-6M+C3Y;U79882XEWJ08R
MGW@1ZC%37L,UQ930V]RUM*ZE5F50Q0^H!XK!OM,T^UT^PTV\N'C6ZF%LJP[U
M68Y,A4C)P2$.7)R>>>:`+Y\0V9MK*>&*[G6\4O&L4#%@!C=N7JN,X(/.>*T;
M:YAO+6&ZMY!)#,@DC<=&4C(-8O\`PBEFUR&F=YK9)994@D)(4R;=WS9R?F#'
MG^^?05NHB1QJD:JJ*,*JC``]!0!#?6<6H6;VTQ<(^#N0X92"""#Z@@&L6[MO
M#.ESRR7D5M$Q<3?O&S\Q9GRJY..59C@#."3TKHJS+S2+6XOUU"1Y1)$O13Q@
M(Z],9Z2-^E`&2;?PO',MEA5D<;XV6Y;.P;4`5PWRK^]`"Y'#<#FFRR>%(HE$
M+JGG3_9]UK(Z'>Q:7DJ1P2'.3QR>Q-69?"]C+%%#]KF5$9#@%<D@Q,O;CF!?
MS/X5;;PG;3QF1-5FN&%PK&4A3EHQ)&0?5OG;)]1VZ4#+,T7A>?34TV6:V2UM
M(,>1Y^T)&R["#@\C#8Z]2.^*=)I?AR3?K<C1M',2YE,[;,L`I(&<9.T#\/K3
M$\'P+/$9+N22""0RP1%%^1BRLV3_`!9*]^F?IB_-HVZTACANFBFANGNHY"@;
M#,SD@CN,.P_(T"*<=GH6J:I-!"CRM;.ES+Y<K>47<[U)`."W1NG0CZ5*_A'1
M9!(K6K[)(C$4\YPH4Q^6<#/]T`9]J?HVBV?AU6BCNG8W!15$S#DJIX7ZX)Q_
M05LT`93>'-+-P9O(969MTH61@LIW%@7&<-AB3SZU9L=*LM,&+2'RQY4<(&XG
MY(QA1R>P-7**`"BBB@#FY/WOQ)MPXR(-)D:+)Z%Y5#?HJU<O_$EGIT\L4L5R
M_ED(6C0$&1EW+&.<[B/;'/6J/B14TO5]*\2-\L-J7M;Q@/NP2X^8^RNJ$^@+
M&MR33K&:Y^U26D#S[=OF,@+8ZXS0!GZKXEMM(9!<03;0$:9\#;`K;L%O7[C<
M#-,?Q=I5NZQW;RVLI?9Y<T>"&P3VR.@'_?2^M+K][H^G36D^H68N+B4LD(6$
M.^`I+=>P&[\^.M8MGXB\,W$)@;2@OE&3*"W#A2K],^I\M6^H7G.*`-=_%^G1
MQ-*\5VJAE4%H=N<L5SST`*D$G'ZBHY?&FG6\;//#=1X.`"@^8EW50#GJ?+=O
MH/PJG>ZWX<D@*7NFR[C(5$+0C>Y#2;\8/(!27(SSSUW#+_M>@RW*V46D.?M4
MRKO$(0-AG^;.<@*V[T^]QWH`NOXQTI9FA!G>78)$1(B6D4@'('7C(SG%7;6\
MM-?TVX58Y5A<&&194VG#*#T/8JP/XTJ:!I,=T;I=/MQ,26W[.A(P<>F>^.M4
M?$UPNFZ'+:V"(E_J!%I:(HQNE9=H;CLJC<?9*`&>`II)_`6AM)]Y;1$Y[A1M
M!_("NBJKIEA%I6E6>GP$F*U@2%"W4A5`&?RJU0`4444`%%%%`!1110`4444`
M0SW,5L8A*V#+((T`&2S'_P"L"?H#5";Q)I<,/FK<B9-[(3%\V"$9^?P4XJS?
M6CW3VDD;A&MYO,Y'4%60_CAB1]*QXO"ELT;QR7US*589)P#D1LG)QR<.3]<4
M`;$>K:=+<26\=[`TT;;702#(//'Z'\C2-J^FJT2F_MLRX\L"4'=D`C'U!'YC
MUK&;PY874;6IU*<HI/DI&RAH=SESSC)SM(Y[9'O2-X5L;*WA@MKMK4).TRG`
M+JN5^1#P550%4#D8QD'B@#8GUK3[6]DM)[I(IHXDE8.<`*[%5Y]2P(Q0VN:4
MJ3.VHVP6%@LA,HPI)P!^)R![BH+_`$*._P!4M[V2XD7R6C<1J!@LA8C)]/G.
M1]*HVOA(0W?VB?49YV$D3C(Z^6S,N2<\_.0<8'`P!0!J2:[I<<9?[=`Y$!N`
MJ.&9HP"=P`Y(P#1/KFEVRRF6^A4Q,BR+NRR%F"J"!R,L0/QK%B\+6WG26]MJ
M9"QP-!-&@&_YPV`^#@CY\@$9&!@XR*G?PJTE]+=R:@\DC;A'O3(4&5)<$9P0
M"@`P%XZY/-`&T+^U\Q(FN(EE?)6-G`8@9Z#/L?RI]M>6U[&9+2XAGC!P6B<,
M,^F16"?"2[I$6['DROYL@:'+[QN`VMG@?-TQZ],FM33=)BTQI3"1MD6-=H0*
M!L4*.GL*`-"BBL*7Q9IIF>"P6XU.9&VNEA$90I]"_"`^Q:@#=HK"75-?ED81
M^'!''@%6N+Y%)_!`V*)=1\1Q;2OA^VF!ZB/41D?]]1@?K0!NT5@GQ.EKSJNE
MZCIZC.99(A+&/<O&6`'N<5LV]Q!=P)/;31S0N,I)&P96'L10!+1110`5R_A(
MBPO=<T%F`-G>M/`@&,03_O%Q[!S(O_`:ZBL+6M$N;B_M]8TB>*WU:W0Q9E4F
M.XB)R8Y,<XSR".5.>H)!`-VBO)_&WQ,\1>#=1TN2YT)$M[E72:"2965V4CF*
M13GH>C*.W'6NY\*>)V\3Z<+IM&U+3?E!VWD6T-G^Z<\CWP*`-^L77(UDU/P^
M&`^74"PX!Y$$U;$CB.)Y"K,%4MA1DG'H.YKC-1\0R7>LZ%)%H^M);07+R7!?
M3I?E!AD53P#_`!,!^-`':T56LKV._@,T<=Q&H8KB>%HF/X,`<>]6:`"N>UKP
MY-J=[)-#>""*6V=)(]A^:7:RQOG/8.V1WPOI70TA(`))P!U)H`XO6/!,]Y8F
M&TDM$FD>:22=HP'WL1L?.TDE1QP0>F",5H:KI<R:%'&8A=^5>-</`$++,K.Y
MVL!SQO!Z'E1Q5B;QEX?AF:%=16XD4[62TC>X*GT/E@X_&F'Q;#O95T?76`.-
MPTV0`_3(%`'/:;X/U1K*U>Y?RI?L(B"_:#^X;RV79]TEERV?O#IW(!J_=^$+
MAKF(6\@6S$CD0Q3&/RBQC.]25;Y@4;IC[W7DUJ'QAI42(UVM]9;_`/GZL9HP
M/J2N!^=:MEJ%EJ4/G6-W!=19QOAD#C/U%`'-_P!B7T,\JB%#'-J$4R.)"[1[
M9&D9R<#`V_*!R<G&2,5UM%%`!1110`4444`,EBCGB>*5%DC=2KHPR&!X((]*
MYB`77@[,#K/>>'QS"Z@R2V*_W&'+/&.Q&2HX.1R.JHH`H1OI>OV,5Q&UK?VI
M.^-U*R+D=P?6GKI.GI+YJV4"N5*G$8`()R>.G6J-SX6TV6[DO;83:?>28\R>
MRD,1?_>`^5O^!`U`NE^)K;?Y'B."X7:0@O=/!;/;+1LF?RH`U)=(TZ9"LEE`
M03G[@'.2W\V8_P#`CZT\Z;9%T?[+%N1MZMM&0=V[(_'FLCR/&)9!_:.AJN?F
M(LI22/;][2+X?U:Y!74_$]Y(A/\`J[*%+4'VW#+_`),*`+>K^(['276V.^ZU
M"09AL;8;YI/?;V7U8X`]:KZ3H]U)?_VWKACDU(J5@AC.8[*,XRB'^)CCYG[]
M!@<5H:7HFFZ+&R:?:1P[SEWY9W/JSG+-^)-7Z`"BBB@`HHHH`****`"BBB@`
MHHHH`*YC4/#M_?7%S+]KC1B[O;-EF\DDQ88#ID!&_P"^OK73US\\VMF_NH5@
M+6\3QM'(47$JNZ?*/]P"3)XZJ:`*HT#48KR:>)K<RRI\TKR-\^%F"HV.2!YJ
MG\#Z"JUKX6OT:)V\I&1I1%B7F)7\DD?*H')C88'][OS4IN]>B_LI62\>9UB>
MY_=+L^9\.O"X&U<]67C'WCFDU6\U+2_#NG_OY[=TL7:5D59)/.6,%00P/&=V
M3[#D9H&1#PIJ4US&)9HTMQ.C72><[?;`K,2[>A((&WIVZ`5=?1=4&B:3;2R1
MW;6A(N(1*R+.NUE7YNORY!YZX]<53:[\3R75\%D>+AQ$J6Q8*N]0C*2NTG:2
M2"Q^@Q3GNO%"WL-NI*PK.RK-)`6\X"7'SA$.!LQ@_*.<YXQ0!L>'](FTI;QK
METDN+F2-Y)5))<K#&A)SWRA_#%;-<C%>ZF]Q")Y+GS%OHQ$SP^6LB-O#IMP#
M\J@DYW#.,$]NNH$%%%%`',ZO&==\21Z#+)+'I\-J+NZ6-BOVG<Q5(R1SM&UB
MP!Y^4'@D&3Q)=?V#HUDMBZV$!O(("8(5/EQL^"%7!'Z59UK1[FZN;?4]+GCM
M]4M59$:1<QS1L06CDQSM)`((Y!&>>0<VXUVQG%O%XB@N-$G@N$F0SL/)=E/&
MV4?*0<]#M/L*`*C>(+VQLKZ\>[N;G3H;FT6*YFLMDC!Y0LJ!0HW@`C!"]6(Y
MQ3I==U*?PUJ6NI<M;)YBQ06JPAI+8"0*V\$$F4Y/R]!P.>IZ20Z?K4"QQW<<
MRI+',#!*#\R,'7IGC*BJ>HZ%IDTEW/<7$ENESY3SJ)0J,T;!E?GHWRA2>X`'
M84`5-#U.ZO?$%U!#=W5U801;9S=VPA>&?(*J/E4L"I)/&.!@\U'K5LGAJYBU
M[3AY$4ES%%J%NGW)DD8)O"]I%9E.1C(R#GC$USJWAZVULW\-[]HU`P>2]O8Y
MG>5<Y7<B`G(.[!XQN:E%CJ'B"^M;K5(/L6G6LJSP618-)+(/NM*1PH4\A`3R
M`2>,4`=)7--H7B,LQ'C&Y`))`^P0<>WW:Z6O)OB3XN^(.BPS_P!EZ$EM8*#_
M`,3"$_:6`]2N!L_$'ZT`=NNB^(E4`^+)6]S80Y_04UM%\3'[GBW'UTZ(_P!:
MKZ!J.OOX=TUQI,=SOM8V\^34<M)E0=Q^3J>M3W&O:Y9PRSW6@6\%O$,O-+J:
M*@''))7@?7TH`J_\(GJ\FJPZE=:]:W5U`A2)YM+0E`3D[<-QR!R/2M7[!X@_
MZ#MK_P""_P#^V54AU[Q!-"LG_"*.5<;E*:A"00>ASFI/[9\0?]"I-_X'0_XT
M`2/8>)?+/EZ]9>9V+:<2/R\S^M0K8^+P^3KVDLOH=+<?^UJ1M=\0J<#P?<M[
MK?0?U:IH-:UAQ^_\*WT7':ZMV_\`:@]J`*&N6?B5_#^HK<:AID\36L@:./3I
M=S?*>%Q*3GTXKF/AS9?$ZUAMQK5S;C3<`F+429+D#T!7I_P(FN\_M?4?^A<U
M#_O];_\`QRJI\37P8*?">M\D<C[.0,_]M:!F_+(D,3RR'"(I9CZ`=:Y73=.D
M\5V\>L:X7:RN%$EII>[$21GE6E`_UCD8)!^5<X`R,GJY(TEB:.10R."K`]P:
MY;3[Z7PE;II6L+(=.MP([/4E4LGE#A5FP/D91@;C\IP#D'(H$)=:U<:8^K0V
M46DV]II:J5AED,1<>6'/084<X!P:;)XYBAOIK62S8SO!:O9VRL/-N))@YV8/
M`VA,D]`,D]*TK/1-.N;Z]U25;*_%Y,DL,GDJVP*BJ`&YSRI.>.M5[OPE!?ZS
MJU]<N!]LM[>*&2,;9;=HB[;E;L<LI'^[SF@`?7]0AU2+2YK?3H[K[&MS,\EV
MRH"6*[5^3)QCKQ]*@T[3].\3:5'K5O;MI6H3;U^U6;@/E7*YW8Q(I*Y&X$$$
M<5-_PBPU"^-SKPL]0\S3ELY5,&`Q#,68`YVY##@=*?%JL'AC2[>PU?4%N;U<
MQP1PH7GG0$A/W:\EMN`2!C.3Q0!#!XFDTRUU:#7=C7FE1K,SP+@7439\MU4G
MAB5*E<\,.N"*ADL]0>WAN=?U74$N+DX6QTL[$B."VT,HWL0`<L6`..`,XJ&3
MPJ_B:WU/4=8MDM;^]A6&S1U5WLD3+(21_&7.YL''09XS4TFN:=<?9;?Q1:/I
M]Y;/YFR9"T$C;2I9),%67#$@$AAQD"@`-]>:$MEJ":C)J>@74B1RM<`>=;EV
M"HZL`-R;B`01D9SG@BNNKDKN[_X2B.#3-'@D&F"9&NKTQF.-41@WEQ@X+%BH
M7(&T`GG.!76T`%%%%`!1110`444$X&30`45S7@8M/X=.HN7+:C=3W?S,3A7D
M;9C/;8%Q72T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!44UO!<;?/A
MCEV-N7>H;:?49[U+10`4444`(0"02!D=/:EHHH`****`"D(#*58`@]012T4`
M9$WA;P_<;S+HFG,S_>;[,@)_'&:9#X0\-P!@FA:=\QR=UNK?S%;5%`$5O;06
ML0BMH(X8QT2-`H'X"I:**`"BBB@!J1I%&(XT5$48"J,`5Y'\0/A7XB\12M=V
MOB:>^"-O2POL(@QSA=H"Y[<K]37KU%`'-QZ;XECCCFMM>5LH";:_LHVP3_"6
MB*8QTXS^-3:?K\XU!-+UNR%A?R9\ADD\R"YP"3Y;X!W``G:P!QSR,FMZLKQ%
MI']M:+-:H_E7*XEM9N\,RG*./H0/J,CO0!JT5E^'=7&NZ!9ZB8S%)*F)HCUC
MD4[73\&!'X5J4`%%%%`!1110!B/X1T0W#7,%G]CG;[TEE*]NQ^NPC/7O3(O#
M+09\K7];`/7?<B3_`-"4UO44`<]'X1A`=;C6-<ND?(*2:@ZC_P`<VFM#3-"T
MO1O,.GV,,#R?ZR15R[_[S'D_B:T:*`"BBB@`HHHH`****`"BBB@`K%\6W\FG
M^%[Z2W_X^I(_(ME[M-(=B`?\"85M5RD+#Q5XEBNT`?1=)=C!)GY;FZ^Z67U6
M,;@#T+,?[M`'0:7I\6E:39Z=!_JK6!(4^B@`?RJW110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`',O9WGAS5KN_T^WDO--OG\VYLXL>9#+CYI8P?O!L#<O7/(
MSDBKD/B[P_-)Y9U6W@F&<Q7+>1(,=?E?!_2MJF2PQ3+MEB20>CJ#0`RVN[:]
MB\VTN(;B/.-\3AAGTR*YCQ)\2/#/AA)ENK\7%U$"6M;0>;(/]X#A?^!$5U44
M4<*;(HTC7.<(H`KFO$OP]\,^*XI/[0TZ-;AA_P`?5O\`NY0?7<.OXY%`&CIW
MB/3KS3K:YFO+."6:)9##]I1BF1G&<\XS5K^V=+_Z"5G_`-_U_P`:IVOA?1X+
M*W@FTVQN)(8EC,KVJ9?:`,GCVJ;_`(1O0O\`H"Z=_P"`J?X4`68M2L)VVPWM
MM(PZA)5)_G4_G1?\]4_[Z%9I\,Z`3DZ'II([FTC_`,*7_A&=!_Z`FF_^`D?^
M%`&D)$;[KJ?H:=6'/X,\,W+J\N@Z<648!%NH_D*9_P`(1X7_`.@%8_\`?H4`
M;]%8'_"$>&/^@%8_]^A5O3O#>C:3<FXT_3;:VF*E"\:8.#V_04`:9(52S$``
M9)/:LNP\2:/JFI3:?I^H0W=Q`@>80-O6,$X`9AP">>,YX-1^(_"VD^*]/-EJ
MT#R1X.TI(R,N>X(/\ZY/P;\,1X5OM45]2NI[6X,;P20SO`XQG*NJ$!NHP?KP
M*`/1:*YX^$XR2?[;UT9[?;VIT7A2".0N^K:W+D8VOJ4H'Z$4`;Y(`R3@"L6X
M\5:/#,;:&Z%[=C_EVLAYTF?<+G;]6P*B'@OP^7#S6!NF#;A]KFDGY^CL:V;:
MTMK*$0VMO%!$.B1(%4?@*`.?>RUCQ)@:COTK2C]ZSCD!N+@>DCJ<(I[JI)/]
MX=*Z*""*UMXX((DBAC4(D:+A54<``=A4E%`!1110`4444`%%%%`!1110`444
(4`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
